DATE to end January 2026					
Drug Name	**Formulations**	**BNF Chapter**	**Formulary status A = approved; R = restricted; NA = not approved,**	**Indication/Use** **Red List. Drugs that are in the Red List are individually annotated. In addition the following drug groups are also in the Red List:** **all IV antibacterials** **All antiretroviral drugs for the treatment/prophylaxis of HIV infection** **Oncology use of all intravenous and oral cytotoxics** **Biologic agents for treatment of autoimmune conditions** **Biologic agents used in ophthalmology** **All injectable cytotoxic drugs** **Oral cytotoxic drugs for non-cancer**	**PBR;** **PBR funding form required (F);** **National Cancer Drug Fund requiring a notification form (NCDF);** **Drug on the local Red List (RL)**
5-methoxypsoralen	tablets 20mg (unlicensed)	13.05.2	R	Restricted for use by Dermatology teams only.	RL
8-methoxypsoralen	tablets 10mg (unlicensed); bath lotion 1.2% solution in an aqueous base (unlicensed); gel 0.005% in aqueous gel (unlicensed)	13.05.2	R	Restricted for use by Dermatology teams only.	RL
abacavir	tablets 300mg oral liquid 20mg in 1ml sugar free	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
abacavir / lamivudine	tablets 600mg/300mg available in a range of generic products (first line) and Kivexa ® brand	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
abaloparatide	pre-filled pen, 3mg in 1.5ml solution	6.06.1	R	In line with NICE TA guidance no. 991, August 2024: Abaloparatide is recommended as an option for treating osteoporosis after menopause in women, trans men and non-binary people, only if they have a very high risk of fracture. It is only recommended if the company provides it according to the commercial agreement.	PBR

abatacept	injection 250mg pre-filled syringe 125mg/mL	10.01.3	R	1. In line with NICE TA guidance no. 375, Jan-2016 : Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and **abatacept**, all in combination with methotrexate, are recommended as options for treating rheumatoid arthritis only if disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and disease has not responded to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs) and the companies provide certolizumab pegol, golimumab, **abatacept** and tocilizumab as agreed in their patient access schemes.	PBR
abatacept	injection 250mg pre-filled syringe 125mg/mL	10.01.3	R	2. In line with NICE TA guidance no. 373, December 2015: **Abatacept**, adalimumab, etanercept and tocilizumab are recommended, within their marketing authorisations, as options for treating polyarticular juvenile idiopathic arthritis (JIA), including polyarticular-onset, polyarticular-course and extended oligoarticular JIA. That is for abatacept, people 6 years and older whose disease has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs) including at least 1 tumour necrosis factor (TNF) inhibitor.	PBR
abatacept	injection 250mg pre-filled syringe 125mg/mL	10.01.3	R	3. In line with NICE TA guidance no 715, July 2021: Adalimumab, etanercept, infliximab and **abatacept** for treating moderate rheumatoid arthritis after conventional DMARDs have failed, as outlined in the TAG document.	PBR
abatacept	injection 250mg pre-filled syringe 125mg/mL	10.01.3	R	4. For management of refractory idiopathic inflammatory myopathies in adults and children aged 2 and over, in line with the NHS England commissioning policy (December 2021).	PBR
abemaciclib	tablets 50mg, 100mg, 150mg	8.01.5	R	1. In line with NICE TA guidance no. 563, February 2019: Abemaciclib with an aromatase inhibitor is recommended, within its marketing authorisation, as an option for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer as first endocrine-based therapy in adults. Abemaciclib is recommended only if the company provides it according to the commercial arrangement.	PBR RL

abemaciclib	tablets 50mg, 100mg, 150mg	8.01.5	R	2. In line with NICE TA guidance no. 725, September 2021 (replaced TA guidance no 579, May 2019): Abemaciclib plus fulvestrant is recommended as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had endocrine therapy only if exemestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor and the company provides abemaciclib according to the commercial arrangement.	PBR RL
abemaciclib	tablets 50mg, 100mg, 150mg	8.01.5	R	3. In line with NICE TA guidance no. 810, July 2022: Abemaciclib with endocrine therapy is recommended, within its marketing authorisation, as an option for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer in adults whose disease is at high risk of recurrence, defined by the following clinical and pathological features, at least 4 positive axillary lymph nodes, or 1 to 3 positive axillary lymph nodes, and at least one of the following criteria: – grade 3 disease (defined as at least 8 points on the modified Bloom–Richardson grading system or equivalent), or – primary tumour size of at least 5 cm. It is recommended only if the company provides it according to the commercial arrangement.	PBR RL
Abidec ®	Drops 0.6ml contains vitamin A 4000 units, thiamine hydrochloride (vitamin B1) 1mg, riboflavin (vitamin B2) 400 micrograms, pyridoxine hydrochloride (vitamin B6) 500 micrograms, calciferol (vitamin D) 400 units, nicotinamide 5mg and ascorbic acid 50mg.	9.06.7	A		
abiraterone	tablets 250mg	8.03.4	R	1. In line with NICE TA guidance no. 259, June 2012: Abiraterone (in combination with prednisone or prednisolone) is recommended as an option for the first-line treatment of castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.	PBR RL
abiraterone	tablets 250mg	8.03.4	R	2. In line with NICE TA guidance no. 387, April 2016: Abiraterone in combination with prednisone or prednisolone is recommended, within its marketing authorisation, as an option for treating metastatic hormone-relapsed prostate cancer in people who have no or mild symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated only when the company rebates the drug cost of abiraterone from the 11th month until the end of treatment for people who remain on treatment for more than 10 months.	PBR RL

abiraterone	tablets 250mg	8.03.4	R	3. In line with NICE TA guidance no. 1110, Novemeber 2025: Abiraterone plus androgen deprivation therapy (ADT), with prednisolone or prednisone can be used, within its marketing authorisation, as an option to treat newly diagnosed high-risk hormone-sensitive metastatic prostate cancer in adults.	PBR RL
abrocitinib	tablets 50mg, 100mg, 200mg	10.01.3	R	In line with NICE TA guidance no 814, August 2022: **Abrocitinib** and upadacitinib are recommended as options for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in adults and young people 12 years and over, only if the disease has not responded to at least 1 systemic immunosuppressant, or these are not suitable the companies provide abrocitinib and upadacitinib according to the commercial arrangement.	PBR RL
acarbose	tablets 50mg, 100mg	6.01.2	R	Non-insulin dependent diabetics on maximum doses of sulphonylureas in whom metformin is either ineffective or contraindicated and who are known to be compliant with diet and other treatments. Restricted for use by Endocrinology teams.	
acenocoumarol	tablets 1mg	2.08.2	R	For patients intolerant to warfarin (NDP September 2011)	
acetazolamide	tablets 250mg; injection 500mg; liquid (unlicensed) 250mg in 5 mls;	11.06	A		
acetic acid	solution 5% (unlicensed); solution 3% (unlicensed)	21	A		
acetylcholine chloride	Solution for intra-ocular irrigation, 1% with mannitol 3%, when reconstituted (Miochol ®).	11.08.2	A	Miphtel® brand in use during supply problems with Miochol® (NDP May 2022)	
acetylcysteine	Eye drops, 5% with hypromellose 0.35% (Ilube ®). Eye drops, 5%, 10%, preservative free (unlicensed product) Eye drops, 10% (unlicensed product)	11.08.1	R	Unlicensed preparations can be obtained from Moorfields Hospital. Although normally held in stock they may not always be immediately available.	
acetylcysteine	injection 2g in 10ml tablets 600mg (effervescent)	17	R	1. In line with the product licence - as a mucolytic agent. 1st line (NDP January 2025) 2. Tablets for prevention of contrast media nephropthy; for chronic renally impaired patients and in Radiology and Cardiac Catheter Lab for renally impaired patients. 3. For interstitial lung disease (ILD), in particular idiopathic pulmonary fibrosis (IPF).	
aciclovir	cream 5%	13.10.3	A		

aciclovir	dispersible tablets 200mg, 400mg, 800mg; suspension 200mg in 5ml, 400mg in 5ml; intravenous infusion 250mg, 500mg	5.03.2	A	Level 1 non-reserved anti-infective	
acitretin	capsules 10mg, 25mg (hospital or specified retail pharmacy only).	13.05.2	R	Dermatologists only to prescribe.	RL
aclidinium/formaterol (Duaklir® Genuair®)	Dry powder for inhalation 340mcg/12mcg per dose	3.02	A	For use in COPD as per the relevant national guidelines. (NDP November 2015)	
actichlor	tablets 500mg; granules	16	A	no longer pharmacy; ordered from supplies	
activated charcoal	oral powder 50g; oral suspension; tablets	17	A		
adalimumab	injection 40mg pre-filled pen or pre-filled syringe	10.01.3	R	1. In line with NICE TA guidance no. 375, Jan-2016 : **Adalimumab**, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept, all in combination with methotrexate, are recommended as options for treating rheumatoid arthritis only if disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and disease has not responded to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs) and the companies provide certolizumab pegol, golimumab, abatacept and tocilizumab as agreed in their patient access schemes. **Adalimumab**, etanercept, certolizumab pegol or tocilizumab can be used as monotherapy for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the aforementioned criteria are met.	PBR
adalimumab	injection 40mg pre-filled pen or pre-filled syringe	1.05.3	R	2. In line with NICE TA guidance no. 187, May-10: Infliximab and **adalimumab**, within their licensed indications, are recommended as treatment options for adults with severe active Crohn's disease whose disease has not responded to conventional therapy (including immunosuppressive and/or corticosteroid treatments), or who are intolerant of or have contraindications to conventional therapy. Infliximab or adalimumab should be given as a planned course of treatment until treatment failure (including the need for surgery), or until 12 months after the start of treatment, whichever is shorter. People should then have their disease reassessed to determine whether ongoing treatment is still clinically appropriate. Treatment should normally be started with the less expensive drug (taking into account drug administration costs, required dose and product price per dose). This may need to be varied for individual patients because of differences in the method of administration and treatment schedules.	PBR

adalimumab	injection 40mg pre-filled pen or pre-filled syringe	10.01.3	R	3. In line with NICE TA guidance no 329, Feb-2015: Infliximab, **adalimumab** and golimumab are recommended, within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.	PBR
adalimumab	injection 40mg pre-filled pen or pre-filled syringe	10.01.3	R	4. In line with NICE TA guidance no. 199, Aug-10: Etanercept, infliximab and **adalimumab** are recommended for the treatment of adults with active and progressive psoriatic arthritis the person has peripheral arthritis with three or more tender joints and three or more swollen joints, and the psoriatic arthritis has not responded to adequate trials of at least two standard disease-modifying antirheumatic drugs (DMARDs), administered either individually or in combination. Treatment should normally be started with the least expensive drug (taking into account drug administration costs, required dose and product price per dose).	PBR
adalimumab	injection 40mg pre-filled pen or pre-filled syringe	10.01.3	R	5. In line with NICE TA guidance no. 383, Feb-2016: **Adalimumab**, certolizumab pegol, etanercept, golimumab and infliximab are recommended, within their marketing authorisations, as options for treating severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs. Infliximab is recommended only if treatment is started with the least expensive infliximab product. People currently receiving infliximab should be able to continue treatment with the same infliximab product until they and their NHS clinician consider it appropriate to stop. **Adalimumab**, certolizumab pegol and etanercept are recommended, within their marketing authorisations, as options for treating severe non-radiographic axial spondyloarthritis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs.	PBR
adalimumab	injection 40mg pre-filled pen or pre-filled syringe	10.01.3	R	6. Induction of remission, including fistula healing, in patients with moderate to severe Crohn's unresponsive to or intolerant of 1st line immunosuppression (e.g. azathioprine, methotrexate) +/- steroids, after treatment failure or intolerance to Infliximab.	PBR
adalimumab	injection 40mg pre-filled pen or pre-filled syringe	10.01.3	R	7. Maintenance of remission in patients with moderate to severe Crohn's unresponsive to or intolerant of 1st line immunosuppression (e.g. azathioprine, methotrexate) +/- steroids, after treatment failure or intolerance to Infliximab.	PBR

adalimumab	injection 40mg pre-filled pen or pre-filled syringe	13.05.3	R	8. In line with NICE TA guidance no. 146, Jun-08: As a treatment option for adults with plaque psoriasis for whom anti-tumour necrosis factor (TNF) treatment is being considered and when the disease is severe and the psoriasis has not responded to standard systemic therapies including ciclosporin, methotrexate and PUVA; or the person is intolerant of, or has a contraindication to, these treatments. Adalimumab should be discontinued in people whose psoriasis has not responded adequately at 16 weeks.	PBR
adalimumab	injection 40mg pre-filled pen or pre-filled syringe	10.01.3	R	9. In line with NICE TA guidance no. 195, Aug-10: **Adalimumab**, etanercept, infliximab and abatacept, each in combination with methotrexate, are recommended as treatment options only for adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to rituximab, or when rituximab is withdrawn because of an adverse event. **Adalimumab** monotherapy and etanercept monotherapy are recommended as treatment options for adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to methotrexate, or when methotrexate is withdrawn because of an adverse event.	PBR
adalimumab	injection 40mg pre-filled pen or pre-filled syringe	10.01.3	R	10. In line with NICE TA guidance no. 373, December 2015: Abatacept, **adalimumab**, etanercept and tocilizumab are recommended, within their marketing authorisations, as options for treating polyarticular juvenile idiopathic arthritis (JIA), including polyarticular-onset, polyarticular-course and extended oligoarticular JIA. That is for adalimumab, people 2 years and older whose disease has responded inadequately to 1 or more DMARD.	PBR

adalimumab	injection 40mg pre-filled pen or pre-filled syringe	10.01.3	R	11. In line with NICE TA guidance no. 392, June 2016: Adalimumab is recommended, within its marketing authorisation, as an option for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy. The drug is recommended only if the company provides it at the price agreed in the patient access scheme. Assess the response to adalimumab after 12 weeks of treatment, and only continue if there is clear evidence of response, defined as a reduction of 25% or more in the total abscess and inflammatory nodule count and no increase in abscesses and draining fistulas.	PBR
adalimumab	injection 40mg pre-filled pen or pre-filled syringe	10.01.3	R	12. In line with NICE TA guidance no 715, July 2021: **Adalimumab**, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed, as outlined in the TAG document.	PBR
adapalene	cream 0.1%; gel 0.1%	13.06.1	A		
adapalene/benzoyl peroxide	gel 0.1%/2.5%, 0.3%/2.5%	13.06.1	A	NDP March 2024	
Adcal-D3 ®	Tablets (chewable), calcium carbonate 1.5g (calcium 600mg/15.1mmol), colecalciferol 10 micrograms (400 units) Caplets, calcium carbonate 750mg (calcium 300mg/7.55mmol, colecalciferol 5 micrograms (200 units)	9.06.4	A	the product with the lowest acquisition cost will be used first line	
Adcal-D3 ® Dissolve	Effervescent tablets, lemon flavour, calcium carbonate 1.5g (calcium 600mg/15.1mmol), colecalciferol 10 micrograms (400 units)	9.06.4	A	(NDP November 2009)	
Addiphos®	solution (20ml)	9.03	A		
adenosine	injection 6mg in 2ml	2.03.2	A	Restricted for use by Cardiology, Accident and Emergency teams and on PICU and NICU only.	
adenosine	injection 30mg in 10ml	2.03.2	R	Stress test for myocardial imaging.	
adrenaline/epinephrine	injection 1 in 1000 (1mg in 1ml) 1ml, 10ml; injection 1 in 10,000 (100mcg in 1ml) 10ml (unlicensed); Min-I-Jet syringe 1 in 1000 1ml; Min-I-Jet syringe 1 in 10,000 3ml, 10ml	2.07.3	A		

adrenaline/epinephrine	inhaler 220mcg/dose	3.04.3	A	for use by the respiratory and allergy team for laryngeal oedema and some cases of croup.	
adrenaline/epinephrine	Eye drops, 1%. Eye drops, 0.01%, 0.1%, 0.5%. Eye drops, 0.1%, preservative free (Unlicensed product.)	11.06	R	Preparation is unlicensed and can be obtained from Moorfields Hospital. Although normally held in stock at CXH they may not always be immediately available.	
adrenaline/epinephrine	pre-filled auto-injector delivering 150mcg (**EpiPen Junior, Jext®**), 300mcg (**EpiPen®**), 150mcg, 300mcg, 500mcg (**Emerade®**) Injection 1 in 1,000, 1ml	3.04.3	A		
adrenaline/epinephrine (EURneffy®)	nasal spray, 2mg in 100microlitres.	3.04.3	R	For prescribing by paediatric specialist allergy services only, as per the product licence. GPs should not be asked to prescribe. (NDP January 2026).	
adrenaline/epinephrine	solution 1 in 1000, 30ml (unlicensed)	12.03.4	A		
Aerochamber®	adult, child, infant	3.01.5	R	Use if Volumatic not appropriate - replaced by Easychmaber® (May 2024)	
Aethoxysklerol® (lauromacrogol-400)	injection 10mg in 2ml	2.13	R	For use by vascular team, replaced an unlicensed preparation (September 2025)	
afatinib	tablets 20mg, 30mg, 40mg, 50mg	8.01.5	R	In line with NICE TA guidance no. 310, April 2014: Afatinib is recommended as an option, within its marketing authorisation, for treating adults with locally advanced or metastatic non-small-cell lung cancer only if the tumour tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation, and the person has not previously had an EGFR-TK inhibitor and the manufacturer provides afatinib with the discount agreed in the patient access scheme.	PBR
aflibercept	solution for intravitreal injection 40mg in 1mL pre-filled syringe 114.3mg in 1ml	11.08.2	R	1. In line with NICE TA guidance no. 294, July 2013: Aflibercept solution for injection is recommended as an option for treating wet age-related macular degeneration only if it is used in accordance with the recommendations for ranibizumab in NICE technology appraisal guidance 155 (re-issued in May 2012) and the manufacturer provides aflibercept solution for injection with the discount agreed in the patient access scheme.	PBR
aflibercept	solution for intravitreal injection 40mg in 1mL pre-filled syringe 114.3mg in 1ml	11.08.2	R	2. In line with NICE TA guidance no. 305, February 2014: Aflibercept solution for injection is recommended as an option for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion only if the manufacturer provides aflibercept solution for injection with the discount agreed in the patient access scheme.	PBR

aflibercept	solution for intravitreal injection 40mg in 1mL pre-filled syringe 114.3mg in 1ml	11.08.2	R	3. In line with NICE TA guidance no. 346, July 2015: Aflibercept solution for injection is recommended as an option for treating visual impairment caused by diabetic macular oedema only if: the eye has a central retinal thickness of 400 micrometres or more at the start of treatment and the company provides aflibercept with the discount agreed in the patient access scheme.	PBR
aflibercept	solution for intravitreal injection 40mg in 1mL pre-filled syringe 114.3mg in 1ml	11.08.2	R	4. In line with NICE TA guidance no. 409, September 2016: Aflibercept is recommended as an option within its marketing authorisation for treating visual impairment in adults caused by macular oedema after branch retinal vein occlusion, only if the company provides aflibercept with the discount agreed in the patient access scheme.	PBR
aflibercept	solution for intravitreal injection 40mg in 1mL pre-filled syringe 114.3mg in 1ml	11.08.2	R	5. In line with NICE TA guidance no. 486, November 2018: Aflibercept is recommended, within its marketing authorisation, as an option for treating visual impairment because of myopic choroidal neovascularisation in adults, only if the company provides aflibercept with the discount agreed in the patient access scheme.	PBR
ajmaline	injection 50mg (unlicensed)	not classified	R	for cadiology to diagnose Brugada syndrome	
albendazole	tablets 400mg	5.05.7	A	Level 1 non-reserved anti-infective	
albumin (human)	Isotonic Solution 4.5%, 5% (100mls, 250mls, 500mls); Concentrated Solution 20% (100mls)	9.02.2	A		
Albustix		19.01	A		
alclometasone dipropionate	cream 0.05%; ointment 0.05%	13.04			
alcohol	dehydrated injection 2ml, 5ml, 10ml	not classified	A		
alcohol	Industrial Methylated Spirit BP	13.11.1		no longer pharmacy; ordered from supplies	
aldesleukin	injection 18 million units	8.02.4	R	For treatment of metastatic renal cell carcinoma according to local protocol.	PBR
alectinib	capsules, 150mg	8.01.5	R	In line with NICE TA guidance no. 536, August 2018: Alectinib is recommended, within its marketing authorisation, as an option for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults. It is recommended only if the company provides alectinib according to the commercial arrangement.	PBR RL

alectinib	capsules, 150mg	8.01.5	R	In line with NICE TA guidance no. 1014, November 2024: Alectinib is recommended, within its marketing authorisation, as an option for the adjuvant treatment of stage 1B (tumours 4 cm or larger) to 3A ALK-positive non small-cell lung cancer (NSCLC) after complete tumour resection in adults. It is only recommended if the company provides it according to the commercial arrangement.	PBR RL
alemtuzumab (previous Campath 1H)	Concentrate for intravenous infusion, 30 mg in 3ml.	8.02.3	R	1. For BMT conditioning in patients undergoing unrelated transplants, to reduce the risk of rejection and prevent graft versus host disease. 2. As salvage for advanced chronic lymphocytic leukaemia (CLL) after fludarabine. 3. Jul-04 Prescribing extended to renal/transplant unit for induction of immunosuppression in kidney and pancreas transplants (Jul-04). 4. For use in Paediatrics for BMT 5. For use by Haematology teams for refractory CLL (3rd line).	
alemtuzumab (Lemtrada®)	12mg in 1.2ml vial	8.02.4	R	In line with NICE TA guidance no 312, May 2014 (Updated May 2024): Alemtuzumab is recommended as an option, within its marketing authorisation, for treating highly active relapsing–remitting multiple sclerosis in adults with highly active disease despite a full and adequate course of treatment with at least 1 disease-modifying therapy, or rapidly evolving severe relapsing–remitting multiple sclerosis defined by 2 or more relapses in the previous year, and baseline MRI evidence of disease activity. **NHS England, April 2019: Use according to revised restrictions in response to safety alerts.**	PBR
alendronic acid	tablets 10mg, 70mg	6.06.2	R	In line with NICE TA guidance no. 161, October 2008 (updated as TA 464, August 2017): For the secondary prevention of osteoporatic fragility fractures in women aged 75 years and older.	
alfacalcidol (1-alpha-hydroxycolecalciferol)	capsules 250 nanograms, 500 nanograms, 1mcg; oral drops 2mcg/ml; injection 1mcg in 0.5ml, 2mcg in 1ml	9.06.4	A		
alfentanil	injection 1mg in 2ml, 5mg in 10ml, 5mg in 1ml	15.01.4	A		
alfuzosin hydrochloride	tablets 2.5mg; M/R tablets 10mg	7.04.1	A		
Algesal®	Diethylamine Salicylate 10%w/w (cream)	10.03.2	A		
alimemazine	syrup 7.5mg in 5ml, 30mg in 5ml	3.04.1	A		

alirocumab	solution for injection, pre-filled pen 75mg, 150mg	2.12	R	In line with NICE guidance TA no 393, June 2016: Alirocumab is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if low-density lipoprotein concentrations are persistently above the thresholds specified in table 1 despite maximal tolerated lipid-lowering therapy (that is, either the maximum dose has been reached or further titration is limited by intolerance, as defined in NICE's guideline on familial hypercholesterolaemia: identification and management) and the company provides alirocumab with the discount agreed in the patient access scheme.	PBR
alitretinoin	capsules 10mg, 30mg	13.05.1	R	In line with NICE TA guidance no. 177; Aug-09: Alitretinoin is recommended as a treatment option for adults with severe chronic hand eczema that has not responded to potent topical corticosteroids if the person has: • severe disease, as defined by the physician's global assessment (PGA) **and** • a dermatology life quality index (DLQI) score of 15 or more. Alitretinoin treatment should be stopped: • as soon as an adequate response (hands clear or almost clear) as been achieved or • if the eczema remains severe (as defined by the PGA) at 12 weeks or • if an adequate response (hands clear or almost clear) has not been achieved by 24 weeks Only dermatologists, or physicians with experience in both managing severe chronic hand eczema and the use of systemic retinoids, should start and monitor treatment with alitretinoin. (October 2009)	PBR RL
alkaline compound	powder (sodium bicarbonate 50%, sodium chloride 50% - unlicensed)	12.02	A		
allergy prick test	solution (unlicensed)	3.04.2	A	Test kit for the diagnosis of a variety of allergies. Restricted for use by adult and paediatic allergy specialists only in allergy clinics.	
allopurinol	tablets 100mg, 300mg	10.01.4	A	Injection and mouth-wash are non-formulary.	
almotriptan	tablets 12.5mg	4.07.4	A		

alpelisib	tablets, 50mg, 150mg, 200mg	8.01.5	R	In line with NICE TA guidance no. 816, August 2022: Alpelisib plus fulvestrant is recommended as an option for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults, only if their cancer has progressed after a CDK4/6 inhibitor plus an aromatase inhibitor and the company provides alpelisib according to the commercial arrangement).	PBR RL
Alpha tocopheryl	tablets 50mg, 200mg, 100mg (unlicensed)	9.06.5	A		
Alpha tocopheryl acetate	suspension 500mg in 5ml	9.06.5	A		
Alphaderm ®	cream containing hydrocortisone 1% and urea 10%	13.04	A		
Alphosyl ®	cream containing coal tar extract 5% and allantoin 2%; Coal Tar In Emulsifying Ointment, 'Sludge' Ointment, 10%, 20% (Unlicensed product.)	13.05.2	A		
Alphosyl HC ®	cream containing coal tar extract 5%, hydrocortisone 0.5% and allantoin 2%	13.05.2	A		
alprazolam	tablets 250mcg, 500mcg	4.01.2	R	For management of essential tremor for initiation by neurology team. (NDP September 2015) Cannot be prescribed on FP10 prescriptions as black listed for NHS prescribing.	
alprostadil	injection 500mcg in 1ml	7.01.1	A		
alprostadil	Injection 5microgram, 10microgram, 20 microgram, 40 microgram (Caverject ®); cartridges 10 microgram (Caverject ® Dual cartridge) urethral application 125mcg, 250mcg, 500mcg, 1mg (Muse ®);	7.04.5	A	On the Red List if prescribed ousdie Schedule 2 to the National Health Service (General Medical Services Contracts) (Prescription of Drugs etc.) Regulations 2004). November 2021: Muse® unavailable - temporatly substituted with **3mg/g cream (Vitaros®).**	
alteplase	injection 2mg, 10mg, 20mg, 50mg	2.10.2	R	1. In line with NICE TA guidance No. 52, Oct-02: For treatment of acute myocardial infarction.	PBR
alteplase	injection 2mg, 10mg, 20mg, 50mg	2.10.2	R	2. For treatment of large PE according to the local protocol.	PBR
alteplase	injection 2mg, 10mg, 20mg, 50mg	2.10.2	R	3. In line with NICE TA guidance no. 264, September-12: For the treatment of acute ischaemic stroke (review of NICE TA guidance 122, Jun-07).	PBR

alteplase	injection 2mg, 10mg, 20mg, 50mg	2.10.2	R	4. For intra-arterial use in patients who have received streptokinase in the last 12 months, for use by haematologists in patients with paroxysmal nocturnal haemoglobunuria (PNH) or Budd-Chiari syndrome. Extended use to the patients with anterior myocardial infection, with ST elevation and blood pressure below 90mmHg, who present within 4 hours of the onset of chest pain and who are aged 75 or less.	
alteplase	injection 2mg, 10mg, 20mg, 50mg	2.10.2	R	5. With Dornase-alpha, for interpleural fibrinolysis for the management of complex pleural infaections. (NDP March 2016 - unlicensed indication)	
alum	irrigation 1% 1 litre, 3 litres (unlicensed)	7.04.4	A		
aluminium chloride	Alcoholic solution, 25% (unlicensed); Irrigation solution 1%, 3 litre (unlicensed);	13.12	A		
aluminium chloride hexahydrate	20% roll-on applicator	13.12	A		
alverine citrate	capsules 60mg	1.02	A		
amantadine	capsules 100mg; oral liquid 50mg in 5ml	4.09.1	R	For Parkinson's disease. NICE TA guidance no. 168, Feb-09 (replaces TA guidance no. 58): Amantadine is not recommended for the treatment of influenza. NICE TA guidance no. 67, Sept-03: Amantadine is not recommended for either post-exposure or seasonal prophylaxis of influenza.	
amantadine hydrochloride	Capsules, 100mg. Syrup, 50mg in 5ml.	5.03.4	A	Level 1 non-reserved anti-infective	
ambrisentan	tablets 5mg, 10mg	2.05.1	R	As an alternative to bosentan where liver abnormalities or drug interactions with bosentan pose a clinically important problem. Its use is confined to the specialist management of pulmonary hypertension as prescribed by the Pulmonary Hypertension team.	PBR, RL
amikacin	injection 100mg in 2ml, 500mg in 2ml	5.01.4	R	Level 2 anti-infective restricted to specific indications: As per Adult anti-infective policy As per Renal anti-infective policy As per Haematology anti-infective policy Tuberculosis Paediatric ICU	
amikacin	0.4mg in 0.1ml - intravitreal injection pre-pack	not classified	R	for ophthalmology use (NDP December 2017)	

amikacin	liposomal nebuliser dispersion, 590mg	not classified	R	In line with NHS England Clinical Commissioning Policy, October 2022: Nebulised liposomal amikacin is commissioned for the treatment of non tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex refractory to current treatment options (adults and post pubescent children) with the criteria set out in the commissioning document.	RL
amiloride	tablets 5mg; oral solution 5mg in 5ml	2.02.3	A		
aminophylline	MR tablets (Phyllocontin) 225mg, 350mg; injection 250mg in 10ml	3.01.3	A		
Aminoven® 25	infusion	9.03	A		
amiodarone	tablets 100mg, 200mg; injection 150mg in 10ml, 150mg in 3ml; pre-filled syringe 300mg in 10ml	2.03.2	A		
amisulpride	tablets 50mg, 100mg, 200mg, 400mg; oral solution 100mg in 1ml	4.02.1	R		
amitriptyline hydrochloride	tablets 10mg, 25mg, 50mg; mixture 10mg in 5ml; oral solution 25mg in 5ml, 50mg in 5ml	4.03.1	A		
amlodipine	tablets 5mg, 10mg	2.06.2	A		
amobarbital sodium	capsules 200mg	4.01.3	R		
amorolfine	nail lacquer 5%	13.10.2	R	Restricted for use by Dermatology teams only.	
amoxicillin	capsules 250mg, 500mg; syrup 125mg in 5ml, 250mg in 5ml; sachets 3g; injection 250mg, 500mg	5.01.1	A	Level 1 non-reserved anti-infective	
amphotericin	oral suspension 100mg in 1ml	12.03.2	A		
amphotericin	tablets 100mg; suspension 100mg in 1ml; Intravenous infusion 50mg (Fungizone ®);	5.02.3	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required	
amphotericin AmBisome ® or generic liposomal brand	Intravenous infusion amphotericin encapsulated in liposomes 50mg	5.02.3	R	Level 2 anti-infectives restricted to specific indications: As per Haematology anti-infective policy As per Neonatal anti-infective policy As per Renal anti-infective policy As per HIV guidance Paediatric ICU As per Paediatric Oncology/ Haematology protocols	PBR
amphotericin	eye drops 0.15% (unlicensed)	11.03.2	R		
ampicillin	injection 500mg	5.01.1	R	Level 2 anti-infective restricted to specific indications: As per Adult anti-infective policy	
amsacrine	injection 75mg	8.01.5	A		PBR

anagrelide	capsules 500microgram	9.01.4	R	As a platelet lowering agent in at risk essential thrombocythaemia and other myeloproliferative disorders, for use in line with protocol as an alternative to hydroxycarbamide.	RL
anakinra	pre-filled syringe 100mg	10.01.3	R	For systemic onset juvenile rheumatoid arthritis (in children) where methotrexate alone has failed. Prescribing restricted to Paediatric consultants only. (March 2009).	PBR
anakinra	pre-filled syringe 100mg	10.01.3	R	In line with NICE TA guidance no 685, March 2021: Anakinra is recommended as an option for treating Still's disease with moderate to high disease activity, or continued disease activity after non-steroidal antiinflammatory drugs (NSAIDs) or glucocorticoids. It is only recommended for adult-onset Still's disease that has responded inadequately to 2 or more conventional disease-modifying antirheumatic drugs (DMARDs) systemic juvenile idiopathic arthritis in people 8 months and older with a body weight of 10 kg or more that has not responded to at least 1 conventional DMARD. For the treatment of adult-onset Still's disease refractory to second-line therapy as per NHS England commissioning policy. (NDP November 2018)	PBR
anastrazole	tablets 1mg	8.03.4	A	For treatment of estrogen positive breast cancer in line with national and local recommendations.	
andexanet-alfa	vials, 200mg	2.11	R	In line with NICE TA guidance no 697, May 2021 (updated January 2025): Andexanet alfa is recommended as an option for reversing anticoagulation from apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding, only if: • the bleed is in the gastrointestinal tract, and • the company provides andexanet alfa according to the commercial arrangement	PBR
anidulafungin	injection 100mg	5.02.4	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required. Approved for the treatment of Invasive candidiasis in non-neutropenic adult patients where fluconazole is unsuitable. Anidulafungin to replace caspofuning in this setting. Caspofungin will still be used in paediatric and neutropenic patients. (NDP November 2011)	PBR
antacid oxetacaine	oral suspension (10mg oxetacaine, aluminium hydroxide equivalent to 200mg aluminium oxide + 100mg magnesium hydroxide in each 5mls)	1.01.1	A	to replace sucralfate oral solution for oncology, gastroenterology, hepatology and general surgery indications (NDP September 2023)	

Anti-D immunoglobulin	injection 250units, 500units, 1250 units, 1500units	14.05	R	1. In line with NICE TA guidance no. 156; Aug-08 routine antenatal anti-D prophylaxis (RAADP) is recommended as a treatment option for all pregnant women who are rhesus D (RhD) negative and who are not known to be sensitised to the RhD antigen. When a decision has been made to give RAADP, the preparation with the lowest associated cost should be used.	
Anti-D immunoglobulin	intravenous injection 1500units (300mcg)	14.05	Very R	2. for the treatment of autoimmune thrombocytopenic purpura (ATP) in Rh+ve patients to replace existing treatment with intravenous immunoglobulin. Only for use in RhO (D) positive patients.	
Antilymphocyte immunoglobulin horse (ALG Horse)	injection, 50mg in 1ml	14.05	R	For use according to relevant local protocols.	PBR
Antithymocyte globulin (ATG- rabbit.)	Injection, 25mg, 40mg vials (unlicensed)	8.02.4	R	For use according to relevant local protocols.	PBR
Antithymocyte immunoglobulin rabbit (ATG Rabbit)	injection	14.05	R	For use according to relevant local protocols.	PBR
Anusol ®	cream, ointment; suppositories	1.07.1	A		
Anusol HC ®	ointment; suppositories	1.07.2	A		
apalutamide	tablets, 60mg	8.03.4	R	In line with NICE TA guidance no. 740, October 2021: Apalutamide plus androgen deprivation therapy (ADT) is recommended, within its marketing authorisation, as an option for treating hormone-relapsed non-metastatic prostate cancer that is at high risk of metastasising in adults. High risk is defined as a blood prostate-specific antigen (PSA) level that has doubled in 10 months or less on continuous ADT. It is recommended only if the company provides apalutamide according to the commercial arrangement.	PBR RL
apalutamide	tablets, 60mg	8.03.4	R	In line with NICE TA guidance no. 741, October 2021: Apalutamide plus androgen deprivation therapy (ADT) is recommended as an option for treating hormone-sensitive metastatic prostate cancer in adults, only if docetaxel is not suitable the company provides apalutamide according to the commercial arrangement.	PBR RL
apixaban	tablets 2.5mg	2.08.2	A	1. In line with NICE TA guidance no. 245, Janunary 12: Apixaban is recommended as an option for the prevention of venous thromboembolism in adults after elective hip or knee replacement surgery.	

apixaban	tablets 2.5mg, 5mg	2.08.2	A	2. In line with NICE TA guidance no. 275, February 13: Apixabain is recommended as an options for the prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation.	
apixaban	tablets 2.5mg, 5mg	2.08.2	A	3. In lince with NICE TA guidance no 341, June 2015: Apixaban is recommended, within its marketing authorisation, as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults.	
apomorphine hydrochloride	Injection 20mg in 2ml, 50mg in 5ml; pre-filled pen (various strenghts) pre-filled syringe (various strenghts) solution for infusion, 100mg in 20ml	4.09.1	A		RL
apraclonidine	Ophthalmic solution (=eye drops), 1% (as hydrochloride). 0.25ml single units (Iopidine ®) eye drops 0.5%	11.08.2	A	Iopidine® restricted to opthalmology teams	
apremilast	tablets 30mg titration pack 10mg, 20mg 30mg	10.1.3	R	In line with NICE TA guidance no. 419, November 2016: Apremilast is recommended as an option for treating chronic plaque psoriasis in adults only under clinical circumstances as defined in the appraisal.	PBR RL
apremilast	tablets 30mg titration pack 10mg, 20mg 30mg	10.1.3	R	In line with NICE TA guidance no 433, February 2017: Arpemilast alone or in combination with DMARDs is recommended as an option for treating active psoriatic arthritis in adults only under clinical circumstances as defined in the appraisal.	PBR RL
aprepitant	capsules 80mg, 125mg	4.06	R	1. For the prevention of acute and delayed nausea and vomiting in patients on highly emetogenic cisplatin based cancer chemotherapy in adults. As 2nd line addition to treatment in patients who experience sever nausea and vomitting on moderately emetogenic chemotherapy regimens despite standard treatment.	
aprepitant	capsules 80mg, 125mg	4.06	very R	2. For management of cardinal symptoms associated with chronic diabetic gastroparesis where other agents are ineffective or are not tolerated. (NDP November 2018)	
aprepitant	capsules 80mg	4.06	R	3. For prevention of PONV in **bariatric surgery** patients having laparoscopic weight loss surgery, and for management of resistant PONV in **bariatric surgery** patient having laparoscopic weight loss surgery. (NDP July 2024)	
aprotinin	eye drops 20iu/ml	2.11	R	For corneal service.	
aprotinin	injection 500,000 kallikrein inactivator units in 50ml (unlicensed)	2.11	R	Licensed product discontinued. Unlicensed product available; restricted use by cardiothoracic surgeons.	

aqueous cream	cream 30g, 100g, 500g	13.02.1	A	only to be used as a soap substitute	
arachis oil	enema	13.09	R	second line to phosphate enema	
argatroban	injection 250mg in 2.5ml vial	2.08.1	R	Approved for anticoagulation treatment in patients with heparin induced thrombocytopenia (instead of lepirudin which will be withdrawn fro the market in April 2012); to be used on haematology advice. (NDP February 2012)	
arginine	injection 10% 300ml (unlicensed)	not classified	R	for use incombination with GHRH in diagnosng growth hormone deficiency (GHRH-arginine test) (NDP - May 2010)	
argipressin (synthetic vasopressin)	injection 20units in 1ml	6.05.2	A		
aripiprazole	tablets 5mg, 10mg, 15mg, 30mg; dispersible tablets 10mg, 15mg oral solution 1mg in 1ml injection 7.5mg in 1ml (1.3ml)	4.02.1	R		
arsenic trioxide	concentrate for solution for infusion 1mg/ml	not classified	R	In line with NICE TA guidance no 526, June 2018: Arsenic trioxide is recommended, within its marketing authorisation, as an option for inducing remission and consolidation in acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR-alpha gene) in adults with: untreated, low-to-intermediate risk disease (defined as a white blood cell count of 10x103 per microlitre or less), when given with all-trans-retinoic acid (ATRA) relapsed or refractory disease, after a retinoid and chemotherapy.	PBR
artesunate	injection 60mg, 110mg (unlicensed)	5.04.1	R	Level 1 non-reserved anti-infective for treatment of severe malaria. (July 2009)	
artificial saliva	saliva replacement gel Biotene Oralbalance ®	12.03.5	A		
artificial aliva	aerosal spray brand on contract	12.03.5	A		
Artiss®	2ml, 4ml, 10ml (Fibrinogen 91mg/mL, Aprotinin 3000KIU/mL, Thrombin 4IU/mL, Calcium chloride 40micromoles/mL)	2.11	R	Low thrombin sealant: for reduction of drain output or to remove the need for drains. (NDP December 2016)	
asciminib	tablets 20mg, 40mg	8.01.5	R	In line with NICE TA guidance no 813, August 2022: Asciminib is recommended, within its marketing authorisation, as an option for treating chronic-phase Philadelphia chromosome-positive chronic myeloid leukaemia without a T315I mutation after 2 or more tyrosine kinase inhibitors in adults. It is recommended only if the company provides asciminib according to the commercial arrangement.	PBR RL

ascorbic acid	tablets 50mg, 200mg, 500mg; tablets effervescent 1 gram (black listed).	9.06.3	R	1g effervescent tablets are not available on NHS prescription from general practitioners **GPs should not be asked to continue prescribing.**	
ascorbic acid	injection 500mg in 5ml	9.06.3	R	for patients on haemodialysis with high ferritins and low iron for administration after each dialysis for 6 months, to reduce EPO doses and/or to increase Hb with a reduction in ferritin.	
asparaginase (E. coli)	see Crisantaspase (Erwinia L-asparaginase)		R		PBR
aspirin	dispersible tablets 75mg, 300mg; e/c tablets 75mg, 300mg; suppositories 150mg (unlicensed), 300mg	4.07.1	A	In line with NICE TA guidance no. 210, Dec-10: Modified-release dipyridamole in combination with aspirin is recommended as an option to prevent occlusive vascular events: • for people who have had a transient ischaemic attack or • for people who have had an ischaemic stroke only if clopidogrel is contraindicated or not tolerated.	
aspirin	IV injection 500mg (unlicensed)	2.09	R	IV injection to prevent thrombo-embolic complications during endovascular neuroradiological procedures; to be given before the patient recovers from GA (to be able to take oral aspirin).	
atazanavir	hard capsules 150mg, 200mg, 300mg	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
atenolol	tablets 25mg, 50mg, 100mg; syrup 25mg in 5ml; injection 5mg in 10ml	2.04	A		
atezolizumab	1200mg concentrate for solution for infusion (20ml) 840mg concentrate for solution for infusion (14ml) 1875mg solution for subcutaneous injection	8.01.5	R	1. In line with NICE TA guidance no 520, May 2018: Atezolizumab is recommended as an option for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK-positive tumour), only if atezolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses and the company provides atezolizumab with the discount agreed in the patient access scheme.	PBR
atezolizumab	1200mg concentrate for solution for infusion (20ml) 840mg concentrate for solution for infusion (14ml) 1875mg solution for subcutaneous injection	8.01.5	R	2. In line with NICE TA guidance no 525, June 2018: Atezolizumab is recommended as an option for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy, only if atezolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses and the company provides atezolizumab with the discount agreed in the patient access scheme.	PBR

atezolizumab	1200mg concentrate for solution for infusion (20ml) 840mg concentrate for solution for infusion (14ml) 1875mg solution for subcutaneous injection	8.01.5	R	3. In line with NICE TA guidance no 584, June 2019: Atezolizumab plus bevacizumab, carboplatin and paclitaxel is recommended as an option for treating metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults who have not had treatment for their metastatic NSCLC before and whose PD-L1 tumour proportion score is between 0% and 49% or when targeted therapy for epidermal growth factor receptor (EGFR)-positive or anaplastic lymphoma kinase (ALK)-positive NSCLC has failed. It is recommended only if atezolizumab and bevacizumab are stopped at 2 years of uninterrupted treatment, or earlier if there is loss of clinical benefit (for atezolizumab) or if the disease progresses (for bevacizumab) and the company provides atezolizumab and bevacizumab according to the commercial arrangements.	PBR
atezolizumab	1200mg concentrate for solution for infusion (20ml) 840mg concentrate for solution for infusion (14ml) 1875mg solution for subcutaneous injection	8.01.5	R	4. In line with NICE TA guidance no 638, July 2020: Atezolizumab with carboplatin and etoposide is recommended as an option for untreated extensive-stage small-cell lung cancer in adults, only if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and the company provides atezolizumab according to the commercial arrangement.	PBR
atezolizumab	1200mg concentrate for solution for infusion (20ml) 840mg concentrate for solution for infusion (14ml) 1875mg solution for subcutaneous injection	8.01.5	R	5. In line with NICE TA guidance no 639, July 2020: Atezolizumab with nab-paclitaxel is recommended, within its marketing authorisation, for treating triple-negative, unresectable, locally advanced or metastatic breast cancer in adults whose tumours express PD-L1 at a level of 1% or more and who have not had previous chemotherapy for metastatic disease. It is recommended only if the company provides atezolizumab according to the commercial arrangement.	PBR
atezolizumab	1200mg concentrate for solution for infusion (20ml) 840mg concentrate for solution for infusion (14ml) 1875mg solution for subcutaneous injection	8.01.5	R	6. In line with NICE TA guidance no. 666, Decemeber 2020: Atezolizumab plus bevacizumab is recommended as an option for treating advanced or unresectable hepatocellular carcinoma (HCC) in adults who have not had previous systemic treatment, only if they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and the company provides it according to the commercial arrangement.	PBR

atezolizumab	1200mg concentrate for solution for infusion (20ml) 840mg concentrate for solution for infusion (14ml) 1875mg solution for subcutaneous injection	8.01.5	R	7. I line with NICE TA guidance no. 705, June 2021: Atezolizumab is recommended, within its marketing authorisation, as an option for untreated metastatic non-small-cell lung cancer (NSCLC) in adults if: • their tumours have PD-L1 expression on at least 50% of tumour cells or 10% of tumour-infiltrating immune cells • their tumours do not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations and • the company provides atezolizumab according to the commercial arrangement.	PBR
atezolizumab	1200mg concentrate for solution for infusion (20ml) 840mg concentrate for solution for infusion (14ml) 1875mg solution for subcutaneous injection	8.01.5	R	8. In line with NICE TA guidance no. 739, October 2022 (replaced TAG 492, December 2017): Atezolizumab is recommended, within its marketing authorisation, as an option for untreated locally advanced or metastatic urothelial cancer in adults whose tumours express PD-L1 at a level of 5% or more and when cisplatin-containing chemotherapy is unsuitable. This is only if the company provides atezolizumab according to the commercial arrangement.	PBR
atezolizumab	1200mg concentrate for solution for infusion (20ml) 840mg concentrate for solution for infusion (14ml) 1875mg solution for subcutaneous injection	8.01.5	R	9. In line with NICE TA guidance no. 1071, June 2025 (replaces TAG 823, September 2022): Atezolizumab can be used, within its marketing authorisation, as an option for the adjuvant treatment of non-small-cell lung cancer (NSCLC) after complete resection and platinum-based chemotherapy in adults when there is a high risk of recurrence 50% or more of tumour cells express PD-L1 the cancer is not epidermal growth factor receptor (EGFR)-mutant or anaplastic lymphoma kinase (ALK)-positive. Atezolizumab can only be used if the company provides it according to the commercial arrangement.	PBR
atogepant	tablets 10mg, 60mg	4.07.4	R	In line with NICE TA guidance no. 973, May 2024: Atogepant is recommended as an option for preventing migraine in adults who have at least 4 migraine days per month, only if at least 3 preventive medicines have failed.	
atomoxetine	capsules, 10mg, 18mg, 40mg, 60mg	4.04	R	NICE TA guidance no. 98; Mar-06 for the management of attention deficit hyperactivity disorder (ADHD) in children and adolescents. For use by Paediatric Consultants only	
atorvastatin	tablets 10mg, 20mg, 40mg, 80mg	2.12	A		
atosiban	injection 6.75mg in 0.9ml, 37.5mg in 5ml	7.01.3	R	For preterm labour at 24-33 weeks gestation when there are no contraindications to tocolysis.	
atovaquone	suspension 750mg in 5ml	5.04.8	A	Level 1 non-reserved anti-infective	

atracurium besilate (atracurium besylate)	injection 25mg in 2.5ml, 50mg in 5ml, 250mg in 25ml pre-filled syringes 10mg/ml (10ml - unlicensed)	15.01.5	A		
atropine	tablets 600mcg; injection 500mcg in 1ml, 600mcg in 1ml; Min-I-Jet syringe 500mcg in 5ml, 1mg in 10ml, 3mg in 10ml	15.01.3	A		
atropine	Eye drops 0.5%, 1%; Eye ointment 1%; Single use Minims ® eye drops 1%	11.05	A		
avacopan	capsules 10mg	8.02.4	R	In line with NICE TA guidance no. 825, September 2022: Avacopan with a cyclophosphamide or rituximab regimen is recommended, within its marketing authorisation, as an option for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults. It is recommended only if the company provides it according to the commercial arrangement.	PBR RL
avapritinib	tablets 25mg, 50mg, 100mg, 200mg	8.01.5	R	In line with NICE TA guidance no. 1012, November 2024: Avapritinib is recommended, within its marketing authorisation, as an option for treating advanced systemic mastocytosis (including aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm and mast cell leukaemia) in adults. Avapritinib is only recommended if the company provides it according to the commercial arrangement.	PBR RL
avatrombopag	tablets 20mg	9.01.4	R	In line with NICE TA fuidance no 626, June 2020: Avatrombopag is recommended, within its marketing authorisation, as an option for treating severe thrombocytopenia (that is, a platelet count of below 50,000 platelets per microlitre of blood) in adults with chronic liver disease having a planned invasive procedure.	PBR RL
avatrombopag	tablets 20mg	9.01.4	R	In line with NICE TA guidance no. 853, December 2022: Avatrombopag is recommended, within its marketing authorisation, as an option for treating primary chronic immune thrombocytopenia (ITP) refractory to other treatments (for example, corticosteroids, immunoglobulins) in adults. It is only recommended if the company provides it according to the commercial arrangement.	PBR RL

avelumab	vials 10mls 200mg concentrate for solution for infusion	8.01.5	R	In line with NICE TA guidance no 645, September 2020: Avelumab with axitinib is recommended for use within the **Cancer Drugs Fund** as an option for untreated advanced renal cell carcinoma in adults. It is recommended only if the conditions in the managed access agreement for avelumab with axitinib are followed.	PBR
avelumab	vials 10mls 200mg concentrate for solution for infusion	8.01.5	R	In line with NICE TA guidance no 788, May 2022: Avelumab is recommended as an option for maintenance treatment of locally advanced or metastatic urothelial cancer that has not progressed after platinum-based chemotherapy in adults, only if avelumab is stopped at 5 years of uninterrupted treatment or earlier if the disease progresses and the company provides avelumab according to the commercial arrangement.	PBR
axicabtagene ciloleucel	$0.4 – 2 \times 10^8$ cells dispersion for infusion	8.01.5	R	In line with NICE TA guidance no 872, February 2023: Axicabtagene ciloleucel is recommended, within its marketing authorisation, as an option for treating relapsed or refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies. It is recommended only if the company provides axicabtagene ciloleucel according to the commercial arrangement.	PBR
axitinib	tablets 1mg, 5mg	8.01.5	R	In line with NICE TA guidance no 333, February 15: Axitinib is recommended as an option for treating adults with advanced renal cell carcinoma after failure of treatment with a first-line tyrosine kinase inhibitor or a cytokine, only if the company provides axitinib with the discount agreed in the patient access scheme.	PBR RL
azacitidine	injection 100mg	8.01.3	R	In line with NICE TA guidance 218, March 2011: Azacitidine is recommended as a treatment option for adults who are not eligible for haematopoietic stem cell transplantation and have intermediate-2 and high-risk myelodysplastic syndromes according to the International Prognostic Scoring System (IPSS) **or** chronic myelomonocytic leukaemia with 10–29% marrow blasts without myeloproliferative disorder **or** acute myeloid leukaemia with 20–30% blasts and multilineage dysplasia, according to the World Health Organization classification **and** if the manufacturer provides azacitidine with the discount agreed as part of the patient access scheme.	PBR

azacitidine	tablets 200mg, 300mg	8.01.3	R	In line with NICE TA guidance no. 827, October 2022: Oral azacitidine is recommended, within its marketing authorisation, as an option for maintenance treatment for acute myeloid leukaemia (AML) in adults who are in complete remission, or complete remission with incomplete blood count recovery, after induction therapy with or without consolidation treatment, and cannot have or do not want a haematopoietic stem cell transplant. It is recommended only if the company provides oral azacitidine according to the commercial arrangement.	PBR RL
azathioprine	Tablets 25mg, 50mg; Injection 50mg (as sodium salt); oral liquid 30mg in 5ml (unlicensed)	8.02.1	A	For maintainance of remission of immune mediated neurological disorders. (NDP March 2019)	PBR (renal only)
azelaic acid	cream 20%	13.06.1	A		
azelastine	eye drops 0.05%, 8ml	11.04.2	R	For the treatment and prevention of the symptoms of seasonal allergic conjunctivitis in adults and children 4 years and older. For treatment of symptoms of non-seasonal (perennial) allergic conjunctivitis in adults and children 12 years and older. To be used in addition to other eye drops when satisfactory response has not been achieved and in extreme cases to prevent the use of steriod eye drops which have greater risk of side effects especially in children. Olopatidine to be used first line. (NDP July 2009)	
azelastine	nasal spray 140mcg/metered spray	12.02.1	R	For the treatment of both seasonal allergic rhinitis (e.g. hayfever) and perennial allergic rhinitis in children. Mainly to be used where there is nasal itch with no eye symptons and so a systemic anti-histamine is not required. (NDP July 2009)	
azithromycin	capsules 250mg; tablets 250mg, 500mg; oral suspension 200mg in 5ml powder for solution for infusion, 500mg	5.01.5	R	Level 2 anti-infectives restricted to specific indications: As per Jefferiss Wing GUM handbooK As per Paediatric policy Chlamydia Long term prophylaxis in non-cystic fibrosis bronchiectasis (NDP December 2014)	
azithromycin	eye drops (preservative free), 1.5%	11.03.1	R	Level 2 anti-infectives restricted to specific indications: For chlamydial conjuctivits For bacterial conjuctivitis treatment in children (NDP March 2022)	
aztreonam	Injection 500mg, 1g, 2g	5.01.2	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required	
aztreonam/avibactam Emblaveo®	vials, solution for infusion, 1.5g/0.5g	5.01.2	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required (NDP November 2024)	

Bacillus Calmette-Guerin (BCG)	bladder installation 81mg (ImmuCyst) bladder installation 12.5mg (OncoTICE) various brands (unlicensed, during available during shortage of OncoTICE)	8.02.4	Very R	1. for treatment of primary or recurrant bladder carcinoma 2. for prevention of recurrance of bladder carcinoma following trans-urethral resection	
baclofen	tablets 10mg; oral solution 5mg in 5ml	10.02.2	A		
Balance Activ Rx ®	gel 5ml applicator tubes	7.02.2	R	For the treatment and prevention of recurrent bacterial vaginosis (RBV); be used according to the Jefferiss Wing protocol for the treatment of RBV. This is a medical device. Relactagel ® and Balance Activ Rx ® added to the formulary. The less expensive of the two will be used at any one time. The initial supply will be made in the clinic and further supplies in community. NDP September 2010	
Balneum ®	Balneum Plus Bath Additive ® 500ml	13.02.1	R	Dermatology use only.	
baloxavir	tablets 40mg, 80mg	9.05.2	R	In line with NHS England/UKHSA recommendation for 2-3 line therapy of influenza A(H3N2). NDP November 2025	
balsalazide	capsules 750mg	1.05.1	A		
baricitinib	tablets 2mg, 4mg	10.01.3	R	In line with NICE TA guidance no. 466, August 2017: Baricitinib, with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs) as stipulated by NICE.	PBR RL
baricitinib	tablets 2mg, 4mg	10.01.3	R	In line with NICE TA guidance no. 681, March 2021: Baricitinib is recommended as an option for treating moderate to severe atopic dermatitis in adults, only if: the disease has not responded to at least 1 systemic immunosuppressant, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are not suitable, and the company provides it according to the commercial arrangement.	PBR RL
Baritop	suspension	18	A		
barium sulphate	high density diagnostic (EZ) enema; diagnostic suspension EZ Paque, 96% w/w powder for oral suspension (NDP September 2018)	18	A		
basiliximab	injection 20mg	8.02.2	R	1. In line with NICE TA guidance no. 85, Sept-04: Basiliximab is recommended as adjunct to initial immunosuppression for renal transplant in patients at high immunological risk.	PBR
BCG intradermal	Bacillus Calmette-Guerin Vaccine (Live) Intradermal injection	14.04	A		
BCG vaccine	Injection (percutaneous formulation), for bladder instillation	8.02.4	A		

beclometasone	CFC-free aerosol inhalation 50mcg/metered inhalation, 100mcg/metered inhalation, 200mcg/metered inhalation, 250mcg/metered inhalation (Clenil Modulite ®); CFC-free aerosol inhalation 50mcg/metered inhalation, 100mcg/metered inhalation (Qvar ®); CFC-Free Autohaler 50mcg/metered inhalation, 100mcg/metered inhalation (Qvar ®) CFC-Free Easi-Breathe 50mcg/metered inhalation, 100mcg/metered inhalation (Qvar ®) Easyhaler 200mcg/ dose inhalation powder;	3.02	A	Clenil Modulite CFC-free inhalers will be used first-line. Qvar will be supplied for patients already using it. Clenil and Qvar brands of CFC-free inhalers are not interchangeable due to differences in potency. MHRA recommends that CFC-free inhalers are prescribed by brand.	
beclometasone dipropionate (beclomethasone dipropionate)	Aqueous nasal spray (aqueous suspension), 50 micrograms per metered spray (Beconase ®).	12.02.1	A		
beclometasone	MR tablets 5mg	1.05.1	A	Approved for the licensed indication (NDP July 2020)	
bedaquiline	tablets 100mg, 20mg	5.01.0	R	for treatment of multi-drug resistent tuberculosis as per NHS England commissioning statement (last updated July 2019))	
Bee venom extract or wasp venom extract (Alutard ®)	vaccine	3.04.2	R	In line with NICE TA guidance no. 246, Feb-12: pharmalgen is recommended as an option for the treatment of IgE-mediated bee and wasp venom allergy in people who have had a severe systemic reaction to bee or wasp venom, or a moderate systemic reaction to bee or wasp venom and who have one or more of the following: a raised baseline serum tryptase, a high risk of future stings or anxiety about future stings.	
Bee venom extract or wasp venom extract (Venomil ®)	vaccine	3.04.2	R	For prescribing by paediatric allergy teams in line with the hyposensitisation protocol. (NDP Mach 2023)	

belimumab	powder for reconstitution for intravenous infusion, 120mg and 400mg vials solution for injection in pre-filled pen, 200mg in 1ml	10.01.3	R	In line with NICE TA guidance no. 752, December 2022 (replaces NICE TA guidance no. 397, June 2016): Belimumab is recommended as an option as add-on treatment for active autoantibody-positive systemic lupus erythematosus in people with high disease activity despite standard treatment, only if high disease activity is defined as at least 1 serological biomarker (positive antidouble-stranded DNA or low complement) and a SELENA-SLEDAI score of greater than or equal to 10, treatment is continued beyond 24 weeks only if the SELENA-SLEDAI score has improved by 4 points or more the company provides belimumab according to the commercial arrangement. (pre-filled syringes for SC administration, NDP May 2021)	PBR
belzutifan	tablets 40mg	8.01.5	R	In line with NICE TA guidance no. 1011, October 2024: Belzutifan is recommended with managed access as an option for treating von Hippel-Lindau (VHL) disease in adults: who need treatment for VHL-associated renal cell carcinomas, central nervous system hemangioblastomas or pancreatic neuroendocrine tumours, and when localised procedures are unsuitable or undesirable. It is only recommended if the conditions in the managed access agreement for belzutifan are followed.	PBR RL
belumosudil	tablets, 200mg	2.08.1	R	In line with NICE TA guidance no.949, February 2024: Belumosudil is recommended, within its marketing authorisation, for treating chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments. It is recommended only if the company provides it according to the commercial arrangement.	PBR RL
bempedoic acid	tablets 180mg tablets bempedoic acid 180mg/ezetimibe 10mg	2.12	R	In line with NICE guidance TA no 694, April 2021: **Bempedoic acid with ezetimibe** is recommended as an option for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults. It is recommended only if: • statins are contraindicated or not tolerated, • ezetimibe alone does not control low-density lipoprotein cholesterol well enough, and • the company provides bempedoic acid and bempedoic acid with ezetimibe according to the commercial arrangement. Bempedoic acid with ezetimibe can be used as separate tablets or a fixed-dose combination.	
bendamustine	injection (powder for reconstitution) 25mg, 100mg	8.01.1	R	In line with the relevant NHS England clinical policies	PBR

bendamustine	injection (powder for reconstitution) 25mg, 100mg	8.01.1	R	In line with NICE TA guidance no. 216, Feb-11: bendamustine is recommended as an option for the first-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate.	PBR
bendroflumethiazide	tablets 2.5mg, 5mg	2.02.1	A		
benralizumab	pre-filled pen, 30mg in 1ml	3.04.2	R	In line with NICE TA guidance no. 565, September 2019: Benralizumab, as an add-on therapy, is recommended as an option for treating severe eosinophilic asthma that is inadequately controlled in adults despite maintenance therapy with high-dose inhaled corticosteroids and long-acting beta-agonists, as outlined in the TA guidance.	PBR
benralizumab	pre-filled pen, 30mg in 1ml	3.04.2	R	In line with NICE TA guidance no. 1096, September 2025: Benralizumab as an add-on to standard care can be used, within its marketing authorisation, as an option to treat relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA) in adults. It can only be used if the company provides it according to the commercial arrangement.	PBR
benzathine benzylpenicillin	injection 2.4 megaU (unlicensed)	5.01.1	A	Level 1 non-reserved anti-infective	
benzatropine	tablets 2mg; injection 2mg in 2ml	4.09.2	A		
benzocaine	oral gel 20%	15.02	A		
benzoic acid	Benzoic Acid Ointment, Compound, BP (Whitfield's) Ointment, containing benzoic acid 6% and salicylic acid 3% in emulsifying ointment(500g).	13.10.2	A		
benzoin	tincture, compound	3.08	A		
benzoyl peroxide	gel 5%, 60g skin gel 10%, 40g	13.06.1	A	benzoyl peroxyde wash is non-formulary	
benzydamine hydrochloride	oral rinse, 0.15%. Spray, 0.15%.	12.03.1	A		
benzyl benzoate	application 25%.	13.10.4	A		
benzylpenicillin (penicillin G)	injection 600mg, 1.2g	5.01.1	A	Level 1 non-reserved anti-infective	
Bepanthen	ointment	13.02.2	A		
betahistine	tablets 8mg	4.06	A		

betamethasone	tablets 500micrograms; soluble tablets 500micrograms (as sodium phosphate); injection 4mg in 1ml (as sodium phosphate).	6.03.2	A		
betamethasone	drops (for ear, eye or nose) 0.1%; eye ointment 0.1%;	11.04.1	A		
betamethasone and neomycin	drops (for ear, eye or nose) 0.1% with neomycin sulphate 0.5% eye ointment, 0.1% with neomycin sulphate 0.5%	11.04.1	A		
betamethasone and neomycin sulphate	cream, ointment 0.1%/0.5%	13.04	A		
betamethasone dipropionate	cream 0.05% (Diprosone ®); ointment 0.05% (Diprosone ®)	13.04	A		
betamethasone sodium phosphate	drops (for ear, eye or nose), 0.1%.	12.01.1	A		
betamethasone sodium phosphate	drops (for eye, ear or nose), 0.1%	12.02.1	A		
betamethasone sodium phosphate with neomycin sulphate	drops (for ear, eye or nose), betamethasone sodium phosphate 0.1% and neomycin sulphate 0.5%	12.01.1	A		
betamethasone valerate	cream 0.1%; ointment 0.1%; lotion 0.1%; foam scalp application 0.12% (Bettamousse ®) cream 0.025% - 1 in 4 dilution of Betnovate ® cream (Betnovate RD ®); ointment 0.025% - 1 in 4 dilution of betnovate ® ointment (Betnovate RD ®)	13.04	A		
betaxolol	eye drops 0.5%	11.06	A		
bethanechol	tablets 10mg, 25mg.	7.04.1	A		
Betnesol-N ®	drops (for eye, ear, or nose), betamethasone sdiumphosphate 0.1%/, neomycinsulphate 0.5%.	12.02.3	A		
Betnovate 1 in 4 in white soft paraffin with 10% coal tar	cream (unlicensed) ointment (unlicensed)	13.04	R	For dermatology use only	
Betnovate 1 in 4 in white soft paraffin with 5% coal tar	solution (unlicensed)	13.04	R	For dermatology use only	

Betnovate-C ®	cream containing betamethasone valerate 0.1% and clioquinol 3%; ointment containing betamethasone valerate 0.1% with clioquinol 3%	13.04	A		
bevacizumab	vials, 25mg in 1ml concentrate for solution for infusion - 100mg in 4ml, 400mg in 16ml	8.01.5	R	1. 1st line treatment of advanced *(stage IIIc/IV*) epithelial ovarian, fallopian or primary peritoneal cancer in chombination with chemotherapu, when all the **Cancer Drug Fund** specified criteria have been met. (July 2016)	PBR
bevacizumab	vials, 25mg in 1ml concentrate for solution for infusion - 100mg in 4ml, 400mg in 16ml	8.01.5	R	2. 1st line treatment of recurrent or metastatic cervical cancer in combination with chemotherapy as specified by the **Cancer Drug Fund**. (July 2016)	PBR
bevacizumab	2.5mg pre-filled syringe (unlicensed)	8.01.5	R	3. 1. Macular oedema in diabetic eye disease, unresponsive to laser treatment 2. Macular oedema associated with central and branch retinal vein occlusion. 3. Myopic subretinal neovascular membrane 4. Wet age-related macular degeneration in private patients who decline costs for Lucentis and where clinician feels tretment is indicated (NDP January 2009)	PBR
bevacizumab	vials, 25mg in 1ml (100mg in 4ml for intralesional administration)	8.01.5	R	4. For treatment of severe recurrent respiratory papillomatosis (RRP) of the larynx and tracheobronchial tree, in line with the local guideline. (NDP March 2024)	
bevacizumab	vials, 25mg in 1ml	8.01.5	R	5. For severe epistaxis in hereditary haemorrhagic teleangiectasia. (NDP July 2024)	
bevacizumab gamma	vials 25mg in 1ml	11.04.1	R	In line with NICE TA guidance no. 1022, December 2024: Bevacizumab gamma is recommended as an option for treating wet age-related macular degeneration in adults, only if the eye has a best-corrected visual acuity between 6/12 and 6/96 there is no permanent structural damage to the central fovea the lesion size is 12 disc areas or less in greatest linear dimension there are signs of recent disease progression (for example, blood vessel growth as shown by fluorescein angiography, or recent visual acuity changes) the company provides it according to the commercial arrangement.	PBR
bezafibrate	tablets 200mg; MR tablets 400mg	2.12	A		
bicalutamide	tablets 50mg, 150mg	8.03.4	R	1. as monotherapy for locally advanced prostate cancer 2. for the second-line treatment of advanced prostate cancer after failure of LHRH analogues	

bimatoprost	eye drops 100mcg in 1ml eye drops preservative-free single dose 300mcg in 1ml	11.06	A	For use In line with the national/local guidelines.	
bimatoporst/timolol	eye drops 300mcg/5mg in 1ml; eye drops, preservative-free 300mcg/5mg in 1ml;	11.06	A	For use In line with the national/local guidelines.	
bimekizumab	solution for injection 160mg pre-filled syringe, pre-filled pen	10.01.3	R	1. In line with NICE TA guidance no. 723, September 2021: Bimekizumab is recommended as an option for treating plaque psoriasis in adults as outlined in the TAG document.	PBR
bimekizumab	solution for injection 160mg pre-filled syringe, pre-filled pen	10.01.3	R	2. In line with NICE TA guidance no. 916, October 2023: Bimekizumab alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis (defined as peripheral arthritis with 3 or more tender joints and 3 or more swollen joints) in adults whose condition has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have had 2 conventional DMARDs and at least 1 biological DMARD or tumour necrosis factor (TNF)-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis). Bimekizumab is recommended only if the company provides it according to the commercial arrangement.	PBR
bimekizumab	solution for injection 160mg pre-filled syringe, pre-filled pen	10.01.3	R	3. In line with NICE TA guidance no.918, October 2023: Bimekizumab is recommended as an option in adults for treating active nkylosing spondylitis (AS) when conventional therapy has not worked well enough or is not tolerated, or active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation (shown by elevated C-reactive protein or MRI) when non-steroidal anti-inflammatory drugs (NSAIDs), have not worked well enough or are not tolerated. It is recommended only if tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough, and the company provides it according to the commercial arrangement.	PBR
biphasic isophane insulin, human prb; Humulin M3 ®	injection 100units/ml: 3ml cartridge, 3ml pre-filled Kwik Pen	6.01.1	A		
bisacodyl	e/c tablets 5mg; suppositories 10mg; paediatric suppositories 5mg.	1.06.2	A		

bismuth subnitrate and iodoform paste (BIPP)	Paste, 30g- sachet Sterile impregnated gauze, 1.25 x 200cm; 2.5 x 200cm (Bismuth Subnitrate & Iodoform ®)	12.02.3	A		
bismuth subsalicylate Pepto-Bismol®	oral suspension 17.5mg.ml	1.02	Very R	For use 2nd line only for H pylori eradication on gastro and ID/micro recommendation (NDP September 2017)	
bisoprolol	tablets 1.25mg, 2.5mg, 3.75mg, 5mg, 7.5mg, 10mg	2.04	A		
bivalirudin	Injection 250mg	2.08.1	R	1. NICE TA guidance no. 230, Jul-11: Bivalirudin in combination with aspirin and clopidogrel is recommended for the treatment of adults with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. 2. For patients with HITs according to the Trust haematology protocol (unlicensed indication), NDP April 2014.	
bleomycin	injection 15000units	8.01.2	A	In line with the nationa/local guidelines/protocols.	PBR
blinatumomab	powder for concentrate for solution for infusion, 38.5mg	8.01.5	R	In line with NICE TA guidence no. 450, June 2017: Blinatumomab is recommended within its marketing authorisation as an option for treating Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukaemia in adults, only if the company provides it with the discount agreed in the patient access scheme.	PBR
blinatumomab	powder for concentrate for solution for infusion, 38.5mg	8.01.5	R	In line with NICE TA guidence no. 589, July 2019: Blinatumomab is recommended as an option for treating Philadelphiachromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia in adults with minimal residual disease (MRD) of at least 0.1%, only if the disease is in first complete remission and the company provides blinatumomab according to the commercial arrangement.	PBR
blinatumomab	powder for concentrate for solution for infusion, 38.5mg	8.01.5	R	In line with NICE TA guidence no. 1049, March 2025: Blinatumomab with chemotherapy can be used as an option to treat Philadelphia chromosome-negative CD19-positive B-cell precursor acute lymphoblastic leukaemia (ALL) in adults, if the leukaemia is minimal residual disease-negative, it is used at the start of consolidation treatment and the company provides it according to the commercial arrangement.	PBR
bone cement with gentamicin	40g	medical device	A		
bone wax		medical device	A		
Bonjela ®	teething gel	12.03.1	A	contains lidocaine and cetalkonium; for babies after 2 months of age (May '09)	

bortezomib	injection 3.5mg (for intravenous or subcutaneous use)	8.01.5	R	1. In line with NICE TA guidance no. 129, Oct-07: Recommended as monotherapy for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are not suitable for BMT. PCTs to be asked to fund on a cost per case basis before treatment is commenced.	PBR
bortezomib	injection 3.5mg (for intravenous or subcutaneous use)	8.01.5	R	2. In line with NICE TA guidance no. 228, Jul-11: Bortezomib in combination with an alkylating agent and a corticosteroid is recommended as an option for the first-line treatment of multiple myeloma if high-dose chemotherapy with stem cell transplantation is considered inappropriate and the person is unable to tolerate or has contraindications to thalidomide.	PBR
bortezomib	injection 3.5mg (for intravenous or subcutaneous use)	8.01.5	R	3. In line with NICE TA guidance no. 311, April-2014: Bortezomib is recommended as an option within its marketing authorisation, that is, in combination with dexamethasone, or with dexamethasone and thalidomide, for the induction treatment of adults with previously untreated multiple myeloma, who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.	PBR
bortezomib	injection 3.5mg (for intravenous or subcutaneous use)	8.01.5	R	4. In line with NICE TA guidance no. 370, December 2016: Bortezomib is recommended, within its marketing authorisation, as an option for previously untreated mantle cell lymphoma in adults for whom haematopoietic stem cell transplantation is unsuitable.	PBR
bosentan	tablets 62.5mg, 125mg	2.05.1	R	For specialist management of pulmonary hypertension, use in line with the NHS England commissioning policy.	PBR RL
bosutinib	tablets 100mg, 500mg	8.01.5	R	In line with NICE TA guidance no. 401, august 2016: Bosutinib is recommended as an option, within its marketing authorisation, for chronic, accelerated and blast phase Philadelphia chromosome positive chronic myeloid leukaemia in adults, when they have previously had 1 or more tyrosine kinase inhibitor, and imatinib, nilotinib and dasatinib are not appropriate, and the company provides bosutinib with the discount agreed in the patient access scheme (as revised in 2016).	PBR RL
Botulinum Toxin Type A (Botox ®)	botulinum toxin type A complex injection 100units (Botox®)	4.09.3	R	1. Botox ® brand for use by surgical teams for the treatment of chronic anal fissures in vulnerable high risk group patients. (Unlicensed indication)	
Botulinum Toxin Type A (Botox ®)	botulinum toxin type A complex injection 100units (Botox®)	4.09.3	R	2. For oesophageal achalasia (restricted use to gastroenterology) For hyperhidrosis (restricted use to dermatology)	

Botulinum Toxin Type A (Botox ®)	botulinum toxin type A complex injection 100units (Botox®)	4.09.3	R	3. Approved as 3rd or 4th line treatment for overactive/neurogenic bladder symptoms not responding to anti-cholinergic drug treatment and bladder re-training or for patients who have contraindications to anti-cholinergic drugs. (Dec 2007)	
Botulinium Toxin Type A (Botox ®)	botulinum toxin type A complex injection 100units (Botox®)	4.09.3	R	4. In line with NICE TA guidance no. 260, Jun-12: Botulinum toxin Type A is recommended as an option for the prophylaxis of headaches in adults with chronic migraine.	
Botulinum Toxin Type A (Dysport ®)	botulinum type A toxin -haemagglutinin complex injection 500units (Dysport ®)	4.09.3	R	5. Dysport ® brand first line for neurology/pain indications (see no 7 for exceptions)	
Botulinum Toxin Type A (Xeomin ®)	botulinum toxin type A (free from complexing protein) injection 50 units, 100 units vials	4.09.3	R	6. Xeomin® brand is restricted for use by Opthalmology teams for blepharospasm and other opthalmology indications. (NDP September 2014)	
Botulinum Toxin Type A (Xeomin ®)	botulinum toxin type A (free from complexing protein) injection 50 units, 100 units vials	4.09.3	R	7. In line with NICE TA guidance no. 605, October 2019: Xeomin (botulinum neurotoxin type A) is recommended, within its marketing authorisation, as an option for treating chronic sialorrhoea caused by neurological conditions in adults. It is recommended only if the company provides it according to the commercial arrangement.	
brentuximab vedotin	vial 50mg	8.01.5	R	1. In line with NICE TA guidance no.524, June 2018 (replaces TAG 446): Brentuximab vedotin is recommended as an option for treating CD30-positive Hodgkin lymphoma in adults with relapsed or refractory disease, only if they have already had autologous stem cell transplant or they have already had at least 2 previous therapies when autologous stem cell transplant or multi-agent chemotherapy are not suitable and the company provides brentuximab vedotin according to the commercial arrangement.	PBR
brentuximab vedotin	vial 50mg	8.01.5	R	2. In line with NICE TA guidance no. 478, October 2017: Brentuximab vedotin is recommended as an option for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults, only if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and the company provides brentuximab vedotin according to the commercial access agreement with NHS England.	PBR
brentuximab vedotin	vial 50mg	8.01.5	R	3. In line with NICE TA guidance no. 577, April 2019: Brentuximab vedotin is recommended as an option for treating CD30-positive cutaneous T-cell lymphoma (CTCL) after at least 1systemic therapy in adults, only if they havemycosis fungoides stageIIB or over, primary cutaneous anaplastic large cell lymphoma or Sézary syndrome and the company provides brentuximab vedotin according to thecommercial arrangement.	PBR

brentuximab vedotin	vial 50mg	8.01.5	R	4. In line with NICE TA guidance no 641, August 2020: Brentuximab vedotin with cyclophosphamide, doxorubicin and prednisone (CHP) is recommended, within its marketing authorisation, as an option for untreated systemic anaplastic large cell lymphoma in adults. It is only recommended if the company provides brentuximab vedotin according to the commercial arrangement.	PBR
brentuximab vedotin	vial 50mg	8.01.5	R	5. In line with NICE TA guidance no 1059, May 2025 (replaced TAG 594): Brentuximab vedotin plus doxorubicin, dacarbazine and vinblastine is recommended, within its marketing authorisation, as an option for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma in adults. It can only be used if the company provides it according to the commercial arrangement.	PBR
Brevinor ®	21 tablets ethinylestradiol 35 micrograms + norethisterone 500 micrograms	7.03.1	A		
brigatinib	tablets 30mg, 90mg, 180mg	8.01.5	R	In line with NICE TA guidance no. 571, March 2019: Brigatinib is recommended, within its marketing authorisation, for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults who have already had crizotinib. It is recommended only if the company provides it according to the commercial arrangement.	PBR RL
brilliant green and crystal violet BP	paint	13.11.6	A		
brimonidine	eye drops, 2mg in 1ml	11.06	A	For use In line with the national/local guidelines.	
brimonidine/timolol	eye drops, 2mg/5mg in 1ml	11.06	A	For use In line with the national/local guidelines.	
brinzolamide	eye drops, 10mg in 1ml	11.06	A	For use In line with the national/local guidelines. NDP March 2016	
brinzolamide/brimonidine	eye drops, 10mgl/2mg in 1ml	11.06	A	For use In line with the national/local guidelines.	
brinzolamide/timolol	eye drops, 10mg/5mg in 1ml	11.06	A	For use In line with the national/local guidelines. NDP May 2010	
brivaracetam	tablets various strenghts solution 10mg/ml	4.08.1	R	Second line to levetiracetam, where levetiracetam causes unacceptable side effects. (NDP September 2019) (NWL JFC November 2025)	
brodalumab	pre-filled syringe 210mg	10.01.3	R	In lince with NICE TA guidance no 511, March 2018: Brodalumab is recommended as an option for treating plaque psoriasis in adults only if used according to NICE specified criteria.	PBR

brolucizumab	solution for injection, 120mg solution for injection in pre-filled syringe, 120mg	11.08.2	R	In line with NICE TA guidence no. 672, February 2021: Brolucizumab is recommended as an option for treating wet age-related macular degeneration in adults, only if, in the eye to be treated the best-corrected visual acuity is between 6/12 and 6/96,, there is no permanent structural damage to the central fovea, the lesion size is less than or equal to 12 disc areas in greatest linear dimension and there is recent presumed disease progression (for example, blood vessel growth, as shown by fluorescein angiography, or recent visual acuity changes).	PBR
brolucizumab	solution for injection, 120mg solution for injection in pre-filled syringe, 120mg	11.08.2	R	In line with NICE TA guidance no. 820, August 2022: Brolucizumab is recommended as an option for treating visual impairment due to diabetic macular oedema in adults, only if the eye has a central retinal thickness of 400 micrometres or more at the start of treatment the company provides brolucizumab according to the commercial arrangement.	PBR
bromocriptine	tablets, 1mg, 2.5mg (as mesylate). Capsules, 10mg (as mesylate). (see section 6.7)	4.09.1	A		
bromocriptine	tablets, 1mg, 2.5mg (as mesylate); capsules, 10mg (as mesylate).	6.07.1	A		
budesonide	Turbohaler 100mcg/inhalation, 200mcg/inhalation, 400mcg/inhalation; Respules 500mcg in 2ml (SMH - Respules 500mcg/2ml restricted to paediatric teams only), 1mg in 2ml	3.02	A		
budesonide	Nasal spray (aqueous), 64micrograms per metered spray	12.02.1	A		
budesonide	e/c modified-release capsules, 3mg	1.05.2	A		
budesonide	tablets (orodispersible) 0.5mg, 1mg	1.05.2	R	For use according to the product licence by gastroenterology teams only. (NDP July 2019) NICE TAG 707, June 2021.	
budesonide	rectal foam enema, 2mg per actuation	1.05.2	A	NDP September 2019 Most cost effective steroid enema to be prescribed first line.	
budesonide	suppositories 4mg	1.05.2	A	In line with product licence - 1st line - as the most cost-effective preparation (NDP/NWL JF January 2025).	

budesonide	modified-release capsules, 4mg	not classified	R	In line with NICE TA guidance no.937, December 2023: Targeted-release budesonide is recommended as an option for treating primary immunoglobulin A nephropathy (IgAN) when there is a risk of rapid disease progression in adults with a urine protein-to-creatinine ratio of 1.5 g/g or more. Targeted-release budesonide is recommended only if it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), unless these are contraindicated the company provides it according to the commercial arrangement.	PBR RL
bulevirtide	powder for solution for subcutaneous injection, 2mg	5.03.02	R	In line with NICE TA guidance no. 896, June 2023: Bulevirtide is recommended as an option for treating chronic hepatitis D in adults with compensated liver disease only if there is evidence of significant fibrosis (METAVIR stage F2 or above or Ishak stage 3 or above), andtheir hepatitis has not responded to peginterferon alfa-2a (PEG-IFN) or they cannot have interferon-based therapy. Bulevirtide is only recommended if the company provides it according to the commercial arrangement.	PBR
bumetanide	tablets 1mg, 5mg; injections 1mg in 2ml, 2mg in 4ml, 5mg in 10ml; Liquid 1mg in 5ml.	2.02.2	A		
bupivacaine	injection 0.25% 10ml, 0.5% 10ml, 0.75%10ml; injection 5mg/ml in glucose 80mg/ml, 4ml amp	15.02	A		
bupivacaine	0.1% in 0.9% sodium chloride (250ml bag), 0.25% in 0.9% sodium choride (500ml bag) (discontinued by manufacturer), 0.125% in 0.9% sodium chloride (250ml bag)	15.02	R	for epidural use	
bupivacaine with adrenaline	injection 0.25% + adrenaline 1 in 200000 10ml; injection 0.5% + adrenaline 1 in 200000 10ml	15.02	A		
bupivacaine with fentanyl	bupivacaine 0.125% and fentanyl 2micrograms in 1ml in 0.9% sodium chloride 250ml bags, 300ml bags (all unlicensed)	15.01.4	R	for epidural use	

bupivacaine with fentanyl	bupivacaine 0.125% and fentanyl 2micrograms in 1ml in 0.9% sodium chloride 250ml bags, 300ml bags (all unlicensed)	15.02	R	for epidural use	
bupivacaine with fentanyl	bupivacaine 0.125% and fentanyl 2micrograms in 1ml in 0.9% sodium chloride 250ml bags, 300ml bags (all unlicensed)	4.07.2	R	for epidural use	
buprenorphine	sublingual tablets 200mcg, 400mcg, 2mg; injection 300mcg in 1ml	4.07.2	A	In line with NICE TA guidance no. 114, Jan-07: oral buprenorphine is recommended as options for maintenance therapy in the management of opioid dependence.	
buprenorphine	patches '5' patch (releasing 5 micrograms/hour for 7 days), '10' patch (releasing 10 micrograms/hour for 7 days), '15' patch (releasing 15 micrograms/hour for 7 days), '20' patch (releasing 20 micrograms/hour for 7 days)	4.07.2	A		
bupropion	tablets 150mg	4.10.2	R		
buserelin	Injection 5.5mg in 5.5ml; Nasal spray 100 micrograms/metered spray.	8.03.4	A		
buserelin	nasal spray 150mcg/metered spray, (Suprecur ®); injection 5.5mg in 5.5ml	6.07.2	A		
buspirone	tablets 5mg	4.01.2	A		
busulfan	tablets 500mcg, 2mg; tablets 25mg (unlicensed); liquid 4mg in 1ml (unlicensed); injection 60mg in 10ml	8.01.1	A	In line with national/local guidelines/protocols.	PBR RL
C1-esterase inhibitor	injection 500 units	3.04.3	R	Restricted to Chest & Allergy team only. Not for long-term prophylaxis.	PBR RL

cabazitaxel	concentrate for intravenous infusion 40mg in 1ml (1.5ml vial)	8.01.5	R	In line with NICE TA guidance no. 391, May 2016: Cabazitaxel in combination with prednisone or prednisolone is recommended as an option for treating metastatic hormone-relapsed prostate cancer in people whose disease has progressed during or after docetaxel chemotherapy, only if the person has an eastern cooperative oncology group (ECOG) performance status of 0 or 1, the person has had 225 mg/m2 or more of docetaxel and treatment with cabazitaxel is stopped when the disease progresses or after a maximum of 10 cycles (whichever happens first). In addition, cabazitaxel is recommended only if the company provides cabazitaxel with the discount in the patient access scheme agreed with the Department of Health, and NHS trusts purchase cabazitaxel in accordance with the commercial access agreement between the company and NHS England, either in pre-prepared intravenous infusion bags, or in vials, at a reduced price that includes a further discount reflecting the average cost of waste per patient.	PBR
cabergoline	tablets 500mcg, 1mg, 2mg, 4mg	6.07.1	R	Restricted to Obs & Gynae, Neurology and Endocrinology teams.	
cabotegravir	tablets 30mg prolonged-release suspension for injection, 600mg	5.03.1	R	In line with NICE TA guidance no. 757, December 2022: Cabotegravir with rilpivirine is recommended, within its marketing authorisation, as an option for treating HIV-1 infection in adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors. It is recommended only if the company provides it according to the commercial arrangement.	PBR RL
cabotegravir	tablets 30mg prolonged-release suspension for injection, 600mg	5.03.1	R	In line with NICE TA guidance no. 1106, November 2025: Cabotegravir is recommended as an option for pre-exposure prophylaxis (PrEP) alongside safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults and young people at high risk of getting HIV and who weigh at least 35 kg, only if they cannot have oral PrEP cabotegravir is purchased at the Medicines and Procurement Supply Chain framework price.	PBR RL
cabozantinib (Cometriq®)	capsules 20mg, 80mg	8.01.5	R	1. In line with NICE TA guideline no 516, March 2018: Cabozantinib is recommended, within its marketing authorisation, as an option for treating progressive medullary thyroid cancer in adults with unresectable, locally advanced or metastatic disease, only if the company provides cabozantinib with the discount agreed in the patient access scheme.	PBR RL

cabozantinib (Cabometyx®)	capsules 20mg, 40mg, 60mg	8.01.5	R	2. In line with NICE TA guidance no. 463, August 2017: Cabozantinib is recommended, within its marketing authorisation, as an option for treating advanced renal cell carcinoma in adults after vascular endothelial growth factor (VEGF)-targeted therapy, only if the company provides cabozantinib with the discount agreed in the patient access scheme.	PBR RL
cabozantinib (Cabometyx®)	capsules 20mg, 40mg, 60mg	8.01.5	R	3. In line with NICE TA guidance no. 542, October 2018: Cabozantinib is recommended, within its marketing authorisation, for adults with untreated advanced renal cell carcinoma that is intermediate- or poor-risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria. It is recommended only if the company provides cabozantinib according to the commercial arrangement.	PBR RL
cabozantinib (Cabometyx®)	capsules 20mg, 40mg, 60mg	8.01.5	R	4. In line with NICE TA guidance no. 849, Decemeber 2022: Cabozantinib is recommended as an option for treating advanced hepatocellular carcinoma (HCC) in adults who have had sorafenib, only if they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and the company provides it according to the commercial arrangement.	PBR RL
cabozantinib (Cabometyx®)	capsules 20mg, 40mg, 60mg	8.01.5	R	5. In line with NICE TA guidance no. 964, April 2024: Cabozantinib with nivolumab is recommended as an option for untreated advanced renal cell carcinoma in adults, only if their disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria, and nivolumab with ipilimumab or lenvatinib with pembrolizumab would otherwise be offered, and the companies provide cabozantinib and nivolumab according to their commercial arrangements.	PBR RL
caffeine base	oral solution 10mg in 1ml (unlicensed); injection 10mg in 1ml (unlicensed)	3.01.3	R	Restricted to neonates and Neurology teams only.	
Calamine	lotion	13.03	A	no longer pharmacy; ordered from supplies	
Calcichew D3 ®	Tablets (chewable), calcium carbonate 1.25g (calcium 500mg), colecalciferol 5 micorgrams (200 units).	9.06.4	A	the product with the lowest acquisition cost will be used first line	
Calcichew D3 Forte ®	Tablets (chewable), calcium carbonate 1.25g (calcium 500mg), colecalciferol 10 micorgrams (400 units).	9.06.4	A	the product with the lowest acquisition cost will be used first line	
calciferol	oral liquid 3000units in 1ml	9.06.4	A		

calcipotriol	cream 50 micrograms per gram; ointment 50 micrograms per gram; scalp solution 50 micrograms per ml	13.05.2	R	Dermatologists only.	
calcitonin (salmon) /salcatonin	injection 100units in 1ml, 400units in 2ml	6.06.1	R	Used in patients with Raynauds or scleroderma. Restricted for use by Vascular and Rheumatology teams only.	
calcitriol (1,25-dihydroxycolecalciferol)	Capsules, 250 nanograms, 500 nanograms; oral liquid 1microgram in 1ml	9.06.4	A	Note: Alfacalcidol should be used in patients with renal impairment. Calcitriol should be used in patients with liver impairment.	
calcitriol (1,25-dihydroxycolecalciferol)	ointment 3micrograms/g	13.05.2	A		
calcium acetate	tablets 475mg, 950mg	9.05.2	A		
calcium and ergocalciferol	Tablets, contain 2.4mmol calcium and 10 micrograms (400 units) ergocalciferol.	9.06.4	A		
calcium carbonate	Tablets, chewable, calcium carbonate 1.25g, providing 500mg or 12.6mmol calcium per tablet (Calcichew ®); Tablets, chewable, calcium carbonate 2.5g, providing 1g or 25mmol calcium per tablet (Calcichew Forte®).	9.05.1	A		
calcium chloride	injection 5mmol in 10ml (unlicensed); injection 10mmol in 10ml (unlicensed); injection 13.4% (9.1mmol calcium in 10ml); Min-I-Jet injection 10% (6.8mmol Calcium in 10ml).	9.05.1	A		
calcium folinate	tablets 15mg; injection 100mg, 300mg	8.01	A		
calcium gluconate	tablets 600mg (1.35mmol Calcium); injection 10% 10ml (2.25mmol Calcium in 10ml).	9.05.1	A		
calcium gluconate	gel 2.5%	17	A		
calcium polystyrene sulphonate	powder (Calcium Resonium ®); enema 30g in 100ml (unlicensed)	9.02.1	A		
Calcium Syrup Alliance	250ml, 102mg calcium in 5ml (0.51mmol in 1ml)	9.05.1	A	NDP May 2015	

Calvive 1000	effervescent tablets each tablet of contains 2263 mg of calcium lactate gluconate and 1750 mg of calcium carbonate (equivalent to 1000 mg or 25 mmol of calcium).	9.06.4	A	Replacement for Sandolcal 1000 (NDP July 2020)	
canagliflozin	tablets 100mg, 300mg	6.01.2	A	In line with NICE TA guidance no. 315, June-2014: Recommended in a combination with other antidiabetic drugs and/or insulin. In line with NICE TA guidance no 390, May-2016: **Canagliflozin**, dapagliflozin and empagliflozin as monotherapies are recommended as options for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if a dipeptidyl peptidase-4 (DPP-4) inhibitor would otherwise be prescribed and a sulfonylurea or pioglitazone is not appropriate.	
candesartan	tablets 2mg, 4mg, 8mg, 16mg, 32mg	2.05.5	A		
Canestan HC ®	cream containing hydrocortisone 1% and clotrimazole 1%	13.04	A		
cangrelor	vials, powder for concentrate for solution for injection 50mg	2.09	R	For prevention of thromboembolic complications during intra/extra-cranial stenting, in line with the local interventional neuroradiology protocol. NDP May 2022	
cannabidiol	solution 100mg/ml	4.08.1	R	In line with NICE TA guidance no. 614, December 2019: Cannabidiol with clobazam is recommended as an option for treating seizures associated with Dravet syndrome in people aged 2 years and older, only if the frequency of convulsive seizures is checked every 6 months, and cannabidiol is stopped if the frequency has not fallen by at least 30% compared with the 6 months before starting treatment, and the company provides cannabidiol according to the commercial arrangement.	PBR RL
cannabidiol	solution 100mg/ml	4.08.1	R	In line with NICE TA guidance no. 615, December 2019: Cannabidiol with clobazam is recommended as an option for treating seizures associated with Dravet syndrome in people aged 2 years and older, only if the frequency of convulsive seizures is checked every 6 months, and cannabidiol is stopped if the frequency has not fallen by at least 30% compared with the 6 months before starting treatment, and the company provides cannabidiol according to the commercial agreement.	PBR RL

cannabidiol	solution 100mg/ml	4.08.1	R	In line with NICE TA guidance no. 873, March 2023: Cannabidiol is recommended as an add-on treatment option for seizures caused by tuberous sclerosis complex in people aged 2 years and over, only if their seizures are not controlled well enough by 2 or more antiseizure medications (either used alone or in combination) or these treatments were not tolerated, and seizure frequency is checked every 6 months, and cannabidiol is stopped if the frequency has not fallen by at least 30% compared with the 6 months before starting treatment, and the company provides cannabidiol according to the commercial arrangement.	PBR RL
Capasal ®	Shampoo, 250ml	13.09	A		
capecitabine	tablets 150mg, 500mg	8.01.3	R	1. In line with NICE TA no. 61, May-03: Recommended for oral therapy with either capecitabine or tegafur with uracil for the first-line treatment of metastatic colorectal cancer.	PBR RL
capecitabine	tablets 150mg, 500mg	8.01.3	R	2. As an alternative to vinorelbine as 3rd line treatment (after failed CMF and epirubicin) for locally advanced and/or metastatic breast cancer.	PBR RL
capecitabine	tablets 150mg, 500mg	8.01.3	R	3. In line with NICE TA guidnce no. 62, May-03: for the treatment of locally advanced or metastatic breast cancer, capecitabine in combination with docetaxel is recommended in preference to single-agent docetaxel in people for whom anthracycline-containing regimens are unsuitable or have failed. Capecitabine monotherapy is recommended as an option for people with locally advanced or metastatic breast cancer who have not previously received capecitabine in combination therapy and for whom anthracycline and taxane-containing regimens have failed or further anthracycline therapy is contraindicated.	PBR RL
capecitabine	tablets 150mg, 500mg	8.01.3	R	4. As palliative and neo-adjuvant therapy for locally advanced gastro-oesophageal cancer; in combination with chemoradiation (for radio-sensitising); for cervical cancer; all an an alternative to infusional 5-fluorouracil where the use of oral capecitabine avoids the necessity of inserting a Hickman line or when a Hickman line cannot be inserted.	PBR RL
capecitabine	tablets 150mg, 500mg	8.01.3	R	5. as an alternative to infusional 5-fluorouracil in patients with rectal cancer receiving concurrent radiation where the use of oral capecitabine avoids the necessity of inserting a Hickman line or when a Hickman line cannot be inserted. If a patient already has a Hickman line then 5FU will be used.	PBR RL

capecitabine	tablets 150mg, 500mg	8.01.3	R	6. In line with NICE TA guidance no. 100; Apr-06 capecitabine monotherapy as an option for the adjuvant treatment of patients with stage III (Dukes' C) colon cancer following surgery for the condition. Dukes' B patients should not be offered treatment and patients not suitable for IV chemotherapy should not be offered capecitabine.	PBR RL
capecitabine	tablets 150mg, 500mg	8.01.3	R	7. For use in combination with oxaliplatin for the treatment of adjuvant stage III and metastatic colorectal cancer. (May 2009)	PBR RL
capecitabine	tablets 150mg, 500mg	8.01.3	R	8. For use in combination with irinotecan for the second line treatment of metastatic colorectal cancer. (May 2009)	PBR RL
capecitabine	tablets 150mg, 500mg	8.01.3	R	9. For use in combination with mitomycin-C for third line treatment of metastatic colorectal cancer. (May 2009)	PBR RL
capecitabine	tablets 150mg, 500mg	8.01.3	R	10. In the adjuvant setting following the resection of colorectal cancer for high risk Dukes B patients. (May 2009)	PBR RL
capecitabine	tablets 150mg, 500mg	8.01.3	R	11. In line with NICE TA guidance no. 191, Jul 2010: Capecitabine in combination with a platinum-based regimen is recommended for the first-line treatment of inoperable advanced gastric cancer.	PBR RL
capivasertib	tablets 160mg, 200mg	8.01.5	R	In line with NICE TA guidance no. 1063, May 2025: Capivasertib plus fulvestrant is recommended as an option for treating hormone receptor-positive HER2-negative (defined as immunohistochemistry [IHC]0 or IHC1 positive, or IHC2 positive and in situ hybridisation [ISH]1 negative) locally advanced or metastatic breast cancer in adults that has 1 or more PIK3CA, AKT1 or PTEN gene alterations recurred or progressed after a cyclin-dependent kinase (CDK) 4 and 6 inhibitor plus an aromatase inhibitor. Capivasertib plus fulvestrant is only recommended if the company provides it according to the commercial arrangement.	PBR RL
caplacizumab	solution for injection, 10mg	2.11	R	In line with NICE TA guidance no 667, December 2020: Caplacizumab with plasma exchange and immunosuppression is recommended, within its marketing authorisation, as an option for treating an acute episode of acquired thrombotic thrombocytopenic purpura (TTP) in adults, and in young people aged 12 years and over who weigh at least 40 kg. Treatment should be started and supervised by physicians experienced in managing thrombotic microangiopathies. It is recommended only if the company provides caplacizumab according to the commercial arrangement.	PBR
capreomycin	injection 1g	5.01.9	R	Level 2 anti-infective restricted to specific indications: MDR-TB	

capsaicin (Qutenza®)	patch 8%	10.03.2	R	For treatment of treatment resistant neuropathic pain in pain clinic. (NDP April 2014)	RL
capsaicin	cream 0.025%, 0.075%	10.03.2	A		
capsaicin	cream 0.075%	10.03.2	R	For management of suspected cannabinoid hyperemesis syndrome in ED, in line with the local guideline. (NDP July 2023)	
captopril	tablets 12.5mg, 25mg, 50mg; oral liquid 5mg in 5ml	2.05.5	A		
carbamazepine	tablets 100mg, 200mg, 400mg; MR tablets 200mg, 400mg; liquid 100mg in 5ml; suppositories 125mg, 250mg	4.08.1	A		
Carbex gassing agent	solution and granules	18	A		
carbimazole	tablets 5mg, 20mg	6.02.2	A		
carbocisteine	capsules 375mg; 750mg/10ml sugar-free oral solution in sachet	3.07	A	2nd line mucolytic agent (please see acetylcysteine effervescent tablets) - NDP January 2025	
carbomers 980 (polyacrylic acid)	Liquid gel (=eye drops), carbomer 980 (polyacrylic acid), 0.2% (Viscotears ®).	11.08.1	A		
carbomers 980 (polyacrylic acid)	eye drops 0.2% (GelTears ®)	11.08.1	A		
carboplatin	injection 50mg, 150mg, 450mg	8.01.5	A		PBR
carboprost	injection 250mcg in 1ml	7.01.1	A	Approved in conjuction with RCOG and local guidance.	
cardioplegia	injection 20ml; high strength infusion (Harefield)	21	A		
carflizomib	powder for solution for infusion 10mg,30mg,60mg	8.01.1	R	In line with NICE TA guidance no. 657, November 2020: Carfilzomib with dexamethasone is recommended as an option for treating multiple myeloma in adults, only if: • they have had only 1 previous therapy and, • the company provides carfilzomib according to the commercial arrangement.	PBR
carmellose	eye drops 0.5%; 0.5% preservative free; 1% preservative free	11.08.1	A		
carmustine	injection 100mg; implants 7.7mg	8.01.1	R	In line with NICE TA guidance no. 12, Jul-07: Carmustine implants are recommended as an option for the treatment of newly diagnosed high-grade glioma only for patients in whom 90% or more of the tumour has been resected.	PBR

carteolol	eye drops 1%	11.06	A		
carvedilol	tablets 3.125mg, 6.25mg, 12.5mg, 25mg	2.04	A		
caspofungin	infusion 50mg, 70mg	5.02.4	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required except Haematology/Renal if within their policy	PBR
Catephen®	ointment 10%;	13.07	R	For use by GUM and HIV teams only. (second line to Aldara® during supply shortage)	
cefaclor	Suspension 125mg in 5ml, 250mg in 5ml.	5.01.2	A	Level 1 non-reserved anti-infective	
cefalexin (cephalexin)	tablets 250mg, 500mg; oral liquid/suspension 125mg in 5ml, 250mg in 5ml	5.01.2	A	Level 1 non-reserved anti-infective	
cefazolin	powder for concentrate for solution for infusion 1g, 2g	5.01.2	R	PD peritonitis refractory to or unsuitable for conventional PD protocol. To be prescribed following advice from ID consultant, microbiologist or renal PD consultant.	
cefazolin	powder for concentrate for solution for infusion 1g, 2g	5.01.2	R	Level 2 anti-infectives to specific indications: Bacteraemia caused by susceptable Staph aureus and where the use of flucloxacillin is nor feasable or complicated, specifically in patients on intermittent haemodialysis. (NDP December 2016)	
cefepime	powder for concentrate for solution for infusion 1g, 2g	5.01.2	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required (NDP March 2023)	
cefiderocol	powder for concentrate for solution for infusion 1g	5.01.2	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required (NDP September 2021)	
cefixime	tablets 200mg paediatric suspension 100mg/mL	5.01.2	R	Level 2 anti-infectives restricted to specific indications: As per Jefferiss Wing GUM handbook Paediatric anti-infective guidelines	
cefotaxime	powder for concentrate for solution for infusion 500mg, 1g, 2g	5.01.2	R	Level 2 anti-infectives restricted to specific indications: As per Paediatric policy Obstetrics: suspected maternal fever in labour Percutaneous endoscopic gastrostomy (PEG insertion) prophylaxis	
ceftazidime	Eye drops 5% Eye drops, 5%, preservative free (Unlicensed product.)	11.08	R	For corneal service. Not routinely used. Can be obtained at the request of a specialist consultant	
ceftazidime	injection 250mg, 500mg, 1g, 2g	5.01.2	R	Level 2 anti-infectives restricted to specific indications: As per Oncology/ Haematology anti-infective policy Outpatient antibiotic therapy (OPAT) Septic shock (suspected) if penicillin allergic following administration of blood transfusion or platelets.	

ceftazidime/ avibactam	powder for concentrate for solution for infusion 2g/0.5g	5.01.2	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required (NDP November 2018)	
ceftobiprole	powder for reconstitution for intravenous infusion, 500mg vial	5.01.2	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required (NDP December 2016)	
ceftolozane/tazobactam	powder for concentrate for solution for infusion, 1g/0.5g	5.01.2	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required (NDP September 2017)	
ceftriaxone	injection 250mg, 1g, 2g	5.01.2	R	Level 2 anti-infectives restricted to specific indications: As per Adult anti-infective policy As per Paediatric policy Outpatient antibiotic therapy (OPAT) Gonorrhoea in pregnancy. Meningococcal prophylaxis in pregnancy. Neonatal opthalmitis As per Jefferiss Wing GUM handbook	
cefuroxime	tablets 250mg; suspension 125 mg in 5ml*; injection 250mg, 750mg, 1.5g SMH - Eye Drops 5% preservative free (unlicensed)	5.01.2	R	Paediatrics only: Level 1 non-reserved anti-infective Level 2 anti-infective restricted to specific indications: As per Adult anti-infective policy As per Adult surgical prophylaxis policy	
cefuroxime	Eye drops, 5% preservative free (Unlicensed product.)	11.03.1	A		
celecoxib	capsules 100mg, 200mg	10.01.1	R	1. For the treatment of osteoarthritis or rheumatoid arthritis in line with EHH guidelines. Rheumatologists only to initiate or recommend prescribing. NICE TA guidance no. 27; July-01 states that Cox II agents are not for routine use and should only be used when clearly indicated as management of ostearthritis and rheumatoid arthritis (OA and RA) in patients who are deemed at high risk of GI side effects. 2. For pain from surgical intervention for total knee replacement and total hip replacement.as per Enhanced Recovery Program (ERP) for total hip or knee replacement guidelines. (NDP December 2017)	
cemiplimab	vials, concentrate for solution for infusion, 300mg	8.01.5	R	In line with NICE TA guidance no 802, June 2022 (replaces TA guidance no. 592, August 2019): Cemiplimab is recommended as an option for treating metastatic or locally advanced cutaneous squamous cell carcinoma in adults when curative surgery or curative radiotherapy is not suitable, only if it is stopped at 24 months, or earlier if their disease progresses, and the company provides cemiplimab according to the commercial arrangement.	PBR

cenobamate	tablets 12.5mg, 25mg (initiation pack) tablets 50mg, 100mg, 150mg, 200mg	4.08.1	R	In line with NICE TA guidance no 753, December 2022 (last updated July 2025): Cenobamate is recommended as an option for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines. It is recommended only if it is used as an add-on treatment, after at least 1 other add-on treatment has not controlled seizures, and treatment is started by a healthcare professional with expertise in epilepsy, after which treatment can be continued in primary care.	
ceritinib	capsules 150mg	8.01.5	R	In line with NICE TA guidance no. 395, June 2016: Ceritinib is recommended, within its marketing authorisation, as an option for treating advanced anaplastic lymphoma kinase positive non-small-cell lung cancer in adults who have previously had crizotinib and the drug is recommended only if the company provides it with the discount agreed in the patient access scheme.	PRB RL
certolizumab pegol	pre-filled syringe 200mg	10.01.3	R	1. In line with NICE TA guidance no. 375, Jan-2016 : Adalimumab, etanercept, infliximab, **certolizumab pegol**, golimumab, tocilizumab and abatacept, all in combination with methotrexate, are recommended as options for treating rheumatoid arthritis only if disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and disease has not responded to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs) and the companies provide certolizumab pegol, golimumab, abatacept and tocilizumab as agreed in their patient access schemes. Adalimumab, etanercept, **certolizumab pegol** or tocilizumab can be used as monotherapy for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the aforementioned criteria are met.	PBR
certolizumab pegol	pre-filled syringe 200mg	10.01.3	R	2. In line with NICE TA guidance no. 383, Feb-2016: Adalimumab, **certolizumab pego**l, etanercept, golimumab and infliximab are recommended, within their marketing authorisations, as options for treating severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs. Infliximab is recommended only if treatment is started with the least expensive infliximab product. People currently receiving infliximab should be able to continue treatment with the same infliximab product until they and their NHS clinician consider it appropriate to stop.	PBR

certolizumab pegol	pre-filled syringe 200mg	10.01.3	R	3. In line with NICE TA guidance no. 415, October 2016: Certolizumab pegol, in combination with methotrexate or as monotherapy, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to, or who cannot tolerate, other disease-modifying antirheumatic drugs (DMARDs) including at least 1 tumour necrosis factor-alpha (TNF-alpha) inhibitor, only if disease activity is severe and rituximab is contraindicated or not tolerated and the company provides certolizumab pegol with the agreed patient access scheme.	PBR
certolizumab pegol	pre-filled syringe 200mg	10.01.3	R	4. In line with NICE TA guidance no. 445, May 2017: Certolizumab pegol alone, or in combination with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults only if it is used as described in the NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis or the person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has stopped responding after the first 12 weeks. Certolizumab pegol is only recommended if the company provides it as agreed in the patient access scheme.	PBR
certolizumab pegol	pre-filled syringe 200mg	10.01.3	R	5. In line with NICE TA guidance no. 574, April 2019: Certolizumab pegol is recommended as an option for treating severe plaque psoriasis in adults, as per NICE defined criteria and the company provides the drug according to the commercial arrangement.	PBR
Cerumol®	Ear drops, containing chlorobutanol 5%, paradichlorobenzene 2% and arachis oil (peanut oil) 57.3%.	12.01.3	A		
cetirizine	tablets 10mg; oral solution sugar free 1mg/ml	3.04.1	A		
cetomacrogol Formula A	cream	13.02.1	A		
Cetraben®	Emollient cream/ointment contaning white soft paraffin 13.2%, light liquid paraffin 10.5%. 500g pump pack.	13.02.1	A		
cetrorelix	injection 250mcg, 3mg	6.07.2	R	1. For use as adjunct in the treatment of female infertility in patients with a history of poor response to GnRH suppression and patients for whom a shortened treatment cycle is necessary. 2. For use in combination with a gonadotrophin releasing hormone (GnRH) agonist to rapidly suppress levels of luteinising hormone (LH) and follicle stimulating hormone (FSH) in lupus nephritis patients requiring urgent and rapid down regulation prior to commencing 2 weekly intravenous cyclophosphamide therapy for prevention of ovarian failure.	RL

cetuximab	intravenous infusion 100mg in 20ml, 500mg in 100ml	8.01.5	R	1. In line with NICE TA guidance no. 145; June-08, in combination with radiotherapy is recommended as a treatment option only for patients with locally advanced squamous cell cancer of the head and neck whose Karnofsky performance-status score is 90% or greater and for whom all forms of platinum-based chemoradiotherapy treatment are contraindicated.	PBR
cetuximab	intravenous infusion 100mg in 20ml, 500mg in 100ml	8.01.5	R	2. In line with NICE TA guidance no. 439, March 2017 (replaces TA 176, Aug-09): Cetuximab is recommended, within its marketing authorisation, as an option for previously untreated epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in adults in combination with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) or 5-fluorouracil, folinic acid and irinotecan (FOLFIRI).	PBR
cetuximab	intravenous infusion 100mg in 20ml, 500mg in 100ml	8.01.5	R	3. I line with NICE TA guidence no. 473, September 2017 (updated from TA 172): Cetuximab in combination with platinum-based chemotherapy is recommended as an option for treating recurrent or metastatic squamous cell cancer of the head and neck in adults only if the cancer started in the oral cavity and when the company provides the drug in line with the commercial access agreement with NHS England.	PBR
chloral hydrate	elixir 143.3mg in 5ml, syrup 1g in 5ml; mixture 200mg in 5ml; oral solution 500mg in 5ml; suppositories 25mg, 50mg, 100mg, 250mg, 500mg (all unlicensed)	4.01.1	R	Suppositories restricted to paediatric and neonatal areas.	
Chloralieve®	lozenges, 2mg Lidocaine Hydrochloride, 0.6mg Amylmetacresol, 1.2mg 2,4-Dichlorobenzyl Alcohol	12.03.3	A	Following discontinuation of Dequacaine ® lozenges or Merocaine ® lozenges or Tyrazets® lozenges (NDP May 2021)	
chlorambucil	tablets 2mg, 5mg; injection 50mg	8.01.1	A		PBR
chloramphenicol	capsules 250mg; injection 300mg, 1g	5.01.7	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required	
chloramphenicol	eye drops 0.5%; Minims ® eye drops 0.5%; Eye drops 0.5% preservative free (unlicensed); eye ointment 1%	11.03.1	A		
chlordiazepoxide	capsules 5mg, 10mg. tablets 10mg, 25mg	4.01.2	A		

chlorhexidine	Irrigation, chlorhexidine acetate 0.02% (500ml steripak bottles). See section 13.11.2	7.04.4	A		
chlorhexidine	irrigation fluid 0.05%; sachets 0.05%; 0.5% in IMS 70% (clear solution and red dye), spray (pink)	16	A	no longer pharmacy; ordered from supplies	
chlorhexidine	obstetric cream 5%	13.11.2	A		
chlorhexidine	eye drops 0.02% (unlicensed)	11.03.1	A		
chlorhexidine gauze dressing	5cm x 5cm, 10cm x 10cm	A8.01.6	A	no longer pharmacy; ordered from supplies	
chlorhexidine gluconate	Mouthwash, 0.2%. Dental gel, 1%	12.03.4	A		
chlorhexidine gluconate	solution (hand rub) 0.5% in isopropyl alcohol; cleansing solution (scrub and body cleanser), solution 0.05% 25ml sachets, 500ml, 1000ml; solution 2% solution 0.5%	13.11.2	A	no longer pharmacy; ordered from supplies	
chlormethine (mustine)	injection 10mg	8.01.1	R		PBR
chlormethine	gel 160mcg/g	8.01.1	R	In line with NICE TA guidance no. 720, August 2021: Chlormethine gel is recommended as an option for treating early stage (stage 1A, 1B, and 2A) mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in adults, only if the company provides chlormethine gel according to the commercial arrangement.	PBR
chloroquine	Tablets, chloroquine phosphate 250mg, (equivalent to chloroquine base 155mg); Syrup, chloroquine sulphate 80mg in 5ml, (equivalent to chloroquine base 50mg in 5ml) (Malarivon ®).	5.04.1	A		
chlorothiazide	suspension 50mg in 1ml (unlicensed)	2.02.1	A		
chlorphenamine	tablets 4mg; syrup 2mg in 5ml; injection 10mg in 1ml	3.04.1	A		
chlorpromazine hydrochloride	tablets 25mg, 50mg, 100mg; syrups 25mg in 5ml, 100mg in 5ml; injection 25mg in 1ml, 50mg in 2ml	4.02.1 4.06	A		
choline salicylate	Oral gel, sugar-free, choline salicylate 8.7%.	12.03.1	A	Not for use in children (due to salicylate content)	
choriogonadotropin alfa	injection 250 micrograms (Ovitrelle ®)	6.05.1	A	To replace current urinary HCG injections when stocks used.	RL

chorionic gonadotrophin (Human chorionic gonadotrophin, HCG)	injection 5000 unit. For intramuscular injection (Choragon ®). Injection 1500 unit, 5000 unit. For subcutaneous or intramuscular injection (Pregnyl ®).	6.05.1	A	Replaced by choriogonadotropin alfa	RL
ciclesonide	aerosol inhalation 160microgram/metered inhalation, 80microgram/metered inhalation	3.02	R	For mild to moderate (BTS step 2) asthma patients who suffer local side effects with other inhaled steroids (oral thrush, hoarseness). For continuation therapy for inpatients.	
ciclosporin (cyclosporin)	Scalp solution 50 micrograms per ml (60ml).	13.05.3	R	Restricted for use by Dermatology teams and HIV teams only	
ciclosporin (Ikervis®)	eye drops, emulsion 0.1%	11.08	R	In line with NICE TA guidance no. 369, December 2016: Ciclosporin is recommended as an option, within its marketing authorisation, for treating severe keratitis in adult patients with dry eye disease that has not improved despite treatment with tear substitutes.	
ciclosporin (Verkazia®)	eye drops, emulsion 0.1%	11.08	R	Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents. (NPD January 2020)	
ciclosporin (Cequa®)	eye drops, solution in a single-dose container, 0.09%	11.08	R	As per Ikervis® brand. (NWL JFC September 2025 - Amber 2)	
ciclosporin (Neoral ®)	capsules 25mg, 50mg, 100mg; oral solution 100mg in 1ml	8.02.2	A		PBR (renal only) RL
ciclosporin (Capimune ®)	capsules 25mg, 50mg, 100mg	8.02.2	A		PBR (renal only) RL
ciclosporin (Sandimmun ®)	injection 50mg, 250mg	8.02.2	A		PBR (renal only) RL
cidofovir	injection 375mg	5.03.2	R	Level 2 anti-infectives restricted to specific indications: As per Haematology anti-infective policy As per Paediatric Oncology/ Haematology protocols As per Jefferiss Wing GUM handbook As per HIV guidance As per Virology	PBR
cidofovir	injection 375mg (diluted to 20mg in 4mls for intralesional administration)	5.03.2	R	For treatment of severe recurrent respiratory papillomatosis (RRP) of the larynx and tracheobronchial tree, in line with the local guideline. NDP March 2024	
cimetidine	tablets 200mg, 400mg; oral solution 200mg in 5ml;	1.03.1	A		

cinacalcet	tablets 30mg, 60mg, 90mg	9.05.1	R	In line with NICE TA guidance no. 117, Jan-07: Cinacalcet is recommended for the treatment of refractory secondary hyperparathyroidism in patients with end-stage renal disease only in those who have 'very uncontrolled' plasma levels of intact parathyroid hormone that are refractory to standard therapy, and a normal or high adjusted serum calcium level, and in whom surgical parathyroidectomy is contraindicated. Limited approval for use in patients who have had failed parathyroidectomy and continue to be hypercalcaemic or who are unable to tolerate major surgery. Use to be authorised by consultant.	
cinnarizine	tablets 15mg	4.06	A		
ciprofibrate	tablets 100mg	2.12	R		
ciprofloxacin	eye drops, 0.3% (5ml)	11.03.1	A		
ciprofloxacin	ear drops, 0.2%	12.01.1	A	NDP March 2023	
ciprofloxacin/ dexamethasone	ear drops, 0.3%/0/1% (5ml)	12.01.1	A		
ciprofloxacin	IV infusion 100mg in 50ml, 200mg in 100ml; 400mg in 200ml	5.01.12	A	Level 2 anti-infectives restricted to specific indications: As per Adult anti-infective policy As per Oncology/Haematology anti-infective policy As per Renal anti-infective policy As per Paediatric policy Leeches: see entry under oral and switch to oral asap. • Septic shock (suspected) if penicillin allergic following administration of blood transfusion or platelets	

ciprofloxacin	tablets 100mg, 250mg; 500mg suspension 250mg in 5ml	5.01.12	A	Level 2 anti-infectives restricted to specific indications: As per Adult anti-infective policy As per Renal anti-infective policy As per Oncology/Haematology anti-infective policy As per Paediatric Oncology/Haematology protocols As per Neonatal anti-infective policy As per Jefferiss Wing GUM handbook Cholangitis. Gastroenterology: prophylaxis for biliary endoscopic procedures, eg. ERCP; prophylaxis for variceal bleeding; Crohn's disease with fistulating and perianal disease. Leeches: commence morning of application and for 5 days after removal of leeches; if wound still not healed after this contact microbiology/ID. Oncology: diarrhoea post irinotecan therapy Otitis externa in a patient with diabetes if Pseudomonas aeruginosa grown. Suspected meningococcal disease to clear throat carriage Urology: acute or chronic prostatitis, acute epididymitis, prophylaxis for prostate biopsy, pyelonephritis, UTI in men if urological abnormality (often prostatic)	
cisatracurium	Injection, 2mg/ml (2.5ml, 5ml and 10ml amps)	15.01.5	R		
cisplatin	injection 10mg, 50mg, 100mg	8.01.5	A		PBR
citalopram	tablets 10mg, 20mg; oral solution 40mg/ml sugar free	4.03.3	A		
Citramag ®	oral powder	1.06.5	A		
citrulline	oral solution 1g in 10ml (unlicensed)	9.08	A		
cladribine	injection 10mg in 10ml	8.01.3	A	In line with national/local oncology guidelines/protocols.	PBR
cladribine	tablets 10mg	8.02.4	R	In line with NICE TA guidance no. 616, December 2019 (updated 2024): Cladribine is recommended as an option for treating highly active multiple sclerosis in adults, only if the person has rapidly evolving severe relapsing–remitting multiple sclerosis, defined by 2 or more relapses in the previous year, and baseline MRI evidence of disease activity, or relapsing–remitting multiple sclerosis that has responded inadequately to treatment with disease-modifying therapy, defined as 1 relapse in the previous year and MRI evidence of disease activity.	PBR RL

cladribine	tablets 10mg	8.02.4	R	In line with NICE TA guidance no. 1053, April 2025: Cladribine is recommended as an option for treating active relapsing forms of multiple sclerosis in adults, only if they have active relapsing–remitting multiple sclerosis, and when high-efficacy disease-modifying therapies would be offered.	PBR RL
clarithromycin	tablets 250mg, 500mg; suspension 125mg in 5ml, 250mg in 5ml; infusion 500mg	5.01.5	A	Level 1 non-reserved anti-infective	
clascoterone	cream 10mg in 1g	13.06.2	R	In line with the product licence - monotherapy only. AMBER 2 - transfer to primary care after 12 weeks after confirmation of response. (NWL JFC January 2026)	
clindamycin	Topical solution 1% (alcoholic); Lotion 1%. Gel 1%	13.06.1	A	gel 1% NDP September 2018 due to long term supply problems with other formulations	
clindamycin	capsules 150mg; suspension 75mg in 5ml (unlicensed); injection 300mg in 2ml, 600mg in 4ml	5.01.6	R	Paediatrics only: Level 1 non-reserved anti-infective Level 2 anti-infective restricted to specific indications: As per Adult anti-infective policy As per Adult surgical prophylaxis policy As per Maternity anti-infective policy (QCCH & SMH)	
clindamycin/ tretinoin	gel 1%/0.025% w/w	13.06.1	A	NDP March 2024	
clindamycin	vaginal cream 2%	7.02.2	A		
Clinistix		19.01	A		
Clinitest		19.01	A		
clobazam	capsules 10mg; tablets 10mg; liquid 10mg in 5ml	4.08.1	R	on advice of neurology	
clobetasol propionate	cream 0.05%; ointment 0.05%; scalp application 0.05%	13.04	A		
clobetasone butyrate	cream 0.05%; ointment 0.05%	13.04	A		
clofarabine	vial 20ml (1mg in 1ml)	8.01.3	R	Acute myeloblastic leukaemia in patients with relapsed/refractory disease in whom the intent is to use treatment as a bridge to bone marrow transplantation within the **Cancer Drug Fund**. (July 2016)	PBR
clofazamine	capsules 100mg.	5.01.10	R	Level 2 anti-infectives restricted to specific indications: As per Jefferiss Wing GUM handbook MDR-TB	
clomethiazole	capsules 192mg as base; syrup 250mg in 5ml as edisilate	4.01.1	A	Note: for an equivalent therapeutic effect, one capsule = 5ml syrup.	

clomifene	tablets 50mg	6.05.1	A		
clomipramine	capsules, 10mg, 25mg, 50mg. Syrup, 25mg in 5ml.	4.03.1	A		
clonazepam	tablets 500mcg, 2mg; oral drops 2.5mg in 1ml; liquid 500mcg in 5ml; suspension 2mg in 5ml (unlicensed)	4.08.1	A		
clonazepam	injection 1mg in 1ml	4.08.2	A		
clonidine	tablets 25micrograms, 100micrograms, 300micrograms Injection 150mcg in 1ml	4.07.4 2.05.2	A		
clopidogrel	tablets 75mg, 300mg	2.09	R	In line with NICE TA guidance no. 210, Dec-10 (replacing NICE TA guidance no 90, May-05): Clopidogrel is recommended as an option to prevent occlusive vascular events for people who have had an ischaemic stroke or who have peripheral arterial disease or multivascular disease or for people who have had a myocardial infarction only if aspirin is contraindicated or not tolerated.	
clopidogrel	tablets 75mg, 300mg	2.09	R	Clopidogrel should be prescribed in line with the NW London cardiac network guidance (December 2007) for patients with: 1. Non-ST-Segment Elevation ACS (Unstable angina and NSTEMI) (in combination with aspirin); 2. ST-Segment Elevation ACS (STEMI) (in combination with aspirin); 3. Percutaneous Coronary Interventions (PCI): Post-Stent Insertion and “Plain Old Balloon Angioplasty” POBA (in combination with aspirin); 4. Post Coronary Artery Bypass Graft (CABG) in selected patients (in combination with aspirin); 5. Secondary Prophylaxis of Occlusive Vascular Events and Symptomatic Peripheral Arterial Disease for patients with proven aspirin hypersensitivity or history of severe dyspepsia induced by low dose aspirin (clopidogrel alone).	
clotrimazole	Solution, 1% clotrimazole in polyethylene glycol 400 (macrogol 400) (Canesten ®).	12.01.1	A		
clotrimazole	pessaries 100mg, 200mg, 500mg; vaginal cream 10%; topical cream 1%, 2%	7.02.2	A	Combi preparation is non-formulary	
clotrimazole	cream 1%; dusting powder 1%; spray 1% solution 1% in macrogol 400 (polyethylene glycol 400)	13.10.2	A		

clozapine	tablets 25mg, 100mg	4.02.1	R	Restricted for use in registered patients by Mental Health Unit Consultants only. Inpatient dispensing according to the relevat SOP.	RL
coal tar	ointment 2% in white soft paraffin; ointment 2%, 5%, 10%, 20%, 30% in yellow soft paraffin (unlicensed)	13.05.2	A		
coal tar solution in Betnovate RD ointment	Coal tar solution 5% in Betnovate RD ointment, Coal tar solution 10% in Betnovate RD ointment (both unlicensed)	13.05.2	A		
Coal tar, salicylic acid and sulphur	Scalp application (Cocois ®)	13.09	A		
Coal tar, salicylic acid and sulphur	scalp ointment containing coal tar solution 12%, salicylic acid 2%, precipitated sulphur 4% in a coconut oil emollient basis (Cocois ® /Sebco ®).	13.05.2	A		
co-amilofruse	tablets 2.5/20, 5/40	2.02.4	A		
co-amilozide	tablets 2.5/25, 5/50	2.02.4	A		
co-amoxiclav	Tablets 375mg (amoxicillin 250mg and clavulanic acid 125mg); 625mg (amoxicillin 500mg and clavulanic acid 125mg); Suspension 125/31 in 5ml, 250/62 in 5ml; Injection 1.2g (amoxicillin 1g and clavulanic acid 200mg); Injection 600mg (amoxicillin 500mg and clavulanic acid 100mg)	5.01.1	R	Paediatrics only: Level 1 non-reserved anti-infective Level 2 anti-infective restricted to specific indications: As per Adult anti-infective policy As per Adult surgical prophylaxis policy As per Neonatal anti-infective policy (QCCH) As per Maternity anti-infective policy (QCCH & SMH)	
co-amoxiclav Augmentin-Duo ®	Suspension 400/57mg (amoxicillin 400mg and clavulanic acid 57mg) in 5ml	5.01.1	R	Paediatrics only: Level 1 non-reserved anti-infective Level 2 anti-infective restricted to specific indications: As per Adult anti-infective policy As per Adult surgical prophylaxis policy As per Neonatal anti-infective policy (QCCH) As per Maternity anti-infective policy (QCCH & SMH)	

co-beneldopa	capsules 12.5/50 (Madopar ® 62.5 contain levodopa 50mg and benserazide 12.5mg), 25/100 (Madopar ® 125 contain levodopa 100mg and benserazide 25mg), 50/200 (Madopar ® 250 contain levodopa 200mg and benserazide 50mg); dispersible tablets 12.5/50, 25/100; MR capsules 25/100 (Madopar CR ® contain levodopa 100mg and benserazide 25mg);	4.09.1	A		
cobicistat	tablets 150mg	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH) (NDP September 2015)	PBR RL
cocaine	solution 10% (unlicensed)	12.03.4	A		
cocaine	mouthwash 2%, 5% (both unlicensed); sterile solution 10%, 3ml (not for injection) (unlicensed).	15.02	A		
cocaine	eye drops, 4% (unlicensed)	11.07	R	Preparation is unlicensed and can be obtained from Moorfields Hospital. Although normally held in stock at CXH they may not always be immediately available.	
cocaine hydrochloride 10% with adrenaline	1 in 20000 solution (unlicensed)	12.03.4	A		
co-careldopa	tablets 12.5/50, contain levodopa 50mg and carbidopa 12.5mg (Sinemet 62.5 ®). tablets 10/100, contain levodopa 100mg and carbidopa 10mg (Sinemet 110 ®). tablets 25/250, contain levodopa 250mg and carbidopa 25mg (Sinemet 275 ®). tablets 25/100, contain levodopa 100mg and carbidopa 25mg (Sinemet Plus ®). tablets 25/100, modified-release, contain levodopa 100mg and carbidopa 25mg (Half Sinemet CR ®). tablets 50/200, modified-release, contain levodopa 200mg and carbidopa 50mg (Sinemet CR ®); oral suspension 2.5mg/10mg in 5ml (unlicensed)	4.09.1	A		
co-codamol	tablets or capsules 30/500; dispersible tablets 8/500, 30/500	4.07.1	R		

co-cyprindiol	tablets containing cyproterone acetate 2mg and ethinylestradiol 35micrograms (Dianette ®).	13.06.2	A		
co-danthramer	suspension 25/200 in 5ml; strong suspension 75/1000 in 5ml	1.06.2	A		
codeine	linctus 15mg in 5ml	3.09.1	A		
codeine	tablets 15mg, 30mg, 60mg; injection 60mg in 1ml [CD]; oral solution 25mg in 5ml.	4.07.2 1.04.2	A		
co-dydramol	tablets 10/500	4.07.1	A	Tablets, contain paracetamol 500mg and dihydrocodeine tartrate 10mg.	
colchicine	tablets 500mcg	10.01.4	A		
colecalciferol (Cholecalciferol, vitamin D3)	capsules 400 IU 800 IU - NDP February 2014 tablets 20,000 IU (SunVit-D3®) - first line for adults capsules 20,000 IU - paediatric use; oral ampoules 25,000 IU in 1ml (for paediatric use) injection 1mg in 1ml (unlicensed); oral liquid 3000 IU in 1ml (unlicensed)	9.06.4	A	Please refer to the relevant local guidelines (adult and paediatric) for more detailed information regarding the choice of products and dosing regimens.	
colesevelam hydrochloride	tablets 625mg	2.12	R	As add on therapy to statin if ezetemibe is not tolerated. To be initiated by lipidologists in secondary care only	
colestyramine (cholestyramine)	powder 4g per sachet (Questran Light ®); powder, 4g sachets (Questran ®).	2.12	A		
colistimethate sodium	1 million international units powder for nebuliser solution	5.01.7	very R	Lever 3 Restricted anti-infective For out-patient antibiotic prophylaxis for patients with bronchiectasis as per bronchiectasis protocol. (NDP February 2013)	
colistimethate sodium	injection 1 million international units	5.01.7	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required. Nebulised colistin is on the Red List.	
colistin sulphate	tablets 1.5million units	5.01.7	R	Level 2 anti-infective restricted to specific indications: Cystic Fibrosis patients	
colon administration	unit enema	18	A		
co-magaldrox	co-magaldrox 195/220 (Maalox ®) suspension	1.01.1	A		
Combined; estradiol 1mg + dydrogesterone 10mg	tablets (Femoston 1/10 ®)	6.04.1	A		

Combined; estradiol 1mg + medroxyprogesterone 2.5mg	tablets 1mg/2.5mg (Indivina ®)	6.04.1	A		
Combined; estradiol 1mg + medroxyprogesterone 5mg	tablets 1mg/5mg (Indivina ®)	6.04.1	A		
Combined; estradiol 1mg + norethisterone 1mg	tablets 1mg (Elleste-Duet ®)	6.04.1	A		
Combined; estradiol 2mg + dydrogesterone 10mg	tablets (Femoston 2/10 ®)	6.04.1	A		
Combined; estradiol 2mg + medroxyprogesterone 5mg	tablets2mg/5mg (Indivina ®)	6.04.1	A		
Combined; estradiol 2mg + norethisterone 1mg	tablets 2mg (Elleste-Duet ®)	6.04.1	A		
Combined; estradiol 50mcg/24 hours + levonorgestrel 10mcg/24 hours	patches (FemSeven Sequi ®)	6.04.1	A		
Combined; estradiol 50mcg/24 hours+ norethisterone 170mcg/24 hours	patches (Evorel Sequi ®)	6.04.1	A		
Combivir ®	tablets containing zidovudine 300mg and lmivudine 150mg	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
Compound iodine	paint BPC 1968	16	A		
Conjugated oestrogens	tablets 300mcg, 625mcg, 1.25mg (Premarin ®)	6.04.1	A		
Conotrane ®	cream	13.02.2	A		
contact lens cleaning solution - 10/10 ®	3 month pack:	11.09	A		

contact lens cleaning solution - 10/10 ® Cleaning And Disinfecting Solution		11.09	A		
contact lens cleaning solution - 10/10 ® Rinsing And Neutralising Aqueous Solution		11.09	A		
contact lens cleaning solution - 10/10 Care System Pack ®	starter pack.	11.09	A		
contact lens cleaning solution - Miraflow ®	cleaner, for hard, soft and gas permeable lenses.	11.09	A		
contact lens cleaning solution - Total Care ®	starter pack.	11.09	A		
contact lens cleaning solution - Total Care Lens Solution ®	Polyvinyl alcohol in a buffered, isotonic solution, 120ml.	11.09	A		
Continuous combined estradiol 50mcg/24 hours + norethisterone170mcg/24 hours	patches (Evorel Conti ®)	6.04.1	A		
Continuous combined; conjugated oestrogen 300mcg + medroxyprogesterone 1.5mg	tablets (Premique ® low dose)	6.04.1	A		
Continuous combined; estradiol 1mg + dydrogesterone 5mg	tablets (Femoston-conti ®)	6.04.1	A		
Continuous combined; estradiol 1mg + norethisterone 500mcg	tablets (Kliovance ®)	6.04.1	A		
Continuous combined; estradiol 50mcg/24 hours + levonorgestrel 7mcg/24	patches (FemSeven Conti ®)	6.04.1	A		
Continuous combined; oestradiol 2mg + norethisterone 1mg	tablets (Kliofem ® or Elleste-Duet Conti ®)	6.04.1	A		

co-phenotrope	tablets 2.5/0.025	1.04.2	A		
copper sulphate	Injection, 5mg in 5ml, for dilution, 1ml contains 4 micromol copper (Unlicensed)	9.03	A		
co-proxamol - **discontined**	tablets 32.5/325	4.07.1	R	No new patient to be started on co-proxamol.	
corticorelin (CRH)	injection 100microgram (unlicensed)	6.05.1	A		
co-tenidone	tablets 50/12.5, 100/25	2.04	A		
co-triamterzide	tablets 50/25	2.02.4	A		
co-trimoxazole	tablets 480mg, 960mg; dispersible tablets 480mg;	5.01.8	A	Level 1 non-reserved anti-infective	
crisantaspase (Erwinia L-asparaginase)	injection 10,000 units	8.01.5	R	To replace asparaginase (E. Coli) (now discontinued) for clinical trail	PBR
crizotinib	capsules 200mg, 250mg	8.01.5	R	1. In line with NICE TA guidance no.406, September 2016: Crizotinib is recommended, within its marketing authorisation, as an option for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults. The drug is recommended only if the company provides it with the discount agreed in the patient access scheme.	PBR RL
crizotinib	capsules 200mg, 250mg	8.01.5	R	2. In line with NICE TA guidance no.422, December 2016: Crizotinib is recommended, within its marketing authorisation, as an option for previously treated anaplastic lymphoma kinase-positive advanced non-smallcell lung cancer in adults. The drug is recommended only if the company provides it with the discount agreed in the patient access scheme.	PBR RL
crizotinib	capsules 200mg, 250mg	8.01.5	R	3. In line with NICE TA guidance no. 1021, November 2024 (replaces NICE TAG 529, July 2018): Crizotinib is recommended as an option for treating ROS1-positive advanced non small-cell lung cancer in adults, only if they have not had ROS1 inhibitors the company provides it according to the commercial arrangement.	PBR RL
crotamiton	cream 10% (Eurax ®); lotion 10% (Eurax ®).	13.03	A		
Crystal Violet	aqueous paint 0.5% (unlicensed); solution 1%	13.11.6	A		
Cuplex ®	gel containing salicylic acid 11%, lactic acid 4% and copper acetate in collodion basis	13.07	A		
Custodiol HTK	HTK solution	21	R	for pancreas transplants	
cyanocobalamin	tablets 50micrograms; injection 1mg in 1ml	9.01.2	A		

cyclizine	tablets 50mg; injection 50mg in 1ml	4.06	A		
cyclopentolate	Eye drops 0.5%, 1%; Eye drops 1% preservative free (unlicensed); Single use Minims ® eye drops 0.5%, 1%.	11.05	A		
cyclophosphamide	tablets 25mg, 50mg; injection 200mg, 500mg, 1g, 4g in 200ml (4g preparation unlicensed); oral liquid 100mg/5ml (200ml, unlicensed) oral liquid 50mg/5ml (unlicensed)	8.01.1	A		PBR (for oncology)
cycloserine	capsules 250mg	5.01.9	R	Level 2 anti-infective restricted to specific indications: MDR-TB	
cyproheptadine	tablets 4mg	3.04.1	A		
cyproterone acetate	tablets 50mg, 100mg; capsules 3mg (unlicensed)	6.04.2 8.03.4	A		
cytarabine	injection 100mg, 500mg, 1g	8.01.3	A		PBR
dabigatran etexilate	capsules 75mg, 110mg, 150mg	2.08.2	A	1. In line with NICE TA guidance no. 157, Sept-08: Dabigatran etexilate is recommended as an option for the primary prevention of venous thromboembolic events in adults who have undergone elective total hip replacement surgery or elective total knee replacement surgery.	
dabigatran etexilate	capsules 75mg, 110mg, 150mg	2.08.2	A	2. In line with NICE TA guidance no. 249, Mar-12: Dabigatran etexilate is recommended as an option for the prevention of stroke and systemic embolism in atrial fibrillation.	
dabigatran etexilate	capsules 75mg, 110mg, 150mg	2.08.2	A	3. In line with NICE TA guidance no. 327, Dec-14: Dabigatran etexilate is recommended, within its marketing authorisation, as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults.	
dabrafenib	capsules 50mg, 75mg	8.01.5	R	1. In line with NICE TA guidance no. 321, Oct-14: Dabrafenib is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic BRAF V600 mutation-positive melanoma only if the company provides dabrafenib with the discount agreed in the patient access scheme.	PBR RL

dabrafenib	capsules 50mg, 75mg	8.01.5	R	2. In line with NICE TA guidance no. 544, October 2018: Dabrafenib with trametinib is recommended, within its marketing authorisation, as an option for the adjuvant treatment of resected stage III BRAF V600 mutation-positive melanoma in adults. It is recommended only if the company provides dabrafenib and trametinib with the discounts agreed in the commercial arrangements.	PBR RL
dabrafenib	capsules 50mg, 75mg	8.01.5	R	3. In line with NICE TA guidance no. 898, June 2023: Dabrafenib plus trametinib is recommended as an option for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (NSCLC) in adults, only if it is used as first-line treatment of advanced stage cancer, and the company provides it according to the commercial arrangement.	PBR RL
dacarbazine	injection 100mg, 200mg	8.01.5	A	In line with national/local guidelines/protocols.	PBR
dactinomycin (Actinomycin D)	injection 500mcg	8.01.2	A	In line with national/local guidelines/protocols.	PBR
Daktacort ®	cream containing hydrocortisone 1% and miconazole nitrate 2%; ointment containing hydrocortisone 1% and miconazole nitrate 2%	13.04	A		
dalbavancin	vials, powder for dilution , 500mg	5.01.7	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required (NDP November 2024)	
Dalivit ®	Drops, 0.6ml contains vitamin A, thiamine hydrochloride (vitamin B1), riboflavin (vitamin B2), pyridoxine hydrochloride (vitamin B6), calciferol (vitamin D), nicotinamide and ascorbic acid	9.06.7	A		
dalteparin	injection syringe 2500u in 0.2ml, 5000u in 0.2ml; injection 2500 units in 1ml, 4ml amp	2.08.1	R	Use in line with the relevant local guidelines.	
danaparoid	injection 750units in 0.6ml	2.08.1	R	For patient with heparin-induced thrombocytopenia on the direct request of a consultant haematologist only.	
danazol	capsules 100mg, 200mg	6.07.2	A	Injection is non-formulary	
dantrolene	injection 20mg	15.01.8	A		
dantrolene	capsules 25mg, 100mg; oral liquid 10mg in 5ml (unlicensed); suspension 25mg in 5ml (unlicensed)	10.02.2	A		
DAP® penicillin diagnostic test	vials, powder for dilution with diluent	3.04.2	R	for use by allergy teams (NDP March 2022)	

DAP® clavulanate diagnositc test	vials, powder for dilution with diluent	3.04.2	R	for use by allergy teams (NDP March 2022)	
dapagliflozin	tablets 5mg, 10mg	6.01.2	A	1. In line with NICE TA guidance no 390, May-2016: Canagliflozin, **dapagliflozin** and empagliflozin as monotherapies are recommended as options for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if a dipeptidyl peptidase-4 (DPP-4) inhibitor would otherwise be prescribed and a sulfonylurea or pioglitazone is not appropriate. 2. In line with NICE TA guidance no 418, November 2016 (replaces NICE TA guidance no. 288, June 2013) : Dapagliflozin in a triple therapy regimen is recommended as an option for treating type 2 diabetes in adults, only in combination with metformin and a sulfonylurea.	
dapagliflozin	tablets 5mg, 10mg	6.01.2	A	3 . For management of heart failure with reduced ejection fraction (HFrEF). NDP November 2020 As per NICE TA guidance no 679, February 2021.	
dapagliflozin	tablets 5mg, 10mg	6.01.2	A	4. In line with NICE TA guidance no. 1075, July 2025 (replaces TAG 775, March 2022): Dapagliflozin can be used as an option to treat chronic kidney disease (CKD) in adults, ifit is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-2 receptor antagonists, unless these are contraindicated, and people have an estimated glomerular filtration rate (eGFR) of 20- < 45 ml/min/1.73m^2 or 45- 90 ml/min/1.73m^2 and either a urine albumin-to-creatinine ratio of 22.6 mg/mmol or more, or type 2 diabetes.	
dapagliflozin	tablets 5mg, 10mg	6.01.2	A	5. In line with NICE TA guidance 902, June 2023: Dapagliflozin is recommended, within its marketing authorisation, as an option for treating symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults.	
dapoxetine	tablets 30mg, 60mg	not classified	R	In line with the product licence, initiated by sexual health clinic. (NDP January 2026)	
dapsone	tablets 50mg, 100mg	5.01.10	A	Level 1 non-reserved anti-infective	
daptomycin	injection 350mg, 500mg	5.01.7	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required	

daratumumab	concentrate solution for infusion 20mcg in 1ml 5ml, 20ml	8.01.5	R	1. In line with NICE TA guidance no. 897, June 2023 (replaces NICE TA guidance no. 573, April 2019): Daratumumab with bortezomib and dexamethasone is recommended as an option for treating multiple myeloma in adults, only if they have had just 1 previous line of treatment and it included lenalidomide or lenalidomide is unsuitable as a second-line treatment, and the company provides it according to the commercial arrangement.	PBR
daratumumab	concentrate solution for infusion 20mcg in 1ml 5ml, 20ml	8.01.5	R	2. In line with NICE TA guidance no.763, February 2022: Daratumumab (Darzalex, Janssen–Cilag) in combination with bortezomib, thalidomide and dexamethasone, is indicated 'for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant'.	PBR
daratumumab	concentrate solution for infusion 20mcg in 1ml 5ml, 20ml	8.01.5	R	3. In line with NICE TA guidance no 783, April 2022 (replaces earlier TAG no 510, March 2018): Daratumumab monotherapy is recommended as an option for treating relapsed and refractory multiple myeloma in adults who have had a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last treatment, only if they have daratumumab after 3 treatments and the company provides daratumumab according to the commercial arrangement.	PBR
daratumumab	concentrate solution for infusion 20mcg in 1ml 5ml, 20ml	8.01.5	R	4. In line with NICE TA guidance no. 917, October 2023: Daratumumab with lenalidomide and dexamethasone is recommended, within its marketing authorisation, as an option for untreated multiple myeloma in adults, when an autologous stem cell transplant is unsuitable. It is only recommended if the company provides it according to the commercial arrangement.	PBR
daratumumab	concentrate solution for infusion 20mcg in 1ml 5ml, 20ml	8.01.5	R	5. In line with NICE TA guidance no. 959, March 2024: Daratumumab plus bortezomib, cyclophosphamide and dexamethasone is recommended as an option for treating newly diagnosed systemic amyloid lightchain (AL) amyloidosis in adults. It is recommended only if daratumumab is stopped after 24 cycles of treatment, or earlier if the condition progresses, and the company provides daratumumab according to the commercial arrangement.	PBR
darbepoetin alfa	injection - once weekly (all strengths, as per SPC)	9.01.3	R	For treatment of anaemia associated with dialysis. 1mcg darbepoetin is roughly equivalent to 200units erythropoietin. Darbepoetin alfa is not first line for dialysis patients.	PBR (renal only) RL

darbepoetin alfa	injection - once weekly (all strengths, as per SPC)	9.01.3	R	In line with NICE TA guidance no. 323, Nov-14 (replaces NICE TA guidance no 142; May-08), erythropoietin analogues in combination with intravenous iron are recommended: 1. Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy. 2. If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.	RL
daridorexant	tablets 25mg, 50mg	4.01.1	R	In line with NICE TA guidance no. 922, October 2023: Daridorexant is recommended for treating insomnia in adults with symptoms lasting for 3 nights or more per week for at least 3 months, and whose daytime functioning is considerably affected, only if cognitive behavioural therapy for insomnia (CBTi) has been tried but not worked, or CBTi is not available or is unsuitable. The length of treatment should be as short as possible. Treatment with daridorexant should be assessed within 3 months of starting and should be stopped in people whose long-term insomnia has not responded adequately. If treatment is continued, assess whether it is still working at regular intervals.	
darolutamide	tablets, 300mg	8.03.4	R	1. In line with NICE TA guidance no 660, November 2020: Darolutamide with androgen deprivation therapy (ADT) is recommended, within its marketing authorisation, as an option for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease. It is recommended only if the company provides darolutamide according to the commercial arrangement.	PBR RL
darolutamide	tablets, 300mg	8.03.4	R	2. In line with NICE TA guidance no. 903, June 2023: Darolutamide with docetaxel is recommended, within its marketing authorisation, as an option for treating hormone-sensitive metastatic prostate cancer in adults. Darolutamide is only recommended if the company provides it according to the commercial arrangement.	PBR RL
darolutamide	tablets, 300mg	8.03.4	R	3. In line with NICE TA guidance no. 1109, November 2025: Darolutamide with androgen deprivation therapy (ADT) can be used as an option to treat hormone-sensitive metastatic prostate cancer in adults, only if docetaxel is not suitable and the company provides darolutamide according to the commercial arrangement.	PBR RL

darunavir	tablets 100mg, 400mg, 600mg, 800mg liquid 500mg in 5ml (200ml bottle)	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
darunavir/cobicistat (Rezolsta®)	tablets 800mg/150mg	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH) NDP May 2016	PBR RL
darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza®)	tablets 800mg/150mg/200mg/10mg		R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH) As per NHS England commissioning policy September 2018 update NDP November 2018	PBR RL
dasatinib	tablets 20mg, 50mg, 70mg	8.01.5	Very R	1. For the treatment of chronic myeloid leukaemia in adult patients with resistance or intolerance to prior therapy. Dose will be 100mg in chronic phase patients and will not exceed 140mg daily for the accelerated and blastic phase patients.	PBR RL
dasatinib	tablets 20mg, 50mg, 70mg	8.01.5	R	2. In line with NICE TA guidance no. 425, Dec-2016: **Dasatinib** and nilotinib are recommended as options for treating only chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if they cannot have imatinib, or their disease is imatinib-resistant and the companies provide the drugs with the discounts agreed in the relevant patient access schemes.	PBR RL
dasatinib	tablets 20mg, 50mg, 70mg	8.01.5	R	3. In line with NICE TA guidance no. 426, Dec 2016: **Dasatinib** and nilotinib are recommended, within their marketing authorisations, as options for untreated chronic-phase Philadelphiachromosome- positive chronic myeloid leukaemia in adults. The drugs are recommended only if the companies provide them with the discounts agreed in the relevant patient access schemes.	PBR RL
daunorubicin	injection 20mg	8.01.2	A		PBR

deferasirox	tablets dispersible 125mg, 250mg, 500mg (to be discontinued from June 2017) tablets 90mg, 180mg, 360mg (new formulation, NDP Dec 2017)	9.01.3	R	Approved in adults as first line therapy for the prevention and treatment of iron overload in transfusion dependent anaemias and chronic anaemias associated with clinically significant iron overload. Approved as alternative for paediatric patients for thalasaemia and sickle cell disease. Restricted to consultant only initiation of prescribing.	PBR
deferiprone	tablets 500mg; liquid 100mg in 1ml	9.01.3	R	For treatment of iron overload in adult and paediatric patients with thalassaemia, sickle cell and other chronic anaemias in whom other chelation therapy is contraindicated or inadequate. (NDP Feb 2013)	PBR RL
defibrotide	capsules 400mg (unlicensed); injection 200mg (unlicensed)	2.08.1	Very R	Prophylaxis in high risk patients and for treatment for severe hepatic veno-occlusive disease (VOD) in haematopoietic stem cell transplant (HSCT) recipients as outlined in the Haematology protocol. GPs will not be asked to prescribe this drug. Treatment of VOD in Paediatric BMT patients	PBR
degarelix	injection 80mg, 120mg	8.03.4	R	For restricted use in the treatment of prostate cancer emergencies (e.g. impending spinal cord compression where other treatments are unsuitable) when a fast reduction of testosterone levels is clinically necessary. The use is to be restricted to three doses (induction dose, and two maintenance doses, all given one month apart) after which patients will be switched to an LHRH analogue. Consultants only to prescribe. (NDP - November 2010) In line with NICE TA guidance no 404, August 2016: Degarelix is recommended as an option for treating advanced hormone dependent prostate cancer in people with spinal metastases, only if the commissioner can achieve at least the same discounted drug cost as that available to the NHS in June 2016.	
delamanid	tablets 50mg	5.01.9	R	for treatment of multi-drug resistent tuberculosis as per NHS England commissioning statement (last updated July 2019)	
delgocitinib	cream, 20mg in 1g (15g,60g)	13.05.3	R	In line with NICE TA guidance no. 1107, November 2025: Delgocitinib can be used, within its marketing authorisation, as an option to treat moderate to severe chronic hand eczema in adults when topical corticosteroids have not worked or are not suitable. Delgocitinib can only be used if the company provides it according to the commercial arrangement.	
demeclocycline	capsules 150mg	5.01.3	A	Level 1 non-reserved anti-infective	

denosumab	injection 60mg in 1ml pre-filled syringe	6.06.2	R	In line with NICE TA guidance no. 204, Oct-10: Denosumab is recommended as a treatment option for the primary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contraindication to, those treatments and who have a T-score as outlined in the guidance. Denosumab is recommended as a treatment option for the secondary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures who are unable to comply with the special Instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contraindication to, those treatments.	
denosumab	injection 70mg/ml (120mg in 1.7mL vial)	6.06.2	R	In line with NICE TA guidance no 265, Oct-12; denosumab is recommended as an options for preventing skeletal-related events (pathological fracture, radiation to bone, spinal cord complression or surgery to bone) in adults with bone metastases from breast cancer and from solid tumours other than prostate if: - bisphosphonate would otherwise be prescribed **and** **-** the manufacturer provides denosumab with the discount agreed in the patient access scheme.	
Dermamist ®	emollient spray	13.02.1	A	Restricted to use on Micro/ID teams approval only	
Dermol ®	cream containing benzalkonium chloride 0.1%, chlorhexidine hydrochloride 0.1%, isopropyl myristate 10%, liquid paraffin 10%	13.02.1	A	For use by Dermatology teams for atopic eczema and other dermatoses at risk of secondary bacterial infection	
Dermol 200 ®	shower emollient 200ml	13.02.1	A		
Dermol 500 ®	lotion 500ml	13.02.1	A		
Dermol 600 ®	bath emollient containing benzalkonium chloride 0.5%, liquid paraffin 25%, isopropyl myristate 25%	13.02.1	A	for use in infected dermatoses	
Dermovate 1 in 4 in white soft paraffin	clobetasol propionate 0.0125% (unlicensed)	13.04	R	Diluted in the Trust - alternative products may be easier to obtain outside hospital.	
Dermovate 1 in 4 in white soft paraffin with 5% coal tar	solution (unlicensed)	13.04	A		
Dermovate 60% in propylene glycol 40%	cream (unlicensed)	13.04	A		

Dermovate-NN ®	cream containing clobetasol propionate 0.05%, neomycin sulphate 0.5% and nystatin 100,000units/g; ointment containing clobetasol propionate 0.05%, neomycin sulphate 0.5% and nystatin 100,000units/g	13.04	A	Dermovate-NN ® discontinued - generic available	
desferrioxamine mesilate (deferoxamine mesilate)	injection 500mg, 2g	9.01.3	A		PBR
desflurane	240ml	15.01.2	R	For induction of anaesthesia and maintenance using low flow circuits only.	
desmopressin	tablets 100mcg, 200mcg; tablets oral lyophilisates 120mcg, 240mcg (DDAVP ® melts) nasal spray 10 micrograms per metered spray; nasal spray 150mcg/metered spray (for use in line with Haemophila & Von Willebrand's Disease guidelines); intranasal solution 100micrograms per ml; injection 4mcg in 1ml, 15mcg/ml (for SC use in line with Haemophila & Von Willebrand's Disease guidelines);	6.05.2	A		
desogestrel	75mcg tablets	7.03.2	A	oral progesterone-only contraceptive in line with NWL IF (NDP February 2013)	
deucravacitinib	tablets, 6mg	10.01.3	R	In line with NICE TA guidance no. 907, July 2023: Deucravacitinib is recommended as an option for treating moderate to severe plaque psoriasis in adults, as per NICE defined criteria and the company provides deucravacitinib according to the commercial arrangement.	PBR RL
dexamethasone	capsules 100micrograms (unlicensed); tablets 500micrograms, 2mg;	6.03.2	A		
dexamethasone	eye drops 0.1%; preservative free eye drops 0.1% (unlicensed); minims 0.1%	11.04.1	R	Prservative free preparation is unlicensed and can be obtained from Moorfields Hospital. Although normally held in stock at CXH they may not always be immediately available.	
dexamethasone	intravitreal implant 700micrograms	11.04.1	R	In line with NICE TA guidance no. 229, July 2011: Dexamethasone intravitreal implant is recommended as an option for the treatment of macular oedema following central retinal vein occlusion.	PBR

dexamethasone	intravitreal implant 700micrograms	11.04.1	R	In line with NICE TA guidance no. 229, July 2011: Dexamethasone intravitreal implant is recommended as an option for the treatment of macular oedema following branch retinal vein occlusion when treatment with laser photocoagulation has not been beneficial, or treatment with laser photocoagulation is not considered suitable because of the extent of macular haemorrhage	PBR
dexamethasone	intravitreal implant 700micrograms	11.04.1	R	In line with NICE TA guidance no. 824, September 2022: Dexamethasone intravitreal implant is recommended as an option for treating visual impairment caused by diabetic macular oedema in adults only if their condition has not responded well enough to, or if they cannot have non-corticosteroid therapy.	PBR
dexamethasone sodium phosphate	oral solution 500mcg in 5ml (unlicensed); 2mg in 5ml;	6.03.2	A		
dexamethasone sodium phosphate	Injection dexamethasone sodium phosphate 3.3mg in 1ml, 3.8mg in 1ml, 6.6mg in 1ml	10.01.2	A	Note: to avoid confusion please prescribe as sodium phosphate salt.	
dexamfetamine	tablets 5mg	4.04	A		
dexmedetomidine	concentrate solution for infusion 100mcg in 1ml 1ml, 2ml, 4ml, 10ml	15.1.4.4	A	1. For sedation in adult ITU as per the product licence. (NDP March 2016); 2. For sedation in paediatric ITU as per local guideline. (NDP September 2022); 3. For intranasal administration in paediatrics - pre-medication in surgery. (NDP September 2024); 4. For sediation during surgical procedures, including for intubated patients. (NDP September 2025).	
diamorphine	tablets 10mg; injection 5mg, 10mg, 30mg, 100mg, 500mg	4.07.2	A	High strength diamorphine injections (30mg or higher) are restricted as stock items in response to the NPSA alert NPSA/2006/12. The 500mg injection cannot be supplied as a stock item.	
Diastix		19.01	A		
diazepam	tablets 2mg, 5mg, 10mg; oral solution 2mg in 5ml, 5mg in 5ml; suppositories 10mg; rectal tubes 5mg in 2.5ml, 10mg in 2.5ml; injection (emulsion) 10mg in 2ml; injection (solution) 10mg in 2ml	4.01.2	A	Note: 5mg in 5ml oral solution is an NHS black-listed product.	
diazoxide	tablets 50mg; capsules 25mg (unlicensed); injection 300mg in 20ml; oral liquid 50mg in 1ml (unlicensed)	6.01.4	A	In	

diclofenac	gel 1%	13.08.1	A		
diclofenac sodium	e/c tablets 25mg, 50mg; MR capsules/tablets 75mg, 100mg; suppositories 12.5mg, 25mg, 50mg, 100mg; injection 75mg in 3ml;	10.01.1	R	Restricted to rheumatolgy teams and where naproxen and ibuprofen unsuitable (NDP September 2013) Injection for use by the pain and anaesthetic teams.	
diclofenac	eye drops 0.1%	11.08.2	A		
dicobalt edetate	injection 300mg in 20ml	17	A		
dienogest	tablets 2mg	8.03.1	A	Specialist initiation, on NWL IF NDP July 2023	
diethylstilbestrol	tablets 1mg	8.03.1	A		
difelikefalin	solution for injection, 50mg in 1ml	not classified	R	In line with NICE TA guidance no. 890, May 2023: Difelikefalin is recommended, within its marketing authorisation, for treating moderate to severe pruritus in adults with chronic kidney disease (CKD) having in-centre haemodialysis. Difelikefalin is only recommended if the company provides it according to the commercial arrangement.	PBR
difluprednate	eye drops 0.05% (unlicensed)	11.04.1	R	For treatment of chronic macular oedema and uveitic macular oedema second line to dexamethasone/nepafenac ED. Hospital only - Trust to provide full supply (NDP September 2025)	
digoxin	tablets 62.5mcg, 125mcg, 250mcg; elixir 50mcg in 1ml; injection 250mcg in 1ml, injections 500 micrograms in 2ml, 100mcg in 1ml (unlicensed)	2.01.1	A		
digoxin-specific antibody fragments	injection 40mg	17	A		
dihydrocodeine tartrate	tablets 30mg; modified release tablets 60mg injection 50mg in 1ml [CD]	4.07.2	A		
diloxanide	tablets 500mg	5.04.2	A	Level 1 non-reserved anti-infective UK preparation discontinued in Jan-18	

diltiazem	MR tablets 60mg; MR capsules (Tildiem LA ®) 200mg, 300mg; MR tablets (Tildiem Retard ®) 90mg, 120mg; MR capsules (Adizem-XL ®) 120mg, 180mg, 200mg, 240mg, 300mg; MR capsules (Tildiem LA ®) 200mg, 300mg; MR capsules (Slozem ®) 120mg, 180mg, 240mg, 300mg; MR capsules (Dilzem SR ®) 60mg, 90mg, 120mg; MR capsules (Dilzem XL ®) 120mg, 180mg, 240mg MR capsules (Angitil SR ®) 90mg, 120mg; MR tablets (Calcicard CR ®) 90mg, 120mg; MR capsules (Adizem SR ®) 90mg, 120mg, 180mg	2.06.2	A		i
diltiazem	rectal cream 2% (unlicensed) rectal gel 2% (unlicensed)	1.07.4	R	Unlicensed product for the treatment of anal fissures, according to available guidance.	
dimercaprol	injection 100mg in 2ml	17	A		
dimercaptosuccinic acid	300mg capsules (unlicensed)	not classified	R	For treatment of heavy metal poisoning	
dimethyl fumarate (Tecfidera®)	capsules 120mg, 240mg	8.02.4	R	In line with NICE TA guidance no. 320, August 2014: Dimethyl fumarate is recommended as an option for treating adults with active relapsing-remitting multiple sclerosis (normally defined as 2 clinically significant relapses in the previous 2 years), only if they do not have highly active or rapidly evolving severe relapsing-remitting multiple sclerosis and the manufacturer provides dimethyl fumarate with the discount agreed in the patient access scheme.	PBR RL
dimethyl fumarate (Skilarence®)	tablets, 30mg, 120mg		R	In line with NICE TA guidance no. 475, September 2017: Dimethyl fumarate is recommended as an option for treating plaque psoriasis in adults according to the criteria specified by NICE.	PBR RL
dimethyl sulfoxide	bladder instillation 50% 50ml (unlicensed) (Rimso-50 ®)	7.04.4	A		
dinoprostone	vaginal tablets 3mg; SR pessaries 10mg/24 hours (Propess ®); vaginal gel 1mg, 2mg;	7.01.1	A	Propess pessaries for use by the Obs& Gynae teams only	

diphencyprone (dyphenylcyclopropenone)	lotion 0.001%, 0.01%, 0.1%, 0.25%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 6%, 9% (unlicensed)	13.07	R	First line treatment for scalp Alopecia Areata Third line for resistant hand or foot viral warts	
Diphtheria (low dose), tetanus and inactivated poliomyelitis vaccine	injection	14.04	A		
Diphtheria (low dose), tetanus, pertussis and inactivated poliomyelitis (absorbed) vaccine	injection	14.04	A	Repevax® (booster following primary immunisation) Boostrix® (booster following primary immunisation in pregnancy)	
Diphtheria antitoxin	injection	14.04	A		
Diphtheria, tetanus, pertussis and inactivated poliomyelitis (absorbed) - DTaP/IPV	injection	14.04	A		
Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), Haemophi;us influenza type B	injection conjugate vaccine (adsorbed) Infanrix® Hexa	14.04	R	Childhood vaccinations for primary immunisation at 2, 3 and 4 months old (NDP September 2017)	
dipivefrine	eye drops 0.1%	11.06	A		
Diprosalic ®	ointment containing betamethasone dipropionate 0.05% and salicylic acid 3%; scalp application containing betamethasone dipropionate 0.05% and salicylic acid 2%	13.04	A		
dipyridamole	tablets 25mg, 100mg; MR capsules 200mg; oral liquid 50mg in 5ml; injection 10mg in 2ml	2.09	R	In line with NICE TA guidance no. 210; Dec-10 (replacing NICE TA guidance no 90; May-05) modified-release dipyridamole alone is recommended as an option to prevent occlusive vascular events for people who have had an ischaemic stroke only if aspirin and clopidogrel are contraindicated or not tolerated or for people who have had a transient ischaemic attack only if aspirin is contraindicated or not tolerated.	

diroximel fumarate	capsules 231mg	8.02.4	R	In line with NICE TA guidance no. 794, June 2022: Diroximel fumarate is recommended as an option for treating active relapsing–remitting multiple sclerosis (normally defined as 2 clinically significant relapses in the previous 2 years) in adults, only if they do not have highly active or rapidly evolving severe relapsing–remitting multiple sclerosis, and the company provides diroximel fumarate according to the commercial arrangement.	PBR RL
disodium edetate	eye drops, 0.37%. Eye drops, 0.37% preservative free (Unlicensed product.)	11.08	A		
disodium pamidronate	Injection 15mg vial, 90mg vial for use as an infusion; injection 3mg in 1ml, 6mg in 1ml, 9mg in 1ml	6.06.2	A		
disopyramide	capsules 100mg tablets MR 250mg	2.03.2	A		
disulfiram	tablets 200mg	4.10.1	A		
dithranol	cream 1%	13.05.2	A		
Dithranol in Lassar's paste	paste 0.1%, 0.25%, 0.5%, 1% - 6%	13.05.2	A		
dobutamine	injection 250mg in 20ml	2.07.1	A		
docetaxel	injection 20mg in 0.5ml and 80mg in 2ml	8.01.5	R	1. In line with updated NICE TA guidance no. 30; Sept-01 as an option for the treatment of advanced breast cancer where initial chemotherapy (including anthracycline) has failed. Docetaxel in combination with an anthracycline in first-line treatment of advanced breast cancer is not recommended. 2. In line with NICE TA guidance no. 62; May-03, capecitabine in combination with docetaxel is recommended in the treatment of locally advanced or metastatic breast cancer, in preference to single-agent docetaxel in people for whom anthracycline-containing regimens are unsuitable or have failed. 3. In line with NICE TA guidance no. 109; Sept-06, docetaxel may be given concurrently with doxorubicin and cyclophosphamide (the TAC regimen) for the adjuvant treatment of women with early node-positive breast cancer.	PBR
docetaxel	injection 20mg in 0.5ml and 80mg in 2ml	8.01.5	R	4.For neoadjuvant chemotherapy for advanced or at least locally advanced breast cancer that has failed to respond to anthracycline-based chemotherapy. 5. as part of a sequential regimen of three cycles of FEC (flurouracil, epirubicin and cyclophosphamide) followed by three cycles of docetaxel (FEC-T) for the adjuvant treatment of node-positive early breast cancer.	PBR

docetaxel	injection 20mg in 0.5ml and 80mg in 2ml	8.01.5	R	6. In line with NICE TA guidance no. 26; Jun-01, docetaxel monotherapy as second-line therapy for loclly advanced or metastatic non-small cell lung cancer (NSCLC).	PBR
docetaxel	injection 20mg in 0.5ml and 80mg in 2ml	8.01.5	R	7. In line with NICE TA guidance no. 101; Jun-06., as single agent for men with hormone-refractory metastatic prostate cancer only if their Karnofsky performance-status score is 60% or more .	PBR
docetaxel	injection 20mg in 0.5ml and 80mg in 2ml	8.01.5	R	8. for the treatment of squamous cell carcinoma of the head and neck region. a. In combination with platinum for the treatment of patients requiring induction chemotherapy who are unable to tolerate cisplatin-5FU (5FU intolerance) b. As second line treatment for patients who require chemotherapy for tumour recurrence after receiving the cisplatin-5FU regimen. c. As monotherapy in the place of the platinum-5FU regimen in selected patients for induction chemotherapy or inoperable tumours.	PBR
docusate sodium	capsules 100mg; oral solution 12.5mg in 5ml, 50mg in 5ml; enema 120mg in 10g	1.06.2	R		
dolutegravir	tablets 10mg, 25mg, 50mg	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
dolutegravir/abacavir/ lamivudin (Triumeq®)	tablets 50mg/600mg/300mg	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
domperidone	tablets 10mg; suspension 5mg in 5ml; suppositories 30mg (unlicensed)	4.06	A	Use according to local protocols. Use of suppositories is restricted as unlicensed.	
donepezil	tablets 5mg, 10mg	4.11	R	In line with NICE TA guidance no. 217, Mar-11 (last updated May 2016): The three acetylcholinesterase (AChE) inhibitors donepezil, galantamine and rivastigmine are recommended as options for managing mild to moderate Alzheimer's disease.	
dopamine	injection 200mg in 5ml, 800mg in 5ml; strong sterile solution 200mg in 5ml, 400mg in 10ml (Select-A-Jet Dopamine ®)(SMH).	2.07.1	A		

doravirine	tablets 100mg	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH) In line with NHS England commissioning policy (NDP Jan 2020)	PBR RL
doravirine/lamivudine/ tenofovir disoproxil (Delstrigo®)	tablets 100mg/300mg/245mg	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH) In line with NHS England commissioning policy (NDP Jan 2020)	PBR RL
dornase alfa	vials 2500units (2.5mg) in 2.5ml nebuliser solution	3.07	R	With alteplase for interpleural fibrinolysis for the management of complex pleural infaections. (NDP March 2016 - unlicensed indication)	
dornase alfa	vials 2500units (2.5mg) in 2.5ml nebuliser solution	3.07	R	For use as mucolytic of suspected segmental or widespread airway plugs in selected, ventilated, non cystic-fibros PICU patients, as per the local guideline. (NDP September 2021)	
dorzolamide	eye drops 20mg in 1ml	11.06	A	For use In line with the national/local guidelines.	
dorzolamide/timolol	ophthalmic solution (eye drops), 20mg/ 5mg in 1ml	11.06	A	For use In line with the national/local guidelines.	
dostarlimab	vial, 500mg concentrate solution for infusion	8.01.2	R	In line with NICE TA guidance no.1064, May 2025 (replaces TAG 963, April 2024): Dostarlimab with platinum-based chemotherapy can be used as an option to treat primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults when systemic therapy is suitable. Dostarlimab can only be used if the company provides it according to the commercial arrangement.	PBR
dosulepin	capsules 25mg; tablets 75mg	4.03.1	A		
Doublebase ®	Gel 500g. Containing isopropyl myristate 15% & liquid paraffin 15%.	13.02.1	A		
Dovobet® (gel) Dalonev® (ointment)	ointment containing betamethasone dipropionate 0.05% and calcipotriol 50 micrograms/g; gel containing betamethasone dipropionate 0.05% and calcipotriol 50 micrograms/g;	13.05.2	R	Dermatologists only. To be used in patients with plaque psoriasis/scalp psoriasis who have not responded to other topical treatment. (NDP February 2011)	
doxapram hydrochloride	injection 100mg in 5ml; intravenous infusion 1g in 500ml	3.05.1	A		

doxazosin	tablets 1mg, 2mg, 4mg	7.04.1	A		
doxazosin	tablets 1mg, 2mg, 4mg; M/R tablets 4mg,8mg	2.05.4	A		
doxorubicin	injection 10mg, 50mg	8.01.2	A	In line with national/local guidelines/protocols.	PBR
doxorubicin, Liposomal (Myocet ®)	injection 50mg	8.01.2	Very R	for the treatment of metastatic breast cancer in patients with low ejection fraction (<50%)	PBR
doxorubicin, Pegylated Liposomal (Caelyx ®)	injection 20mg in 10ml, 50mg in 25ml	8.01.2	R	1. In line with NICE TA guidance no. 389, April 2016 (replaces TA guidence no. 91, May-05): Pegylated liposomal doxorubicin hydrochloride (PLDH) as monotherapy is recommended within its marketing authorisation as an option for treating recurrent ovarian cancer. PLDH in combination with platinum is recommended as an options for treating recurrent ovarian cancer.	PBR
doxorubicin, Pegylated Liposomal (Caelyx ®)	injection 20mg in 10ml, 50mg in 25ml	8.01.2	R	2. For second line treatment of AIDS' related Kaposi's sarcoma after failed bleomycin/vincristine treatment.	PBR
doxycycline	capsules 50mg, 100mg; dispersible tablets 100mg; injection 100mg/5ml (unlicensed)	5.01.3	A	Level 1 non-reserved anti-infective. Injection restricted - for pleuradisis	
doxylamine succinate/ pyridoxine hydrochloride	tablets 10mg/10mg	not classified	R	Third line option (after trial of at least 2 regular anti-emetics) for the management of moderate to severe nausea and vomiting in pregnancy. (Amber2, NWL JFC May 2025)	
Drapolene ®	cream containing benzalkonium chloride 0.01%, cetrimide 0.2% in a basis containing white soft paraffin, cetyl alcohol and wool fat.	13.02.2	A		

dronedarone	tablets 400mg	2.03.2	NA	Removed from Formulary due to safety concerns (increased cardiovascular risk and reports of severe liver injury). (NDP August 2011) In line with NICE TA guidance no. 197; Aug-10, Dronedarone is recommended as an option for the treatment of non-permanent atrial fibrillation only in people whose atrial fibrillation is not controlled by first-line therapy (usually including beta-blockers), that is, as a second-line treatment option, and who have at least one of the following cardiovascular risk factors: hypertension requiring drugs of at least two different classes; diabetes mellitus; previous transient ischaemic attack; stroke or systemic embolism; left atrial diameter of 50 mm or greater; left ventricular ejection fraction less than 40% or age 70 years or older, and who do not have unstable New York Heart Association (NYHA) class III or IV heart failure.	
droperidol	injection 2.5mg/ml	4.06	R	For management of PONV in theatres (NDP March 2016)	
droperidol	injection 2.5mg/ml	4.06	R	For sedation of patients with acute bahavioural disturbance in Emergency Department accoring to the local guideline. (NDP July 2020)	
drospirenone	tablets 4mg	7.03.2	A	Second line (to desogestrel) oral progesterone-only-contraceptive. NWL JFC November 2025	
Duac ® Once Daily	gel containing benzoyl peroxide 5% and clindamycin 1%	13.06.1	A		
dulaglutide	solution for injection in pre-filled pen 0.75mg in 0.5ml 1.5mg in 0.5ml 3mg in 0.5ml 4.5mg in 0.5ml	6.01.2	R	Use in line with the relevant national/local guidelines. (higher strenghts added in May 2021, NDP)	
duloxetine	capsules 30mg, 60mg	4.03.4	A		
dupilumab	pre-filled syringe 300mg in 2ml pre-filled syringe 200mg in 1.14ml	10.01.3	R	In line with NICE TA guidance no. 534. August 2018: Dupilumab is recommended as an option for treating moderate to severe atopic dermatitis in adults according to the criteria specified in the appraisal. In line with NHS England Early Access to Medicines Scheme, September 2019: Dupilumab in the treatment of adolescent patients ≥12 to <18 years of age with severe atopic dermatitis who have responded inadequately to at least one systemic therapy or where the available systemic therapies are not recommended or are not tolerated.	PBR

DuoResp® Spiromax®	inhalation powder budesonide 160mcg/formoterol fumarate dihydrate 4.5mcg budesonide 320mcg/formoterol fumarate dihydrate 9mcg	3.02	A	NDP September 2015	
durvalumab	vials, concentrate for solution for infusion 50mg in 1ml 2.4ml, 10ml	8.01.5	R	1. In line with NICE TA guidance no 798, June 2022 (replaces TA guidance no 578, May 2019): Durvalumab is recommended as an option for treating locally advanced unresectable non-small-cell lung cancer (NSCLC) in adults whose tumours express programmed cell death ligand 1 (PD-L1) on 1% or more of cells and whose disease has not progressed after platinum-based chemoradiation, only if they have had concurrent platinum-based chemoradiation the company provides durvalumab according to the commercial arrangement.	PBR
durvalumab	vials, concentrate for solution for infusion 50mg in 1ml 2.4ml, 10ml	8.01.5	R	2. In line with NICE TA guidance no. 944, January 2024: Durvalumab plus gemcitabine and cisplatin is recommended, within its marketing authorisation, as an option for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults. It is only recommended if the company provides durvalumab according to the commercial arrangement.	PBR
durvalumab	vials, concentrate for solution for infusion 50mg in 1ml 2.4ml, 10ml	8.01.5	R	3. In line with NICE TA guidance no.1030, January 2025: Durvalumab is recommended, within its marketing authorisation, as neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for treating non-small-cell lung cancer (NSCLC) in adults whose cancer is resectable (tumours 4 cm or over, or node positive) and has no epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. Durvalumab is only recommended if the company provides it according to the commercial arrangement.	PBR
durvalumab	vials, concentrate for solution for infusion 50mg in 1ml 2.4ml, 10ml	8.01.5	R	4. In line with NICE TA guidance no. 1041, February 2025: Durvalumab with etoposide and either carboplatin or cisplatin is recommended as an option for untreated extensive-stage small-cell lung cancer in adults, only if: they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and the company provides durvalumab according to the commercial arrangement.	PBR
durvalumab	vials, concentrate for solution for infusion 50mg in 1ml 2.4ml, 10ml	8.01.5	R	5. In line with NICE TA guidance no. 1090, August 2025: Durvalumab with tremelimumab can be used, within its marketing authorisation, as an option for untreated advanced or unresectable hepatocellular carcinoma (HCC) in adults. Durvalumab with tremelimumab can only be used if the company provides it according to the commercial arrangement.	PBR

durvalumab	vials, concentrate for solution for infusion 50mg in 1ml 2.4ml, 10ml	8.01.5	R	6. In line with NICE TA guidance no. 1099, October 2025: Durvalumab can be used, within its marketing authorisation, as an option to treat limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults. Durvalumab can only be used if the company provides it according to the commercial arrangement.	PBR
dydrogesterone	tablets 10mg	6.04.1	A		
Easychamber	adult, child, infant	3.01.5	R	most cost effective spacer (May 2024)	
EBX-102	capsules (unlicensed)	not classified	R	For treatment of recurrent *C difficil*e infections in line with local and national guidelines. NDP September 2024	
Echovist®	injection	18	A	NDP September 2010	
econazole nitrate	pessaries 150mg	7.02.2	A	Twin pack is non-formulary; Combi pack is non-formulary	
edoxaban	tablets, 15mg,30mg, 60mg	2.08.2	A	1. In line with NICE TA guidance no. 354, August 2015: Edoxaban is recommended, within its marketing authorisation, as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults.	
edoxaban	tablets, 15mg,30mg, 60mg	2.08.2	A	2. In line with NICE TA guidance no 355, September 2015: Edoxaban is recommended, within its marketing authorisation, as an option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more risk factors, including congestive heart failure, hypertension, diabetes, prior stroke or transient ischaemic attack, age 75 years or older.	
edrophonium	injection 10mg in 1ml	10.02.1 15.01.6	A		
EDTA	eye drops	11.08.2	R	For corneal service.	
efanesoctocog alfa	powder and solvent for solution for injection, various strenghts	2.11	R	In line with NICE TA guidance no. 1051, April 2025: Efanesoctocog alfa is recommended as an option for treating and preventing bleeding episodes in people 2 years and over with haemophilia A (congenital factor VIII deficiency), only if they have a factor VIII activity level of less than 1% (severe haemophilia A) the company provides it according to the commercial arrangement.	PBR
efavirenz	capsules 50mg, 100mg, 200mg, 600mg;	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL

elacestrant	tablets 86mg, 345mg	8.01.5	R	In line with NICE TA guidance no, 1036, February 2025: Elacestrant is recommended as an option for treating oestrogen receptor (ER)- positive HER2-negative locally advanced or metastatic breast cancer with an activating ESR1 mutation that has progressed after at least 1 line of endocrine treatment plus a cyclin-dependent kinase (CDK) 4 and 6 inhibitor in women, trans men and non-binary people who have been through the menopause trans women and men. Elacestrant is recommended only if the cancer has progressed after at least 12 months of endocrine treatment plus a CDK 4 and 6 inhibitor, and the company provides it according to the commercial arrangement.	PBR RL
elafibranor	tablets 80mg	1.09.1	R	In line with NICE TA guidance no. 1016, November 2024: Elafibranor is recommended, within its marketing authorisation, as an option for treating primary biliary cholangitis in adults, when used with ursodeoxycholic acid (UDCA), if the primary biliary cholangitis has not responded well enough to UDCA, or alone, if UDCA cannot be tolerated. Elafibranor is only recommended if the company provides it according to the commercial arrangement.	PBR RL
elbasvir/ grazoprevir Zepatir®	tablets 50mg/100mg	5.03.3	R	In line with NICE guidance TA no 413, October 2016: Elbasvir–grazoprevir is recommended, within its marketing authorisation, as an option for treating genotype 1 or 4 chronic hepatitis C in adults, as specified in table 1, only if the company provides the drug at the same price or lower than that agreed with the Commercial Medicines Unit.	PBR RL
eletriptan	tablets 20mg, 40mg	4.07.4	R	Recommended as second line (after almotriptan) for treatment of migraine. See 'Best buy' guidelines for treatment of migraine	
elranatamab	solution for injection 40mg/mL	8.01.5	R	In line with NICE TA guidance no 1023, December 2024: Elranatamab is recommended with managed access as an option for treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody) when the multiple myeloma has progressed on the last treatment. It is only recommended if the conditions in the managed access agreement for elranatamab are followed.	PBR

eltrombopag	tablets 25mg, 50mg, 75mg	9.01.4	R	In line with NICE TA guidance no. 293, July 2013 (review of technology appraisal 205): Eltrombopag is recommended as an options for treating adults with chronic mmune (idiopathic) thrombocytopenic purpura, within its marketing authorisation (that is, in adults who have had a splenectomy and whose condition is refractory to other treatments, or as a second-line treatment in adults who have not had a splenectomy because surgery is contraindicated), only if: - their condition is refractory to standard active treatments and rescue therapies, or - they have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies and - the manufacturer provides eltrombopag with the discount agreed in the patient access scheme. **Paediatric use:** Funding in line with NHS England commissioning policy 28/03/2017 In line with NDP review, November 2025.	PBR RL
Emollin ®	liquid paraffin 50%, white soft paraffin 50% spray	13.02.1	R	for occasional use in patients with Steven-Johnson syndrome when appropriate (NDP Aug 2011)	
empagliflozin	tablets 10mg, 25mg	6.01.2	A	1. In line with NICE TA guidance no 336, March 2015: Empagliflozin, in combination with other diabetic drugs, is recommended as an option for treating tye 2 diabetes in dual and triple therapy regimens, with or without insulin as stipulated in the appraisal. 2. In line with NICE TA guidance no 390, May-2016: Canagliflozin, dapagliflozin and **empagliflozin** as monotherapies are recommended as options for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if a dipeptidyl peptidase-4 (DPP-4) inhibitor would otherwise be prescribed and a sulfonylurea or pioglitazone is not appropriate.	
empagliflozin	tablets 10mg, 25mg	6.01.2	R	3. In line with NICE TA guidance no 773, March 2022: Empagliflozin is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an addon to optimised standard care with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin 2 receptor blocker (ARB), with a beta blocker and, if tolerated, a mineralocorticoid receptor antagonist (MRA), or sacubitril valsartan with a beta blocker and, if tolerated, an MRA.	

empagliflozin	tablets 10mg, 25mg	6.01.2	R	4. In line with NICE TA guidance no 929, November 2023: Empagliflozin is recommended, within its marketing authorisation, as an option for treating symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults.	
empagliflozin	tablets 10mg, 25mg	6.01.2	R	5. In line with NICE TA guidance no 942, December 2023: Empagliflozin is recommended as an option for treating chronic kidney disease (CKD) in adults, only if it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), unless these are contraindicated, and people have an estimated glomerular filtration rate of: – 20 ml/min/1.73 m2 to less than 45 ml/min/1.73 m2 or – 45 ml/min/1.73 m2 to 90 ml/min/1.73 m 2 and either a urine albumin-to-creatinine ratio of 22.6 mg/mmol or more, or type 2 diabetes.	
emtricitabine	capsules 200mg; oral liquid 10mg in 1ml	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
Emulsifying ointment	ointment 100g, 500g	13.02.1	A		
enalapril	tablets 2.5mg, 5mg, 10mg, 20mg	2.05.5	A		
encorafenib	capsules 50mg, 75mg	8.01.5	R	In line with NICE TA guidance no. 562, February 2019: Encorafenib with binimetinib (15mg tablet) is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults. It is recommended only if the company provides encorafenib and binimetinib according to the commercial arrangements.	PBR RL
enflurane		15.01.2	R	For induction of anaesthesia and maintenance using low flow circuits only.	
enfortumab vedotin	powder for solution for infusion 20mg	8.01.5	R	In line with NICE TA guidance no 1097, Septmeber 2025: Enfortumab vedotin with pembrolizumab can be used, within its marketing authorisation, as an option for untreated unresectable or metastatic urothelial cancer in adults when platinum-based chemotherapy is suitable. Enfortumab vedotin with pembrolizumab can only be used if the companies provide them according to their commercial arrangements.	PBR

enfuvirtide	injection 108mg	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
enoxaparin	injection syringe 20mg in 0.2ml, 40mg in 0.4ml, 60mg in 0.6ml, 80mg in 0.8ml, 100mg in 1ml, 120mg in 0.8ml, 150mg in 1ml	2.08.1	A	Use in line with the relevant local guidelines.	
enoximone	injection 100mg in 20ml	2.01.2	R		
Enstilar®	cutaneous foam 50mcg/g calcipotriol/0.5mg/g betamethasone	13.05.2	R	Dermatologists only. In line with national guidelines for management of plaque psoriasis/scalp psoriasis. (NDP May 2017)	
entacapone	tablets 200mg	4.09.1	A	As adjunct to standard preparations of levodopa plus dopa decarboxylase inhibitors for use in Parkinson's disease with end-of-dose deterioration in the response to levodopa.	
entecavir	tablets (as monohydrate) 500 micrograms, 1mg; oral liquid 250mcg/5ml	5.03.3	R	For management of Hepatitis B in line with the latest NICE Clinical Guideline (CG165).	RL
entrectinib	capsules 100mg, 200mg	8.01.5	R	In line with NICE TA guidance no 643, August 2020: Entrectinib is recommended, within its marketing authorisation, as an option for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors. It is recommended only if the company provides entrectinib according to the commercial arrangement.	PBR RL
enzalutamide	capsule 40mg	8.03.4	R	1. In lince with NICE TA guidance no 316, July-14: Enzalutamide is recommended within its marketing authorisation as an option for treating metastatic hormone-relapsed prostate cancer in adults whose disease has progressed during or after docetaxel-containing chemotherapy, only if the manufacturer provides enzalutamide with the discount agreed in the patient access scheme.	PBR RL
enzalutamide	capsule 40mg	8.03.4	R	2. In line with NICE TA guidance no 377, January 2016: Enzalutamide is recommended, within its marketing authorisation, as an option for treating metastatic hormone-relapsed prostate cancer in people who have no or mild symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated and only when the company provides it with the discount agreed in the patient access scheme.	PBR RL

enzalutamide	capsule 40mg	8.03.4	R	3. In line with NICE TA guidance no. 712, July 2021: Enzalutamide plus androgen deprivation therapy (ADT) is recommended, within its marketing authorisation, as an option for treating hormone-sensitive metastatic prostate cancer in adults. It is only recommended if the company provides enzalutamide according to the agreed commercial arrangement.	PBR RL
Epaderm ®	cream	13.02.1	A		
epcoritamab	solution for injection 48mg concentrate for solution for injection 4mg in 0.8ml	8.01.5	R	In line with NICE TA guidance no. 954, March 2024: Epcoritamab is recommended as an option for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults after 2 or more systemic treatments, only if they have had polatuzumab vedotin, or if polatuzumab vedotin iscontraindicated or not tolerated, and the company provides epcoritamab according to the commercial arrangement.	PBR
ephedrine hydrochloride	injection 30mg in 1ml (unlicensed); pre-filled syringe 30mg in 10ml	2.07.2	A		
ephedrine hydrochloride	tablets 15mg, 30mg	3.01.1	A		
epirubicin	injection 2mg in 1ml, 5ml, 25ml, 100ml	8.01.2	A	In line with national/local guidelines/protocols.	PBR
eplerenone	tablets 25mg, 50mg	2.02.3	A		
epoetin alfa (Eprex ®)	injection (all strengths)	9.01.3	R	1. For treatment of anaemia associated with dialysis. 2. For myeloma, myelodysplasia and anaemia of chronic diorders.	PBR (renal only) RL
epoetin alfa (Binocrit ®)	1000units, 2000units, 3000units, 4000units, 5000units, 6000units, 8000units, 10,000units per pre-filled syringes	9.01.3	R	Treatment of anaemia in haemodialysis patients. To evaluate it's use in up to 20 patients for 6 months prior to tendering for ESA contract (January 2009)	PBR (renal only) RL
epoetin beta (NeoRecormon ®)	injection (all strengths)	9.01.3	R	1. For treatment of anaemia associated with dialysis. 2. For myeloma, myelodysplasia and anaemia of chronic diorders.	PBR (renal only) RL
epoetin zeta (Retacrit ®)	1000units, 2000units, 3000units, 4000units, 5000units, 6000units, 8000units, 10,000units per pre-filled syringes	9.01.3	R	Treatment of anaemia in haemodialysis patients. To evaluate it's use in up to 100 patients for 6 months prior to tendering for ESA contract (Jan 2009)	PBR (renal only) RL
epoprostenol	injection 500mcg	2.08.1	A	1. Accepted into the Formulary prior to 1994 without restrictions.	PBR
epoprostenol	injection 500mcg, 1.5mg (Flolan®, Veletri®)	2.08.1	R	2. For treatment of severe pulmonary hypertension (PPH) in line with guidance.	PBR
eptifibatide	injection 20mg in 10ml;	2.09	R	For antiplatelet effect in interventional neuroradiology to treat thromboemboic complications. (NDP May 2022)	

eptinezumab	concentrate for solution for infusion, 100mg in 1ml;	4.07.4	R	In line with NICE TA guidance no 871, March 2023: Eptinezumab is recommended as an option for preventing migraine in adults, only if they have 4 or more migraine days a month at least 3 preventive drug treatments have failed and the company provides it according to the commercial arrangement.	RL
erdafitinib	tablets 3mg, 4mg, 5mg		R	In line with NICE TA guidance no. 1062, May 2025: Erdafitinib is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic urothelial cancer with susceptible FGFR3 genetic alterations in adults after at least 1 line of treatment for unresectable or metastatic cancer that included a PD-1 or PD-L1 inhibitor. Erdafitinib is only recommended if the company provides it according to the commercial arrangement.	PBR RL
erenumab	solution for injection in pre-filled syringe/pen 70mg, 140mg	4.07.4	R	In line with NICE TA guidance no 682, March 2021: Erenumab is recommended as an option for preventing migraine in adults, only if they have 4 or more migraine days a month at least 3 preventive drug treatments have failed the 140 mg dose of erenumab is used and the company provides it according to the commercial arrangement. Stop erenumab after 12 weeks of treatment if in episodic migraine (less than 15 headache days a month) the frequency does not reduce by at least 50% in chronic migraine (15 headache days a month or more with at least 8 of those having features of migraine) the frequency does not reduce by at least 30%.	RL
ergocalciferol (calciferol, vitamin D2)	tablets 250mcg (10,000 units), 1.25mg (50,000 units); injection 7.5mg (300,000 units) in 1ml; 15mg (600,000 units) in 1.5ml, 15mg (600,000 units) in 2ml; oral liquid 250mcg (10,000 units) in 5ml, 75mcg (3,000 units) in 1ml	9.06.4	A		
ergometrine	injection 500mcg in 1ml	7.01.1	A		
eribulin	solution for infusion 0.44mg/ml 2ml, 3ml	8.01.5	R	In line with NICE TA guidance no. 423, December 2016: Eribulin is recommended as an option for treating locally advanced or metastatic breast cancer in adults, only when it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine) and the company provides eribulin with the discount agreed in the patient access scheme.	PBR

erlotinib	tablets 25mg, 100mg, 150mg	8.01.5	R	1. In line with NICE TA guidance no. 258, Jun-12: Erlotinib is recommended as an option for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer.	PBR RL
erlotinib	tablets 25mg, 100mg, 150mg	8.01.5	R	2. In line with NICE TA guidance, no TA 374, December 2016: Erlotinib is recommended as an option for treating locally advanced or metastatic non-small-cell lung cancer that has progressed in people who have had non-targeted chemotherapy because of delayed confirmation that their tumour is epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation-positive, only if the company provides erlotinib with the discount agreed in the patient access scheme revised in the context of NICE technology appraisal guidance 258. Erlotinib is recommended as an option for treating locally advanced or metastatic non-small-cell lung cancer that has progressed after non-targeted chemotherapy in people with tumours of unknown EGFR-TK mutation status, only if the result of an EGFR-TK mutation diagnostic test is unobtainable because of an inadequate tissue sample or poor-quality DNA and the treating clinician considers that the tumour is very likely to be EGFR-TK mutation-positive and the person's disease responds to the first 2 cycles of treatment with erlotinib and the company provides erlotinib with the discount agreed in the patient access scheme revised in the context of NICE technology appraisal guidance 258.	PBR RL
ertapenem	injection 1g	5.01.2	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required	
ertugliflozin L-pyroglutamic acid	tablets 5mg, 15mg	6.01.2	R	In line with NICE TA guidance no. 572, March 2019: **1.1** Ertugliflozin as monotherapy is recommended as an option for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if a dipeptidyl peptidase 4 (DPP-4) inhibitor would otherwise be prescribed and a sulfonylurea or pioglitazone is not appropriate. **1.2** Ertugliflozin in a dual-therapy regimen in combination with metformin is recommended as an option for treating type 2 diabetes, only if a sulfonylurea is contraindicated or not tolerated or the person is at significant risk of hypoglycaemia or its consequences. **1.3** If patients and their clinicians consider ertugliflozin to be 1 of a range of suitable treatments including canagliflozin, dapagliflozin and empagliflozin, the least expensive should be chosen.	

ertugliflozin L-pyroglutamic acid	tablets 5mg, 15mg	6.01.2	R	In line with NICE TA guidance no. 583, June 2019: Ertugliflozin with metformin and a dipeptidyl peptidase-4 (DPP-4) inhibitor is recommended as an option for treating type2 diabetes in adults when diet and exercise alone do not provide adequate glycaemic control, only if the disease is uncontrolled with metformin and a DPP-4 inhibitor, and a sulfonylurea or pioglitazone is not appropriate.	
erythromycin	solution 2% (Stiemycin ®), topical solution, contains erythromycin 4% with zinc acetate 1.2% (30ml).	13.06.1	A		
erythromycin	e/c tablets 250mg, 500mg; suspension 125mg in 5ml, 250mg in 5ml, 500mg in 5ml; IV infusion 1g	5.01.5	A	Level 1 non-reserved anti-infective	
erythropoietin	see darbepoetin	9.01.3	R	In line with NICE TA guidance no. 323, Nov-14 (replaces NICE TA guidance no 142, May-08), erythropoietin analogues in combination with intravenous iron are recommended: 1. Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy. 2. If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.	RL
esmolol	injection 10mg in 1ml, 10ml ampoule; infusion 10mg in 1ml, 250ml	2.04	A		
esomeprazole	tablets 20mg, 40mg Injection 40 mg	1.03.5	R	1. The most cost effective PPI shoulc be used first line. 2. Pantoprazole injection is currently first choice injectable (in adults). Gastroenterologists agreed to use least costly PPI injection. 3. Esomperazole injection first line in paediatc patients.	
estradiol	tablets 1mg, 2mg; gel 0.06%; patches 25, 50, 75, 100mcg (Evorel ®); patches 40, 80mcg (Fematrix ®); patches 50, 75, 100mcg (FemSeven ®); vaginal tablets 10mcg, 25mcg	6.04.1	A		
estradiol	gel in sachets (0.1%) 500mcg in 500mg, 1mg in 1g (Sandrena ®);	6.04.1	A		
estradiol	Vaginal Ring, releasing estradiol approx. 7.5micrograms/24 hours (Estring ®).	7.02.1	A		

estradiol	patches (Estradot) 25, 37.5, 50, 75, 100mcg	6.04.1	R - GP recommendation only	For 3rd line use in patients who cannot use the less costly patches. Added to the Formulary as suitable for recommending to GPs, but the pharmacy will not purchase.	
estramustine	capsules 140mg	8.01.1	A	In line with national/local guidelines/protocols.	PBR
estriol	intravaginal cream 0.01% (Gynest ®); intravaginal cream 0.1% (Ovestin ®)	7.02.1	A		
etanercept	injection 25mg, 50mg	10.01.3	R	1. In line with NICE TA guidance no. 383, Feb-2016: Adalimumab, certolizumab pegol, **etanercept**, golimumab and infliximab are recommended, within their marketing authorisations, as options for treating severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs. Infliximab is recommended only if treatment is started with the least expensive infliximab product. Adalimumab, certolizumab pegol and **etanercept** are recommended, within their marketing authorisations, as options for treating severe non-radiographic axial spondyloarthritis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs.	PBR
etanercept	injection 25mg, 50mg	10.01.3	R	2. In line with NICE TA guidance no. 373, December 2016 (replaces TA 35, Mar-02): Abatacept, adalimumab, **etanercept** and tocilizumab are recommended, within their marketing authorisations, as options for treating polyarticular juvenile idiopathic arthritis (JIA), including polyarticular-onset, polyarticular-course and extended oligoarticular JIA. That is for etanercept, people 2 years and older whose disease has responded inadequately to, or who are intolerant of, methotrexate.	PBR;
etanercept	injection 25mg, 50mg	10.01.3	R	3. In line with NICE TA guidance no. 375, Jan-2016 : Adalimumab, **etanercept**, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept, all in combination with methotrexate, are recommended as options for treating rheumatoid arthritis only if disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and disease has not responded to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs) and the companies provide certolizumab pegol, golimumab, abatacept and tocilizumab as agreed in their patient access schemes.	PBR

etanercept	injection 25mg, 50mg	10.01.3	R	4. In line with NICE TA guidance no. 103; Jul-06, at a dose not exceeding 25 mg twice weekly, for the treatment of adults with plaque psoriasis only when the disease is severe and the psoriasis has failed to respond to standard systemic therapies including ciclosporin, methotrexate and PUVA or the person is intolerant to, or has a contraindication to, these treatments.	PBR
etanercept	injection 25mg, 50mg	10.01.3	R	5. In line with NICE TA guidance no. 199; Aug-10: **Etanercept**, infliximab and adalimumab are recommended for the treatment of adults with active and progressive psoriatic arthritis the person has peripheral arthritis with three or more tender joints and three or more swollen joints, and the psoriatic arthritis has not responded to adequate trials of at least two standard disease-modifying antirheumatic drugs (DMARDs), administered either individually or in combination. Treatment should normally be started with the least expensive drug (taking into account drug administration costs, required dose and product price per dose).	PBR
etanercept	injection 25mg, 50mg	10.01.3	R	6. For the treatment of Behcet's Syndrome in line with approved protocol.	PBR
etanercept	injection 25mg, 50mg	10.01.3	R	7. In line with NICE TA guidance no. 195; Aug-10, Adalimumab, etanercept, infliximab and abatacept, each in combination with methotrexate, are recommended as treatment options only for adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to rituximab, or when rituximab is withdrawn because of an adverse event. Adalimumab monotherapy and etanercept monotherapy are recommended as treatment options for adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to methotrexate, or when methotrexate is withdrawn because of an adverse event.	PBR
etanercept	injection 25mg, 50mg	10.01.3	R	8. In line with NICE TA guidance no 715, July 2021: Adalimumab, **etanercept**, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed, as outlined in the TAG document.	PBR
etanercept	injection 25mg, 50mg	10.01.3	R	9. Option for treatment of toxic epidermal necrolysis and Stephen-Johnson syndrome. (NDP March 2022)	

etelcalcetide	solution for injection 2.5mg, 5mg 10mg	9.05.1	R	In line with NICE TA guidance no. 448, June 2017: Etelcalcetide is recommended as an option for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis, only if treatment with a calcimimetic is indicated but cinacalcet is not suitable and the company provides etelcalcetide with the discount agreed in the patient access scheme.	PBR
ethambutol	tablets 100mg, 400mg; oral liquid 100mg in 1ml	5.01.9	A	Level 1 non-reserved anti-infective	
ethamsylate	tablets 500mg	2.11	A		
ethanolamine oleate	injection 5% 5ml	2.13	A		
ethosuximide	capsules 250mg; syrup 250mg in 5ml.	4.08.1	A		
ethyl chloride	spray	15.02	A		
etodolac		10.01.1	NA	In line with NICE TA guidance no. 27, July-01: Cox II agents are not for routine use and should only be used when clearly indicated as management of ostearthritis and rheumatoid arthritis (OA and RA) in patients who are deemed at high risk of GI side effects.	
etomidate	injection 20mg in 10ml	15.01.1	A		
etonogestrel	implant 68mg (Nexplanon ®)	7.03.2	A	Brand name changed from Implanon ® - Dec 2010	
etoposide	capsules 50mg, 100mg; injection 100mg	8.01.4	A		PBR
etranacogene dezaparvovec	concentrate for solution for infusionm, 10ml	2.11	R	In line with NICE TA guidance no. 989, July 2024: Etranacogene dezaparvovec is recommended with managed access as an option for treating moderately severe haemophilia B (congenital factor XI [FIX] deficiency) in adults without anti-FIX antibodies. It is only recommended if he conditions in the managed access agreement for etranacogene dezaparvovec are followed.	PBR
etrasimod	tablets 2mg	10.01.3	R	In line with NICE TA guidance no. 956, March 2024: Etrasimod is recommended, within its marketing authorisation, as an option for moderately to severely active ulcerative colitis in people aged 16 years and over when conventional or biological treatments cannot be tolerated or the condition has not responded well enough, or lost response to treatment. Etrasimod is only recommended if the company provides it according to the commercial arrangement. ICHNT commissioned to provide for adult patients only.	PBR RL

etravirine	tablets 25mg, 100mg, 200mg	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
Eurax-hydrocortisone ®	cream containing hydrocortisone 0.25% and crotamiton 10%	13.04	A		
everolimus (Afinitor®)	tablets 2,5mg, 5mg, 10mg	8.01.5	R	1. In line with NICE TA guidance no. 421, December 2016: Everolimus, in combination with exemestane, is recommended within its marketing authorisation, as an option for treating advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women without symptomatic visceral disease that has recurred or progressed after a non-steroidal aromatase inhibitor. Everolimus is recommended only if the company provides it with the discount agreed in the patient access scheme.	PBR RL
everolimus (Afinitor®)	tablets 2.5mg, 5mg, 10mg	8.01.5	R	2. In line with NICE TA guidance no. 432, February 2017: Everolimus is recommended within its marketing authorisation as an option for treating advanced renal cell carcinoma that has progressed during or after treatment with vascular endothelial growth factor targeted therapy, only if the company provides it with the discount agreed in the patient access scheme.	PBR RL
everolimus (Afinitor®)	tablets 2,5mg, 5mg, 10mg	8.01.5	R	3. In line with NICE TA guidance no.449, June 2017: Everolimus is recommended, within their marketing authorisations, as options for treating well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease.	PBR RL
everolimus (Votubia®)	tablets 2.5mg, 5mg,10mg	8.01.5	R	4. In line with NHS England commissioning policy for treatment of angiomyolipomas associated with tuberous sclerosis and for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex.	PBR RL
everolimus (Votubia®)	tablets 2.5mg, 5mg,10mg	8.01.5	R	5. In line with NHS England commissioning policy for treatment of refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above).	PBR RL
Evicel ®	sealant glue containing fibrinogen and thrombin	2.11	R	Supportive treatment for improvement of haemostasis where standard techniques are not sufficient. Restricted for use in obstetric and gynaecological surgery. (NDP January 2010).	

evinacumab	vials, concentrate for solution for infusion, 345mg, 1200mg	2.12	R	In line with NICE TA guidance no. 1002, September 2024: Evinacumab alongside diet and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies is recommended, within its marketing authorisation, as an option for treating homozygous familial hypercholesterolaemia (HoFH) in people 12 years and over. It is only recommended if the company provides it according to the commercial arrangement.	PBR
Eviplera ®	tablets emtricitabine 200mg, rilpivirine 25mg (as hydrochloride) and tenofovir disoproxil 245mg (as fumerate)	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
evolocumab	solution for injection, pre-filled pen 140mg		R	In line with NICE TA guidance no. 394, June 2016: Evolocumab is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if the dosage is 140 mg every 2 weeks, low-density lipoprotein concentrations are persistently above the thresholds despite maximal tolerated lipid-lowering therapy (that is, either the maximum dose has been reached, or further titration is limited by intolerance, as defined in NICE's guideline on familial hypercholesterolaemia) and the company provides evolocumab with the discount agreed in the patient access scheme.	PBR RL
Evra®	patch 6 mg norelgestromin and 600 micrograms ethinylestradiol	7.03.1	A	NDP September 2018	
exagamglogene autotemcel	dispersion for infusion 4-13x10^6 cell/ml	not classified	R	In line with NICE TA guidance no 1003, September 2024: Exagamglogene autotemcel (exa-cel) is recommended with managed access as an option for treating transfusion-dependent beta-thalassaemia in people 12 years and over when a haematopoietic stem cell transplant (HSCT) is suitable, but a human leukocyte antigen-matched related haematopoietic stem cell donor is not available only if the conditions in the managed access agreement for exa-cel are followed.	PBR

exagamglogene autotemcel	dispersion for infusion 4-13x10^6 cell/ml	not classified	R	In line with NICE TA guidance no. 1044, February 2025: Exagamglogene autotemcel (exa-cel) is recommended with managed access as an option for treating sickle cell disease (SCD)in people 12 years and over: who have: – recurrent vaso-occlusive crises (VOCs) and – a β^S/β^S, β^S/β^+ or βS/β0 genotype and • when haematopoietic stem cell transplant (HSCT) is suitable, but a human leukocyte antigen-matched related haematopoietic stem cell donor is not available. It is only recommended for people who have had at least 2 VOCs per year during the 2 previous years and if the conditions in the managed access agreement for exa-cel are followed.	PBR
exemestane	tablets 25mg	8.03.4	R	In line with the local /national guidelines and protocols.	
Extraneal	bags, 2000ml	20	A	Peritoneal dialysised as an alternative to Physioneal	

ezetimibe	tablets 10mg	2.12	R	In line with NICE TA guidance no. 385, Feb 2016. (This guidance should be read in conjunction with NICE clinical guidelines): 1. Ezetimibe monotherapy is recommended as an option for treating primary (heterozygous-familial or non-familial) hypercholesterolaemia in adults in whom initial statin therapy is contraindicated. 2. Ezetimibe monotherapy is recommended as an option for treating primary (heterozygous-familial or non-familial) hypercholesterolaemia in adults who cannot tolerate statin therapy. 3. Ezetimibe, co-administered with initial statin therapy, is recommended as an option for treating primary (heterozygous-familial or non-familial) hypercholesterolaemia in adults who have started statin therapy when serum total or low-density lipoprotein (LDL) cholesterol concentration is not appropriately controlled either after appropriate dose titration of initial statin therapy or because dose titration is limited by intolerance to the initial statin therapy and a change from initial statin therapy to an alternative statin is being considered. 4. When prescribing ezetimibe co-administered with a statin, ezetimibe should be prescribed on the basis of lowest acquisition cost. 5. For the purposes of this guidance, intolerance to initial statin therapy is defined as the presence of clinically significant adverse effects that represent an unacceptable risk to the patient or that may reduce compliance with therapy. 6. For the purposes of this guidance, appropriate control of cholesterol concentrations should be based on individual risk assessment according to national guidance on managing cardiovascular disease in the relevant populations.	
factor IX fraction, dried	dried recombinant; high purity plasma derived 500 units, 1000 units (BeneFIX ®)	2.11	R		PBR
factor IX recombinant	500 units and 1000 units (BeneFIX ®)	2.11	R	For all children under the age of 16 and new patients in line with Health Service Circular HSC 1999/006 (22 January 1999)	PBR
factor VII fraction,	dried recombinant; high purity plasma derived 500 units (eg Monoclate-P ®, Immuno FVII ®)	2.11	R	Restricted for use by haematology teams only	PBR

factor VIIa recombinant	injection 1mg, 2mg, 5mg, 8mg (NovoSeven ®)	2.11	R	1. for treatment of babies with severe internal bleeding where it is suspected that this may be due to a new presentation of a hereditary coagulopathy for immediate treatment to control life threatening bleeding before a definitive diagnosis can be confirmed once the baby's condition has stabilised. 2. for intractable haemorrhage failing to respond to standard measures and after adequate replacement therapy. e.g. obstetric haemorrhage, or a patient in whom a surgical approach is not feasible or is thought to be associated with unacceptable risk e.g. post bypass surgery. Stocks of rFVIIa will be held in the haemophilia unit at HH and the haematology lab at CXH. Pharmacy will not hold stocks. For both indications a consultant haematologist will authorise the use of rFVIIa following a discussion with a consultant from the treating department. The cost of the rFVIIa used will be re-charged to that department.	PBR
factor VIIa, recombinant	injection 1mg, 2mg, 5mg, 8mg (NovoSeven ®)	2.11	R	For use in haemophilia patients with antibodies (inhibitors) to factors VIII and IX. Haematology teams only	PBR
factor VIII fraction, dried (Human Antihaemophilic Fraction, Dried)	500 units, 1000 units (Haemate P ®, Voncento®) 1000 units (Replenate ®)	2.11	R		PBR
factor VIII inhibitor bypassing fraction	1000 units (FEIBA ®)	2.11	R		PBR
factor VIII recombinant	250units, 500 units, 1000 units, 1500 units, 2000 units, 3000 units (Advate ®); 500 units, 1000 units (Kogenate ®); 250 units, 500 units, 1000 units (ReFacto ®) 250units, 500 units, 1000units, 1500units, 2000units, 3000units (NovoEight®)	2.11	R	Restricted for use by haematology teams.	PBR
famciclovir	tablets 125mg, 250mg	5.03.2	R	Restricted to GUM for treatment resistant herpes non responsive to aciclovir or valaciclovir	
famotidine	20mg, 40mg tablets	1.03.1	A	Replaces ranitidine (Jan 2020)	
Fansidar ®	tablets containing pyrimethamine 25mg and sulfadoxine 500mg	5.04.1	A	Level 1 non-reserved anti-infective	

faricimab	vials, solution for injection, 120mg/ml pre-filled syringes, solution for injection, 120mg/ml	11.08.2	R	1. In line with NICE TA guidance no. 799, June 2022: Faricimab is recommended as an option for treating visual impairment due to diabetic macular oedema in adults, only if the eye has a central retinal thickness of 400 micrometres or more at the start of treatment the company provides faricimab according to the commercial arrangement. If patients and their clinicians consider faricimab to be 1 of a range of suitable treatments (including aflibercept and ranibizumab), choose the least expensive treatment. Take account of administration costs, dosage, price per dose and commercial arrangements.	PBR
faricimab	vials, solution for injection, 120mg/ml pre-filled syringes, solution for injection, 120mg/ml	11.08.2	R	2. In line with NICE TA guidance no. 800, June 2022: Faricimab is recommended as an option for treating wet age-related macular degeneration in adults, only if the eye has a best-corrected visual acuity between 6/12 and 6/96, there is no permanent structural damage to the central fovea, the lesion size is 12 disc areas or less in greatest linear dimension there are signs of recent disease progression (for example, blood vessel growth as shown by fluorescein angiography, or recent visual acuity changes), the company provides faricimab according to the commercial arrangement. If patients and their clinicians consider faricimab to be 1 of a range of suitable treatments (including aflibercept and ranibizumab), choose the least expensive treatment. Take account of administration costs, dosage, price per dose and commercial arrangements.	PBR
faricimab	vials, solution for injection, 120mg/ml pre-filled syringes, solution for injection, 120mg/ml	11.08.2	R	3. In line with NICE TA guidance no. 1004, September 2024: Faricimab is recommended, within its marketing authorisation, as an option for treating visual impairment caused by macular oedema after central or branch retinal vein occlusion in adults. It is only recommended if the company provides it according to the commercial arrangement.	PBR
febuxostat	tablets 80mg, 120mg	10.01.4	R	In line with NICE TA guidance no. 164, Dec-08: Febuxostat is recommended as an option for the management of chronic hyperuricaemia in gout only for people who are intolerant of allopurinol or for whom allopurinol is contraindicated.	

fedratinib	capsules, 100mg	8.01.5	R	In line with NICE TA guidance no. 1018, November 2024 (replaces NICE TAG 756, December 2021): Fedratinib is recommended as an option for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis. It is recommended for adults, only if: they have had ruxolitinib, and momelotinib is unsuitable, and the company provides fedratinib according to the commercial arrangement.	PBR RL
felodipine	MR tablets 2.5mg, 5mg;	2.06.2	A		
Femodene ®; Minulet ®	21 tablets ethinylestradiol 30 micrograms + gestodene 75 micrograms	7.03.1	A		
fenfluramine	oral solution, 2.2mg in 1ml	4.08.1	R	In line with NICE TA guidance no. 808, July 2022: Fenfluramine is recommended as an add-on to other antiseizure medicines for treating seizures associated with Dravet syndrome in people aged 2 years and older, only if seizures have not been controlled after trying 2 or more antiseizure medicines the frequency of convulsive seizures is checked every 6 months, and fenfluramine is stopped if it has not fallen by at least 30% compared with the 6 months before starting treatment the company provides fenfluramine according to the commercial arrangement.	PBR RL
fenfluramine	oral solution, 2.2mg in 1ml	4.08.1	R	In line with NICE TA guidance no. 1050, March 2025: Fenfluramine is recommended as an option for treating seizures associated with Lennox–Gastaut syndrome (LGS), as an add-on to other antiseizure medicines, for people 2 years and over. It is recommended only if the frequency of drop seizures is checked every 6 months, and fenfluramine is stopped if the frequency is not reduced by at least 30% compared with the 6 months before starting treatment the company provides it according to the commercial arrangement.	PBR RL
fenofibrate	capsules (micronised) 67mg, 200mg, 267mg; tablets (micronised) 160mg	2.12	A		
fentanyl	injection 100mcg in 2ml, 500mcg in 10ml;	15.01.4	A		
fentanyl	Oral transmucosal lozenges 200mcg, 400mcg, 600mcg, 800mcg, 1.2mg, 1.6mg	4.07.2	removed from the Formulary (NDP November 2011)		

fentanyl	Buccal tablets 100mcg, 200mcg, 400mcg, 600mcg, 800mcg (Effentora ® brand only)	4.07.2	R	For the treatment of breakthrough pain (BTP) in adult patients who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. The doses of the different brands of buccal tablets are not equivalent. Only the Palliative Care specialists will prescribe this BTP; the buccal tablets will not be prescribed for chronic pain. The fentanyl lozenges removed from the Formulary (NDP November 2011)	
fentanyl	nasal spray 100mcg, 400mcg	4.07.2	R	For the treatment of breakthrough pain (BTP) in adult patients who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Only the Palliative Care specialists will prescribe this BTP; the buccal tablets will not be prescribed for chronic pain. (NDP November 2011)	
fentanyl	injection 100 micrograms in 2ml, 500 micrograms in 10ml; patches, self-adhesive & transparent 12mcg, 25mcg, 37.5mcg, 50mcg, 75mcg and 100mcg/hour. 72 hour patches.	4.07.2	R		
fentanyl	PCA infusion 3mg in 300ml (unlicensed)	4.07.2	R	PCA for sickle cell patients under care of Acute Pain Team and for epidural use.	
ferric carboxymaltose (Ferinject®)	50mg iron in 1ml vials, 2ml, 10ml, 20ml	9.01.1	A	For treatment of iron deficiency, where approved by individual specialties. To replace Monofer® as parenteral iron preparation of choice, for faster administration. Cosmofer® still first line parenteral iron. (NDP September 2015)	
ferric maltol	capsules, 30mg	9.01.1	R	For treatment of iron deficiency anaemia in IBD. Prescribing by gastroenterology only. GPs not to be asked to continue prescribing. To be supplied via Lloyds outpatient dispensaries. NDP May 2022	
ferrous fumarate	tablets 210mg (68mg iron), 322mg (100mg iron) ; syrup 140mg in 5ml (45mg iron in 5ml).	9.01.1	A		
ferrous gluconate	tablets 300mg (35mg iron).	9.01.1	A		
ferrous sulphate	tablets 200mg (65mg iron); MR tablets 325mg (105mg iron).	9.01.1	A		

fesoterodine	tablets SR 4mg, 8mg	7.04.2	A		
fibrinogen	1g powder	2.11	A		PBR
fidaxomicin	200mg tablets 40mg/mL granules for suspension	5.01.7	very R	Level 3 restricted anti-infective - approved as an option for treatment of recurrent *C difficile* associated disease after 2nd or 3rd relapse on ID/Microbiology consultant recommendation only. (September 2012)	
filgotinib	tablets 100mg, 200mg	10.01.3	R	In line with NICE TA guidance no 676, February 2021: Filgotinib as monotherapy or in combination with methotrexate is recommended as an option for the treatment of active rheumatoic arthritis as stipulated by NICE and the company provides filgotinib according to the commercial arrangement.	PBR RL
filgotinib	tablets 100mg, 200mg	10.01.3	R	In line with NICE TA guidance no. 792, June 2022: Filgotinib is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or if the disease has not responded well enough or has stopped responding to these treatments, and if the company provides filgotinib according to the commercial arrangement.	PBR RL
filgrastim (Recombinant human granulocyte-colony stimulating factor, G-CSF)	injection 30 million units in 0.5ml; injection 48 million units in 0.5ml (Neupogen ®)	9.01.6	R	Restricted for a small number of indications where Zarzio®/Accofil® cannot be used.	RL
filgrastim (Recombinant human granulocyte-colony stimulating factor, G-CSF)	pre-filled injection 30 million units in 0.5ml; pre-filled injection 48 million units in 0.8ml (Ratiograstim ®)	9.01.6	R	This is a biosimilar medicine approved for use to replace Neupogen ® where clinicians decide to do so. (July 2009)	RL
filgrastim (Recombinant human granulocyte-colony stimulating factor, G-CSF)	pre-filled syringe 30 million units in 0.5ml; pre-filled syringe 48 million units in 0.5ml; (Zarzio®) (Accofil)	9.01.6	R	1. This is a biosimilar medicine approved for use to replace Neupogen ® where clinicians decide to do so. (Aug 2011) 2. To replace pegfilgrastim for haematology and oncology patients according to local protocols (May 2014)	RL
finasteride	tablets 5mg	6.04.2	A		

finerenone	tablets 10mg, 20mg	2.02.3	R	In line with NICE TA guidance no. 877, March 2023: Finerenone is recommended as an option for treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults. It is recommended only if: • it is an add-on to optimised standard care; this should include, unless they are unsuitable, the highest tolerated licensed doses of: – angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) and – sodium–glucose cotransporter-2 (SGLT2) inhibitors and • the person has an estimated glomerular filtration rate (eGFR) of 25 ml/min/ 1.73 m2 or more.	
fingolimod	capsules 500micrograms	8.02.4	R	In line with NICE TA guidance no. 254, April 2012: fingolimod is recommended as an option for the treatment of highly active relapsing–remitting multiple sclerosis in adults, only if they have an unchanged or increased relapse rate or ongoing severe relapses compared with the previous year despite treatment with beta interferon, and the manufacturer provides fingolimod with the discount agreed as part of the patient access scheme.	PBR RL
flecainide	tablets 50mg, 100mg; injection 150mg in 15ml	2.03.2	A		
flucloxacillin	capsules 250mg, 500mg; syrup 125mg in 5ml, 250mg in 5ml; injection 250mg, 500mg, 1g	5.01.1	A	Level 1 non-reserved anti-infective	
fluconazole	capsules 50mg, 150mg, 200mg; suspension 50mg in 5ml, 200mg in 5ml; IV infusion 50mg in 25ml, 200mg in 100ml	5.02.1	A	Level 1 non-reserved anti-infective.	
flucytosine	tablets 500mg (unlicensed); Intravenous infusion 2.5g in 250ml	5.02.5	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required	
fludarabine	injection 50mg; tablets 10mg	8.01.3	R	1. In line with NICE TA guidance no. 29; Sept-01, as second line therapy for the treatment for B-cell chronic lymphocytic leukaemia (CLL) for patients who have failed, or are intolerant of, first line chemotherapy, and who would otherwise have received combination chemotherapy. The oral formulation is preferred to the intravenous formulation on the basis of more favourable cost effectiveness. Intravenous fludarabine should only be used when oral fludarabine is contraindicated.	PBR
fludarabine	injection 50mg; tablets 10mg	8.01.3	R	2. For the oral treatment of patients with relapsed indolent (low-grade) Non-Hodgkin's Lymphoma (NHL) as second line therapy.	PBR
fludrocortisone acetate	tablets 100mcg	6.03.1	A		

fludroxycortide (flurandrenolone)	cream 0.0125%; ointment 0.0125%; tape 4 micrograms/sq.cm	13.04	R	Restricted for use by Dermatology teams only.	
flumazenil	injection 500mcg in 5ml	15.01.7	A		
fluocinolone acetonide Iluvien®	Intravitreal implant 190micrograms	11.04.1	R	In line with NICE TA guidance no 953, March 2024 (to replace NICE TA 301 and 613): Fluocinolone acetonide intravitreal implant is recommended, within its marketing authorisation, as an option for treating visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available treatments in adults. It is recommended only if the company provides it according to the commercial arrangement.	PBR
fluocinolone acetonide Iluvien®	Intravitreal implant 190micrograms	11.04.1	R	In line with NICE TA guidance no 590, july 2019: Fluocinolone acetonide intravitreal implant is recommended, within its marketing authorisation, as an option for preventing relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye. It is recommended only if the company provides it according to the commercial arrangement.	PBR
fluocinolone acetonide	cream 0.025% (30g); ointment 0.025%; gel 0.025% (For use on scalp and other hairy areas); cream 0.00625% (Synalar 1 in 4 Dilution ®); ointment 0.00625% (Synalar 1 in 4 Dilution ®); cream 0.0025% (Synalar 1 in 10 Dilution ®)	13.04	A		
fluocinonide	FAPG cream 0.05%; ointment 0.05%	13.04	A		
fluorescein sodium	eye-drops preservative-free, 1%, 2% Strips	11.08.2	A		
fluorescein sodium	injection 5% (unlicensed), 10%	19.02	A		
fluorescein with proxymetacaine	Minims ®, Proxymetacaine And Fluorescein. Eye drops, proxymetacaine hydrochloride 0.5%, fluorescein sodium 0.25%.	11.07	A		
fluorometholone	eye drops 0.1%	11.04.1	A		
fluorouracil	injection 250mg, 500mg, 2.5g; capsules 250mg (named patient)	8.01.3	A		PBR
fluorouracil	cream 5%	13.08.1	A		

fluorouracil/salcylic acid	5%/10% cutaneous solution	13.08.1	A	NDP July 2024	
fluoxetine	capsules 20mg; liquid 20mg in 5ml	4.03.3	A		
flupentixol	tablets 3mg	4.02.1	A		
flupentixol	tablets 500mcg, 1mg	4.03.4	A		
flupentixol decanoate	injection (oily) 12.5mg in 0.5ml, 20mg in 1ml, 40mg in 2ml, 50mg in 0.5ml, 100mg in 1ml; 200mg in 1ml	4.02.2	A		
fluphenazine	tablets 1mg, 2.5mg	4.02.1	A		
fluphenazine decanoate	injection (oily) 12.5mg in 0.5ml, 50mg in 2ml, 100mg in 1ml. Contains sesame oil.	4.02.2	R	Restricted to mental health- for continuation only.	
flurbiprofen	Tablets, 50mg & 100mg.	10.01.1	R	For use by ophthalmologists only for occular inflammation only.	
flurbiprofen	eye drops 0.03% preservative free	11.04.2	R		
flutamide	tablets 250mg	8.03.4	A		
fluticasone	Evohaler ® aerosol inhalation 50mcg/metered inhalation, 125mcg/metered inhalation, 250mcg/metered inhalation; Accuhaler ® 50mcg/blister, 100mcg/blister, 250mcg/blister, 500mcg/blister	3.02	R	for use in patients requiring > 1000mcg/day inhaled beclometasone or budesonide.	
fluticasone furoate	nasal spray, 27.5 micrograms per metered spray	12.02.1	A	For allergic rhinitis in adults and children over the age of 6 years; the main usage is expected in primary care. Avamys ® is currently the least costly glucocorticosteroid ester. As the difference between the available preparations is not in their efficacy but in the type of delivery devices, the first line treatment in the future should be the least costly preparation unless there is a specific reason for preference for a particular type of device. (NDP - November 2010)	
fluticasone furoate/ vilanterol (Relvar® Ellipta®)	inhalation powder 92mcg/22mcg 184mcg/22mcg	3.02	R	For initiation by respiratory teams. (NDP March 2015)	
fluticasone propionate	cream 0.05%; ointment 0.005%	13.04	R	to be used second line after betnovate	
fluticasone propionate	Aqueous nasal spray, 50 micrograms per metered spray (Flixotide ®). Nasal drops, fluticasone propionate 400 micrograms/unit dose (Flixonase Nasule®).	12.02.1	R	For use as a second line drug by ENT surgeons or respirologists only. Nasules for nasal polyps.	

Flutiform®	metered dose inhaler, formoterol fumarate dihydrate/fluticasone propionate 5mcg/50mcg per dose, 120 doses 5mcg/125mcg per dose, 120 doses 10mcg/250 mcg per dose, 120 doses	3.02	A	In line with the local /national guidelines (NDP May 2013).	
Fobumix®	Easyhaler (inhalation powder), budesonide (mcg)/ formoterol fumarate (mcg) 80/4.5, 160/4.5, 320/9	3.02	A	NWL JF committee, January 2025	
folic acid	tablets 400mcg, 5mg; syrup 2.5mg in 5ml; injection 15mg in 1ml	9.01.2	A		
follitropin alfa and beta (recombinant human follicle stimulating hormone)	pre-filled pens, Gonal-F® brand pre-filled pens, Bemfola® brand	6.05.1	A	various strengths of each brand kept in pharmacy	RL
fomepizole	injection 100mg in 20ml (unlicensed)	not classified	R	Emergeny use in A&E for ethylene glycol and mathanol poisoning	PBR
fondaparinux	injection 5mg in 1ml (1.5mg, 2.5mg pre-filled syringes); injection 12.5mg in 1ml (5mg, 7.5mg, 10mg pre-filled syringes)	2.08.1	R	1. In line with NICE Clinical Guidelines no. 9, March 2010: Unstable angina and NSTEMI 2. For treatment of HITs accorting to haematology protocol (unlicensed indication), NDP April 2014.	RL
Forceval ®	capsules; tablets (effervescent and junior effervescent)	9.06.7	R	For patients with gastrointestinal malabsorption.	
formoterol	Turbohaler® 6mcg/inhalation, Turbohaler ®12mcg/inhalation, Inhalation capsules 12mcg Easyhaler® 12mcg/inhalation powder	3.01.1	A		
fosamprenavir	tablets 700mg	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
fosaprepitant	injection 150mg	4.06	R	for the prevention of acute and delayed nausea and vomiting in patients on highly emetogenic cisplatin based cancer chemotherapy in adults as 2nd line addition to treatment in patients who experience sever nausea and vomitting on moderately emetogenic chemotherapy regimens despite standard treatment	

foscarnet	Intravenous infusion 6g in 250ml	5.03.2	R	Level 2 anti-infectives restricted to specific indications: As per Haematology anti-infective policy As per Paediatric Oncology/ Haematology protocols As per Paediatric HIV and congenital CMV protocols	PBR
fosfomycin	2g fosfomycin (as disodium) powder for solution for infusion 3g sachets for oral administration (fosfomycin trometamol)	5.01.13	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required For treatment of (a) lower urinary tract infections caused by multi-drug resistant organisms b) last line therapy caused by multi-drug resistant organisms. (NDP February 2014)	
foslevodopa-foscarbidopa	solution for infusion, 10ml vials (240mg/ml and 12mg/ml)	4.09.1	R	In line with NICE TA guidance 934, November 2023: Foslevodopa–foscarbidopa is recommended as an option for treating advanced levodopa-responsive Parkinson's in adults whose symptoms include severe motor fluctuations and hyperkinesia or dyskinesia, when available medicines are not working well enough, only if they cannot have apomorphine or deep brain stimulation, or these treatments no longer control symptoms, and the company provides foslevodopa–foscarbidopa according to the commercial arrangement.	PBR
Fostair® Luforbec® Bibecfo®	aerosol inhalation, beclometasone dipropionate 100mcg/200mcg, formoterol fumarate 6mcg per metered inhalation	3.02	A	For treatment of moderate asthma in adults requiring a combination of inhaled steroid and a long acting beta agonist. (NDP Jan 2010) In line with the local and national guidelines. For new patients ***Luforbec/Bibecfo*** *are* the inhalers of choice as of June 2024 in line with NWL JF.	
Fostair ® NEXThaler	inhalation powder, beclomethasone dipropionate/formaterol fumarate 100/6, 200/6	3.02	A	NDP September 2016	
fostamatinib	tablets 100mg, 150mg	9.01.4	R	In line with NICE TA guidance no. 835, October 2022: Fostamatinib is recommended as an option for treating refractory chronic immune thrombocytopenia (ITP) in adults, only if: they have previously had a thrombopoietin receptor agonist (TPO-RA), or a TPO-RA is unsuitable the company provides fostamatinib according to the commercial arrangement.	PBR RL
framycetin	Solution, 0.5% for donor eyes.	11.03.1	A		

fremanezumab	pre-filled pen/syringe, 225mg	4.07.4	R	In line with NICE TA guidance no 631, June 2020: Fremanezumab is recommended as an option for preventing migraine in adults, only if the migraine is chronic, that is, 15 or more headache days a month for more than 3 months with at least 8 of those having features of migrain, at least 3 preventive drug treatments have failed and the company provides it according to the commercial arrangement. Stop fremanezumab if the migraine frequency does not reduce by at least 30% after 12 weeks of treatment.	RL
fremanezumab	pre-filled pen/syringe, 225mg	4.07.4	R	In line with NICE TA guidance no 764, February 2022: Fremanezumab is recommended as an option for preventing migraine in adults, only if they have 4 or more migraine days a month at least 3 preventive drug treatments have failed and the company provides it according to the commercial arrangement. Stop fremanezumab after 12 weeks of treatment if in episodic migraine (fewer than 15 headache days a month), the frequency does not reduce by at least 50% in chronic migraine (15 headache days a month or more with at least 8 of those having features of migraine), the frequency does not reduce by at least 30%.	RL
frovatriptan	tablets 2.5mg	4.07.4	R	For use in patients whose headaches are relatively prolonged so that they have to take several doses of a shorter acting triptan. The dispensaries will not routinely hold stock of this drug.	
fructose	powder 25g	19.01	R	for hydrogen breath test	
fruquintinib	capsules 1mg, 5mg	8.01.3	R	In line with NICE TA guidance no. 1079, July 2025: Fruquintinib can be used as an option at third line or later to treat metastatic colorectal cancer in adults when previous treatment has included fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without anti-vascular endothelial growth factor (VEGF) treatment, and anti-epidermal growth factor receptor (EGFR) treatment if the cancer is RAS wild-type, unless this was not suitable. Fruquintinib can only be used if trifluridine–tipiracil with bevacizumab is not suitable the company provides it according to the commercial arrangement.	PBR
FuciBet ®	cream containing betamethasone valerate 0.1% and fusidic acid 2%	13.04	R	Restricted to dermatology and HIV only	
Fucidin H ®	cream containing hydrocortisone acetate 1% and fusidic acid 2%	13.04	R	Dermatologists only.	
Fuller's earth		17	A		
fulvestrant	injection 250mg in 5ml	8.03.4	R	4th line therapy for postmenopausal women with OR positive, locally advanced or metastatic breast cancer.	

furosemide	tablets 20mg, 40mg, 500mg; oral liquid 1mg in 1ml, 10mg in 1ml oral solution 20mg in 5ml, 40mg in 5ml, 50mg in 5ml; injections 20mg in 2ml, 50mg in 5ml, 250mg in 25ml	2.02.2	A		
fusidic acid	cream 2%; ointment 2%; gel 2%	13.10.1	A		
fusidic acid	eye drops 1%; MR eye drops 1%	11.03.1	A		
futibatinib	tablets, 4mg	8.01.5	R	In line with NICE TA guidance no. 1005, September 2024: Futibatinib is recommended, within its marketing authorisation, as an option for treating locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that has progressed after at least 1 line of systemic treatment in adults. Futibatinib is only recommended if the company provides it according to the commercial arrangement.	
gabapentin	capsules 100mg, 300mg, 400mg; titration pack, tablets 600mg oral solution (sugar free) 50mg in 5ml	4.08.1	A	800mg tablets are non-formulary	
gadobutrol (Gadovist®)	pre-filled injection 7.5ml, 10ml, 15ml	18	R	MRI to use most cost effective product (Gadovist, Multihance, Magnevist or ProHance) except when there is a clinical indication for a specific product. Gadovist is currently considered the safest priduct when used in renal impairment. (July 2009)	
gadolinium (Magnevist®)	injection 9.38g in 20ml	18	R	MRI to use most cost effective product (Multihance, Magnevist or ProHance) except when there is a clinical indication for a specific product.	
gadoteridol (ProHance®)	injection 279.3mg in 1ml	18	R	MRI to use most cost effective product (Multihance, Magnevist or ProHance) except when there is a clinical indication for a specific product.	
gadoxetic acid, disodium (Primovist®)		18		For MRI of the liver. Prof Gedroyc to use in study to compare cost effectiveness (NDP January 2009). Prof Gedroyc to continue to use and audit. To feedback to Panel in 12 months (NDP November 2009)	
galantamine	MR capsules 8mg, 16mg, 24mg oral solution 4mg in 1ml	4.11	R	In line with NICE TA guidance no. 217, Mar-11 (last updated May 2016): The three acetylcholinesterase (AChE) inhibitors donepezil, galantamine and rivastigmine are recommended as options for managing mild to moderate Alzheimer's disease.	

galcanezumab	pre-filled pen, 120mg	4.07.4	R	In line with NICE TAG no 659, November 2020: Galcanezumab is recommended as an option for preventing migraine in adults, only if: • they have 4 or more migraine days a month • at least 3 preventive drug treatments have failed and • the company provides it according to the commercial arrangement. Stop galcanezumab after 12 weeks of treatment if: • in episodic migraine (less than 15 headache days a month) the frequency does not reduce by at least 50% • in chronic migraine (15 headache days a month or more with at least 8 of those having features of migraine) the frequency does not reduce by at least 30%.	RL
ganciclovir	capsules 250mg; injection 500mg	5.03.2	R	Level 2 anti-infectives restricted to specific indications: As per Haematology anti-infective policy As per Paediatric Oncology/ Haematology protocols As per Renal anti-infective policy As pre Paediatric HIV and congenital CMV protocols	PBR RL
ganciclovir	ophthalmic gel 0.15%	11.03.3	A		
ganirelix	injection 250mcg in 0.5ml	6.07.2	R		RL
Gastrografin ®	solution 76% (100ml); liquid (12ml, 100ml)	18	A		
Gastromiro	solution, 20ml	18	A		
Gaviscon ®	Gaviscon Advance ® Suspension; Infant Gaviscon ® Oral powder; Gaviscon® Original	1.01.2	A	Gaviscon® Original replaces Peptac® (July 2023)	
gefitinib	tablets 250mg	8.01.5	R	In line with NICE TA guidance no. 192; Jul-10. Gefitinib is recommended as an option for the first-line treatment of people with locally advanced or metastatic non-small-cell lung cancer (NSCLC) if they test positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and the manufacturer provides gefitinib at the fixed price agreed under the patient access scheme.	PBR; RL
GelX®	oral spray	9.05.2	R	For prevention and treatment of oral stomatitis/mucositis, in line with the local guideline. (NDP November 2025)	
gelatin	Intravenous infusion Gelofusine ® 500ml; Volplex ® 500ml	9.02.2	A		

gemcitabine	injection 200mg, 1g	8.01.3	R	1. For use combined with platinum (carboplatin/cisplatin) for palliative treatment of advanced ovarian cancer. (updated NDP July 2013)	PBR
gemcitabine	injection 200mg, 1g	8.01.3	R	2. In line with NICE TA guidance no. 25; May-01, for the treatment of patients with advanced metastatic adrenocarcinoma of the pancreas according to the NICE set criteria.	PBR
gemcitabine	injection 200mg, 1g	8.01.3	R	3. In line with NICE TA guidance no. 26; Jun-01, as part of first-line therapy for advanced (stage III and IV) non-small cell lung cancer (NSCLC).	PBR
gemcitabine	injection 200mg, 1g	8.01.3	R	4. In combination with cisplatin for advanced bladder cancer. Cancer Services will have to apply for funding for this treatment at Hammersmith and Fulham PCT and Ealing PCT.	PBR
gemcitabine	injection 200mg, 1g	8.01.3	R	5. In combination with platinum for the palliative treatment of relapsed metastatic testicular germ cell tumours in 2-3 patients p.a.	PBR
gemcitabine	injection 200mg, 1g	8.01.3	R	6. To standardise practice, for use in combination with vinorelbine and ifosfamide for the treatment of relapsed Non Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for patients in 1st relapse who are not eligible for stem cell transplant or for patients in 2nd relapse post stem cell transplant.	PBR
gemcitabine	injection 200mg, 1g	8.01.3	R	7. for treatment of metastatic uveal melanoma, used in combination with treosulfan,	PBR
gemfibrozil	tablets 600mg	2.12	A		
gemtuzumab ozogamicin	injection 5mg	8.02.4	R	for the treatment of relapsed CD33-positive acute myeloid leukaemia (AML) in patients over 60 years of age	PBR
gentamicin	injection 20mg in 2ml, 80mg in 2ml; infusion 80mg in 80ml 0.9% sodium chloride, 240mg in 80ml 0.9% sodium chloride, 360mg in 120ml 0.9% sodium chloride; intrathecal injection 5mg in 1ml; beads	5.01.4	A	Level 2 anti-infectives restricted to specific indications Beads for use in theatres only.	
gentamicin	Drops (for ear or eye), 0.3% (Genticin ®)	12.01.1	A		
gentamicin	Drops (for ear or eye), 0.3%. Eye drops, 0.3% preservative free (Unlicensed product.). Eye drops, 1.5%. Eye drops, 1.5% preservative free. Eye ointment, 0.3%. Single use Minims ® eye drops, 0.3%.	11.03.1	A		

gentamicin	cream 0.1% (unlicensed)	13.10.1	R	For peritoneal dialysis exit site infections known to be colonised with pseudomonas.	
Gentisone HC ®	Ear drops, hydrocortisone acetate 1%, gentamicin 0.3% (as sulphate)	12.01.1	A	Gentisone HC not to be recommended for primacy care prescribing. (as per NWL IF, March 2024)	
gestrinone	capsules 2.5mg	6.07.2	A		
gilteritinib	tablets 40mg	8.01.5	R	In line with NICE TA guidanance no. 642, August 2020: Gilteritinib monotherapy is recommended as an option for treating relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia (AML) in adults only if the company provides gilteritinib according to the commercial arrangement. Gilteritinib should not be given as maintenance therapy after a haematopoietic stem cell transplant.	PBR; RL
glatiramer acetate	injection 20mg/ml pre-filled syringe injection 40mg/ml pre-filled syringe	8.02.4	R	For use as specified in the NHS England commissioning statement (August 2015), Multiple Sclerosis: Fist line disease modifying agents. Part of DH Risk Share Scheme. (NDP September 2015)	PBR RL
glecaprevir/ pribrentasvir (Maviret®)	tablets, granules in sachets 100mg/40mg	5.03.3	R	In line with NICE TA guidance no. 499, January 2018: Glecaprevir–pibrentasvir is recommended, within its marketing authorisation, as an option for treating chronic hepatitis C in adults, only if the company provides the drug at the same price or lower than that agreed with the Commercial Medicines Unit.	PBR RL
gliclazide	tablets 40mg, 80mg; MR tablets 30mg	6.01.2	A	MR Tablets are non-formulary.	
glimepiride	tablets 1mg, 2mg, 3mg, 4mg	6.01.2	R	For use by Endocrinology Teams - for patients with hypoglycaemia not controlled with other sulphonlureas.	
glofitamab	2.5mg, 10mg concentrate for solution for infusion	8.02.3	R	In line with NICE TA guidance no. 927, October 2023: Glofitamab is recommended, within its marketing authorisation, as an option for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments. Glofitamab is only recommended if the company provides it according to the commercial arrangement.	PBR
glucagon	injection 1 unit (1mg), 10mg	6.01.4	A		

glucose	IV infusion 5% (100ml, 250ml, 500ml, 1 litre); IV infusion 10% (500ml, 1 litre); IV infusion 10% (10ml - unlicensed), IV infusion 15% (500ml); IV infusion 20% (20ml, 500ml); IV infusion 40% (500ml); IV infusion 50% (50ml, 500ml); injection 50% (50ml vials/ampoules); Min-I-Jet syringe 50% (50ml)*; IV infusion 70% (500ml)	9.02.2	A		
glucose	powder 50g, 75g; Min-I-jet ® pre-filled syringe, glucose 50%, 50ml; injection 10%, 20%; infusion 50%, 500ml bag; gel 40% 10g	6.01.4	A		
glucose 4% and sodium chloride 0.18%	IV infusion (500ml, 1 litre)	9.02.2	A	Not for use in paediatrics	
glucose 5% and sodium chloride 0.9%	IV infusion (500ml)	9.02.2	A		
Glucostix		19.01	R	For patients with Glucometers only.	
glutaraldehyde	solution 10%	13.07	A		
glycerin	Eye drops, 10%, 30%, 50% all preservative free (unlicensed).	11.06	A		
glycerol BP	injection 4ml (unlicensed); liquid 1.1g in 1mL	16	A		
glycerol (glycerin)	suppositories, 1g (infant), 2g (child), 4g (adult)	1.06.2	A		
glyceryl trinitrate	sublingual tablets 500mcg; buccal modified-release tablets 2mg, 3mg;	2.06.1	A		
glyceryl trinitrate	rectal ointment 0.4% (Rectogesic ®) Rectal ointment 0.2%, unlicensed	1.07.4	R	0.4% product approved for adults for the treatment of anal fissures. SMH - 0.2% unlicensed product for use by paediatrics only	
glycine	irrigation 1.5% 1 litre, 3 litre	7.04.4	A		
glycine 1.5% & ethanol 1%	urological irrigation fluid	7.04.4	A	Medical device	
glycopyrronium bromide	50mcg dry powder capsules fo use with Breezhaler®	3.01.2	A	For COPD according to national guidelines. (NDP May 2014)	

glycopyrronium bromide/formoterol fumarate/beclometasone propionate (Trimbow® pMDI) (Trimbow® NEXThaler® DPI)	Pressured inhalation solution 9mcg/5mcg/87mcg per dose Dry Powder Inhaler 9mcg/5mcg/88mcg per dose Pressured inhalation solution 9mcg/5mcg/172mcg per dose	3.02	R	For use in line with the relevant national and local guidelines. (NDP September 2019) On recommendation of respiratory team. NEXThaler (NDP March 2022)	
glycopyrronium bromide	powder	13.12	R		
glycopyrronium bromide (glycopyrrolate)	injection 200mcg in 1ml, 600mcg in 3ml; tablets 1mg, 2mg (unlicensed - for Paediatrics only);	15.01.3	A		
glycopyrronium bromide (Sialanar®)	oral solution 250ml (400mcg in 1ml as glycopyrronium bromide or 320mcg in 1ml of glycopyrronium base)	15.01	R	For paediatric use only as per the product licence (NDP May 2018)	
golimumab	injection 50mg pre-filled pen; pre-filled syringe	1.5.3	R	1. In line with NICE TA guidance no 329, Feb-2015: Infliximab, adalimumab and **golimumab** are recommended, within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies. Golimumab is recommended only if the company provides the 100 mg dose of golimumab at the same cost as the 50 mg dose, as agreed in the patient access scheme.	PBR
golimumab	injection 50mg pre-filled pen; pre-filled syringe	10.01.3	R	2. In line with NICE TA guidance no. 220, Apr-11: Golimumab is recommended as an option for the treatment of active and progressive psoriatic arthritis in adults only if it is used as described for other tumour necrosis factor (TNF) inhibitor treatments (NICE TA guidance no. 199), and the manufacturer provides the 100 mg dose of golimumab at the same cost as the 50 mg dose.	PBR

golimumab	injection 50mg pre-filled pen; pre-filled syringe	10.01.3	R	3. In line with NICE TA guidance no. 375, Jan-2016 : Adalimumab, etanercept, infliximab, certolizumab pegol, **golimumab**, tocilizumab and abatacept, all in combination with methotrexate, are recommended as options for treating rheumatoid arthritis only if disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and disease has not responded to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs) and the companies provide certolizumab pegol, **golimumab**, abatacept and tocilizumab as agreed in their patient access schemes.	PBR
golimumab	injection 50mg pre-filled pen; pre-filled syringe	10.01.3	R	4. In line with NICE TA guidance no. 383, Feb-2016: Adalimumab, certolizumab pegol, etanercept, **golimumab** and infliximab are recommended, within their marketing authorisations, as options for treating severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs. Infliximab is recommended only if treatment is started with the least expensive infliximab product. People currently receiving infliximab should be able to continue treatment with the same infliximab product until they and their NHS clinician consider it appropriate to stop.	PBR
golimumab	injection 50mg pre-filled pen; pre-filled syringe	10.01.3	R	5. In line with NICE TA guidance no. 497, January 2018: Golimumab is recommended, within its marketing authorisation, as an option for treating severe non-radiographic axial spondyloarthritis in adults whose disease has responded inadequately to, or who cannot tolerate, nonsteroidal anti-inflammatory drugs. If patients and their clinicians consider golimumab to be one of a range of suitable treatments, including adalimumab, etanercept and certolizumab pegol, the least expensive (taking into account administration costs and patient access schemes) should be chosen.	PBR
gonadorelin (gonadotrophin-releasing hormone, GnRH, LH-RH)	Injection 100 microgram vial (HRF ®). Injection 1000 micrograms in 2ml (Fertiral ®).	6.05.1	A		RL
goserelin	implant 3.6mg syringe (as acetate) (Zoladex ®). Implant 10.8mg syringe (as acetate) (Zoladex LA ®). see sectiom 8.03.4	6.07.2	A	The least costly gonadorelin analogue will be used first line for their licensed indication.	
granisetron	tablets 1mg, 2mg; injection 3mg in 3ml	4.06	R	Oncology use where local protocols indicate.	

grass pollen extract (Grazax ®)	tablets, freeze dried 75,000 units	3.04.2	R	**Adult and paediatric use** - for treatment of grass pollen induced rhinitis and conjunctivitis in adult patients (18 years and older) with clinically relevant symptoms and diagnosed with a positive skin prick test and / or specific IgE test to grass pollen; approved as a second line treatment after the failure of symptomatic treatment. To be prescribed in line with licensed indication: Restricted to consultant only prescribing. (unlicensed for children younger than 5 years old).	RL
griseofulvin	tablets 125mg, 500mg; suspension 125mg in 5ml.	5.02.5	A	Level 1 non-reserved anti-infective	
growth hormone releasing hormone	injection 50mcg (Somatorelin ®) (unlicensed product)	not classified	R	For use incombination with arginine in diagnosing growth hormone deficiency (GHRH-arginine test). (NDP May 2010)	
guselkumab	solution for injection 100mg	10.01.3	R	1. In line with NICE TA guidance no. 521, June 2018: Guselkumab is recommended as an option for treating plaque psoriasis in adults as stipulated by NICE.	PBR
guselkumab	solution for injection 100mg	10.01.3	R	2. In line with NICE TA guidance no. 815, August 2022 (replaces TAG 711, June 2021): Guselkumab, alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them in line with NICE stipulations.	PBR
guselkumab	solution for injection 100mg	10.01.3	R	3. In line with NICE TA guidance 1094, August 2025: Guselkumab can be used as an option for treating moderately to severely active ulcerative colitis in adults when a conventional treatment, biological treatment or Janus kinase (JAK) inhibitor has not worked (that is, the condition has not responded well enough or lost response to treatment), or cannot be tolerated, and a tumour necrosis factor (TNF)-alpha inhibitor has not worked, cannot be tolerated or is not suitable. Guselkumab can only be used if the company provides it according to the commercial arrangement.	PBR
guselkumab	solution for injection 100mg	10.01.3	R	4. In line with NICE TA guidance no 1095, August 2025: Guselkumab can be used as an option for previously treated moderately to severely active Crohn's disease in adults, when conventional or biological treatment has not worked (that is, the condition has not responded well enough or lost response to treatment), or cannot be tolerated, and a tumour necrosis factor (TNF)-alpha inhibitor has not worked, cannot be tolerated or is not suitable. Guselkumab can only be used if the company provides it according to the commercial arrangement.	PBR

haemophilus influenzae type B vaccine (HiB)	injection	14.04	A		
haloperidol	tablets 500 micrograms; tablets 1.5mg, 5mg, 10mg, 20mg; oral liquid 5mg in 5ml; injection 5mg in 1ml, 20mg in 2ml;	4.02.1	A		
haloperidol decanoate	injection (oily) 50mg in 1ml, 100mg in 1ml	4.02.2	A		
halothane	250ml	15.01.2	R	For induction of anaesthesia and maintenance using low flow circuits only.	
Hemosol®	(for haemofiltration)	20	A		
heparin sodium (preservative free)	Intravenous injection 1,000 units per ml (1ml, 5ml and 10ml ampoules);	2.08.1	A	1000 units in 1ml is for use by Winnicott Baby Unit and Paediatrics.	
heparin sodium/calcium	Subcutaneous injection 5,000units in 0.2ml; CV catheter solution 50 units in 5ml, 200 units in 2ml; injection 5,000units in 5ml, 25,000units in 5ml, 10,000units in 10ml, 20,000units in 20ml, 50units in 5ml, 25,000units in 1ml ampoules; 500units in 500ml 0.9% sodium chloride, 1,000units in 500ml, 2,000units in 1l; 500units 0.45% sodium chloride in 500ml (for neonatal use);	2.08.1	A	Use in line with the relevant local guidelines.	
heparinoid	cream 0.3%; gel 0.3%	13.13	A		
feparinoid and salicylic acid	Movelat ® cream containing heparinoid 0.2%, salicylic acid 2%; gel containing heparinoid 0.2%, salicylic acid 2% in a colourless gel basis	13.13	A		
hepatitis A vaccine	injection 1ml; injection 0.5ml	14.04	R		
hepatitis A with hepatitis B vaccine	injection 720 ELISA units HepatitisA with 20mg Hepatitis B in 1ml, 1ml pre-filled syringe (Twinrix ® Adult); 0.5ml pre-filled syringe (Twinrix ® Paediatric)	14.04	A		
hepatitis B immunoglobulin	injection	14.05	A		

hepatitis B vaccine	injection 10mcg in 1ml, 20mcg in 1ml, 40mcg in 1ml Engerix B ® (10mcg/0.5ml - paediatric) HbvaxPRO ® (10mcg/ml)	14.04	A		
Histoacryl ®	Tissue adhesive containing enbucrilate with blue dye, 500mg vial.	13.10.5	A		
Homatropine	Single use Minims ® eye drops, 2%.	11.05	A		
House Dust Mite Vaccine	Vials containing 1/64, 1/8 and 1 relative therapeutic units (unlicensed) Acaroid® (injections - unlicensed)	N/A	R	for paediatric use, NDP September 2013 Acaroid (for adult use - NDP November 2025)	
House Dust Mite allergen extract (Acarizax®)	sublingual tablets, oral lyophilisate 12 SQ-HDM	3.04.2	R	For use in line with the product licence by adult and paediatric specialist allergy services. (NPD September 2022) In line with NICE TA guidence no. 1045, March 2025 (replaces TA 834)	
Human papilloma virus vaccine	pre-filled syringe 0.5ml (Gardasil®9)	14.04	A	as part of childhood immunisation schedule	
Human papilloma virus vaccine	pre-filled syringe 0.5ml (Gardasil®9)	14.04	R	For use by ENT team for vaccination in Laryngeal Papillomatosis. (NDP July 2020)	
Human Thrombin		9.01	R		
hyaluronidase	injection (ovine) 1500 units (Hyalase ®)	10.03.1	A		
hydralazine	tablets 25mg, 50mg; injection 20mg;	2.05.1	A		
Hydromol ®	ointment	13.02.1	A	to replace Epaderm ® ointment; Epaderm ® ointment to be removed from Formulary	
hydrocortisone	Pellets (lozenges), 2.5mg (as sodium succinate).	12.03.1	A		
hydrocortisone	cream 0.5%, 1%, 2.5%; ointment 0.5%, 1%, 2.5%	13.04	A		
hydrocortisone	tablets 2.5mg, 5mg, 10mg, 20mg	6.03.2	A		
hydrocortisone sodium phosphate	injection 100mg/ml	6.03.2	R		
hydrocortisone sodium succinate	injection 100mg	6.03.2	A		

hydrocortisone acetate	Injection, intra-articular/soft-tissue aqueous suspension, 25mg in 1ml.	10.01.2	A		
hydrocortisone acetate	Eye ointment, hydrocortisone acetate, 0.5%, 1%. Drops, hydrocortisone acetate 1%.	11.04.1	A		
hydrocortisone acetate	injection 25mg in 1ml	10.01.2	A		
hydrocortisone butyrate	cream 0.1%; lipocream 0.1%; ointment 0.1%; scalp lotion 0.1%	13.04	A		
hydrocortisone sodium phosphate	eye drops 3.35mg in 1 ml	11.04.1	A	NDP July 2023	
hydrogen peroxide	solution 3% (10 volume)	12.03.4	A		
hydrogen peroxide	cream 1%	13.11.6	A	for molluscum contagiosum in children where other therapeutic options are limited	
hydrogen peroxide	solution 10 volume (3%), 20 volume (6%), 30 volume (9%)	13.11.6	A		
hydroxocobalamin	injection 1mg in 1ml, 2.5g (unlicensed); suspension 500mg in 5ml (unlicensed)	9.01.2	A		
hydroxycarbamide	capsules 200mg, 300mg (unlicensed), 500mg; 200mg/5ml oral solution 200mg/5ml (unlicensed); suspension 500mg/5ml (unlicensed)	8.01.5	A		
hydroxychloroquine sulphate	tablets 200mg; oral liquid 100mg in 5ml, 200mg in 5ml	10.01.3	A		
hydroxypropylmethylcellulose (HPMC)	eye drops 2% (unlicensed, removed from the formulary September 2012); intra-occular injection 2 % pre-filled syringe	11.08.1	R	Eye drops are unlicensed and can be obtained from Moorfields Hospital. Although normally held in stock they may not always be immediately available.	
hydroxyzine	tablets 10mg, 25mg	3.04.1	A	For managments of pruritus. Suspension has been discountinued	
hydroxyzine	tablets 10mg, 25mg.	4.01.2	R	For management of anxiety, restricted for short term use and in adults only. Suspension has been disconitnued.	
hyoscine butylbromide	tablets 10mg; injection 20mg in 1ml	1.02	A		

hyoscine hydrobromide	tablets 300mcg; injection 400 micrograms in 1ml, 600 micrograms in 1ml; patch releasing approx. 1mg/72 hours	4.06	A		
hyoscine hydrobromide	injection 400mcg in 1ml, 600mcg in 1ml	15.01.3	A		
hypromellose	eye drops 0.3%; eye drops 0.3% preservative free (unlicensed product); eye drops 0.5% (Isopto plain) eye drops 1% (Isopto Alkaline)	11.08.1	R	Unlicensed preparation can be obtained from Moorfields Hospital. Although normally held in stock they may not always be immediately available. 0.32% single use peservative free eye drops are non-Formulary	
ibandronic acid	tablets 50mg; injection 3mg in 3mL pre-filled syringe	6.06.2	R	1. For prevention of skeletal events in patients with breast cancer and bone metastases. 2. In line with NICE TA guidance 464, August 2017.	
ibrutinib	capsule 140mg	8.01.5	R	1. In line with NICE TA guidance no. 429, January 2017: Ibrutinib alone is recommended within its marketing authorisation as an option for treating CLL in adults who have had at least one prior therapy or who have a 17p deletion or YP53 mutation and in whom chemo-immunotherapy is unsuitable and only when the company provides ibrutinib with the discount agreed in the simple discount agreement.	PBR RL
ibrutinib	capsule 140mg	8.01.5	R	2. In line with NIC TA guidence no 502, Jan 2018: Ibrutinib is recommended as an option for treating relapsed or refractory mantle cell lymphoma in adults, only if they have had only 1 previous line of therapy and the company provides ibrutinib with the discount agreed in the commercial access agreement with NHS England.	PBR RL
ibrutinib	capsule 140mg	8.01.5	R	3. In line with NICE TA guidance no. 891, May 2023: Ibrutinib plus venetoclax is recommended, within its marketing authorisation, as an option for untreated chronic lymphocytic leukaemia (CLL) in adults. This is only if the companies provide both drugs according to the commercial arrangements.	PBR RL
ibuprofen	Tablets 200mg, 400mg, 600mg; syrup 100mg in 5ml.	10.01.1	A		
ibuprofen	IV injection 10mg in 2ml	7.01.1	Very R	For the symptomatic (not prophylactic) treatment of persistent ductus arteriosus (PDA) in preterm infants.	

icosapent ethyl	soft capsules, 998mg	2.12	R	In line with NICE TA guidance no. 805, July 2022: Icosapent ethyl is recommended as an option for reducing the risk of cardiovascular events in adults. It is recommended if they have a high risk of cardiovascular events and raised fasting triglycerides (1.7 mmol/litre or above) and are taking statins, but only if they have: • established cardiovascular disease (secondary prevention), defined as a history of any of the following: – acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation) – coronary or other arterial revascularisation procedures – coronary heart disease – ischaemic stroke – peripheral arterial disease, and • low-density lipoprotein cholesterol (LDL-C) levels above 1.04 mmol/litre and below or equal to 2.60 mmol/litre.	
idarubicin	capsules 5mg, 10mg, 25mg; injection 5mg, 10mg	8.01.2	R	In line with the local/national guidelines and protocols.	PBR
idarucizumab	solution for infusion 2.5g in 50mL	2.11	R	For refersal of effect of dabigatran before emergency surgery/urgent procedure and in life-threatening or uncontrolled bleeding on advice of haematologist. (NDP May 2016)	
idelalisib	tablets 100mg, 150mg	8.01.5	R	In line with NICE TA guidance no 359, Oct-2015: Idelalisib, in combination with rituximab, is recommended for untreated chronic lymphocytic leukaemia in adults with a 17p deletion or TP53 mutation or for chronic lymphocytic leukaemia in adults when the disease has been treated but has relapsed within 24 months. Idelalisib is recommended only if the company provides the drug with the discount agreed in the simple discount agreement.	PBR
ifosfamide	injection 1g, 2g; injection 8g in 100ml (unlicensed)	8.01.1	A		PBR
iloprost	infusion 100mcg in 1ml; nebuliser solution 10micrograms/ml	2.05.1	R	1. for Raynauds, critical limb ischaemia in peripheral vascular disease and in vasculitis. 2. For severe pulmonary hypertension. Funding for treatment of each patient must be approved by a commissioner before iloprost can be offered. For use in line with European Society of Cardiology Consensus Guidelines.	PBR RL
imatinib	tablets 100mg, 400mg	8.01.5	R	1. In line with NICE TA guidance no. 70, Oct-03: Recommended as first-line treatment for people with Philadelphia-chromosome-positive chronic myeloid leukaemia (CML) in the chronic phase.	PBR RL

imatinib	tablets 100mg, 400mg	8.01.5	R	2. In line with NICE TA guidance no. 70, Oct-03: Recommended as an option for the treatment of people with Philadelphia-chromosome-positive CML who initially present in the accelerated phase or with blast crisis. 3. In line with (NICE TA guidance no. 70, Oct-03: additionally, imatinib is an option for people who present in the chronic phase and then progress to the accelerated phase or blast crisis if they have not received imatinib previously.	PBR RL
imatinib	tablets 100mg, 400mg	8.01.5	R	4. In line with NICE TA guidance no. 86, Oct-04: treatment at 400 mg/day, as first-line management of people with KIT (CD117)-positive unresectable and/or KIT (CD117)-positive metastatic gastro-intestinal stromal tumours (GISTs).	PBR RL
imatinib	tablets 100mg, 400mg	8.01.5	R	5. In line with NICE TA guidance no. 426, Dec-2016: Imatinib is recommended as an option for untreated, chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults. This guidance partially updates NICE TA guidance no. 70 (Oct-03) and no 251 (April-12).	PBR RL
imatinib	tablets 100mg, 400mg	8.01.5	R	6. In line with NICE TA guidance no. 326, Nov-14 (review of NICE TA196): Imatinib is recommended as an option as adjuvant treatment for up to 3 years for adults who are at high risk of relapse after surgery for KIT (CD117)-positive gastrointestinal stromal tumours, as defined by the Miettinen 2006 criteria (based on tumour size, location and mitotic rate).	PBR RL
imipenem with cilastatin	Intramuscular injection 500mg of each component; Intravenous infusion 500mg of each component	5.01.2	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required	
imiquimod (Aldara®)	Cream, 5%, Sachets	13.07	R	For use by GUM and HIV teams only.	
immunoglobulin (Intravenous Immunoglobulin)	injection 1g, 2.5g, 5g, 10g	14.05	R	In line with the latest NHS England clinical commissioning policy.	PBR

inclisiran	solution for injection in pre-filled syringe, 284mg	2.12	R	In line with NICE TA guidance no 733, October 2021: Inclisiran is recommended as an option for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults. It is recommended only if: • there is a history of any of the following cardiovascular events: – acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation) – coronary or other arterial revascularisation procedures – coronary heart disease – ischaemic stroke or – peripheral arterial disease, and • low-density lipoprotein cholesterol (LDL-C) concentrations are persistently 2.6 mmol/l or more, despite maximum tolerated lipid-lowering therapy, that is: – maximum tolerated statins with or without other lipid-lowering therapies or, – other lipid-lowering therapies when statins are not tolerated or are contraindicated, and • the company provides inclisiran according to the commercial arrangement.	**requires Blueteq form completion before treatment initiation**
indacaterol	150 microgram inhalation powder, hard capsules (Onbrez Breezhaler ®); 300 microgram inhalation powder, hard capsules (Onbrez Breezhaler ®)	3.01.1	A	For use in COPD according to the latest national and local guidelines. (NDP February 2011)	
indacaterol/ glycopyrronium	Ultibro® Breezhaler® inhalation powder, hard capsule indacaterol 110mcg per capsule glycopyrronium 50mcg capsule	3.01.1	A	For use in COPD according to the latest national and local guidelines. (NDP June 2017)	
indapamide	tablets 2.5mg; MR tablets 1.5mg	2.02.1	A		
Indigo carmine	injection 0.8% 5ml	19.02	A	Blumyne® brand - licensed as medicine - use in line with the product licence.	
indocyanine green	injection 25mg, 50mg	19.02	R	as adjunct to Fundus Flourescein Angiogram for ophthalmic angiography of the choroidal vasculature	
indometacin (indomethacin)	injection 1mg	7.01.1	R	For neonatal use only	
indometacin (indomethacin)	capsules 25mg, 50mg; MR capsules 75mg; Suspension 25mg in 5ml; suppositories 100mg	10.01.1	A	MR Capsules restricted for use by Rheumatology teams only. Only 75mg MR capsules are formulary.	

indoramin	tablets 20mg, 25mg	7.04.1	A		
Infacol ®	oral liquid	1.01.1	R	Contains simeticone; for post-operative wind pain following bariatric surgery (in-patients only). Patients will not be given TTOs and GPs will not be asked to prescribe.	
infliximab	Intravenous infusion 100mg solution for injection in pre-filled pen 120mg	1.05.3	R	1. In line with NICE TA guidance no. 187, May-10: **Infliximab** and adalimumab, within their licensed indications, are recommended as treatment options for adults with severe active Crohn's disease whose disease has not responded to conventional therapy (including immunosuppressive and/or corticosteroid treatments), or who are intolerant of or have contraindications to conventional therapy. Infliximab or adalimumab should be given as a planned course of treatment until treatment failure (including the need for surgery), or until 12 months after the start of treatment, whichever is shorter. People should then have their disease reassessed to determine whether ongoing treatment is still clinically appropriate. Treatment should normally be started with the less expensive drug (taking into account drug administration costs, required dose and product price per dose). This may need to be varied for individual patients because of differences in the method of administration and treatment schedules.	PBR
infliximab	Intravenous infusion 100mg solution for injection in pre-filled pen 120mg	1.05.3	R	2. In line with NICE TA guidance no. 187, May-10: Infliximab, within its licensed indication, is recommended as a treatment option for people with active fistulising Crohn's disease whose disease has not responded to conventional therapy (including antibiotics, drainage and immunosuppressive treatments), or who are intolerant of or have contraindications to conventional therapy. Infliximab should be given as a planned course of treatment until treatment failure (including the need for surgery) or until 12 months after the start of treatment, whichever is shorter. People should then have their disease reassessed to determine whether ongoing treatment is still clinically appropriate.	PBR
infliximab	Intravenous infusion 100mg solution for injection in pre-filled pen 120mg	1.05.3	R	3. In line with NICE TA guidance no. 187, May-10: Infliximab, within its licensed indication, is recommended for the treatment of people aged 6–17 years with severe active Crohn's disease whose disease has not responded to conventional therapy (including corticosteroids, immunomodulators and primary nutrition therapy), or who are intolerant of or have contraindications to conventional therapy. The need to continue treatment should be reviewed at least every 12 months.	PBR

infliximab	Intravenous infusion 100mg solution for injection in pre-filled pen 120mg	1.05.3	R	4. In line with NICE TA guidance no 329, Feb-2015: **Infliximab**, adalimumab and golimumab are recommended, within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.	PBR
infliximab	Intravenous infusion 100mg	10.01.3	R	5. In line with NICE TA guidance no. 199; Aug-10, etanercept, **infliximab** and adalimumab are recommended for the treatment of adults with active and progressive psoriatic arthritis the person has peripheral arthritis with three or more tender joints and three or more swollen joints, and the psoriatic arthritis has not responded to adequate trials of at least two standard disease-modifying antirheumatic drugs (DMARDs), administered either individually or in combination. Treatment should normally be started with the least expensive drug (taking into account drug administration costs, required dose and product price per dose).	PBR
infliximab	Intravenous infusion 100mg	10.01.3	R	6. In line with NICE TA guidance no. 134; Jan-08. Infliximab is recommended as a treatment option for adults with very severe plaque psoriasis when the disease is very severe and the psoriasis has failed to respond to standard systemic therapies such as ciclosporin, methotrexate or PUVA (psoralen and long-wave ultraviolet radiation), or the person is intolerant to or has a contraindication to these treatments.	PBR
infliximab	Intravenous infusion 100mg	10.01.3	R	7. In line with NICE TA guidance no. 375, Jan-2016 : Adalimumab, etanercept, **infliximab**, certolizumab pegol, golimumab, tocilizumab and abatacept, all in combination with methotrexate, are recommended as options for treating rheumatoid arthritis only if disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and disease has not responded to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs).	PBR
infliximab	Intravenous infusion 100mg	10.01.3	R	8. For the treatment of Behcet's Syndrome in line with approved protocol.	PBR
infliximab	Intravenous infusion 100mg	10.01.3	R	9. In line with NICE TA guidance no. 163; Dec-08. Infliximab is recommended as an option for the treatment of acute exacerbations of severe active ulcerative colitis only in patients in whom ciclosporin is contraindicated or clinically inappropriate. (NDP Jan 2009)	PBR

infliximab	Intravenous infusion 100mg	10.01.3	R	10. For use in severe active Crohn's disease, fistulating Crohn's disease, and maintenance of remission (5mg/kg) in responders. The panel did not support the use of the 10mg/kg dose for secondary non-responders as this was considered not cost effective. The costs of the 10mg/kg would be met by the division should they wish to. (NDP May 2009)	PBR
infliximab	Intravenous infusion 100mg	10.01.3	R	11. For treatment for neurosarcoidosis in selected patients. Funding will be requested on a case by case basis. (NDP November 2009)	PBR
infliximab	Intravenous infusion 100mg	10.01.3	R	12. In line with NICE TA guidance no. 195; Aug-10, Adalimumab, etanercept, **infliximab** and abatacept, each in combination with methotrexate, are recommended as treatment options only for adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to rituximab, or when rituximab is withdrawn because of an adverse event.	PBR
infliximab	Intravenous infusion 100mg	10.01.3	R	13. For the treatment of systemic vasculitis in addition to standard therapy, or for steroid sparing where clinically indicated (NDP March 2011)	PBR
infliximab	Intravenous infusion 100mg	10.01.3	R	14. In line with NICE TA guidance no. 383, Feb-2016: Adalimumab, certolizumab pegol, etanercept, golimumab and **infliximab** are recommended, within their marketing authorisations, as options for treating severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs. **Infliximab** is recommended only if treatment is started with the least expensive infliximab product. People currently receiving infliximab should be able to continue treatment with the same infliximab product until they and their NHS clinician consider it appropriate to stop.	PBR
infliximab	Intravenous infusion 100mg	10.01.3	R	15. In line with NICE TA guidance no 715, July 2021: Adalimumab, etanercept, **infliximab** and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed, as outlined in the TAG document.	PBR
infliximab	Intravenous infusion 100mg	10.01.3	R	16. For treatment of refractory sarcoidosis (exclusing neurosarcoidosis) - in line with NHS England commissioning policy (December 2023) NPD January 2024	PBR

infliximab	Intravenous infusion 100mg	10.01.3	R	17. For treatment of moderate to severe *Hidradenitis suppurativa* , as a thrid line biologic option. (NDP September 2025)	PBR
influenza vaccine, inactivated	injection	14.04	A		
influenza vaccine, live attenuated influenza virus (Fluenz Tetra®)	nasal spray	14.04	A	as per DoH recommendation (NDP December 2014)	
inotuzumab ozogamicin	powder for concentrate for solution for infusion, 1mg	8.01.5	R	In line with NICE TA guidence no 541, September 2018: Inotuzumab ozogamicin is recommended, within its marketing authorisation, as an option for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults. People with relapsed or refractory Philadelphia-chromosome-positive disease should have had at least 1 tyrosine kinase inhibitor. Inotuzumab ozogamicin is recommended only if the company provides it according to the commercial arrangement.	PBR
insulin Aspart (recombinant human insulin analogue); NovoRapid ® Trurapi® biosimilar	injection 100u/ml, 10ml vial, 3ml cartridge, 3ml pen	6.01.1	A	Use in line with the current national/local guidelines.	
insulin Aspart (recombinant human insulin analogue); Fiasp ®	vial 10ml (100units/ml)	6.01.1	R	For use in Type I diabetic patients on insulin pump who are not adequately controlled on NovoRapid®. Must be prescribed as brand to avoid confusion with NovoRapid®. (NDP June 2017)	
insulin Aspart biphasic (intermediate-acting) NovoMix ® 30)	injection 100u/ml, 3ml cartridge, 3ml pen	6.01.1	A		
insulin Detemir (recombinant human insulin analogue - long acting); Levemir ®	injection 100u/ml, 3ml cartridge; 3ml FlexPen; 3ml Innolet pre-filled syringe	6.01.1	A	Use in line with the current national/local guidelines.	

insulin Glargine (recombinant human insulin analogue - long acting); Lantus ® Abasaglar®, biosimilar Semglee® biosimilar	injection 100u/ml, 10ml vial, 3ml cartridge, 3ml pre-filled pens, 3ml OptiClik cartridges; Solostar pre-filled syringes	6.01.1	A	Use in line with the current national/local guidelines.	
insulin, isophane - intermediate acting, human sequence; Humulin I ®	Injection 100 units/ml: 3ml cartridges, 3ml pre-filled syringes, 3ml KwikPen pre-filled syringes	6.01.1	A	Use in line with the current national/local guidelines.	
insulin, isophane - intermediate acting, human sequence; Insulatard ®	Injection 100 units/ml, 10ml vial, 3ml cartridges, 3ml pre-filled injection (Innolet ®)	6.01.1	A		
insulin lispro (recombinant human insulin analogue); Humalog ®	100units/ml, 200units/ml (KwikPen only) 10ml vial; 3ml cartridge; 3ml pre-filled pen; 3ml KwikPen pre-filled pen	6.01.1	A	Use in line with the current national/local guidelines.	
insulin lispro biphasic (Intermediate-acting insulin); Humalog Mix25 ®	3ml cartridge; 3ml pre-filled pen; 3ml KwikPen pre-filled pen	6.01.1	A	Use in line with the current national/local guidelines.	
insulin lispro biphasic (Intermediate-acting insulin); Humalog Mix50 ®	3ml cartridge; 3ml pre-filled pen; 3ml KwikPen pre-filled pen	6.01.1	A	Use in line with the current national/local guidelines.	
insulin lispro (biosimilar)	100unitls/ml 3ml cartridge; 3ml pre-filled pen; 10ml vial	6.01.1	A	Use in line with the current national/local guidelines. (NDP November 2018)	
insulin lispro (Lyumjev®)	solution for injection, 100units in 1ml (vials, cartridges, KwikPen®, Junior KwikPen®) 200units in 1ml (KwikPen®)	6.01.1	A	Use in line with the current national/local guidelines. (NDP September 2024, NWL JF July 2024) Lyumjev brand is not interchangable with other short acting insulins.	
insulin, soluble, human Actrapid ®	injection 100units/ml 10ml vial;	6.01.1	A		

insulin, soluble, human; Humulin S ®	injection 100units/ml: 3ml cartridge	6.01.1	A	Use in line with the current national/local guidelines.	
Insulin eye drops	solution 1iunit in 1ml (5ml) (unlicensed)	11.8	R	For treatment of persistent epithelial defects in refractory patients who have failed to respond to standard 1st and 2nd line therapies, in line with ophthalmology advice. (NDP March 2025)	
interferon alfa Interferon alfa-2b (rbe)	Injection, 18 million units in 3ml. For subcutaneous injection.	8.02.4	R	For use as specified in the NHS England commissioning statement, Multiple Sclerosis: Treatment Algorithm for Multiple Sclerosis Disease-Modifying Therapies.	PBR RL
interferon beta-1a	all strenght pre-filled syringes, pre-filled pens, solution for injection in cartridge	8.02.4	R	For use as specified in the NHS England commissioning statement, Multiple Sclerosis: Treatment Algorithm for Multiple Sclerosis Disease-Modifying Therapies.	PBR RL
interferon beta-1b	powder for solution for injection, 300mcg	8.02.4	R	For use as specified in the NHS England commissioning statement, Multiple Sclerosis: Treatment Algorithm for Multiple Sclerosis Disease-Modifying Therapies.	PBR RL
Intrafusin 22 ®	IV infusion (500ml)	9.03	A		
Intralipid ®	Infusion, 100ml, 500ml (Intralipid 10% ®). Infusion, 100ml, 500ml (Intralipid 20% ®). Infusion, 333ml (Intralipid 30% ®)	9.03	R	Intralipid 20%; 1. Neonates 2. For clinical areas where epidurals are used	
Iodanol ®	injection	18	A	Ex-panel Sept 2010	
iodine	aqueous oral solution (Lugol's solution); tincture	6.02.2	A	Oral solution, contains iodine 5% and potassium iodide 10% in purified water; total iodine 130mg/ml.	
Iodised oil ultrafluid	injection 40%	18	A		
iomerol 400	injection	18	A	Ex-panel Sept 2010	
Ipecacuanha	paediatric emetic mixture (unlicensed)	17	A		
ipilimumab	5mg/ml injection; 10ml and 40ml vial	8.01.5	R	In line with NICE TA guidance no. 268, Dec-2012, ipilimumab is recommended as an option for treating advanced (unresectable or metastatic) melanoma in people who have received prior therapy, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme.	PBR
ipilimumab	5mg/ml injection; 10ml and 40ml vial	8.01.5	R	In line with NICE TA guidance no. 319, July-14: Ipilimumab is recommended, within its marketing authorisation, as an option for treating adults with previously untreated advanced (unresectable or metastatic) melanoma, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme.	PBR
ipratropium bromide	aerosol inhalation 20mcg/metered inhalation; nebuliser solution 250mcg in 1ml, 500mcg in 2ml unit dose vials	3.01.2	A		

ipratropium bromide		12.02.2	A		
irbesartan	tablets 75mg, 150mg, 300mg	2.05.5	A	1. For treatment of hypertension in patients who are unable to tolerate ACE inhibitors because of cough. 2. For treatment of renal disease in diabetic and non-diabetic patients with hypertension in chronic kidney disease or end-stage kidney disease. To be used either alone following a switch from an ACE inhibitor or for use together with an ACE inhibitor.	
irbesartan and hydrochlorothiazide	irbesartan 150mg / hydrochlorothiazide 12.5mg tablets irbesartan 300mg / hydrochlorothiazide 12.5mg tablets irbesartan 300mg / hydrochlorothiazide 25mg tablets	2.05.5	R	1. For treatment of hypertension in patients who are unable to tolerate ACE inhibitors because of cough. 2. For treatment of renal disease in diabetic and non-diabetic patients with hypertension in chronic kidney disease or end-stage kidney disease. To be used either alone following a switch from an ACE inhibitor or for use together with an ACE inhibitor.	
irinotecan	infusion 40mg in 2ml, 100mg in 5ml, 300mg in 15ml	8.01.5	R	1. In line with NICE TA guidance no. 93; Aug-05, in combination with 5-fluorouracil and folinic acid as a treatment option for people with advanced colorectal cancer as first-line therapy, and irinotecan alone in subsequent therapy.	PBR
irinotecan	infusion 40mg in 2ml, 100mg in 5ml, 300mg in 15ml	8.01.5	R	2. For use in 5 - 10 patients p.a. as third line treatment in patients with recurrent high grade glicomas.	PBR
irinotecan	infusion 40mg in 2ml, 100mg in 5ml, 300mg in 15ml	8.01.5	R	3. In line with NICE TA guidnce no. 176; Aug-09, cetuximab in combination with 5-FU, folinic acid and irinotecan (FOLFIRI), is recommended for the first-line treatment of metastatic colorectal cancer only when all of the following criteria are met: • The primary colorectal tumour has been resected or is potentially operable. • The metastatic disease is confined to the liver and is unresectable. • The patient is fit enough to undergo surgery to resect the primary colorectal tumour and to undergo liver surgery if the metastases become resectable after treatment with cetuximab. • The patient is unable to tolerate or has contraindications to oxaliplatin. Patients who meet the criteria in sections 1 and 2 should receive treatment with cetuximab for no more than 16 weeks. At 16 weeks, treatment with cetuximab should stop and the patient should be assessed for resection of liver metastases.	PBR
iron dextran (A complex of ferric hydroxide with sucrose containing 5% (50 mg/mL) of iron)	Injection, iron (as dextran) 100mg in 2ml, 500mg in 10ml (CosmoFer ®).	9.01.1	A		

iron sucrose (A complex of ferric hydroxide with sucrose containing 2% (20 mg/mL) of iron)	Injection, intravenous, 100mg in 5ml (Venofer ®).	9.01.1	A		
isatuximab	solution for injection, 20mg/ml 100mg in 5ml 500mg in 25ml	8.01.1	R	In line with NICE TA guidance no 658, November 2020: Isatuximab, plus pomalidomide and dexamethasone, is recommended for use within the **Cancer Drugs Fund** as an option for treating relapsed and refractory multiple myeloma in adults who have had lenalidomide and a proteasome inhibitor, and whose disease has progressed on their last treatment, only if they have had 3 previous lines of treatment the conditions in the managed access agreement for isatuximab plus pomalidomide and dexamethasone are followed.	PBR
isatuximab	solution for injection, 20mg/ml 100mg in 5ml 500mg in 25ml	8.01.1	R	In line with NICE TA guidance no 1098, September 2025: Isatuximab plus bortezomib, lenalidomide and dexamethasone can be used, within its marketing authorisation, as an option for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable. It can only be used if the company provides it according to the commercial arrangement.	PBR
isoflurane	250ml	15.01.2	R	For induction of anaesthesia and maintenance using low flow circuits only.	
isoniazid	tablets 50mg, 100mg; elixir 50mg in 5ml (unlicensed); injection 50mg in 2ml	5.01.9	A	Level 1 non-reserved anti-infective	
isopaque cysto	injection	18	A		
isoprenaline	isoprenaline (hydrochloride) 200mcg in 1ml isoprenaline (hydrochloride) 2mg in 2ml (unlicensed)	2.07.1	A	Licensed isoprenaline in used as of September 2021. Unlicensed preparation remains on the formulary in case the licensed preparation cannot be sourced. (NDP September 2021)	
isopropyl alcohol (IPA)	wipes (sterets and Alcowipes)	16	A		
isosorbide dinitrate	tablets 10mg, 20mg; MR tablets 20mg; MR capsules 40mg; injection 10mg in 10ml	2.06.1	A		
isosorbide mononitrate	tablets 10mg, 20mg; MR capsules 25mg, 50mg; MR tablets 25mg, 40mg,60mg	2.06.1	A		
isotretinoin	Capsules, 5mg, 10mg, 20mg (hospital or specified retail pharmacy only)	13.06.2	R	Dermatologists only.	RL
Isovist 300	10ml	18	A		
ispaghula husk	granules 3.5g/sachet (orange flavoured or plain)	1.06.1	A		

itraconazole	capsules 100mg; oral liquid 10mg in 1ml; 250mg/25ml solution for injection ampoules and diluent.	5.02.1	R	Level 2 anti-infectives restricted to specific indications: As per Haematology anti-infective policy As per Paediatric Haematology protocols	
ivabradine	tablets 5mg, 7.5mg	2.06.3	R	3rd line treatment in patients with refractory angina where re-vascularisation is not possible and who continue to suffer from angina despite maximum anti-anginal treatment or for patients contraindicated/intollerant to beta blockers/diltiazem or verapamil. Beta blockers will remain first choice, then calcium antagonists. The addition of ivabradine will be authorised in person by a Consultant Cardiologist.	
ivabradine	tablets 5mg, 7.5mg	2.06.3	R	In line with NICE TA guidance no 267, Nov-2012: ivabradine is recommended as an option for treating chronic heart failure. Please refer to the full guidance (TA 267) for the details of the patient selection criteria.	
Ivelip ®	Infusion 500ml (Ivilip 10% ®). Infusion 100ml, 500ml (Ivilip 20% ®).	9.03	A		
ivermectin	tablets 3mg	5.05.6	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required	
ivermectin	cream, 10mg/g	13.10.01	A	For the topical treatment of rosacea as per the product licence. (NDP March 2018)	
ivosidenib	tablets, 250mg	8.01.5	R	In line with NICE TA guidance no. 948, January 2024: Ivosidenib is recommended, within its marketing authorisation, as an option for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments. It is only recommended if the company provides it according to the commercial arrangement.	PBR RL
ivosidenib	tablets, 250mg	8.01.5	R	In line with NICE TA guidance no. 979, June 2024: Ivosidenib plus azacitidine is recommended, within its marketing authorisation, as an option for untreated acute myeloid leukaemia (AML) with an IDH1 R132 mutation in adults who cannot have standard intensive induction chemotherapy. It is only recommended if the company provides it according to the commercial arrangement.	PBR RL
isavuconazole	capsules 100mg powder for conscentrate for solution for infusion 200mg	5.02.1	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required	PBR

ixazomib	capsules 2.3mg, 3mg, 4mg	8.01.5	R	In line with NICE TA guidance no. 870, February 2023 (replaces TAG 505, February 2018): Ixazomib, with lenalidomide and dexamethasone, is recommended as an option for treating multiple myeloma in adults, only if they have had 2 or 3 lines of therapy and the company provides ixazomib according to the commercial arrangement.	PBR RL
ixekizumab	pre-filled pen and syringe 80mg in 1ml	10.01.3	R	1. In line with NICE TA guidance no 442, April 2017: Ixekizumab is recommended as an option for treating plaque psoriasis in adults, only if the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 the disease has not responded to standard systemic therapies, for example, ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or these treatments are contraindicated or the person cannot tolerate them, and the company provides the drug with the discount agreed in the patient access scheme	PBR
ixekizumab	pre-filled pen and syringe 80mg in 1ml	10.01.3	R	2. In line with NICE TA guidance no 537, August 2018: Ixekizumab alone, or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults as per NICE specified criteria. Ixekizumab is only recommended if the company provides it according to the commercial arrangement.	PBR
ixekizumab	pre-filled pen and syringe 80mg in 1ml	10.01.3	R	3. In line with NICE TA guidance no 718, July 2021: Ixekizumab is recommended as an option for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy, or active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs), in adults. It is recommended only if tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough, and the company provides ixekizumab according to the commercial arrangement.	PBR
Kaletra ®	tablets containing lopinavir 200mg and ritonavir 50mg; capsules containing lopinavir 133.3mg and ritonavir 33.3mg; oral solution containing lopinavir 400mg and ritonavir 100mg in 5ml	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL

ketamine	Injection 10mg/ml (20-ml vial), 50mg/ml (10-ml vial), 100mg/10ml, 100mg/ml (10-ml vial); 25mg/ml (preservative free), 50mg/2ml (preservative free) oral solution 50mg in 5ml (SF, unlicensed);	15.01.1	R	Oral solution for pain management in line with Trust Guidelines Ketamine S approved for Paediatric Anaesthetic team at SMH- consultant anaesthetist use only. Named Patient item, paediatric use only.	
ketoconazole	tablets 200mg; suspension 100mg in 5ml.	5.02.2	A	Level 1 non-reserved anti-infective	
ketoconazole	cream 2%; shampoo 2%	13.10.2	A		
ketorolac trometamol	eye drops, 0.5%, 5ml.	11.08.2	A	Replaces indomethacin eye drops (special from Moorfields)	
ketorolac	injection 10mg in 1ml, 30mg in 1ml	15.01.4	A		
Ketostix		19.01	A		
ketotifen	eye drops, 0.025% (preservative free)	11.08.2	A	For symptomatic treatment of seasonal allergic conjunctivitis (in adults and children). NDP May 2021	
ketovite	tablets; liquid	9.06.7	A		
kidney perfusion	fluid - unlicensed	21	A		
L-alanyl-L-glutamine	solution 10mg in 50ml, 20mg in 100ml (Dipeptiven ®)	9.03	R	1. As supplement to TPN for haematology patients. Use to be audited and decrease in bed occupancy reviewed after one year. 2. As supplement to TPN for patients on ITU who have undergone upper GI surgery or who have multiple organ failure with gut dysfunction.	PBR
L-ornithine L-aspartate (LOLA)	5g in 10ml injection for IV infusion	not classified	R	For the treatment of refractory Overt Hepatic Encephalopathy [OHE] not responding to conventional treatments, for up to 7 days (NDP May 2015). **Oral LOLA is non-formulary.**	
labetalol	tablets 50mg, 100mg, 200mg, 400mg; injection 100mg in 20ml	2.04	A		
lacosamide	tablets 50mg, 100mg, 150mg, 200mg; syrup 15mg in 1ml; infusion 200mg in 20ml	4.08.1	R	For use according to the product licence and the relevant national guidelines. (NDP, October 2009)	
lactose	powder	19.02	A		
lactulose	solution	1.06.4	A		
lamivudine (3TC)	tablets 150mg, 300mg; oral solution 50mg in 5ml;	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL

lamivudine (3TC)	tablets 100mg	5.03.1	R	For management of Hepatitis B in line with the latest NICE Clinical Guideline (CG165).	RL
lamotrigine	tablets 25mg, 50mg, 100mg, 200mg; dispersible tablets 5mg, 25mg, 100mg	4.08.1	A		
lanreotide	injection 30mg; Injection prefilled syringe 60 mg, 90 mg, 120 mg (Autogel ®)	8.03.4	R	For the treatment of carcinoid tumours and acromegaly.	PBR RL
lansoprazole	Orodispersible tablet, 15mg, 30mg. capsules 15mg, 30mg;	1.03.5	A	1st line of PPI for patients with swallowing difficulties or feeding tubes.	
lanthanum carbonate	tablets 500mg, 750mg, 1g sachets 750mg, 1g	9.05.2	R	To control hyperphosphataemia in dialysis patients with severe hyperparathyroidism, to replace high dose sevelamer (2.4g tds) in patients who cannot tolerate calcium carbonate. Calcium carbonate will continue to be used first-line.	
latanoprost	eye drops 50mcg in 1ml eye drops preservative free, 50mcg in 1ml	11.06	A	In line with national/local guidelines.	
latanoprost 50mcg, netarsudil 200mcg/ml	eye drops solution	11.06	R	In line with NICE TA guidance no. 1009, October 2024: Latanoprost–netarsudil is recommended as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone has not reduced IOP enough, only if they have then tried a fixed-dose combination treatment and it has not reduced IOP enough, or a fixed-dose combination treatment containing beta-blockers is unsuitable.	
lebrikizumab	solution for injection, pre-filled pen and pre-filled syringe 250mg	10.01.3	R	In line with NICE TA guidance no. 986, July 2024: Lebrikizumab is recommended as an option for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in people 12 years and over with a body weight of 40 kg or more, only if the atopic dermatitis has not responded to at least 1 systemic immunosuppressant or these treatments are not suitable, and dupilumab or tralokinumab would otherwise be offered, and the company provides it according to the commercial arrangement.	PBR
leflunomide	tablets 10mg, 20mg, 100mg	10.01.3	R	Treatment of acute rheumatic arthritis in adults in patients unable to tolerate or who fail to respond adequately to methotrexate and/or sulphasalazine for use in rheumatology clinic only. GPs will not be asked to prescribe until after treatment of 3 months.	
lemon and glycerin	swabs (unlicensed)	12.03.5	A		
lemon mucilage	(unlicensed)	12.03.5	A		

lenalidomide	capsules 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg, 25mg	8.01.5	R	1. In line with NICE TA guidance no.171, Jun-09: Lenalidomide in combination with dexamethasone is recommended, within its licensed indication, as an option for the treatment of multiple myeloma only in people who have received two or more prior therapies, with the following condition: The drug cost of lenalidomide (excluding any related costs) for people who remain on treatment for more than 26 cycles (each of 28 days; normally a period of 2 years) will be met by the manufacturer.	PBR RL
lenalidomide	capsules 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg, 25mg	8.01.5	R	2. In line with NICE TA guidance no. 322, Sep-2014: Lenalidomide is recommended as an option within its marketing authorisation, that is for treating transfusion-dependent anaemia caused by low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenic abnormality when other therapeutic options are insufficient or inadequate, with the condition that the drug cost of lenalidomide (excluding any related cost) for people who remain on treatment for more thatn 26 cycles (each of 28 days; normally a period of 2 years) will be met by the company.	PBR RL
lenalidomide	capsules 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg, 25mg	8.01.5	R	3. In line with NICE TA guidance, no 586, June 2019: Lenalidomide plus dexamethasone is recommended as an option for treating multiple myeloma in adults only if they have had only 1 previous therapy, which included bortezomib, and the company provides it according to the commercial arrangement.	PBR RL
lenalidomide	capsules 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg, 25mg	8.01.5	R	4. In line with NICE TA guidance, no 587, June 2019: Lenalidomide plus dexamethasone is recommended as an option for previously untreated multiple myeloma in adults who are not eligible for a stem cell transplant, only if thalidomide is contraindicated (including for pre-existing conditions that it may aggravate) or the person cannot tolerate thalidomide, and the company provides lenalidomide according to the commercial arrangement.	PBR RL
lenalidomide	capsules 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg, 25mg	8.01.5	R	5. In line with NICE TA guidance, no 627, April 2020: Lenalidomide with rituximab is recommended, within its marketing authorisation, as an option for previously treated follicular lymphoma (grade 1 to 3A) in adults. It is only recommended if the company provides lenalidomide according to the commercial arrangement.	PBR RL

lenalidomide	capsules 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg, 25mg	8.01.5	R	6. In line with NICE TA guidance, no 680, March 2021: Lenalidomide is recommended as maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults, only if the dosage schedule is 10 mg per day on days 1 to 21 of a 28-day cycle and the company provides lenalidomide according to the commercial arrangement.	PBR RL
lenograstim (Recombinant human granulocyte-colony stimulating factor, rHuG-CSF)	injection 13.4million units (105 mcg), 33.6 million units (263 mcg)	9.01.6	A		RL
lenvatinib	capsules 4mg, 10mg	8.01.5	R	1. In line with NICE TA guidance no. 535, August 2018: **Lenvatinib** and sorafenib are recommended as options for treating progressive, locally advanced or metastatic differentiated thyroid cancer (papillary, follicular or Hürthle cell) in adults whose disease does not respond to radioactive iodine, only if they have not had a tyrosine kinase inhibitor before or they have had to stop taking a tyrosine kinase inhibitor within 3 months of starting it because of toxicity (specifically, toxicity that cannot be managed by dose delay or dose modification). **Lenvatinib** and sorafenib are recommended only if the companies provide them according to the commercial arrangements.	PBR RL
lenvatinib	capsules 4mg, 10mg	8.01.5	R	2 In line with NICE TA fuidance no. 551, December 2018: Lenvatinib is recommended as an option for untreated, advanced, unresectable hepatocellular carcinoma in adults, only if they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and the company provides it according to the commercial arrangement.	PBR RL
lenvatinib	capsules 4mg, 10mg	8.01.5	R	3. In line with NICE TA guidance no. 858, January 2023: Lenvatinib with pembrolizumab is recommended as an option for untreated advanced renal cell carcinoma in adults, only if their disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria and nivolumab with ipilimumab would otherwise be offered and the companies provide lenvatinib and pembrolizumab according to the commercial arrangements.	PBR RL

letermovir	tablets 240mg	5.03.2	R	In line with NICE TA guidance no. 591, July 2019: Letermovir is recommended, within its marketing authorisation, as an option for preventing cytomegalovirus (CMV) reactivation and disease after an allogeneic haematopoietic stem cell transplant (HSCT) in adults who are seropositive for CMV. It is recommended only if the company provides it according to the commercial arrangement.	PBR RL
letrozole	tablets 2.5mg	8.03.4	R	For use in line with NICE TA guidance no.112; Dec-06, as extended adjuvant treatment of postmenopausal node positive breast cancer in patients who have received standard 5 years tamoxifen therapy. GPs may be asked to prescribe. In line with the local/national guidelines/protocols.	
leuprorelin	injection 3.75, 11.25mg	8.03.4	A		
levamisole	tablets 25mg 50mg (unlicensed)	5.05.2	A		
levetiracetam	tablets 250mg, 500mg, 1g; oral liquid 500mg in 5ml; infusion 500mg in 5ml	4.08.1	R	To be used in line with NICE guidance for control of epilepsy.	
levetiracetam	oral solution 100mg in 1ml; infusion 100mg in 1ml	4.08.1	R	Fourth line treatment option for managing neonatal seizures and for adjunctive therapy of neonatal seizures. (NDP September 2011)	
levobunolol	unit dose eye drops 0.5%	11.06	A		
levobupivacaine	injection 25mg in 10ml, 50mg in 10 ml, 75mg in 10ml	15.02	A		
levobupivacaine with fentanyl	bupivicaine 0.1% and fentanyl 2micrograms in 1ml in 0.9% sodium chloride for epidural use, pre-filled syringes 10ml, bags 50ml, 240ml, 250ml, 480ml, 500ml; (all unlicensed)	15.02	R	for epidural use in Obstetrics	
levofloxacin	Tablets 250 mg, 500 mg; Intravenous infusion 500mg in 100ml.	5.01.12	R	Level 2 anti-infectives restricted to specific indications: As per Adult anti-infective policy As per Jefferiss Wing GUM handbook	
levofloxacin	0.5% preservative free eye drops	11.03.1	R	for the management of severe ocular infections including endophthalmitis, blebitis, microbial keratitis. for peri-operative prophylaxis during cataract surgery to reduce the risk of endophthalmitis.	
levomepromazine (methotrimeprazine)	tablets 25mg, 6mg (unlicensed); injection 25mg in 1ml.	4.02.1	A		
levonorgestrel	tablets 1.5mg (Levonelle ® 1500, Levonelle ® One Step);	7.03.5	A	Levonelle ® 1500 are less costly; Levonelle ® One Step can be sold to the public	

levonorgestrel	tablets 30mcg (Norgeston ®); 1500mcg (Levonelle ® 1500); intra-uterine system 20mcg/24hours (Mirena ®, Levosert®) intra-uterine system 13.5mg (Jaydess®) intra-uterine system 19.5mg (Kyleena®)	7.03.2	A	Mirena for use as a contraceptive. IUS other than Mirena (NDP September 2018)	
levosimendan	concentrate for solution for infusion 5ml (2.5mg in 1ml), unlicensed	(not classified)	R	Use in critical care in line with the local guideline. (NDP July 2023)	
levothyroxine (thyroxine sodium)	tablets 25mcg, 50mcg, 100mcg; suspension 50mcg in 5ml, 100mcg in 5ml	6.02.1	A	Suspension not to be used by neonates or paedaitrics. Note: Sept 2010; There is a 10% increase in potency of the Evotrox ® brand of the suspensions (25mcg in 5ml, 50mcg in 5ml, 100mcg in 5ml). For more information contact Medicines Information on ext. 11700	
levovist	injection	18	R	An ultrasound contrast agent for diagnosis of renal artery stenosis and image of portal vein shunt tips.	
lidocaine hydrochloride	injection 100mg in 5ml (2%); Min-I-Jet syringe 100mg in 10ml (1%), 100mg in 5ml (2%); infusions 1mg in 1ml (0.1%), 2mg in 1ml (0.2%), 4mg in 1ml (0.4%) in 5% glucose 500ml	2.03.2	A		
lidocaine hydrochloride	patches 5%	15.02	R	for neuropathic pain associated with evoked allodynia and hyperalgesia. GPs should not be asked to prescribe.	
lidocaine hydrochloride	injection 0.5% (10ml); injection 1% (2ml, 5ml, 10ml, 20ml); injection 2% (2ml, 5ml, 20ml, 2ml cartridges); injection 20% (10ml); epidural injection 1% (10ml - unlicensed) epidural injection 2% (5ml - unlicensed); gel 2%; spray 10%; topical solution 4%; ointment 5%	15.02	A		
lidocaine hydrochloride	ointment 5% (15g).	13.03			
lidocaine	cream 4% (LMX4 ®)	15.02	A		

lidocaine with adrenaline	injection 0.5% with adrenaline 1 in 200,000 20ml; injection 1% with adrenaline 1 in 200,000 20ml; injection 2% with adrenaline 1 in 200,000 20ml; injection 2% with adrenaline 1 in 80,000 2ml cartridge;	15.02	A		
lidocaine 4% w/v/ adrenaline 1:1000/ tetracaine 0.5% w/v	gel (LAT gel)	not classified	R	Restricted for use in paediatric A&E for local anaesthesia unlicensed (NDP September 2017)	
lidocaine and fluorescein	Minims lidocaine 4% and fluorescein 0.25% preservative free	11.07	A		
lidocaine and hydrocortisone	mouthwash containing lidocaine 1% and hydrocortisone 0.1%	15.02	A	To replace cocaine mouthwash	
lidocaine with chlorhexidine	Gel containing lidocaine hydrochloride 2% and chlorhexidine gluconate 0.25%, 6ml, 11ml syringe (Instillagel ®).	15.02	A	no longer pharmacy; ordered from supplies	
lidocaine with phenylephrine	topical solution containing lidocaine hydrochloride 5% and phenylephrine hydrochloride 0.5%	15.02	A		
lidocaine with phenylephrine	nasal spray containing lidocaine hydrochloride 5% and phenylephrine hydrochloride 0.5%	12.02.1	A		
lidocaine with prilocaine	cream containing lidocaine 2.5% and prilocaine 2.5% (Emla ®).	15.02	A		
lidocane with phenazone (Otigo®)	ear drops sloution containing lidocaine hydorchloride 10mg/g and phenazone 40mg/g	11.04.1	A	In line with NICE guideline (NG91, March 2022): 'Otitis media (acute): antimicrobial prescribing'. NDP January 2023	
linaclotide	capsules 290mcg	1.06.07	R	for specialist initiation (NPD December 2014)	
linagliptin	5mg f/c tablets	6.01.2	R	To be prescribed in line with the relevant national guideline. (September 2012)	
linezolid	tablets 600mg; suspension 100mg in 5ml; infusion 600mg in 300ml	5.01.7	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required except Renal if within their policy	

linzagolix	tablets, 100mg, 200mg	6.04.1	R	In line with NICE TA guidance no. 996, August 2024: Linzagolix is recommended as an option for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age only if it is intended to be used for longer-term treatment (normally for more than 6 months and not for people who need short-term treatment, for example, before planned surgery), the following dosage is used: with hormonal add-back therapy (ABT): 200 mg once daily, without hormonal ABT: 200 mg once daily for 6 months, then 100 mg once daily.	
linzagolix	tablets, 100mg, 200mg	6.04.1	R	In line with NICE TA guidance no. 1067, June 2025: Linzagolix with hormonal add-back therapy can be used within its marketing authorisation as an option to treat symptoms of endometriosis in adults of reproductive age who have had medical or surgical treatment for their endometriosis.	
liothyronine sodium (L-tri-iodothyronine sodium)	tablets 20mcg; injection 20mcg	6.02.1	A		
Lipiodol	ultra fluid 10ml	18	A		
liquid and white soft paraffin	ointment containing liquid paraffin 50% and white soft paraffin 50% 50g, 200g, 500g	13.02.1	A		
liquid paraffin	Eye ointment, with white soft paraffin (Lacri-Lube ®, Hylo-Night® or Xailin Night® depending on availability)	11.08.1	A		
liraglutide	injection 18mg in 3ml pre-filled pens	6.01.2	R	Use in line with the relevant national/local guidelines.	

liraglutide (Saxenda®)	injecton 18mg in 3ml pre-filled pens	4.05.1	R	In line with NICE TA guidance no. 664, December 2020: Liraglutide is recommended as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults, only if: • they have a body mass index (BMI) of at least 35 kg/m2 (or at least 32.5 kg/m2 for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population) and • they have non-diabetic hyperglycaemia (defined as a haemoglobin A1c level of 42 mmol/mol to 47 mmol/mol [6.0% to 6.4%] or a fasting plasma glucose level of 5.5 mmol/litre to 6.9 mmol/litre) and • they have a high risk of cardiovascular disease based on risk factors such as hypertension and dyslipidaemia and • it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service and • the company provides it according to the commercial arrangement.	RL
lisinopril	tablets 2.5mg, 5mg, 10mg, 20mg	2.05.5	A		
lisocaptagene maraleucel	dispersion for infusion 1.1-70x106 cell/ml	8.01.5	R	In line with NICE TA guidance no 1048, March 2025: Lisocabtagene maraleucel (liso-cel) is recommended as an option for treating large B-cell lymphoma that is refractory to, or has relapsed within 12 months after, first-line chemoimmunotherapy in adults with diffuse large B-cell lymphoma, high-grade B-cell lymphoma primary mediastinal large B-cell lymphoma, or follicular lymphoma grade 3B. Liso-cel is recommended only if an autologous stem cell transplant would be considered suitable, and the company provides it according to the commercial arrangement.	PBR
lithium carbonate	tablets 250mg (Camcolit ® 250); MR tablets 200mg, 400mg (Priadel ®)	4.02.3	A	Different lithium preparations vary widely in bioavailability. A change in preparation used requires the same precautions as initiation of treatment.	
lithium citrate	liquid 520mg in 5ml (Priadel ®); MR tablets 564mg.(Litarex ®); oral solution 509mg in 5ml (Li-liquid ®)	4.02.3	A		
Locoid C ®	cream containing hydrocortisone butyrate 0.1% and chlorquinaldol 3%	13.04	A		
Locorten - Vioform	ear drops flumetasone pivalate 0.02%, cliquinol 1%	12.01.1	A		
lodoxamide	eye drops 0.1%	11.04.2	R	For corneal service.	

lofepramine	tablets 70mg; oral suspension 70mg in 5ml	4.03.1	A		
Logynon ®; Trinordiol ®	21 tablets: 6 tablets ethinylestradiol 30 micrograms + levonorgestrel 50 micrograms, 5 tablets ethinylestradiol 40 micrograms + levonorgestrel 75 micrograms, 10 tablets ethinylestradiol 30 micrograms + levonorgestrel 125 micrograms.	7.03.1	A		
Logynon ED ®	28 tablets: 6 tablets ethinylestradiol 30 micrograms + levonorgestrel 50 micrograms, 5 tablets ethinylestradiol 40 micrograms + levonorgestrel 75 micrograms, 10 tablets ethinylestradiol 30 micrograms + levonorgestrel 125 micrograms, 7 placebo tablets.	7.03.1	A		
lomustine	capsules 40mg	8.01.1	A		
loncastuximab tesirine	powder for concentrate for solution for infusion, 10mg	8.01.5	R	In line with NICE TA guidance no. 947, January 2024: Loncastuximab tesirine is recommended as an option for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) after 2 or more systemic treatments in adults, only if they have previously had polatuzumab vedotin, or if polatuzumab vedotin is contraindicated or not tolerated, and the company provides it according to the commercial arrangement.	PBR
Lonsurf® (tifluridine-tipiracil)	tablets trifluridine 15mg/tipiracil 16.4gm trigluridine 20mg/tipiracil 8.19mg	8.01.3	R	1. In line with NICE TA guidance no.405, August 2016: Trifluridine–tipiracil is recommended, within its marketing authorisation, as an option for treating metastatic colorectal cancer, that is in adults who have had previous treatment with available therapies including fluoropyrimidine-, oxaliplatin- or irinotecan-based chemotherapies, anti-vascular endothelial growth factor (VEGF) agents and anti-epidermal growth factor receptor (EGFR) agents, or when these therapies are not suitable, and only when the company provides trifluridine–tipiracil with the discount agreed in the patient access scheme.	PBR RL
Lonsurf® (tifluridine-tipiracil)	tablets trifluridine 15mg/tipiracil 16.4gm trigluridine 20mg/tipiracil 8.19mg	8.01.3	R	2. In line with NICE TA guidance no. 852, December 2022: Trifluridine–tipiracil is recommended, within its marketing authorisation, as an option for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults who have had 2 or more treatment regimens. It is only recommended if the company provides trifluridine–tipiracil according to the commercial arrangement.	PBR RL

Lonsurf® (tifluridine-tipiracil)	tablets trifluridine 15mg/tipiracil 16.4gm trigluridine 20mg/tipiracil 8.19mg	8.01.3	R	3. In line with NICE TA guidance no. 1008, September 2024: Trifluridine–tipiracil with bevacizumab is recommended, within its marketing authorisation, for treating metastatic colorectal cancer in adults who have had 2 lines of treatment (including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, antivascular endothelial growth factor or anti-epidermal growth factor receptor treatments). Trifluridine–tipiracil with bevacizumab is only recommended if the company provides trifluridine–tipiracil according to the commercial arrangement.	PBR RL
loperamide	tablets or capsules 2mg;	1.04.2	A		
loratadine	tablets 10mg; syrup 5mg in 5ml	3.04.1	A	Re-instated on formulary to replace desloratadine.	
lorazepam	tablets 1mg, 2.5mg; Injection 4mg in 1ml.	4.01.2	A		
lorlatinib	tablets 25mg, 100mg	8.02.4	R	In line with NICE TA guidance no 628, May 2020: Lorlatinib is recommended, within its marketing authorisation, as an option for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor, or crizotinib and at least 1 other ALK tyrosine kinase inhibitor. It is recommended only if the company provides lorlatinib according to the commercial arrangement.	PBR RL
lorlatinib	tablets 25mg, 100mg	8.02.4	R	In line with NICE TA guidance no. 1103, October 2025: Lorlatinib can be used as an option for ALK-positive advanced non-small-cell lung cancer in adults who have not had an ALK inhibitor. Lorlatinib can only be used if the company provides it according to the commercial arrangement.	PBR RL
lormetazepam	tablets 500mcg, 1mg	4.01.1	A		
losartan	tablets 12.5mg, 25mg, 50mg, 100mg	2.05.5	A	For treatment of hypertension in patients who are unable to tolerate ACE inhibitors because of cough.	
Lotriderm ®	cream containing betamethasone dipropionate 0.064% and clotrimazole 1%.	13.04	A	Dermatology only	
lubricating jelly		13.05	A		
lusutrombopag	tablets 3mg	9.01.4	R	In line with NICE TA guidance no. 617, January 2020: Lusutrombopag is recommended, within its marketing authorisation, as an option for treating severe thrombocytopenia (that is, a platelet count of below 50,000 platelets per microlitre of blood) in adults with chronic liver disease having planned invasive procedures.	PBR RL

lutetium (177Lu) oxodotreotide	intravenous infusion	not classified	R	In line with NICE TA guidance no. 539, August 2019: Lutetium (177Lu) oxodotreotide is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (NETs) in adults. It is recommended only if the company provides it according to the commercial arrangement.	PBR
lutropin alfa (Recombinant human luteinising hormone)	injection 75 unit	6.05.1	R	for stimulation of follicular development in women with severe LH and FSH deficiency. (May 2009)	RL
lymecycline	capsules 408mg	5.01.3	A	Level 1 non-reserved anti-infective	
Maalox ® Plus	suspension	1.01.1	R	1. antacid containing simeticone; for post-operative wind pain following bariatric surgery (in-patients only). Patients will not be given TTOs and GPs will not be asked to prescribe.	
macimorelin	granules for oral suspension (sachets), 60mg	not classified	R	For the diagnosis of growth hormone deficiency (GHD) in adults in line with the local protocol. NDP July 2025	
macitentan	tablets 10mg	2.05.1	R	For long term management of pulmonary arterial hypertension under specialist management of the pulmonary hypertension team. (NDP July 2014)	PBR RL
macrogol compound oral powder	oral powder; paediatric oral powder	1.06.4	A		
magnesium carbonate	Mixture BPC, contains light magnesium carbonate 500mg and sodium bicarbonate 800mg in 10ml (contains 5.5mmol magnesium, 9.6mmol sodium and 9.6mmol bicarbonate in 10ml) (unlicensed); capsules 500mg as heavy magnesium carbonate BP (contains 5.2mmol magnesium per capsule) (unlicensed)	1.01.1	A		
magnesium chloride	Injection, 40mmol in 20ml (Unlicensed)	9.05.1	A		
magnesium glycerophosphate	tablets 1g (4mmol magnesium per tablet); mixture (10mmol magnesium 10ml, unlicensed)	9.05.1	A		
magnesium hydroxide	mixture BP 8%	1.06.4	A		

magnesium hydroxide and liquid paraffin	oral emulsion BP	1.06.4	A		
magnesium sulphate	injection 50% (20mmol Magnesium in 10ml); pre-filled syringe 50%; injection 10% (4mmol Magnesium in 10ml) (unlicensed)	9.05.1	R	pre-filled syringes for use in line with ALS guidelines	
magnesium sulphate	mixture (unlicensed)	1.06.4	A		
magnesium sulphate paste BP	Paste containing magnesium sulphate 45%, phenol 0.5% and glycerol 55%	13.10.5	A		
Malarone ®	tablets containing proguanil 100mg and atovaquone 250mg (Malarone ®); tablets containing proguanil 25mg and atovaquone 62.5mg (Malarone ® Paediatric);	5.04.1	R	Level 1 non-reserved anti-infective for use in line with British Infection Society malaria recommendations as a treatment option for uncomplicated falciparum malaria where 1st line is not suitable or for resistant malaria.	
malathion	liquid 0.5% in an aqueous base (Derbac-M ®)	13.10.4	A		
mannitol	infusion 10%, 20%	2.02.5	A		
maraviroc	tablets 150mg, 300mg	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
maribavir	tablets, 200mg	5.03.2	R	In line with NICE TA guidance no 860, January 2023: Maribavir is recommended, within its marketing authorisation, as an option for treating cytomegalovirus (CMV) infection that is refractory to treatment including cidofovir, foscarnet, ganciclovir or valganciclovir in adults who have had a haematopoietic stem cell transplant or solid organ transplant. It is recommended only if the company provides it according to the commercial arrangement.	PBR RL
Marshall's solution	organ preservation solution	not classified	R	for renal transplants	

marstacimab	solution for injection in pre-filled pen, 150mg in 1ml	2.11	R	In line with NICE TA guidance no TA 1073, June 2025: Haemophilia B - Marstacimab is recommended, within its marketing authorisation, as an option for preventing bleeding episodes caused by severe (factor IX [9] activity less than 1%) haemophilia B (congenital factor 9 deficiency) in people 12 years and over who weigh at least 35 kg and do not have factor 9 inhibitors (anti-factor antibodies). Marstacimab is only recommended if the company provides it according to the commercial arrangement. Marstacimab is not recommended by NICE for Haemophilia A.	PBR
Marvelon ®; Gedarel 30 ®	21 tablets ethinylestradiol 30 micrograms + desogestrel 150 micrograms	7.03.1	A		
mavacamten	capsules 2.5mg, 5mg	2.05.5	R	In line with NICE TA guidance no 913, September 2023: Mavacamten is recommended as an option for treating symptomatic obstructive hypertrophic cardiomyopathy in adults who have a New York Heart Association class of 2 to 3. It is recommended only if it is an add-on to individually optimised standard care that includes beta-blockers, non-dihydropyridine calcium-channel blockers or disopyramide, unless these are contraindicated, and the company provides it according to the commercial arrangement.	PBR RL
Maxidex ®	Eye drops 0.1% with hypromellose 0.5%; Eye drops 0.1% with hypromellose 0.5% preservative free (unlicensed)	11.04.1	A		
Maxitrol ®	Eye drops dexamethasone 0.1%, hypromellose 0.5%, neomycin sulphate 0.35%, polymyxin B sulphate 6000units in 1ml.	11.04.1	A		
measles, mumps and rubella (MMR) vaccine	live vaccine	14.04	A		
mebendazole	Tablets, chewable, 100mg. Suspension, 100mg in 5ml.	5.05.1	A	Level 1 non-reserved anti-infective	
mebeverine	tablets 135mg; MR capsules 200mg; oral suspension 50mg/5ml (as embonate)	1.02	A		
medroxyprogesterone acetate	tablets 100mg, 200mg, 400mg	8.03.2	A		
medroxyprogesterone acetate	tablets 2.5mg, 5mg, 10mg	6.04.1	A		

medroxyprogesterone acetate	Injection, 150mg in 1ml suspension (Depo-Provera ®) for **intramuscular** administration	7.03.2	A		
medroxyprogesterone acetate	Injection, 104mg in 0.65ml suspension (Sayana PRESS®) for **subcutaneous** injection	7.03.2	A	NDP July 2020	
mefenamic acid	Capsules 250mg; tablets 500mg	10.01.1	A		
mefloquine	tablets 250mg	5.04.1	A	Level 1 non-reserved anti-infective Not to be prescribed for malaria prophylaxis	
megestrol acetate	tablets 40mg, 160mg	8.03.2	A		
melatonin	tablets M/R 2mg; oral liquid 1mg in 1ml (unlicensed)	4.01.1	R	1. Approved for use in paediatric patients for sleep disturbance in children with neurological and behavioural disorders. (NDP February 2011)	
melatonin	tablets M/R 2mg; oral liquid 1mg in 1ml (unlicensed)	4.01.1	R	2. For management of parasomnia in patients under the care of sleep services. (NDP September 2021)	
melatonin	tablets M/R 2mg; oral liquid 1mg in 1ml (unlicensed)	4.01.1	R	3. In line with the produce license - as monotrherapy for short term treatment of primary insomnia in the elderly while in hospital. **GPs should not be asked to continue prescribing.**	
meloxicam	tablets 7.5mg, 15mg	10.01.1	R	For use in line with NICE TA guidance no. 27; July-01. Cox II agents are not for routine use and should only be used when clearly indicated as management of ostearthritis and rheumatoid arthritis (OA and RA) in patients who are deemed at high risk of GI side effects.	
melphalan	tablets 2mg, 5mg; injection 50mg	8.01.1	A	In line with national/local guidelines/protocols.	PBR
memantine	tablets 5mg, 10mg, 15mg, 20mg oral solution 10mg in 1ml orodiseprsible tablets, 5mg, 10g, 15mg, 20mg	4.11	R	In line with NICE TA guidance no. 217; Mar-11 (last updated May 2016), memantine is recommended as an option for managing Alzheimer's disease for people with moderate Alzheimer's disease who are intolerant of or have a contraindication to acetylcholinesterase (AChE) inhibitors (donepezil, galantamine and rivastigmine) **or** for management of severe Alzheimer's disease. Most cost-effective preparation to be used where ordinary tablets unsuitable. (NDP March 2022)	

menadiol sodium phosphate (Water-Soluble Vitamin K)	tablets 10mg	9.06.6	A	For vitamin K deficiency in biliary obstruction or hepatic disease.	
meningococcal group B vaccine (Bexsero®)	injection	14.04	R	For adult and paediatric splenectomy patients according to the Trust protocol (NDP Dec-2014/March-2015) For paediatric patients with complement disorders (NDP March 2015) Part of routine immunisation (NDP September 2015) For prevention of gonorrhoea in adults as outlined in JCVI advice (November 2023)	
meningococcal group C conjugate vaccine with Haemophilus Influenza type B vaccine	injection	14.04	A		
meningococcal A, C, W135, Y conjugate vaccine	injection	14.04	A		
menotrophin (human menopausal gonadotrophins)	injection FSH 75units and LH 75units.For intramuscuclar or subcutaneous injection.	6.05.1	A		RL
menthol in aqueous	cream 0.5% 100g, 2% 100g (both unlicensed)	13.03	A		
mepacrine	tablets 100mg (unlicensed)	5.04.4	R	Level 2 anti-infectives restricted to specific indications	
mepolizumab	pre-filled pen, 100mg in 1ml	3.04.2	R	In line with NICE TA guidance no. 671, February 2021: Mepolizumab, as an add-on therapy, is recommended as an option for treating severe refractory eosinophilic asthma, a outlined in the TA guidance.	PBR
mercaptopurine	tablets 10mg (unlicensed), 50mg; suspension 100mg in 5ml	8.01.3	A	SMH - 10mg tablets restricted for use by Paediatric teams only.	PBR (for oncology)
Mercilon ®; Gedarel 20 ®	21 tablets ethinylestradiol 20 micrograms + desogestrel 150 micrograms	7.03.1	A		
meropenem	injection 500mg, 1g	5.01.2	R	Level 2 anti-infectives restricted to specific indications: As per Haematology anti-infective policy As per Renal anti-infective policy As per Neonatal anti-infective policy Head injury, history of epilepsy or patients with meningitis not able to have imipenem. Paediatric ICU As per Paediatric Oncology/Haematology protocols	

mesalazine	MR tablets 400mg, 800mg, 1600mg (Octasa®) MR tablets 500mg, 1g (Pentasa ®); gastro-resistant prolonged release granules 500mg, 1g, 1.5g, 3g (Salofalk ®); retention enema 1g in 100ml; enema 2g in 59ml (Salofalk ®) (NDP - May 2010); foam enema 1g/application; suppositories 1g	1.05.1	A	Octasa ® and Asacol ® are considered equivalent so the pharmacy will stock and dispense the least costly brand in Primary Care when treatment is started by the hospital. The labels will identify the brand dispensed. When a patient is already taking another brand that brand will be re-dispensed. Octasa ® to replace Mesren® (discontinued), NDP Feb 2013 Asacol brand removed from the formularY, NDP Jan 2020 Note: Pentasa ® tablets may be dispersed in water.	
mesna	tablets 400mg; injection, 400mg in 4ml, 1g in 10ml.	8.01	A	For oral administration, contents of ampoule may be taken in fruit juice or cola - may be stored in a 'fridge for up to 24 hours in a sealed container.	PBR
Metanium ®	ointment	13.02.2	A		
metaraminol	injection 10mg in 1ml	2.07.2	A		
metformin	tablets 500mg, 850mg; SR tablets 500mg (Glucophage SR ®) suspension 500mg in 5ml	6.01.2	A	Metformin SR is restricted to the diabetic team- for those patients who are intolerant of IR metformin due to GI side effects or compliance problems.	
methadone	linctus 2mg in 5ml	3.09.1	A		
methadone	tablets 5mg; injection 10mg in 1ml; Injection 50mg in 5ml	4.07.2	A		
methadone	Mixture, 1mg in 1ml Mixture, sugar-free, 1mg in 1ml.	4.10.3	A	NICE TA guidance no. 114, Jan-07: Oral methadone and buprenorphine is recommended as options for maintenance therapy in the management of opioid dependence.	
methenamine hippurate	tablets 1g	5.01.13	R	In line with the local guidelines/policies. As per NWL JF	
methionine	tablets 500mg	17	R	for 2nd line for paracetamol poisoning, to be kept at SMH A&E	
methotrexate	Tablets 2.5mg, 10mg; Injection 5mg in 2ml, 50mg in 2ml (preservative-free). Suitable for intrathecal administration; Injection 200mg in 8ml, 500mg in 20ml, 1g in 10ml, 5g in 50ml; Pre-filled syringes 7.5mg in 0.15ml, 10mg in 0.2ml, 12.5mg in 0.25ml, 15mg in 0.3ml, 17.5mg in 0.35ml, 20mg in 0.4ml, 22.5mg in 0.45ml, 25mg in 0.5ml, 27.5mg in 0.55ml, 30mg in 0.6ml; Oral liquid 10mg in 5ml	8.01.3	A	High alert. Note that the oral preparations are given as a once-weekly dose. Close attention should be paid to the strength of methotrexate tablets prescribed and the frequency of dosing as well as regular monitoring once treatment has commenced. 10mg tablets restricted for use by Paediatric teams only. For adults 10mg tablets only dispensed as continuation	PBR (oncology use)

methotrexate	Tablets 2.5mg, 10mg; Oral liquid 10mg in 5ml	8.01.3	A	For maintainance of remission of immune mediated neurological disorders. (NDP March 2019)	
methotrexate	Tablets, 2.5mg, 10mg see section 8.01	10.01.3	A	High alert. Note that the oral preparations are given as a once-weekly dose. Close attention should be paid to the strength of methotrexate tablets prescribed and the frequency of dosing as well as regular monitoring once treatment has commenced.	
methoxyflurane Penthrox®	inhalation vapour liquid inhaler, vial 3ml	not classified	R	For emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain. To be used by Emergancy Medicines only. (NDP December 2017) Extended to paediatric A&E prescribing (NDP November 2025)	
methoxy polyethylene glycol-epoetin beta (Mircera ®)	pre-filled syringe 30mcg, 50mcg, 75mcg, 100mcg, 150mcg, 200mcg, 250mcg	9.01.3	Very R	Renal Medicine only.	PBR (renal only) RL
methyl-5-aminolevulinate	Cream, 2g (Metvix ®)	13.08.1	A		
methylcellulose	tablets 500mg (Celevac ®); enema 4%	1.06.1	A	for mixing calcium resonium for rectal use	
methyldopa	tablets 125mg, 250mg, 500mg	2.05.2	A		
methylphenidate hydrochloride	tablets 5mg, 10mg; MR tablets 18mg, 27mg, 36mg (Delmosart®XL); MR tablets 18mg, 27mg, 36mg, 54mg (Xaggitin®XL) MR capsules 5mg, 10mg, 20mg, 30mg, 40mg (Medikinet®XL) MR tablets 10mg, 20mg, 30mg (Equasym XL®)	4.04	R	NICE TA guidance no. 98; Mar-06. Where drug treatment is considered appropriate, methylphenidate, atomoxetine and dexamfetamine are recommended as options for the management of attention deficit hyperactivity disorder (ADHD) in children and adolescents. For use by Paediatric Consultants only	
methylprednisolone	tablets 100mg	6.03.1	A		
methylprednisolone acetate	Depot injection, 40mg in 1ml, 80mg in 2ml, 120mg in 3ml (Depo-Medrone ®).	6.03.2	A		
methylprednisolone acetate (Depo-Medrone ®)	injection 40mg in 1ml, 80mg in 2ml, 120mg in 3ml	10.01.2	A		
methylprednisolone with lidocaine	injection methylprednisolone acetate 40mg + lidocaine 10mg in 1ml, injection methylprednisolone acetate 80mg + lidocaine 20mg in 2ml (Depo-Medrone ® with Lidocaine)	10.01.2	A		

methylprednisolone sodium succinate	injection 40mg, 125mg, 500mg, 1g (Solu-Medrone ®).	6.03.2	A		
methylthioninium chloride (methylene blue)	injection 1% (unlicensed)	19.02	A		
metoclopramide	tablets 5mg, 10mg; oral solution 5mg in 5ml; injection 10mg in 2ml, 8mg in 4ml, 100mg in 2ml	4.06	A		
metolazone	tablets 5mg	2.02.1	A		
metoprolol	tablets 50mg, 100mg; injection 5mg in 5ml	2.04	A		
metronidazole	Tablets 200mg, 400mg; Suspension 200mg in 5ml; Suppositories 500mg, 1g; Intravenous infusion 500mg in 100ml.	5.01.11	A	Level 1 non-reserved anti-infective	
metronidazole	vaginal gel 0.75%	7.02.2	A		
metronidazole	cream 0.75% (Rozex ®); gel 0.75% (Zyomet ®); gel 0.8% (Metrotop ®)	13.10.1	R	Dermatologists only.	
metyrapone	capsules 250mg	6.07.3	A		RL
mexiletine	capsules 50mg, 100mg; capsules 167mg (Namuscla® brand)	2.03.2	R	1. For cardiology use. 2. For neurology use in line with NICE TA guiadance no 748, December 2021: Mexiletine (Namuscla®) is recommended, within its marketing authorisation, as an option for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders. It is recommended only if the company provides mexiletine (Namuscla®) according to the commercial arrangement.	PBR (for neurology)
micafungin (Mycamine®)	powder for solution for infusion 100mg	5.02.5	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required. Empirical treatment of pyrexia of unknown origin unresponsive to broad spectrum antimicrobials, and for the treatment of confirmed candidiasis in immunocompromised patients, according to the protocol in place. (NDP September 2013)	PBR
miconazole	oromucosal gel (SF) 20mg in 1g.	12.03.2	A		

miconazole nitrate	Intravaginal cream 2%; Pessaries 100mg	7.02.2	A		
miconazole nitrate	cream 2%	13.10.2			
miconazole nitrate	eye drops 1% (unlicensed)	11.03.2	R		
Microgynon 30 ®; Ovranette ®; Rigevidon ®	21 Tablets ethinylestradiol 30 micrograms + levonorgestrel 150 micrograms	7.03.1	A		
Microgynon 30 ED ®	28 tablets: 21 tablets levonorgestrel 150mcg + ethinylestradiol 30 mcg, 7 inactive tablets.	7.03.1	A		
midazolam	injection 1mg in 1ml - 2ml, 5ml, 50ml; 2mg in 1ml - 5ml; 5mg in 1ml - 2ml, 10ml;	15.01.4	R	In response to the NPSA alert regarding midazolam, the 5mg/ml (2ml) strength is restricted as stock to the following areas: **paediatrics, oncology, palliative care and level 3 critical care (all sites)**. Midazolam 5mg/ml (2ml) may be also be supplied on an individual patient basis; this needs to be ordered in the CD book giving the patient's details. The 2mg/ml (5ml) strength injection is restricted to **neonatal** units.	
midazolam	Buccolam® oromucosal solution, hydrochloride salt - buccal liquid 2.5mg in 0.5ml prefilled oral syringes; 5mg in 1ml prefilled oral syringes; 7.5mg in 1.5ml prefilled oral syringes; 10mg in 2ml prefilled oral syringes Buccal liquid 10mg in 1ml (Epistatus ®, maleate salt)	4.08.2	R	Buccolam ® contains the hydrochloride salt; Epistatus is the maleate salt. The doses are equivalent in mg, however strengths are different. Counselling is needed when transferring partients to different preparations.	
midodrine	tablets, 2.5mg, 5mg	not classified	A		
midostaurin	capsules, 25mg	8.01.5	R	In line with NICE TA guidance no. 523, June 2018: Midostaurin is recommended, within its marketing authorisation, as an option in adults for treating newly diagnosed acute FLT3-mutation-positive myeloid leukaemia with standard daunorubicin and cytarabine as induction therapy, with high-dose cytarabine as consolidation therapy, and alone after complete response as maintenance therapy. It is recommended only if the company provides midostaurin with the discount agreed in the patient access scheme.	PBR RL

midostaurin	capsules, 25mg	8.01.5	R	In line with NIC TA guidance no. 728, September 2022: Midostaurin monotherapy is recommended, within its marketing authorisation, as an option for treating aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, or mast cell leukaemia in adults. It is recommended only if the company provides midostaurin according to the commercial arrangement.	PBR RL
mifepristone	tablets 200mg	7.01.2	A		
Migraleve ®	Compound anti-migraine drugs pink tablets containing buclizine hydrochloride 6.25mg, paracetamol 500mg and codeine phosphate 8mg; yellow tablets containing paracetamol 500mg and codeine phosphate 8mg (Migraleve ®).	4.07.4	A		
milrinone	injection 10mg in 10ml	2.01.2	R		
minadex	syrup	9.06.7	R	Not available on NHS prescription from general practitioners	
mineralised methylated spirit		16	A		
minocycline	tablets 50mg, 100mg; MR capsules 100mg	5.01.3	A	Level 1 non-reserved anti-infective MR capsules not on NWL JF	
minoxidil	tablets 2.5mg, 5mg, 10mg.	2.05.1	A	for use as antihypertensive	
mirabegron	tablets 25mg, 50mg	7.04.2	A	In line with NICE TA guidance no 290, June 2013: Mirabegron is recommended as an option for treating the symptoms of overactive bladder only for people in whom antimuscarinic drugs are containdicated or clinically ineffective, or have unacceptable side effects.	
mirikizumab	100mg, 300mg concentrate for solution for infusion	1.05.1	R	In line with NICE TA guidance no 925, October 2023: Mirikizumab is recommended as an option for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or lost response to treatment, only if a tumour necrosis factor (TNF)-alpha inhibitor has not worked (that is the condition has not responded well enough or has lost response to treatment) or a TNF-alpha inhibitor cannot be tolerated or is not suitable and the company provides it according to the commercial arrangement.	PBR

mirikizumab	100mg, 300mg concentrate for solution for infusion	1.05.1	R	In line with NICE TA guidance no 1080, July 2025: Mirikizumab can be used as an option to treat moderately to severely active Crohn's disease in adults, only if: the disease has not responded well enough or stopped responding to a previous biological treatment, or a previous biological treatment was not tolerated, or tumour necrosis factor (TNF)-alpha inhibitors are not suitable. Mirikizumab can only be used if the company provides it according to the commercial arrangement.	PBR
mirtazapine	Tablets 15mg, 30mg, 45mg Orodispersible (soluble) tablets (Zispin SolTab ®); 15mg, 30mg, 45mg.	4.03.4	A		
misoprostol	tablets 200mcg	1.03.4	R	For the medical management of early pregnancy failure (up to 13 weeks gestation). This involves uterine priming with 200mg of oral mifepristone, followed 24 to 48 hours later by 600mcg misoprostol inserted vaginally. For use in Obstetric Haemorrhage as per current guidelines	
misoprostol	tablets 25mcg	7.01.1	A	For use by obstetric teams in line with local and national guidelines. (NDP September 2022)	
mitomycin	Injection, 2mg, 10mg, 20mg, 40mg	8.01.2	A	Due to supply problems - unlicensed product in use. (NPD January 2020)	PBR
mitomycin	injection (subconjuctival) 250mcg in 0.5ml (0.05%)	not classified	R	unlicensed, for opthalmology use only (NDP May 2022)	
mitotane	tablets 500mg	8.01.5	R	Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma	PBR (oncology and haematology only)
mitoxantrone	injection 20mg; injection 90mg in 45ml (unlicensed)	8.01.2	R	Restricted for oncology and haematology use (as per licence) and neurology use (unlicensed).	
mivacurium	injection 10mg in 5ml, 20mg in 10ml	15.01.5	A		
mobocertinib	capsules 40mg	8.01.5	R	In line with NICE TA guidance no. 855, January 2023: Mobocertinib is recommended, within its marketing authorisation, as an option for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) after platinum-based chemotherapy in adults whose tumours have epidermal growth factor receptor (EGFR) exon 20 insertion mutations. It is recommended only if the company provides it according to the commercial arrangement.	PBR RL
modafinil	tablets 100mg	4.04	R	Patients should be stabilized on treatment for 3-6 months before GPs are asked to prescribe.	

molnupiravir	capsules 200mg	5.03.5	R	In line with NICE TA guidance no. 1056, April 2025: Molnupiravir is recommended as an option for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test, only if they have 1 or more risk factors for progression to severe COVID-19 (as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19) and both nirmatrelvir plus ritonavir and sotrovimab are contraindicated or unsuitable.	PBR
momelotinib	tablets, 100mg, 150mg, 200mg	8.01.5	R	In line with NICE TA guidance no. 957, March 2024: Momelotinib is recommended as an option for treating myelofibrosis-related splenomegaly or symptoms in adults with moderate to severe anaemia who have not had a JAK inhibitor or have had ruxolitinib, only if they have intermediate-2 or high-risk myelofibrosis, and the company provides momelotinib according to the commercial arrangement.	PBR RL
mometasone furoate	Aqueous nasal spray, 50micrograms per metered spray (Nasonex ®).	12.02.1	A		
mometasone furoate	cream 0.1%; ointment 0.1%;	13.04	R	Dermatology only.	
monobenzone	monobenzylether of hydroquinone 20% cream (unlicensed)	not classified	R	Dermatology only (NDP May 2017)	
Monsel's	solution (unlicensed)	13.13	A		
montelukast	tablets 10mg; chewable tablets 4mg, 5mg granules 4mg	3.03.3	R	In line with BTS guidelines for chest, allergy and paediatric teams.	
morphine sulphate	tablets 10mg, 20mg, 50mg (Sevredol ®); MR tablets 10mg, 15mg, 30mg, 60mg, 90mg, 100mg, 200mg (Morphgesic SR ®); MR capsules 100mg (Zomorph®) MR capsules 10mg, 30mg, 60mg, 90mg, 150mg, 200mg (MXL ®). MR tablets 5mg (MST ®); oral solution 10mg in 5ml. Concentrated oral solution 100mg in 5ml (Oramorph ®), oral soilution 100mcg/ml (unlicensed); MR suspension 20mg/sachet, 30mg/sachet, 60mg/sachet; gel 10mg in 10ml (unlicensed); injection 1mg in 1ml, 10mg in 1ml, 15mg in 1ml, 30mg in 1ml, 60mg in 2ml; infusion for PCA 200mg in 100ml suppositories, 15mg, 30mg	4.07.2	A	High strength morphine injections (30mg or higher) are restricted as stock items in response to the NPSA alert NPSA/2006/12.	

Moviprep ®	oral powder	1.06.5	A	NDP February 2014	
moxifloxacin	tablets 400mg	5.01.12	R	Level 2 anti-infectives restricted to specific indications: As per Adult anti-infective policy As per Renal anti-infective policy Treatment of MDR-TB	
moxifloxacin	intravenous infusion 400mg in 250ml	5.01.12	R	Treatment of MDR-TB for patients unable to have oral moxifloxacin (NDP May 2013)	
moxifloxacin	eye drops, solution 0.5% w/v	11. 3. 1	R	Use for bacterial ulcers where previously levofloxacin PF had been used. (NDP September 2016)	
moxonidine	tablets 200mcg, 300mcg, 400mcg	2.05.2	R	As third line treatment for mild to moderate hypertension in patients unable to tolerate first line therapy (thiazides or beta-blockers) or second line therapy (calcium channel blockers or ACE inhibitors).	
Mucogel	suspension	1.01.1	A		
Multihance	injection 5ml, 10ml, 20ml	18	R	for liver MRI and MRA (mainly renal).	
Multistix 10 S.G		19.01	A	Pharmacy only stock Multistix 8SG ® for urinalysis.ng strips.	
Multistix 8 S.G		19.01	R	Occupational Health only at HH.	
Multistix 8SG ®	Urinalysis testing strips.	19.02	A		
Multistix S.G		19.01	A		
multivitamin	Capsules, contain vitamin A 2500 units, thiamine hydrochloride (vitamin B1) 1mg, riboflavin (vitamin B2) 500 micrograms, nicotinamide 7.5mg, ascorbic acid 15mg and vitamin D 300 units; Renal multivitamin tablets without zinc (Renavit ®)	9.06.7	A		
mupirocin	cream 2%; ointment 2%; nasal ointment 2%	13.10.1	A	For use in line with Infection Control policies only.	

mycophenolate mofetil	capsules 250mg (CellCept® and generic brands on contract); tablets 500mg (CellCept® and generic brands on contract); suspension 1g in 5ml (CellCept® and generic brands on contract); injection 500mg	8.02.1	R	1. In line with NICE TA guidance no. 85, September 2004: For adults as an option as part of an immunosuppressive regimen only: • where there is proven intolerance to calcineurin inhibitors, such as nephrotoxicity leading to risk of chronic allograft dysfunction or • in situations where there is a very high risk of nephrotoxicity necessitating minimisation or avoidance of a calcineurin inhibitor. 2. NICE TA guidance no. 99, April 2006: Mycophenolate mofetil (MMF) is recommended as an option as part of an immunosuppressive regimen for child and adolescent renal transplant recipients only when: • there is proven intolerance to calcineurin inhibitors or • there is a very high risk of nephrotoxicity necessitating the minimisation or avoidance of a calcineurin inhibitor until the period of high risk has passed. **NOTE**: Brand of capsules and tablets should be specified by prescriber	PBR (renal only) RL
mycophenolic acid	tablets 180mg, 360mg	8.02.1	R	3. For the prophylaxis of acute transplant rejection in patients receiving allogenic renal transplants for patients who remain intollerant of mycophenolate mofetil despite dose modification.	PBR RL
mycophenolate mofetil	capsules/tablets 250mg, 500mg	8.02.1	R	4. For management of auto-immune thrombocytopenia (ITP).	
mycophenolate mofetil	capsules/tablets 250mg, 500mg	8.02.1	R	5. For maintainance of remission of immune mediated neurological disorders. (NDP March 2019)	
Mycota ®	cream containing zinc undecenoate 20% and undecenoic acid 5%; dusting powder containing zinc undecenoate 20% and undecenoic acid 2%	13.10.2			
Mydriasert®	Ophthalmic insert containing phenylephrine 5.4mg and tropicamide 0.28mg	11.05	R	For pupil dilation in preparation for cataract surgery. (NDP September 2012)	
Mydrane®	intracameral single use injection: tropicamide 0.2mg/mL, phenylephrine hydrochloride 3.1mg/mL, lidocaine hydrochloride 10mg/mL	11.05	R	For pupil dilation in preparation for cataract surgery. (NDP March 2019)	
nabilone	capsules 1mg	4.06	A		
nabumetone	tablets 500mg	10.01.1	A		

nadolol	tablets 80mg	2.04	R	For long QT-syndrome and catecholaminergic polymorphic ventricular tachycardia. (NDP March 2015)	
nafarelin	nasal spray 200mcg/metered spray;	6.07.2	A		
naftidrofuryl oxate	capsules 100mg	2.06.4	R	In line with NICE TA guidance no. 223; May-11 naftidrofuryl oxalate is recommended as an option for the treatment of intermittent claudication in people with peripheral arterial disease for whom vasodilator therapy is considered appropriate after taking into account other treatment options. Treatment with naftidrofuryl oxalate should be started with the least costly licensed preparation.	
naldemedine	tablets 200mcg	1.06.7	R	In line with NICE TA guidance no 651, September 2020: Naldemedine is recommended, within its marketing authorisation, as an option for treating opioid-induced constipation in adults who have had laxative treatment.	
nalmefene	tablets 18mg	4.10.3	R	In line with NICE TA guidance, no 325, November 2014: Nalmefene is recommended within its marketing authorisation, as an option for reducing alcohol consumption, for people with alcohol dependence as outlined in the guidance. NDP July 2019	
naloxegol	tablets, 12.5mg, 25mg	1.06.7	A	In line with NICE TA guidance no. 345, July 2015: Naloxegol is recommended, within its marketing authorisation, as an option for treating opioid induced constipation in adults whose constipation has not adequately responded to laxatives. An inadequate response is defined as opioid-induced constipation symptoms of at least moderate severity in at least 1 of the 4 stool symptom domains (that is, incomplete bowel movement, hard stools, straining or false alarms) while taking at least 1 laxative class for at least 4 days during the prior 2 weeks.	
naltrexone	tablets 50mg	4.10.3	R	NICE TA guidance no. 115, January 07: Naltrexone is recommended as a treatment option in detoxified formerly opioid-dependent people who are highly motivated to remain in an abstinence programme.	
naloxone hydrochloride	injection 400mcg in 1ml pre-filled syringe 1mg in 1ml	15.01.7	A	pre-filled syringes for A&E use only as a part of 'naloxone kits' (NDP November 2024)	
naproxen	tablets 250mg, 500mg; suspension 125mg in 5ml	10.01.1	A	Naproxen 275mg (Synflex ®) is non-formulary	
naratriptan	Tablets 2.5mg	4.07.4	R	For acute migraine attacks. Not to be stocked by Trust pharmacies but to allow it to be recommended to GP's when appropriate.	

Naseptin ®	Nasal cream, contains chlorhexidine hydrochloride 0.1% and neomycin sulphate 3,250 units/g. Contains arachis (peanut) oil.	12.02.3	A		
natalizumab	intravenous infusion 300mg in 15ml	8.02.4	R	In line with NICE TA guidance no. 127, Aug 2007 (updated May 2024): Natalizumab (branded or biosimilar) is recommended as an option for the treatment only of rapidly evolving severe relapsing–remitting multiple sclerosis (RES-RRMS) in adults. RES-RRMS is defined by 2 or more relapses in the previous year, and baseline MRI evidence of disease activity	
natamycin	eye drop, aqueous suspension 5% (unlicensed)	11. 3. 2	R	fungal eye infections, as a more cost-effective option to voriconazole eye drops (NDP March 2022)	
nebivolol	tablets 5mg	2.04	R	For treatment of heart failure where it is clinically desired to administer a beta blocker, for patients who have not tolerated previous beta blocker therapy. To be prescribed by heart failure teams. (March 2009)	
nedocromil sodium	Eye drops, 2% (Rapitil ®)	11.04.2	A		
nefopam	tablets 30mg	4.07.1	A		
NeilMed® Sinus Rinse	Regular Ki (1 Bottle, 1 Cap, 1 Tube, 60 Regular Mixture Packets)	Not classified	R	Device - supplied by pharmacy for ENT team, post nasal surgery only on discharge. GPs should not be asked to provide further supply - if further supply required to be obtained OTC. (NDP July 2020)	
Neo-cortef ®	Ointment (for ear or eye), hydrocortisone acetate 1.5%, neomycin sulphate 0.5%.	11.04.1	A		
neomycin	1g in 10ml liquid	5.01.4	A	Level 1 non-reserved anti-infective	
neomycin	eye ointment 0.5%; Minims 0.5% - preservative free	11.03.1	A	0.5% eye drops discontinued (June 09)	
Neonatal PN	with sodium and with peditrace 360ml, 800ml; without sodium and with peditrace 240ml, 800ml; with sodium and without peditrace 360ml, 800ml; without sodium and without peditrace 240ml, 800ml	9.03	A		
neostigmine	Tablets (as bromide) 15mg. Injection (as methylsulphate) 2.5mg in 1ml.	10.02.1	A		
neostigmine	Tablets neostigmine bromide 15mg. Injection neostigmine methylsulphate 2.5mg in 1ml.	15.01.6	A		

neostigmine metisulfate with glucopyrronium (neostigmine metylsulphate)	injection neostigmine 2.5mg + glycopyrronium 500mcg in 1ml	15.01.6	A		
nelarabine	vial 50ml (5mg in 1ml)	8.01.5	R	Treatment of refractory T-cell lymphoblastic non-Hodgkin's lymphoma as a bridge to bone marrow transplantation within the **Cancer Drug Fund**. (April 2021)	PBR
nelarabine	vial 50ml (5mg in 1ml)	8.01.5	R	Treatment of refractory T-cell acute lymphoblastic leukaemia as a bridge to bone marrow transplantation within the **Cancer Drug Fund**. (April 2021)	PBR
nemolizumab	powder and solvent for solution for injection in pre-filled pen, 30mg	13.5.01	R	In line with NICE TA guidance no. 1077, July 2025: Nemolizumab with topical corticosteroids or calcineurin inhibitors, or both, can be used as an option to treat moderate to severe atopic dermatitis. It can be used in people 12 years and over with a body weight of 30 kg or more when systemic treatment is suitable, only if: the atopic dermatitis has not responded to at least 1 systemic immunosuppressant, or these treatments are not suitable, and a biological medicine would otherwise be offered, and the company provides nemolizumab according to the commercial arrangement.	PBR
nepafenac	eye drops, 5ml (1mg/ml, 3mg/ml)	11.08.2	R	for opthalmology teams only perioperatively for cataract surgery (NDP September 2014) The most cost-effective strenght to be prescribed.	
neratinib	tablets 40mg	8.01.5	R	In line with NICE TA guidance no. 612, November 2019: Neratinib is recommended as an option for the extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults who completed adjuvant trastuzumab-based therapy less than 1 year ago only if trastuzumab is the only HER2-directed adjuvant treatment they have had, and if they had neoadjuvant chemotherapy-based regimens, they still had residual invasive disease in the breast or axilla following the neoadjuvant treatment, and the company provides neratinib according to the commercial arrangement.	PBR RL
netupitant/palonsentron (Akynzeo®)	300mf/0.5mg	4.06	R	Prevention of acute and delayed nausea and vomiting associated with highly emetogenic and moderately emetogenic cancer therapy according to local protocols. NDP May 2016	

nevirapine	tablets 200mg; tablets MR 50mg, 100mg, 400mg suspension 50mg in 5ml	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
nicardipine	solution for infusion 10mg in 10ml	2.6.2	A	For treatment of acute life theatening hypertension - only to be used with intra-arterial blood pressure monitoring and in areas with facilities for such monitoring i.e. in high dependancy and intesive care units. (NDP March 2015, updated December 2017)	
niclosamide	tablets chewable 50mg, 500mg (unlicensed)	5.05.3	A	Level 1 non-reserved anti-infective	
nicorandil	tablets 10mg, 20mg	2.06.3	A		
nicotinamide	tablets 250mg (unlicensed)	9.06.2	A		
nicotine	patches (all strengths); chewing gum 2mg, 4mg; sublingual tablet 2mg; lozenge (all strenghts); mouth spray 1mg/spray; inhalation 10mg; nasal spray.	4.10.2	A		
nicotinic acid	tablets 50mg; capsules 50mg, 500mg (unlicensed); tablets MR 375mg, 500mg, 750mg, 1g; titration pack (375mg, 500mg & 750mg)	2.12	A	Pharmacy will only stock titration starter pack of MR tablets. Restricted for use in the lipid clinic by the endocrinology team. To be used alone, in combination with a statin or as an alternative to fibrates.	
nifedipine	capsules 5mg, 10mg; MR tablets (Adalat Retard or equivalent) 10mg, 20mg; MR tablets (Adalat LA or equivalent) 30mg; MR capsules 30mg	2.06.2	A		
nilotinib	capsules 150mg, 200mg	8.01.5	R	In line with NICE TA guidance no. 425; Dec-16: Dasatinib and **nilotinib** are recommended as options for treating only chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if they cannot have imatinib, or their disease is imatinib-resistant and the companies provide the drugs with the discounts agreed in the relevant patient access schemes. This guidance partially updates TA guidance no 70 (October 13) and 241 (January 12).	PBR RL

nilotinib	capsules 150mg, 200mg	8.01.5	R	In line with NICE TA guidance no. 426, Dec-16: Dasatinib and **nilotinib** are recommended, within their marketing authorisations, as options for untreated chronic-phase Philadelphiachromosome- positive chronic myeloid leukaemia in adults. The drugs are recommended only if the companies provide them with the discounts agreed in the relevant patient access schemes. This guidance partially updates NICE TA guidance no. 70 (Oct-03) and no. 251 (April-12)	PBR RL
nimodipine	tablets 30mg; injection 10mg in 50ml	2.06.2	A		RL
nintedanib Vargatef®	capsules, 100mg, 150mg	8.01.5	R	In line with NICE TA guidance no 347, July 2015: Nintedanib in combination with docetaxel is recommended, within its marketing authorisation, as an option for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer of adenocarcinoma histology that has progressed after first-line chemotherapy, only if the company provides nintedanib with the discount agreed in the patient access scheme.	PBR RL
nintedanib Ofev®	capsules, 100mg, 150mg	3.11	R	In line with NICE TA guidance no 379, January 2016: Nintedanib is recommended as an option for treating idiopathic pulmonary fibrosis, only if the person has a forced vital capacity (FVC) between 50% and 80% of predicted, the company provides nintedanib with the discount agreed in the patient access scheme and treatment is stopped if disease progresses (a confirmed decline in percent predicted FVC of 10% or more) in any 12-month period. In line with NICE TA guidance no 864, February 2023 (partially replaced TAG 379): Nintedanib is recommended as an option for treating idiopathic pulmonary fibrosis in adults, only if they have a forced vital capacity of above 80% predicted the company provides it according to the commercial arrangement.	PBR RL
nintedanib Ofev®	capsules, 100mg, 150mg	3.11	R	In line with NICE TA guidance no 747, November 2021: Nintedanib is recommended, within its marketing authorisation, as an option for treating chronic progressive fibrosing interstitial lung diseases (PF-ILD) in adults.	PBR RL
niopam	injection 300	18	A		PBR

niraparib	capsules, 100mg	8.1.5	R	In line with NICE TA guidance no 784, April 2022 (replaces earlier TAG no 528, July 2018): Niraparib is recommended as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults. It is recommended only if they have a BRCA mutation and have had 2 courses of platinum-based chemotherapy or they do not have a BRCA mutation and have had 2 or more courses of platinum-based chemotherapy, and the company provides it according to the commercial arrangement. .	PBR
niraparib	capsules, 100mg	8.1.5	R	In line with NICE TA guidance no 673, February 2021: Niraparib is recommended for use within the **Cancer Drugs Fund** as an option for maintenance treatment for advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults. It is recommended only if the conditions in the managed access agreement for niraparib are followed.	PBR
nirmatrelvir	tablets 150mg	5.03.5	R	With **ritonavir (100mg tablets, Paxlovid®),** for the treatment of hospital onset COVID-19 in line with the national and local guidelines. (NDP March 2022) NICE TA guidance 878, April 2023 (updated May 2025)	
nirsevimab	solution for injection in pre-filled syringe 50mg, 100mg	5.03.5	R	For passive immunisation against RSV in at risk infants (2025/26 RSV season), in line with NHS England policy. (NDP September 2025)	PBR
nitisinone	capsules 2mg, 5mg	9.08.1	Very R	Tp paediatric for heriditary tyrosinaemia on advice from specialist team at GOSH	
nitrazepam	tablets 5mg; suspension 2.5mg in 5ml	4.01.1	A		PBR
nitric oxide	inhaled gas 400ppm	2.05.1	R	1. For persistent pulmonary hypertension in neonates. 2. for vasoreactivity testing at cardiac catheterisation in patients with pulmonary arterial hypertension (PAH).	PBR
nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	1. In line with NICE TA guidance no. 384, February 2016: Nivolumab as monotherapy is recommended, within its marketing authorisation, as an option for treating advanced (unresectable or metastatic) melanoma in adults.	PBR
nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	2. In line with NICE TA guidance no. 400, July 2016: Nivolumab in combination with ipilimumab is recommended, within its marketing authorisation, as an option for treating advanced (unresectable or metastatic) melanoma in adults, only when the company provides ipilimumab with the discount agreed in the patient access scheme.	PBR

nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	3. In line with NICE TA guidance no. 417, November 2016: Nivolumab is recommended, within its marketing authorisation, as an option for previously treated advanced renal cell carcinoma in adults, when the company provides nivolumab with the discount agreed in the patient access scheme.	PBR
nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	4. In line with NICE TA guidance no. 462, July 2017: Nivolumab is recommended, within its marketing authorisation, as an option for treating relapsed or refractory classical Hodgkin lymphoma in adults after autologous stem cell transplant and treatment with brentuximab vedotin, when the company provides nivolumab with the discount agreed in the patient access scheme.	PBR
nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	5. In line with NICE TA guidance no. 684, March 2021 (replaces TA guidance no 558, January 2019): Nivolumab is recommended, within its marketing authorisation, as an option for the adjuvant treatment of completely resected melanoma in adults with lymph node involvement or metastatic disease. It is recommended only if the company provides nivolumab according to the commercial arrangement.	PBR
nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	6. In line with NICE TA guidance no 655, October 2020: Nivolumab is recommended as an option for treating locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy, only if it is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses and they have not had a PD-1 or PD-L1 inhibitor before. It is recommended only if the company provides nivolumab according to the commercial arrangement.	PBR
nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	7. In line with NICE TA guidance no 707, June 2021: Nivolumab is recommended, within its marketing authorisation, for treating unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults after fluoropyrimidine and platinum-based therapy. It is recommended only if the company provides nivolumab according to the commercial arrangement.	PBR
nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	8. In line with NICE TA guidance no 713, July 2021: Nivolumab is recommended as an option for treating locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy, only if: • their tumours are PD-L1 positive, and • it is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses, and • they have not had a PD-1 or PD-L1 inhibitor before. It is recommended only if the company provides nivolumab according to the commercial arrangement.	PBR

nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	9. In line with NICE TA guidance no 716, July 2021: Nivolumab plus ipilimumab is recommended, within its marketing authorisation, as an option for treating metastatic colorectal cancer with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency after fluoropyrimidinebased combination chemotherapy. It is recommended only if the company provides nivolumab and ipilimumab according to the commercial arrangement.	PBR
nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	10. In line with NICE TA guidance no. 724, September 2022: Nivolumab plus ipilimumab and 2 cycles of platinum-doublet chemotherapy is not recommended, within its marketing authorisation, for untreated metastatic non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations.	PBR
nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	11. In line with NICE TA guidance no 746, November 2021: Nivolumab is recommended, within its marketing authorisation, for adjuvant treatment of completely resected oesophageal or gastro-oesophageal junction cancer in adults who have residual disease after previous neoadjuvant chemoradiotherapy. It is recommended only if the company provides nivolumab according to the commercial arrangement.	PBR
nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	12. In line with NICE TA guidance no 736, October 2022: Nivolumab is recommended as an option for treating recurrent or metastatic squamous cell carcinoma of the head and neck in adults whose disease has progressed on platinum-based chemotherapy, only if the disease has progressed within 6 months of having chemotherapy, and the company provides it according to the commercial arrangement.	PBR
nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	13. In line with NICE TA guidance no 780, March 2022: Nivolumab with ipilimumab is recommended, within its marketing authorisation, as an option for untreated advanced renal cell carcinoma in adults whose disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria and only if the company provides nivolumab with ipilimumab according to the commercial arrangement.	PBR

nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	14. In line with NICE TA guidance no. 817, August 2022: Nivolumab is recommended as an option for the adjuvant treatment of muscle-invasive urothelial cancer that is at high risk of recurrence after radical resection in adults whose tumours express PD-L1 at a level of 1% or more. It is recommended only if adjuvant treatment with platinum-based chemotherapy is unsuitable, and the company provides nivolumab according to the commercial arrangement.	PBR
nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	15. In line with NICE TA guidance no. 818, August 2022: Nivolumab plus ipilimumab is recommended as an option for untreated unresectable malignant pleural mesothelioma in adults, only if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 the company provides it according to the commercial arrangement.	PBR
nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	16. In line with NICE TA guidance no. 857, January 2023: Nivolumab with platinum- and fluoropyrimidine-based chemotherapy is recommended, within its marketing authorisation, as an option for untreated HER2-negative, advanced or metastatic gastric, gastrooesophageal junction or oesophageal adenocarcinoma in adults whose tumours express PD-L1 with a combined positive score (CPS) of 5 or more. Nivolumab is only recommended if the company provides it according to the commercial arrangement.	PBR
nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	17. In line with NICE TA guidance no. 865, February 2023: Nivolumab with fluoropyrimidine-based and platinum-based combination chemotherapy is recommended as an option for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults whose tumours express PD-L1 at a level of 1% or more. It is recommended only if pembrolizumab plus chemotherapy is not suitable and the company provides nivolumab according to the commercial arrangement.	PBR
nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	18. In line with NICE TA guidance no. 876, March 2023: Nivolumab with chemotherapy is recommended, within its marketing authorisation, as an option for the neoadjuvant treatment of resectable (tumours at least 4 cm or node positive) non-small-cell lung cancer (NSCLC) in adults. It is only recommended if the company provides it according to the commercial arrangement.	PBR

nivolumab/relatlimab	concentrate for solution for infusion, 12 mg of nivolumab and 4 mg of relatlimab	8.01.5	R	19. In line with NICE TA guidance no 950, February 2024: Nivolumab–relatlimab is recommended as an option for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over, only if nivolumab–relatlimab is stopped after 2 years of treatment, or earlier if the cancer progresses, and the company provides it according to the commercial arrangement.	PBR
nivolumab	concentrate solution for infusion 10mg in 1ml 4ml, 10ml vial	8.01.5	R	20. In line with NICE TA guidance no. 1065, May 2025: Nivolumab plus ipilimumab can be used, within its marketing authorisation, as an option for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults. Nivolumab plus ipilimumab can be used only if the company provides it according to the commercial arrangements.	PBR
nitrofurantoin	capsules (Macrodantin ®) 50mg, 100mg; tablets 50mg, 100mg; suspension 25mg in 5ml capsules MR, tablets MR 100mg	5.01.13	A	Level 1 non-reserved anti-infective	
noradrenaline acid tartrate/norepinephrine bitartrate	injection 8mg in 4ml; pre-filled syringes 4mg in 50mls glucose 5%, 8mg in 50mls glucose 5%, 16mg in 50mls glucose 5%; injection 200 micrograms in 2ml, 400 micrograms in 2ml.	2.07.2	A		
norethisterone	tablets 1mg, 5mg	6.04.1	A		
norethisterone Noriday ®	tablets 350mcg; injection (oily) norethisterone enantate 200mg/ml (Noristerat ®)	7.03.2	A		
Norimin ®	21 tablets ethinylestradiol 35 micrograms + norethisterone 1mg	7.03.1	A		
nortriptyline	tablets 10mg, 25mg	4.03.1	A		
Nova-T 380	intra-uterine device	7.03.4	A		
NuvaRing®	vaginal delivery system - ethinylestradiol 2.7mg, etonogestrel 11.7mg	7.03.1	A	NDP September 2018	
Nystaform ®	Cream containing nystatin 100,000 units/g and chlorhexidine hydrochloride 1%	13.10.2	A		

Nystaform-HC ®	cream containing hydrocortisone 0.5% and nystatin 100,000units/g and chlorhexidine hydrochloride 1%; ointment containing hydrocortisone 0.5% and nystatin 100,000units/g and chlorhexidine hydrochloride 1%	13.04	A		
nystatin	oral suspension 100,000units in 1ml;	12.03.2	A		
obeticholic acid	tablets 5mg, 10mg	1.09.1	R	In line with NICE TA guidance no. 433, April 2017: Obeticholic acid is recommended, within its marketing authorisation, as anoption for treating primary biliary cholangitis in combination with ursodeoxycholic acid for people whose disease has responded inadequately to ursodeoxycholic acid or as monotherapy for people who cannot tolerateursodeoxycholic acid. Obeticholic acid is recommended only if the company provides it with the discount agreed in the patient access scheme. Assess the response to obeticholic acid after 12 months. Only continue if there is evidence of clinical benefit.	PBR RL
obinutuzumab	solution for infusion 1,000mg	8.02.3	R	1. In lines with the NICE TA guidance no. 343, June 2015: Obinutuzumab, in combination with chlorambucil, is recommended as an option for adults with untreated chronic lymphocytic leukaemia who have comorbidities that make full-dose fludarabine-based therapy unsuitable for them, only if bendamustine-based therapy is not suitable **and** the company provides obinutuzumab with the discount agreed in the patient access scheme.	PBR
obinutuzumab	solution for infusion 1,000mg	8.02.3	R	2. In line with the NICE TA guidance no.513, March 2018: Obinutuzumab is recommended as an option for untreated advanced follicular lymphoma in adults (that is, first as induction treatment with chemotherapy, then alone as maintenance therapy), only if the person has a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2 or more the company provides obinutuzumab with the discount agreed in the patient access scheme.	PBR
obinutuzumab	solution for infusion 1,000mg	8.02.3	R	3. In line with the NICE TA guidance no. 629, May 2020: Obinutuzumab with bendamustine followed by obinutuzumab maintenance is recommended, within its marketing authorisation, as an option for treating follicular lymphoma that did not respond or progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen. It is recommended only if the company provides it according to the commercial arrangement.	PBR

obinutuzumab	solution for infusion 1,000mg	8.02.3	R	4. For treatment of glomerular renal disease, and non-renal systemic vasculitis. NDP March 2024	
ocrelizumab	concentrate for solution for infusion 30mg/ml (10ml) solution for subcutaneous injection, 920mg	8.02.4	R	In line with the NICE TA guidance no 533, July 2018: Ocrelizumab is recommended as an option for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features, only if alemtuzumab is contraindicated or otherwise unsuitable and the company provides ocrelizumab according to the commercial arrangement.	PBR
ocriplasmin	injection 0.5mg in 0.2ml concentrate solution	11.08.2	R	For non-surgical treatment of vitreomacular traction, including when associated with macular hole of diameter less than or equal to 400microns. (NDP July 2013) In line with NICE TA guidance no. 297, Oct-2013: Ocriplasmin is recommended as an option for treating vitreomacular traction in adults only if epiretinal membrane is not present, **and** they have a stage II full-thickness macular hole with a diameter of 400 micrometers or less **and/or** they have severe symptoms.	PBR
octreotide	injection 50mcg in 1ml, 100mcg in 1ml, 500mcg in 1ml; depot injection 20mg, 30mg; pre-filled syringe various strenghts	8.03.4	R	Depot injection for treatment of carcinoid tumours and acromegaly.	PBR
octreotide	Injection (microsphere powder for aqueous suspension) 10mg, 20mg, 30mg	8.03.4	R	For the treatment of carcinoid tumours and acromegaly.	PBR
ofatumumab	vials 20mg in 0.4ml	8.02.4	R	In line with NICE TA guidance no 699, May 2021: Ofatumumab is recommended as an option for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features. This is only if the company provides ofatumumab according to the commercial arrangement.	PBR
ofloxacin	tablets 200mg, 400mg	5.01.12	R	Level 2 anti-infectives restricted to specific indications: As per Jefferiss Wing GUM handbook	
ofloxacin	eye drops 0.3%	11.03.1	A		
Oilatum ®	cream	13.02.1	A		
Oilatum ® Emollient (also known as Junior Bath Additive)	bath additive (fragrance free)	13.02.1	A		
Oilatum ® Plus	bath additive	13.02.1	R	Dermatologists only.	
Oilatum ® shower	emollient gel	13.02.1	A		

olanzapine	tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg; dispersible tablets 5mg, 10mg, 15mg, 20mg; injection 10mg	4.02.1	A	Injection to be used for rapid tranquilisation in line with guidance (due to shortage of lorazepam injection) (NDP February 2011)	
olaparib	capsules 50mg, 100mg, 150mg	8.01.5	R	1. In line with NICE TA guidance no 886, May 2023: Olaparib (alone or with endocrine therapy) is recommended, within its marketing authorisation, as an option for the adjuvant treatment of HER2-negative high-risk early breast cancer that has been treated with neoadjuvant or adjuvant chemotherapy in adults with germline BRCA1 or 2 mutations. It is only recommended if the company provides it according to the commercial arrangement.	PBR RL
olaparib	capsules 50mg, 100mg, 150mg	8.1.5	R	2. In line with NICE TA guidance no 887, May 2023: Olaparib is recommended, within its marketing authorisation, as an option for treating hormone-relapsed metastatic prostate cancer with BRCA1 or BRCA2 mutations that has progressed after a newer hormonal treatment (such as abiraterone or enzalutamide) in adults. Olaparib is only recommended if the company provides it according to the commercial arrangement.	PBR RL
olaparib	capsules 50mg, 100mg, 150mg	8.01.5	R	3. In line with NICE TA guidance no. 908, July 2023: Olaparib is recommended as an option for the maintenance treatment of relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults whose cancer has responded to platinum-based chemotherapy only if they have a BRCA1 or BRCA2 mutation, they have had 2 or more courses of platinum-based chemotherapy, and the company provides olaparib according to the commercial arrangement.	PBR RL
olaparib	capsules 50mg, 100mg, 150mg	8.01.5	R	4. In line with NICE TA guidance no. 946, January 2024: Olaparib with bevacizumab is recommended, within its marketing authorisation, for maintenance treatment of high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults whose cancer: has completely or partially responded after first-line platinum-based chemotherapy with bevacizumab is advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) and is homologous recombination deficiency (HRD) positive (defined as having either a BRCA1 or BRCA2 mutation, or genomic instability).	PBR RL
olaparib (with abiraterone)	capsules 50mg, 100mg, 150mg	8.01.5	R	5. In line with NICE TA guidance no. 951, February 2024: Olaparib with abiraterone and prednisone or prednisolone is recommended, within its marketing authorisation, as an option for untreated hormone-relapsed metastatic prostate cancer in adults who cannot have or do not want chemotherapy. It is only recommended if the company provides it according to the commercial arrangements.	PBR RL

olaparib	capsules 50mg, 100mg, 150mg	8.01.5	R	6. In line with NICE TA guidance no 962, March 2024 (replaces TAG 598): Olaparib is recommended, within its marketing authorisation, as an option for maintenance treatment of BRCA mutation-positive, advanced (FIGO stages 3 and 4), high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to first-line platinum-based chemotherapy in adults. It is only recommended if the company provides it according to the commercial arrangement.	PBR RL
olaparib	capsules 50mg, 100mg, 150mg	8.01.5	R	7. In line with NICE TA guidance no 1040, February 2025: Olaparib is recommended, within its marketing authorisation, as an option for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults who have had an anthracycline and a taxane as neoadjuvant or adjuvant treatment, or for metastatic disease, unless these are not suitable, and endocrine therapy if they have hormone receptor (HR)-positive breast cancer, unless this is not suitable. Olaparib is only recommended if the company provides it according to the	PBR RL
olive oil	enema	not classified	A	Instead of arachis oil, and for carrier for paraldehyde	
olopatadine	eye drops 1mg in 1ml, 5ml	11.04.2	R	For treatment of ocular signs and symptoms of seasonal allergic conjunctivitis in paediatric patients (three years of age and older). This would be the first line eye drop for patients with seasonal allergic conjuntivitis. Usage of sodium cromoglygate eye drops will reduce. (July 2009)	
olsalazine	capsules 250mg, tablets 500mg	1.05.1	A		
Omacor ® (omega-3 acid ethyl esters)	capsules 1g (Omacor ®).	2.12	R	on specialist advice only for hypertriglyceridaemia	
omalizumab	injection 150mg; pre-filled syringe 75mg; pre-filled syringe 150mg	3.04.2	R	1. As add on therapy to standardise therapy in young patients (< 45 years) who have been identified as having severe unstable asthma and who are steroid dependent patients managed in the Asthma Clinic. These patients satisfy the NICE criteria for use of omalizumab but have not attended A&E or required admission as they have been taught to manage exacerbations by adjusting their steroid doses in order to prevent hospital admission.	PBR;

omalizumab	injection 150mg; pre-filled syringe 75mg; pre-filled syringe 150mg	3.04.2	R	2. In line with NICE TA guidance no. 278, April 2013 (update on TA 133, Nov-07 and TA 201, Oct-10): Omalizumab is recommended as an option for treating severe persistent confirmed allergic IgE-mediated asthma as an add-on to optimised standard therapy in people aged 6 years and older - who need continuous or frequent treatment with oral corticosteroids (defined as 4 or more courses in the previous year), and - only if the manufacturer makes omalizumab available with the discount agreed in the patient access scheme. Optimised standard therapy is defined as a full trial of and, if tolerated, documented compliance with inhaled high-dose corticosteroids, long-acting beta2 agonists, leukotriene receptor antagonists, theophyllines, oral corticosteroids, and smoking cessation if clinically appropriate.	PBR
omalizumab	injection 150mg; pre-filled syringe 150mg	10.01.3	R	3. In line with NICE TA guidance no. 339, June 2015: Omalizumab is recommended as an option as add-on therapy for treating severe chronic spontaneous urticaria in adults and young people aged 12 years only if used as per NICE defined criteria.	PBR
omeprazole	capsules 10mg, 20mg, 40mg; dispersible tablets, film-coated, 10mg, 20mg (Losec MUPS ®) suspension, 20mg in 5mls	1.03.5	A	1. Losec capsules 10mg and MUPS ® 10mg for paediatric/neonatal use only. 2. suspension - only for children .with fine bore feeding tube in situ	
Omnipaque ®	injection	18	A	Ex-panel Sept 2010, replaced by Iomeron® - during supply problems	
Omniscan ®	injection	18	A		
ondansetron	tablets 4mg, 8mg; oral liquid 4mg in 5ml; injection 4mg in 2ml, 8mg in 4ml;	4.06	A		
oral rehydration salts	Oral powder, one sachet reconstituted with 200ml water provides sodium 12mmol, potassium 4mmol, chloride 12mmol, citrate 2mmol and glucose 18mmol (Dioralyte ® or Electrolade ® sachets, blackcurrant flavoured or plain)	9.02.1	A	Use most cost effective product.	
orlistat	capsules 120mg	4.05.1	R	In line with NICE TA guidance no. 22, November 2001, for the treatment of obesity in adults who have lost at least 2.5kg in weight by dietary control in the month prior to the first prescription and have a BMI of 28kg/m2 in the presence of significany co-morbidities or a BMI of 30kg/m^2 or more with no associated co-morbidities.	

orphenadrine	tablets 50mg; oral solution 50mg in 5ml (sugar-free)	4.09.2	A		
Ortho Gyne-T 380	Slimline intra-uterine device	7.03.4	A		
oseltamivir	capsules 30mg, 45mg, 75mg; suspension 6mg in 1ml	5.03.4	R	Level 2 anti-infectives restricted to specific indications: Per NICE or HPA guidelines/Virology involvement 1. In line with NICE TA guidance no. 168; Feb-09, (replaces TA guidance no. 58), for the treatment of influenza in at-risk adults and children who present with influenza-like illness and who can start therapy within 48 hours of the onset of symptoms. Oseltamivir is not recommended for the treatment of influenza in children or adults unless they are considered to be 'at risk'.	
oseltamivir	capsules 30mg, 45mg, 75mg; suspension 6mg in 1ml	5.03.4	R	Level 2 anti-infectives restricted to specific indications: Per NICE or HPA guidelines/Virology involvement 2. In line with NICE TA guidance no. 158; Sept-08: Oseltamivir is recommended for the post-exposure prophylaxis of influenza if all of the following circumstances apply; National surveillance schemes have indicated that influenza virus is circulating; the person is in an at-risk group; the person has been exposed to an influenza-like illness and is able to begin prophylaxis within the timescale specified in the marketing authorisations of the individual drugs; the person has not been effectively protected by vaccination. Oseltamivir is not recommended for seasonal prophylaxis of influenza.	
osilodrostat	tablets 1mg, 5mg and 10mg	6.07.03	R	Second line for endogenous Cushing Syndrome in Adults. To be reviewed once the commissioning policy in place. NDP January 2024	RL
osimertinib	tablets 40mg, 80mg	8.1.5	R	1. In line with NICE TA guidance no 653, October 2020: Osimertinib is recommended as an option for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic nonsmall-cell lung cancer (NSCLC) in adults, only if their disease has progressed after first-line treatment with an EGFR tyrosine kinase inhibitor and the company provides osimertinib according to the commercial arrangement.	PBR RL
osimertinib	tablets 40mg, 80mg	8.1.5	R	2. In line with NICE TA guidance no 654, October 2020: Osimertinib (Tagrisso, AstraZeneca) is indicated 'for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations'.	PBR RL

osimertinib	tablets 40mg, 80mg	8.1.5	R	3. In line with NICE TA guidance no 1043, February 2025 (replaces TAG 761, January 2022): Osimertinib is recommended, within its marketing authorisation, as an option for the adjuvant treatment of stage 1b to 3a non-small-cell lung cancer (NSCLC) after complete tumour resection. It is for adults whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or EGFR exon 21 (L858R) substitution mutations. It is only recommended if osimertinib is stopped at 3 years, or earlier if there is disease recurrence or unacceptable toxicity and the company provides it according to the commercial arrangement.	PBR RL
osimertinib	tablets 40mg, 80mg	8.1.5	R	4. In line with NICE TA guidance no 1060, May 2025: Osimertinib with pemetrexed and platinum-based chemotherapy is recommended, within its marketing authorisation, as an option for untreated advanced non-small-cell lung cancer (NSCLC) in adults whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. Osimertinib with pemetrexed and platinum-based chemotherapy is only recommended if the company provides it according to the commercial arrangement.	PBR RL
Otomize ®	Ear spray, dexamethasone 0.1%, neomycin sulphate 3250 units/ml, glacial actetic acid 2%.	12.01.1	A		
Otosporin ®	Ear drops, hydrocortisone 1%, neomycin sulphate 3400 units, polymyxin B sulphate 10,000 units/ml.	12.01.1	A		
Otrivine-Antistin ®	eye drops	11.04.2	A		
oxaliplatin	injection 50mg, 100mg	8.01.5	R	1. In line with NICE TA guidance no. 93; Aug-05, in combination with 5-fluorouracil and folinic acid, as a treatment option for people with advanced colorectal cancer as first-line or subsequent therapy.	PBR
oxaliplatin	injection 50mg, 100mg	8.01.5	R	2. For use in line with national/local guidelines/protocols for treatment of metastatic colorectal cancer.	PBR
oxaliplatin	injection 50mg, 100mg	8.01.5	R	3. In line with NICE TA guidance no. 100; Apr-06, in combination with 5-fluorouracil and folinic acid, as an option for the adjuvant treatment of patients with stage III (Dukes' C) colon cancer following surgery for the condition.	PBR

oxaliplatin		8.01.5	R	4. In line with NICE TA guidnce no. 176; Aug-09, cetuximab in combination with 5-fluorouracil (5-FU), folinic acid and oxaliplatin (FOLFOX), is recommended for the first-line treatment of metastatic colorectal cancer only when all of the following criteria are met: • The primary colorectal tumour has been resected or is potentially operable. • The metastatic disease is confined to the liver and is unresectable. • The patient is fit enough to undergo surgery to resect the primary colorectal tumour and to undergo liver surgery if the metastases become resectable after treatment with cetuximab. • The manufacturer rebates 16% of the amount of cetuximab used on a per patient basis. Patients who meet these criteria should receive treatment with cetuximab for no more than 16 weeks. At 16 weeks, treatment with cetuximab should stop and the patient should be assessed for resection of liver metastases.	PBR
oxandrolone	tablets 2.5mg (unlicensed)	6.04.2	R	For short term use (2.5mg daily for 3 months) in constitutional delay of growth and puberty.	PRB
oxcarbazepine	tablets 150mg, 300mg, 600mg; oral suspension 300mg in 5ml.	4.08.1	R	To be used in line with NICE guidance for control of epilepsy.	
oxidised cellulose gauze	dressing (Oxycel, Surgicel)	13.13	A		
oxprenolol	ablets 40mg, 80mg; M/R tablets 160mg.	2.04			
oxybuprocaine (benoxinate)	Minims 0.4% - preservative free	11.07	A		
oxybuprocaine (benoxinate) and fluorescein	oxybuprocaine (benoxinate) 0.3% and fluorescein 0.125% eye drops (unlicensed)	11.07	A		
oxybutynin	tablets 2.5mg, 5mg; MR tablets 5mg, 10mg; elixir 2.5mg in 5ml; patches 3.9mg/24 hours;	7.04.2	A		
oxycodone	capsules 5mg, 10mg, 20mg; MR tablets 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, 80mg, 120mg; oral solution 5mg in 5ml, 50mg in 5ml; injection 10mg in 1ml; 50mg in 1ml; PCA 100mg in 102ml 0.9% sodium chloride (unlicensed).	4.07.2	A		

oxymethalone	tablets 50mg (unlicensed)	9.01.3	A		
oxytetracycline	tablets 250mg	5.01.3	A	Level 1 non-reserved anti-infective	
oxytocin	injection 5 units in 1ml, 10units in 1ml	7.01.1	A		
ozanimod	capsules 0.23mg, 0.46mg, 0.92mg	10.01.3	R	In line with NICE TA guidance no. 828, October 2022: Ozanimod is recommended as an option for treating moderately to severely active ulcerative colitis in adults, only if conventional treatment cannot be tolerated or is not working well enough and infliximab is not suitable, or biological treatment cannot be tolerated or is not working well enough, and the company provides it according to the commercial arrangement.	PBR RL
paclitaxel	infusion 30mg in 5ml, 100mg in 16.7ml, 300mg in 50ml	8.01.5	R	1. In line with NICE TA guidance no. 30, September 2001: Paclitaxel is recommended as an option for the treatment of advanced breast cancer where initial chemotherapy (including anthracycline) has failed.	PBR
paclitaxel	infusion 30mg in 5ml, 100mg in 16.7ml, 300mg in 50ml	8.01.5	R	2. In line with NICE TA guidance no. 34, March 2002: Paclitaxel in combination with trastuzumab as an option for people with tumours expressing human epidermal growth factor receptor 2 (HER2) scored at levels of 3+ who have not received chemotherapy for metastatic breast cancer and in whom anthracycline treatment is inappropriate.	PBR
paclitaxel	infusion 30mg in 5ml, 100mg in 16.7ml, 300mg in 50ml	8.01.5	R	3. In line with NICE TA guidance no. 55, Jan-03: Paclitaxel is recommended for first-line treatment of ovarian cancer in combination with cisplatin (or platinum-based therapy alone).	PBR
paclitaxel	infusion 30mg in 5ml, 100mg in 16.7ml, 300mg in 50ml	8.01.5	R	4. In line with NICE TA guidance no. 389, April 2016 (replaces NICE TA guidance no, 91, May-05): Paclitaxel in combination with platinum or as monotherapy is recommended within its marketing authorisation as an option for treating recurrent ovarian cancer.	PBR
paclitaxel	infusion 30mg in 5ml, 100mg in 16.7ml, 300mg in 50ml	8.01.5	R	5. For relapsed germ cell tumour (GCT) prior to high dose chemotherapy with autologous bone marrow transplantation.	PBR
paclitaxel	infusion 30mg in 5ml, 100mg in 16.7ml, 300mg in 50ml	8.01.5	R	6. In line with NICE TA guidance no. 26; Jun-01, as part of first-line therapy for advanced (stage III and IV) non-small cell lung cancer (NSCLC).	PBR
paclitaxel	infusion 30mg in 5ml, 100mg in 16.7ml, 300mg in 50ml	8.01.5	R	7. For relapsed /metastatic cervical and vaginal cancer, as combination therapy with carboplatin for patients pre-treated with platinum for 3 cycles on average, up to a maximum of 6 cycles per patient. For patients not fit for combination therapy paclitaxel may be used as single agent for second line treatment.	PBR

paclitaxel	infusion 30mg in 5ml, 100mg in 16.7ml, 300mg in 50ml	8.01.5	R	8. In line with NICE TA guidance no. 476, September 2017 (replaces TA 360): Paclitaxel as albumin-bound nanoparticles (nab-paclitaxel) with gemcitabine is recommended as an option for untreated metastatic adenocarcinoma of the pancreas in adults, only if other combination chemotherapies are unsuitable and they would otherwise have gemcitabine monotherapy and the company provides nab-paclitaxel with the discount agreed in the patient access scheme.	PBR
paclitaxel	infusion 30mg in 5ml, 100mg in 16.7ml, 300mg in 50ml	8.01.5	R	9. For advanced anal cancer. (NDP July 2013)	
paediatric multivitamins	Powder, containing vitamins, minerals, low sodium and potassium, and trace elements (Paediatric Seravit ®).	9.06.7	A		
palbociclib	capsules, 75mg, 100mg, 125mg	8.01.5	R	In line with NICE TA guidance no. 495, Dec-2017: Palbociclib, with an aromatase inhibitor, is recommended within its marketing authorisation, as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer as initial endocrine-based therapy in adults. Palbociclib is recommended only if the company provides it with the discount agreed in the patient access scheme.	PBR RL
palbociclib	capsules, 75mg, 100mg, 125mg	8.01.5	R	In line with NICE TA guidance no 836, October 2022: Palbociclib plus fulvestrant is recommended as an option for treating hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in adults who have had endocrine therapy only if exemestane plus everolimus is the most appropriate alternative to a cyclindependent kinase 4 and 6 (CDK4/6) inhibitor and the company provides it according to the commercial arrangement.	PBR RL
palivizumab	injection 50mg, 100mg	5.03.5	R	For prevention of lower respiratory tract infection caused by RSV in high risk infants, as outlined in the NHS England commissioning statement. October 2018. Last updated November 2020 under RAPID COVID POLICY STATEMENT	PBR RL
Pamergan P100 ®	Pamergan P100 ® injection containing pethidine hydrochloride 100mg and promethazine hydrochloride 50mg in 2ml.	4.07.2	R		
pancreatin	Creon ® 10,000 capsules; Creon ® 25,000 capsules; Creon ® 40,000 capsules; Creon® Micro; Pancrex V ® capsules; Pancrex V ® powder	1.09.4	A	August 2024 - national shortages dictate that in a short term any available brand may need to be used. Currently **Nutrizyme 22.**	

pancreolauryl	test	19.02	A		
pancuronium bromide	injection 4mg in 2ml	15.01.5	A		
panitumumab	vial 20mg in ml concentrate for solution for infusion 5mL, 10mL and 20mL	8.01.5	R	In line with NICE TA guidance no. 439, March 2017: Panitumumab is recommended, within its marketing authorisation, as an option for previously untreated RAS wild-type metastatic colorectal cancer in adults in combination with FOLFOX or FOLFIRI. The drugs are recommended only when the companies provide them with the discounts agreed in their patient access schemes.	PBR
panobinostat	capsule 10mg, 15mg, 20mg	8.01.5	R	In line with NICE TA guidance no. 380, January 2016: Panobinostat in combination with bortezomib and dexamethasone is recommended, within its marketing authorisation, as an option for treating multiple myeloma, that is, for 'adult patients with relapsed and/or refractory multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent' when the company provides panobinostat with the discount agreed in the patient access scheme.	PBR RL
pantoprazole	tablets 20mg, 40mg; injection 40mg	1.03.5	R	1. For use only in patients who would be at risk of drug interactions on omeprazole. 2. Pantoprazole injection is currently first choice injectable. Gastroenterologists agreed to use least costly PPI injection.	
papaverine	injection 40mg in 1ml (unlicensed); Injection, 30mg in 1ml, 60mg in 2ml	7.04.5	R	The strenght of choice contingent on availability of individual products	
para-aminosalicylic acid	granules	5.01.9	R	for multi-resistant tuberculosis	
paracetamol	tablets 500mg; dispersible tablets 500mg; caplets 500mg; oral liquid 120mg in 5ml, 250mg in 5ml; infusion 100mg in 10ml; 500mg in 50ml, 1g in 100ml; suppositories 125mg, 250mg, 500mg, 1g	4.07.1	A	Intravenous paracetamol - approved for perioperative use in theatres and for treatment of mild to moderate pain or fever when oral route unsuitable; switch to oral preparation as soon as possible.	
paraffin	liquid emulsion BP	1.06.3	A		
paraffin	sterile liquid	13.05	A		
paraffin gauze dressing	10cm x 10cm (individually wrapped); 5cm x 5cm, 10cm x 40cm	A8.01.6	A		
paraffin, white soft		13.02.1	A	no longer pharmacy; ordered from supplies	
paraffin, yellow soft	15g, 30g & 500g.	13.02.1	A	no longer pharmacy; ordered from supplies	

paraldehyde	injection 5ml, 10ml (at present there is no supplier - Aug 08); 50% rectal oily solution (in sunflower oil or olive oil); enema 10ml 50:50 in sunflower oil	4.08.2	A	If the neat injection is to be used rectally it must be mixed with sunflower oil first. For rectal administration use the Baxa or Medicina purple enteral syringes, provided the dose is given immediately after it is drawn up. Otherwise glass syringes must be used.	
parecoxib	injection 40mg	15.01.4	R	For peri-operative pain.	PBR (renal only)
Paranteral Nutrition (Adult)					
Lipoflex®	Plus, 1266ml Special, 1891nl	9.03	A	Replaced Nutriflex® standard PN bags following discontinuation (NDP March 2022)	
Braun®	PN Imperial 18G infusion, 1875ml	9.03	A		
paricalcitol	injection 5mcg in 1ml; capsules 1mcg, 2mcg, 4mcg	9.06.4	R	as 3rd line treatment for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure in haemodialysis patients with persistent severe hyperparathyroidism resistant to cinacalcet GPs will not be asked to prescribe this medicine.	
paromomycin	tablets 250mg (unlicensed)	5.04.5	A	Level 1 non-reserved anti-infective	
paroxetine	tablets 20mg, 30mg; oral suspension 10mg in 5ml (sugar-free)	4.03.3	A		
pasireotide	injections, various strengths	6.07.3	R	For the treatment of Cushing's disease, in line with NHS England commissioning policy, December 2016. (NDP March 2023)	PBR
patch test allergens		19.02	A		
patent blue	injection 2ml	19.02	A		
patiromer sorbitex calcium	powder for oral suspension 8.4g, 16.8g, 25.2g	9.02.1	R	In line with NICE TA guidance no. 623, February 2020: Patiromer is recommended as an option for treating hyperkalaemia in adults only if used in emergency care for acute life-threatening hyperkalaemia alongside standard care or for people with persistent hyperkalaemia and stages 3b to 5 chronic kidney disease or heart failure, if theyhave a confirmed serum potassium level of at least 6.0 mmol/litre and are not taking, or are taking a reduced dosage of, a renin-angiotensinaldosterone system (RAAS) inhibitor because of hyperkalaemia and are not on dialysis. Stop patiromer if RAAS inhibitors are no longer suitable.	

pazopanib	tablets 200mg, 400mg	8.01.5	R	In line with NICE TA guidance no. 215, Feb-11: Pazopanib is recommended as a first-line treatment option for people with advanced renal cell carcinoma who have not received prior cytokine therapy and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and if the manufacturer provides pazopanib with a 12.5% discount on the list price, and provides a possible future rebate linked to the outcome of the head-to-head COMPARZ trial, as agreed under the terms of the patient access scheme and to be confirmed when the COMPARZ trial data are made available.	PBR RL
Peditrace ®	injection 10ml	9.03	A		
pegaspargase	vials, powder for solution for injection, 3750units	8.01.5	R	In line with NICE TA guidance no. 408, September 2016: Pegaspargase, as part of antineoplastic combination therapy, is recommended as an option for treating acute lymphoblastic leukaemia in children, young people and adults only when they have untreated newly diagnosed disease.	PBR
pegfilgrastim	pre-filled syringe 6mg	9.01.6	very R	Very restricted use in line with oncology and haematology protocols. (May 2014)	RL
peginterferon alfa	injection 135microgram, 180microgram	8.02.4	R	For management of Hepatitis B in line with the latest NICE Clinical Guideline (CG165).	PBR RL
peginterferon beta-1a Plegridy®	all strenghts, pre-filled pens	8.02.4	R	In line with NICE TA guidance no. 624, February 2020: Peginterferon beta-1a is recommended, within its marketing authorisation, as an option for treating relapsing–remitting multiple sclerosis in adults.	PBR
pegvisomant	injection 10mg, 15mg, 20mg, 25mg	6.05.1	R	For adult patients with acromegaly who have an inadequate response to surgery and /or radiotherapy, and in whom an appropriate medical treatment with cabergoline and /or somatostatin analogues has not normalised growth hormone (GH) or serum insulin-like growth factor 1 (IGF-1) levels OR who are intolerant of appropriate medical treatment with cabergoline and /or somatostatin analogues. (NDP October 2009) NHS England, January 2017	PRB
pembrolizumab	vial 50mg, 100mg	8.01.5	R	1. In line with NICE TA guidance no. 357, Oct-2015: Pembrolizumab is recommended as an option for treating advanced (unresectable or metastatic) melanoma in adults only: after the disease has progressed with ipilimumab and, for BRAF V600 mutation-positive disease, a BRAF or MEK inhibitor **and** when the company provides pembrolizumab with the discount agreed in the patient access scheme.	PRB

pembrolizumab	vial 50mg, 100mg	8.01.5	R	2. In line with NICE TA guidance no. 366, Nov-2015: Pembrolizumab is recommended as an option for treating advanced (unresectable or metastatic) melanoma that has not been previously treated with ipilimumab, in adults, only when the company provides pembrolizumab with the discount agreed in the patient access scheme.	PBR
pembrolizumab	vial 50mg, 100mg	8.01.5	R	3. In line with NICE TA guidance no. 428, January 2017: Pembrolizumab is recommended as an option for treating locally advanced or metastatic PD-L1-positive non-small-cell lung cancer in adults who have had at least one chemotherapy (and targeted treatment if they have an epidermalgrowth factor receptor [EGFR]- or anaplastic lymphoma kinase [ALK]-positive tumour), only if pembrolizumab is stopped at 2 years of uninterrupted treatment and no documented disease progression, and the company provides pembrolizumab with the discount agreed in the patient access scheme revised in the context of this appraisal.	PBR
pembrolizumab	vial 50mg, 100mg	8.01.5	R	4. In line with NICE TA guidance no. 531 , July 2018 (replaces TA guidance no.447, June 2017): Pembrolizumab is recommended as an option for untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults whose tumours express PD-L1 (with at least a 50% tumour proportion score) and have no epidermal growth factor receptor- or anaplastic lymphoma kinase-positive mutations, only if pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier in the event of disease progression and the company provides pembrolizumab according to the commercial access agreement.	PBR
pembrolizumab	vial 50mg, 100mg	8.01.5	R	5. In line with NICE TA guidance no. 683, March 2021 (replaces TA guidance no 557, January 2019): Pembrolizumab with pemetrexed and platinum chemotherapy is recommended as an option for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)-positive or anaplastic lymphoma kinase (ALK)-positive mutations. This is only if it is stopped at 2 years of uninterrupted treatment, or earlier if the disease progresses and the company provides pembrolizumab according to the commercial arrangement.	PBR

pembrolizumab	vial 50mg, 100mg	8.01.5	R	6. In line with NICE TA guidance no. 661, November 2020: Pembrolizumab is recommended as an option for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a combined positive score (CPS) of 1 or more. This is only if: • pembrolizumab is given as a monotherapy, • pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if disease progresses, and • the company provides pembrolizumab according to the commercial arrangement.	PBR
pembrolizumab	vial 50mg, 100mg	8.01.5	R	7. In line with NICE TA guidance no. 709, June 2021: Pembrolizumab is recommended as an option for untreated metastatic colorectal cancer with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency in adults, only if: • pembrolizumab is stopped after 2 years and no documented disease progression, and • the company provides pembrolizumab according to the commercial arrangement.	PBR
pembrolizumab	vial 50mg, 100mg	8.01.5	R	8. In line with NICE TA guidance no. 997, August 2024 (replaces TAG no. 737, October 2021): Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy is recommended, within its marketing authorisation, as an option for untreated locally advanced unresectable or metastatic HER2-negative gastric or gastro oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a combined positive score (CPS) of 1 or more. Pembrolizumab is only recommended if the company provides it according to the commercial arrangement.	PBR
pembrolizumab	vial 50mg, 100mg	8.01.5	R	9. In line with NICE TA guidance no 766, February 2022 (replaces TAG no 553, December 2018): Pembrolizumab is recommended, within its marketing authorisation, as an option for the adjuvant treatment of completely resected stage 3 melanoma with lymph node involvement in adults. It is recommended only if the company provides pembrolizumab according to the commercial arrangement.	PBR

pembrolizumab	vial 50mg, 100mg	8.01.5	R	10. In line with NICE TA guidance no 770, February 2022 (replaces TAG no 600, September 2019): Pembrolizumab with carboplatin and paclitaxel is recommended as an option for untreated metastatic squamous non-small-cell lung cancer (NSCLC) in adults, only if their tumours express PD-L1 with a tumour proportion score of 0% to 49% their tumours express PD-L1 with a tumour proportion score of 50% or more and they need urgent clinical intervention it is stopped at 2 years of uninterrupted treatment or earlier if their disease progresses and the company provides pembrolizumab according to the commercial arrangement.	PBR
pembrolizumab	vial 50mg, 100mg	8.01.5	R	11. In line with NICE TA guidance no 772, February 2022: Pembrolizumab is recommended as an option for treating relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older. It is recommended if they have had an autologous stem cell transplant that has not worked or they have had at least 2 previous therapies and an autologous stem cell transplant is not an option, and only if they have not had brentuximab vedotin and the company provides pembrolizumab according to the commercial arrangement.	PBR
pembrolizumab	vial 50mg, 100mg	8.01.5	R	12. In line with NICE TA guidance no. 801, June 2022: Pembrolizumab plus chemotherapy (paclitaxel or nab-paclitaxel) is recommended as an option for treating triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease. It is recommended only if: the tumours express PD-L1 with a combined positive score (CPS) of 10 or more and an immune cell staining (IC) of less than 1%, and the company provides pembrolizumab according to the commercial arrangement.	PBR
pembrolizumab	vial 50mg, 100mg	8.01.5	R	13. In line with NICE TA guidance no. 830, October 2022: Pembrolizumab is recommended, within its marketing authorisation, as an option for the adjuvant treatment of renal cell carcinoma at increased risk of recurrence after nephrectomy, with or without metastatic lesion resection, in adults. It is recommended only if the company provides it according to the commercial arrangement.	PBR
pembrolizumab	vial 50mg, 100mg	8.01.5	R	14. In line with NICE TA guidance no 837, October 2022: Pembrolizumab is recommended, within its marketing authorisation, as an option for the adjuvant treatment of completely resected stage 2B or 2C melanoma in people 12 years and over. It is recommended only if the company provides pembrolizumab according to the commercial arrangement.	PBR

pembrolizumab	vial 50mg, 100mg	8.01.5	R	15. In line with NICE TA guidance no. 851, December 2022: Pembrolizumab is recommended, within its marketing authorisation, as an option with chemotherapy for neoadjuvant treatment and then continued alone as adjuvant treatment after surgery for adults with triple-negative early breast cancer at high risk of recurrence or locally advanced breast cancer. It is recommended only if the company provides pembrolizumab according to the commercial arrangement.	PBR
pembrolizumab	vial 50mg, 100mg	8.01.5	R	16. In line with NICE TA guidance no. 904, June 2023: Pembrolizumab plus lenvatinib is recommended, within its marketing authorisation, for treating advanced or recurrent endometrial cancer in adults whose cancer has progressed on or after platinum-based chemotherapy, and who cannot have curative surgery or radiotherapy. Pembrolizumab plus lenvatinib is recommended only if the companies provide them according to the commercial arrangements.	PBR
pembrolizumab	vial 50mg, 100mg	8.01.5	R	17. In line with NICE TA guidance no. 914, Septembr 2023: Pembrolizumab is recommended as an option for treating tumours with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency in adults with advanced or recurrent endometrial cancer that has progressed during or after a platinum-based therapy, who cannot have curative surgery or radiotherapy, unresectable or metastatic gastric, small intestine or biliary cancer that has progressed during or after 1 therapy, colorectal cancer after fluoropyrimidine combination therapy, only if they cannot have nivolumab with ipilimumab. It is only recommended if pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if the cancer progresses, and the company provides it according to the commercial arrangement.	PBR
pembrolizumab	vial 50mg, 100mg	8.01.5	R	18. In line with NICE TA guidance no. 939, December 2023: Pembrolizumab plus chemotherapy with or without bevacizumab is recommended as an option for treating persistent, recurrent or metastatic cervical cancer in adults whose tumours express PD-L1 with a combined positive score of at least 1. It is recommended only if pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if the cancer progresses, and the company provides it according to the commercial arrangements.	PBR

pembrolizumab	vial 50mg, 100mg	8.01.5	R	19. In line with NICE TA guidance no. 967, May 2024: Pembrolizumab is recommended as an option for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over who have had at least 2 previous treatments and cannot have an autologous stem cell transplant (ASCT). It is recommended only if they have already had brentuximab vedotin and pembrolizumab is stopped after 2 years of treatment or earlier if the person has a stem cell transplant or the disease progresses and the company provides it according to the commercial arrangement	PBR
pembrolizumab	vial 50mg, 100mg	8.01.5	R	20. in line with NICE TA guidance no. 1017, November 2024: Pembrolizumab is recommended, within its marketing authorisation, as an option for neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for resectable non-small-cell lung cancer (NSCLC) with a high risk of recurrence in adults. Pembrolizumab is only recommended if the company provides it according to the commercial arrangement.	PBR
pembrolizumab	vial 50mg, 100mg	8.01.5	R	21. In line with NICE TA guidance no. 1037, February 2025: Pembrolizumab is recommended, within its marketing authorisation, as an option for the adjuvant treatment of non-small-cell lung cancer (NSCLC) with a high risk of recurrence after complete resection and platinum-based chemotherapy in adults. Pembrolizumab is only recommended if the company provides it according to the commercial arrangement.	PBR
pembrolizumab	vial 50mg, 100mg	8.01.5	R	22. In line with NICE TA guidance no. 1092, August 2025: Pembrolizumab with carboplatin and paclitaxel can be used, within its marketing authorisation, as an option for untreated primary advanced or recurrent endometrial cancer in adults. It can only be used if the company provides it according to the commercial arrangement.	PBR
pemetrexed	injection 500mg	8.01.3	R	1. In line with NICE TA guidance no. 135, Jan-08: as a treatment option for malignant pleural mesothelioma only in people who have a World Health Organization (WHO) performance status of 0 or 1, who are considered to have advanced disease and for whom surgical resection is considered inappropriate.	PBR
pemetrexed	injection 500mg	8.01.3	R	2. For the second-line treatment of patients with locally advanced or metastatic non small cell lung cancer other than predominantly squamous cell histology. This switch is based on a discount that brings the cost of premetrexed (used for this indiction only) in line with docetaxel. If this discount is lost in the future then oncology will revert to using docetaxel while it is less costly. (NDP May 2009)	PBR

pemetrexed	injection 500mg	8.01.3	R	3. In line with NICE TA guidance no. 181, Sept-09: in combination with cisplatin as an option for the first-line treatment of patients with locally dvanced or metastatic non-small-cell lung cancer (NSCLC) only if the histology of the tumour has been confirmed as adenocarcinoma or large-cell carcinoma.	PBR
pemetrexed	injection 500mg	8.01.3	R	4. In line with NICE TA guidance no. 190: Jun-10: Pemetrexed is recommended as an option for the maintenance treatment of people with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology if disease has not progressed immediately following platinum-based chemotherapy in combination with gemcitabine, paclitaxel or docetaxel. People who have received pemetrexed in combination with cisplatin as first-line chemotherapy cannot receive pemetrexed maintenance treatment.	PBR
pemetrexed	injection 500mg	8.01.3	R	5. In line with NICE TA guidance no 402, August 2016: Pemetrexed is recommended as an option for the maintenance treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer in adults when their disease has not progressed immediately after 4 cycles of pemetrexed and cisplatin induction therapy, their Eastern Cooperative Oncology Group (ECOG) performance status is 0 or 1 at the start of maintenance treatment, and the company provides the drug according to the terms of the commercial access agreement as agreed with NHS England.	PBR
pemigatinib	tablets 4.5mg, 9mg, 13.5mg	8.01.5	R	In line with NICE TA guidance no 722, August 2021: Pemigatinib is recommended, within its marketing authorisation, as an option for treating locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that has progressed after systemic therapy in adults. It is recommended only if the company provides pemigatinib according to the commercial arrangement.	PBR
penicillamine	tablets, 125mg, 250mg	10.01.3	A		
penicillin	Eye drops, benzylpenicillin sodium 0.3% in buffered solution (5000units in 1ml) (Unlicensed product.)	11.03.1	A	Not routinely stocked. Supplies can be obtained if requested.	
pentagastrin	injection 500mcg in 2ml	19.02	A		
pentamidine isethionate	injection 300mg; nebuliser solution 300mg	5.04.8	R	Level 2 anti-infectives restricted to specific indications	RL
pentolinium mesylate	injection 10mg in 1ml (unlcensed)	2.05.6	A		PBR

pentosan polysulfate sodium	capsules 100mg	7.04.2	R	In line with NICE TA guidance no 610, November 2019: Pentosan polysulfate sodium is recommended as an option for treating bladder pain syndrome with glomerulations or Hunner's lesions in adults with urinary urgency and frequency, and moderate to severe pain, only if their condition has not responded to an adequate trial of standard oral treatments, it is not offered in combination with bladder instillations, any previous treatment with bladder instillations was not stopped because of lack of response, it is used in secondary care and the company provides pentosan polysulfate sodium according to the commercial arrangement. **GPs cannot be asked to prescribe.**	
pentostatin	injection 10mg	8.01.5	A		
pentoxifylline		2.06.4	N/A	NICE TA guidance no. 223; May-11. Cilostazol, pentoxifylline and inositol nicotinate are not recommended for the treatment of intermittent claudication in people with peripheral arterial disease	
peppermint oil	capsules 0.2ml	1.02	A	The least costly brand will be used.	
peppermint water	oral liquid (unlicensed)	1.02	A		
perampanel	tablets 2mg, 4mg, 6mg, 8mg, 10mg, 12mg	4.08.1	R	2nd line adjunctive treatment of partial onset seizures with or without secondary generalisation for patients age 12 and above. (NDP May 2013)	
pergolide	tablets 50mcg, 250mcg, 1mg	4.09.1	R	Restricted for use by the Care of the Elderly and Neurology teams only.	
perindopril	tablets 2mg, 4mg, 8mg	2.05.5	A		
permethrin	cream rinse 1%; dermal cream 5%	13.10.4	A	Restricted for specialist use by ID and HIV/GUM teams only	
pertussis (acellular)	vaccine (named patient supply)	14.04	A		
pertuzumab	concentrate for solution for infusion 30mg in 1ml (420mg in 14ml)	8.01.5	R	1. In line with NICE TA guidance no. 424, December 2016: Pertuzumab, in combination with trastuzumab and chemotherapy, is recommended, within its marketing authorisation, as an option for the neoadjuvant treatment of adults with human epidermal growth factor receptor 2 (HER2)-positive breast cancer; that is, in patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence. It is recommended only if the company provides pertuzumab with the discount agreed in the patient access scheme.	PBR

pertuzumab	concentrate for solution for infusion 30mg in 1ml (420mg in 14ml)	8.01.5	R	2. In line with NICE TA guidance no. 509, March 2018: Pertuzumab, in combination with trastuzumab and docetaxel, is recommended, within its marketing authorisation, for treating HER2-positive metastatic or locally recurrent unresectable breast cancer, in adults who have not had previous anti-HER2 therapy or chemotherapy for their metastatic disease, only if the company provides pertuzumab within the agreed commercial access arrangement.	PBR
pertuzumab	concentrate for solution for infusion 30mg in 1ml (420mg in 14ml)	8.01.5	R	3. In line with NICE TA guidance no. 569, March 2019: Pertuzumab, with intravenous trastuzumab and chemotherapy, is recommended for the adjuvant treatment of human epidermal growth factor receptor2 (HER2)-positive early stage breast cancer in adults, only if they have lymph node-positive disease the company provides it according to thecommercial arrangement.	PBR
pethidine	tablets 50mg; injection 50mg in 1ml, 100mg in 2ml;	4.07.2	A		
phenazopyridine	tablets 100mg (unlicensed)	19.02	A		
phenelzine	tablets 15mg	4.03.2	A		
phenindione	tablets 10mg, 25mg, 50mg	2.08.2	A		
phenobarbital	tablets 15mg, 30mg, 60mg; mixture 50mg in 5ml (alcohol-free, unlicensed); injection 15mg in 1ml, 30mg in 1ml, 60mg in 1ml, 200mg in 1ml.	4.08.1	A		
phenol	injection 5% in oil; injection 5% in glycerol	1.07.3	A		
phenol	aqueous injection 6% (unlicensed) aqueous injection 7% (unlicensed)	1.07.3	A	The formulation of choice contingent on availability of individual products	
phenoxybenzamine	capsules 10mg; injection 100mg in 2ml	2.05.4	A		
phenoxymethylpenicillin (penicillin V)	tablets 250mg; oral solution 125mg in 5ml, 250mg in 5ml	5.01.1	A	Level 1 non-reserved anti-infective	
phentolamine	injection 10mg in 1ml (unlicensed)	2.05.4	A	UK preparation discountinued (2013)	
phentolamine	phentolamine 2mg + aviptadil 25mcg in 0.35ml vial (Invicorp®)	7.04.5	R	NDP November 2018	
phentolamine	phentolamine 1mg + papaverine 30mg injection (unlicensed)	7.04.5	R		

phenylephrine	injection 10mg in 1ml	2.07.2	A		
phenylephrine	Eye drops, 10%. Eye drops, 2.5%, 5%. unlicensed product. Unit dose eye drops Minims ®, 2.5%, 10%.	11.05	A		
phenytoin	capsules phenytoin sodium 25mg, 50mg, 100mg, 300mg; tablets phenytoin sodium 50mg, 100mg, 200mg; tablets phenytoin, chewable, 50mg; suspension phenytoin 30mg in 5ml, 90mg in 5ml	4.08.1	A	phenytoin sodium tablets are considerably more expensive than the capsules	
phenytoin	injection phenytoin sodium 250mg in 5ml	4.08.2	A		
phosphate	buffered saline	19.02	A		
phosphates	Infusion, 500ml polyfusor, contains phosphate 100mmol, sodium 162mmol and potassium	9.05.2	A		
phosphates	rectal standard tube enema 128ml (Fletchers ®); short tube enema 128ml (Fletchers ®)	1.06.4	A		
Phosphate-Sandoz ®	Tablets, effervescent, 500mg, containing 16.1mmol phosphate, 20.4mmol sodium and 3.1mmol potassium per tablet (Phosphate Sandoz ®).	9.05.2	A		
Phoxilium® solutions	haemofiltration solution	20	R	CRRT (haemofiltration) solution for use in Paediatric Intensive Care Unit (January 2025).	
Physioneal® solutions	range of dialysis solutions	20	R	Solutions for CAPD and APD .	
physostigmine salicylate	injection 1mg in 1ml (unlicensed)	not classified	A		
physostigmine salicylate	Injection 2mg/ml.	not classified	R	Restricted to ITU teams only. Martindale states can be used to reverse anaesthesia post-op - to reverse central as well as peripheral effects of agents with antimuscarinic actions in post-op patients and following over-dosage but not to be used routinely.	
phytomenadione - Colloidal formulation Konakion MM ®	Injection 10mg in 1ml in a mixed micelles vehicle.	9.06.6	A	For slow intravenous injection or infusion. Do not give intramuscularly.	
phytomenadione - Konakion MM Paediatric ®	Injection 2mg in 0.2ml in a mixed micelles vehicle.	9.06.6	A	May be administered by mouth or by intramuscular or intravenous injection.	

phytomenadione (Fat-Soluble Vitamin K)	10mg in 1ml (Konakion MM)	9.06.6	A		
pilocarpine	tablets 5mg	12.03.5	R	To increase salivation in head and neck cancer.	
pilocarpine	Eye drops 0.5%, 1%, 2%, 3%, 4%, 6%; Eye drops 1%, 2%, 3%, 4%, 6% all preservative free (unlicensed) Single use Minims ® eye drops (as nitrate) 1%, 2%, 4%.	11.06	A		
pimecrolimus	cream 1%	13.05.3	R	In line with NICE TA guidance no 82, Aug-04: Topical pimecrolimus as an option for the second line treatment of moderate atopic eczema on the face and neck of children aged 2 to 16 years, that has not been controlled by topical corticosteroids, where there is a serious risk of important adverse effects from further topical corticosteroid use, particularly irreversible skin atrophy. Topical pimecrolimus is not recommended for the treatment of mild atopic eczema or as first line treatment for atopic eczema of any severity.	
pimozide	tablets 4mg, 10mg	4.02.1	A		
pioglitazone	tablets 15mg, 30mg, 45mg	6.01.2	R	Use in lines with the relevant national guidelines.	
piperacillin with tazobactam	injection 2.25g (piperacillin 2g and tazobactam 250mg), 4.5g (piperacillin 4g and tazobactam 500mg)	5.01.1	R	Level 2 anti-infectives restricted to specific indications: As per Adult anti-infective policy As per Oncology/Haematology anti-infective policy As per Renal anti-infective policy As per Neonatal anti-infective policy As per Paediatric policies Paediatric ICU Biliary endoscopic procedures, e.g. ERCP ITU: for nosocomial pneumonia, abdominal sepsis or septicaemia Respiratory infections: treatment of Pseudomonas aeruginosa Septic shock (suspected) after blood transfusion or platelets	
pirfenidone	tablets, 267mg, 534mg, 801mg	3.11	R	In line with NICE TA guidance no. 504, Jan-2018 (update of TA282, April 2013): Pirfenidone is recommended as an option for treating idiopathic pulmonary fibrosis in adults only if the person has a forced vital capacity (FVC) between 50% and 80% predicted the company provides pirfenidone with the discount agreed in the patient access scheme and treatment is stopped if there is evidence of disease progression (an absolute decline of 10% or more in predicted FVC within any 12-month period).	PBR RL

piroxicam	gel 0.5%	10.03.2	A		
piroxicam	capsules 10mg, 20mg;	10.01.1	R		
pitolisant	tablets 4.5mg, 18mg	4.01.1	R	For management of narcolepsy. (NDP November 2020)	PBR RL
pivmecillinam	tablets 200mg	5.01.1	R	for treatment of acute uncomplicated cystitis and chronic or recurrent bacteriuria due multi-resistant gram negative organisms on micro advice only. (NDP Feb 2012)	
pixantrone	powder for solution for infusion 29mg vail	8.01.5	R	In line with NICE TA guidance TA 306, Feb-14: Pixatrone monotherapy is recommended as an option for treating adults with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma only if: - the person has previously been treated with rituximab and - the person is receiving third- or fourth-line treatment and - the manufacturer provides pixantrone with the discount agreed in the patient access scheme	PBR
pizotifen	tablets 500mcg, 1.5mg; elixir 250mcg in 5ml	4.07.4	A		
Plasma-Lyte® 148	Balanced mixed electrolyte solution for infusion	9.03	A	For fluid replacement (NDP Feb 2013)	
Plasma-Lyte® 148 & Glucose 5% w/v	Balanced mixed electrolyte solution for infusion	9.03	R	For fluid replacement, paediatric use only (NDP July 2019)	
Plaster remover		13.05	A		
Plenvu®	oral powder	1.06.5	R	NDP July 2019	
plerixafor	injection 24mg in 1.2ml	9.01.7	R	Approved for a maximum of 2 doses for mobilisation of haematopoietic stem cells in combination with G-CSF in patients with lymphoma and multiple myeloma who have failed a previous mobilisation with chemotherapy and G-CSF, or G-CSF only when the use of mobilisation chemotherapy is contraindicated. (NDP March 2010)	PBR
plicamycin (Mithramycin)	Injection, 2.5mg vial.	not classified	A		
pneumococcal polysaccharide conjugate vaccine (adsorbed)	injection (Prevenar 13 ®)	14.04	R	For children ages from 2 months of age to 5 years of age. Three single doses to be given at 2, 3 and 4 months of age for the specified at-risk groups.	
pneumococcal polysaccharide vaccine	injection (Pneumovax ® 23)	14.04	A		

podophyllotoxin	solution 0.5% (Warticon or Condyline for men, Carticon Fem [with mirror] for women); Cream, 0.15%, 5g (Warticon ® and Warticon Fem ®)	13.07	R	For use by GUM and HIV teams only.	
podophyllum resin in benzoin compound tincture	15%, 25% (both unlicensed)	13.07	A		
podophyllum resin in IMS	10%, 25% (both unlicensed)	13.07	A		
polatuzumab vedotin	powder for solution for infusion 30mg, 140mg	8.01.5	R	In line with NICE TA guidance no 649, September 2020: Polatuzumab vedotin with rituximab and bendamustine is recommended, within its marketing authorisation, as an option for treating relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have a haematopoietic stem cell transplant. It is recommended only if the company provides polatuzumab vedotin according to the commercial arrangement.	PBR
polatuzumab vedotin	powder for solution for infusion 30mg, 140mg	8.01.5	R	In line with NICE TA guidance no. 874, March 2023: Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) is recommended for untreated diffuse large B-cell lymphoma (DLBCL) in adults, only if they have an International Prognostic Index (IPI) score of 2 to 5 and the company provides it according to the commercial arrangement.	PBR
polihexanide (polyhexamethylene biguanide)	eye drops, 0.02% (preservative free)	11.03.01	R	For treatent of *Acanthamoeba* ocular infrections in line with the local anti-infective guidelines. (NDP March 2022)	
poliomyelitis vaccine, inactivated	inactivated vaccine (unlicensed)	14.04	A		
poliomyelitis vaccine, live (orall)	suspension (named patient supply)	14.04	A		
pollen from white birch (*Betula verrucosa)* ITULAZAX®	12 SQ-Bet sublingual lyophilisate	3.04.2	R	For adult and paediatric patients in line with product licence for prescribing by allergy teams only. NDP January 2024, November 2024 In line with NICE TA guidance no. 1087, August 2025: Betula verrucosa can be used as an option to treat moderate to severe allergic rhinitis or conjunctivitis caused by pollen from the birch homologous group of trees in adults with symptoms despite using symptom-relieving medicines a positive sensitisation test (skin prick test or specific immunoglobulin E) to a member of the birch homologous group.	

Pollinex ® Quattro	injection	3.04.2	R	Consultant only prescribing, for 2nd line therapy for paediatric patients (6 yrs +) with allergic rhino-conjunctivitis who test positive to grass pollen or tree pollen on skin prick testing or specific IgE testing, and who respond poorly to combined antihistamine and topical steroid treatment.	
Pollinex ® tree pollen subcutaneous immunotherapy (initial & extension)	injection	3.04.2	R	for use by allergy teams (NDP March 2022)	
Polytar ®	emollient	13.05.2	A		
Polytar ®	shampoo	13.09	A		
polyvinyl alcohol	eye drops 1.4%	11.08.1	A		
pomalidomide	tablets 1mg,2mg,3mg,4mg	8.02.4	R	In line with NICE TA guidance no. 427, January 2017: Pomalidomide with low-dose dexamethasone, is recommended as an option for treating multiple myeloma in adults at third or subsequent relapse, that is, after 3 previous treatments including both lenalidomide and bortezomib, only where the company provides pomalidomide with the discount agreed in the patient access scheme.	PBR RL
ponatinib	tablets 15mg, 30mg, 45mg	8.01.5	R	In line with NICE TA guidance no 451, June 2017: Ponatinib is recommended, within its marketing authorisation, as an option for treating chronic-, accelerated- or blast-phase chronic myeloid leukaemia in adults when the disease is resistant to dasatinib or nilotinib or they cannot tolerate dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate or the T315I gene mutation is present.	PBR
ponesimod	tablets, 2mg - 10mg (treatment initiation pack) 20mg (maintanance pack)	8.02.4	R	In line with NICE TA guidance no.767, February 2022: Ponesimod is recommended for treating relapsing–remitting multiple sclerosis with active disease defined by clinical or imaging features in adults, only if the company provides ponesimod according to the commercial arrangement.	PRB RL
poractant alfa	suspension 120mg in 1.5ml, 240mg in 3ml	3.05.2	R	For use in neonates only. See guidelines.	PBR
posaconazole	suspension 200mg in 5ml tablets 100mg injection 300mg	5.02.1	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required	PBR RL

posaconazole	suspension 200mg in 5ml tablets 100mg injection 300mg	5.02.1	R	For **prophylaxis** of invasive fungal infections in adult haematology patients: 1. With graft-versus-host disease requiring ongoing immunosuppresion; 2. Receiving azacitidine+venetoclax chemotherapy regimen for AML; 3. With high risk receiving high risk CAR-T cell therapy; 4. Who cannot tolerate voriconazole or voriconazole is contraindicated. NDP meeting January 2024	RL
Posalfilin ®	ointment containing podophyllum resin 20% and salicylic acid 25%	13.07	A		
potassium acid phosphate	injection 13.6%	9.05.2	A		
potassium ascorbate	Eye drops, 10% preservative free (Unlicensed	11.06	A		
potassium ascorbate	eye drops 10%*	11.08	R	Preparation is unlicensed and can be obtained from Moorfields Hospital. Although normally held in stock at CXH they may not always be immediately available.	
potassium canrenoate	injection 200mg in 10ml (unlicensed)	2.02.3	A		
potassium chloride	MR tablets 600mg, containing 8mmol potassium and 8mmol chloride oral solution 1mmol in 1ml (unlicensed)	9.02.1	A	Avoid using modified release preparations unless tablets or liquid preparations are inappropriate. Unlicensed oral solution for paediatric use following Kay-Cee-L® discontinuation. (July 2025)	

potassium chloride	potassium 0.15% (1.5g, 20mmol per litre) in 5% glucose (500ml, 1 litre); potassium 0.3% (3g, 40mmol per litre) in 5% glucose (500ml, 1 litre); potassium 0.15% (1.5g, 20mmol per litre) in 0.9% sodium chloride (500ml, 1 litre); potassium 0.3% (3g, 40mmol per litre) in 0.9% sodium chloride (500ml, 1 litre); potassium 0.45 (4.5g, 60mmol per litre) in 0.9% sodium chloride (1 litre); potassium 0.15% (1.5g, 20mmol per litre) in 0.18% sodium chloride and 4% glucose (500ml, 1 litre); potassium 0.3% (3g, 40mmol per litre) in 0.18% sodium chloride and 4% glucose (500ml, 1 litre); potassium 0.075% (0.75g, 10mmol per litre) in 0.9% sodium chloride and 5% glucose (500ml); potassium 0.15% (1.5g, 20mmol per litre) in 0.9% sodium chloride and 5% glucose (500ml); potassium 0.075% (0.75g, 10mmol per litre) in 0.45% sodium chloride and 5% glucose (500ml); potassium 0.15% (1.5g, 20mmol per litre) in 0.45% sodium chloride and 5% glucose (500ml)	9.02.2	A		
potassium chloride	Injection concentrated 15% (1.5g, 20mmol in 10ml) - restricted to wards with level 3 beds; potassium 1.5% (15g, 20mmol in 100ml) in 0.9% sodium chloride (100ml) (unlicensed) - restricted to wards with level 2 beds; potassium 3% (30g, 40mmol in 100ml) in 5% glucose (100ml) (unlicensed) - restricted to wards with level 2 beds; potassium 3% (30g, 40mmol in 100ml) in 0.9% sodium chloride (100ml) (unlicensed) - restricted to wards with level 2 beds	9.02.2	R	Stock supplies of ‘strong’ potassium (potassium chloride 15% and 3%) are restricted to critical care areas where it is required urgently. ‘Strong’ potassium solutions must be stored in clinical areas in a separate locked cupboard or in the CD cupboard	

potassium citrate	soluble tablets (Effercitrate - 1 tablet equivalent to 5ml potassium citrate); slow release tablets (unlicensed, Urocit-K 10, 1080mg) mixture 1.5g in 5ml	7.04.3	A	Urocit-K 10 (unlicensed) to used only when Effercitrate unavailable (NDP September 2015)	
potassium hydroxide	solution 5%, 20% (both unlicensed)	13.05	A		
potassium iodide	tablets, 65mg	6.02.2	A	NDP May 2021 (replaces unlicensed capsules)	
potassium perchlorate	tablets 200mg (unlicensed)	6.02.2	A		
potassium permanganate	solution tablets 400mg	13.11.6	R	To be prescribed by or under the direction of dermatology, vascular surgery or tissue viability in line with the lates national alert. (NDP September 2022)	
potassium phosphate	injection 17.42% (20mmol K+ + 10mmol monohydrogen phosphate in 10ml, unlicensed); injection 8.71% 10ml (unlicensed)	9.05.2	A		
potassium; Sando-K ®	Tablets effervescent, potassium bicarbonate and chloride, containing 12mmol potassium and 8mmol chloride per tablet.	9.02.1	A		
povidone iodine	ointment 10%; dry powder spray 2.5%; antiseptic aqueous solution 10%; alcoholic solution 10%; surgical scrub solution 7.5%;	13.11.4	A	no longer pharmacy; ordered from supplies	
povidone-iodine	eye drops 5%	11.08.2	R	for use prior to intravitreal injection	
pramipexole	tablets 88mcg, 180mcg,700mcg prolonged release tablets 260mcg, 520mcg, 1.05mg, 1.57mg, 2.1mg, 2.62mg, 3.15mg	4.09.1	R	For use in line with NICE Clinical Guidance on Parkinson's disease.	
prasugrel	tablets 5mg, 10mg	2.09	R	In line with NICE TA guidance no. 317, July 2014 (replaces TA guidance no 182, October-09): Prasugrel 10 mg in combination with aspirin is recommended as an option within its marketing authorisation, that is, for preventing atherothrombotic events in adults with acute coronary syndrome (unstable angina [UA], non-ST segment elevation myocardial infarction [NSTEMI] or ST segment elevation myocardial infarction [STEMI]) having primary or delayed percutaneous coronary intervention. Please refer to the appropriate ICHNT guidelines for further information.	

prasugrel	tablets 5mg, 10mg	2.09	R	For use by interventional neuroradiology in line with the local protocol. NDP May 2022	
pravastatin	tablets 10mg, 20mg, 40mg	2.12	A		
praziquantel	tablets 500mg, 600mg (unlicensed) capsules 600mg (unlicensed)	5.05.3	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required.	
prazosin	tablets 500mcg, 1mg, 2mg	2.05.4	A		
Precision Plus	testing strips	19.01	A		
prednisolone	retention enema, short tube, 20mg in 100ml (as sodium phosphate)(Predsol ®); retention enema, long tube, 20mg in 100ml (as sodium metasulphobenzoate)(Predenema ®); foam enema, 20mg per metered application (as sodium metasulphobenzoate)(Predfoam ®); suppositories 5mg (as sodium phosphate);	1.05.2	A	Most cost effective steroid enema to be prescribed first line. Prednisolone 5mg suppositories to be used 2nd line to budesonide 4mg suppositories (NDP/NWL JF January 2025)	
prednisolone	Tablets, 500mcg, 1mg, 5mg, 20mg, 25mg. Tablets, enteric-coated, 2.5mg, 5mg. Tablets, soluble, 5mg (as sodium phosphate).	6.03.2	A	5mg soluble tablets - very restricted High strenght tablets: most cost effective strenght to be used at any given time.	
prednisolone	Eye drops 0.003%, 0.01%, 0.03%, 0.1%, 0.3%; Drops (for ear or eye) 0.5%, (as sodium phosphate); Eye drops 1.0% (as acetate); Eye drops 0.01%, 0.03%, 0.1%, 0.3%, all preservative frees (unlicensed); Drops (for ear or eye) 0.5% (as sodium phosphate) with neomycin sulphate 0.5%; Unit dose eye drops Minims ® 0.5%.	11.04.1	R	Preservative-free preparation is unlicensed and can be obtained from Moorfields Hospital. Although normally held in stock at CXH they may not always be immediately available.	
prednisolone acetate	Injection (aqueous suspension), 25 mg/ml.	10.01.2	A	For intramuscular injection, see section 6.3.2	
prednisolone sodium phosphate	Drops (for ear or eye), prednisolone sodium phosphate 0.5%.	12.01.1	A		
Predsol N	eye drops	11.04.1	A		

pregabalin	capsules 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg	4.08.1	R	1. for first or second line treatment of neuropathic pain in adults. To be used in line with the relevant national/local guidelines. 2. For drug-refractory focal epilepsy (Consultant prescribing only) as 3rd or 4th line therapy in patients who have failed on other treatments, for use in place of one of a patient's existing drugs.	
pregnancy testing kit		19.02	A		
prilocaine hydrochloride	injection 1% (20ml); injection 4% (80mg in 2ml) cartridge	15.02	A		
prilocaine with felypressin	injection prilocaine 3% (30mg/ml) and felypressin 0.03unit/ml injection (2ml cartridge)	15.02	A		
primaquine	tablets 7.5mg (unlicensed)	5.04.1	A	Level 1 non-reserved anti-infective	
primidone	Tablets 50mg, 250mg; suspension 250mg in 5ml.	4.08.1	A		
Pripsen ®	oral powder containing piperazine phosphate 4g and sennosides 15.3mg per sachet;	5.05.1	A	Level 1 non-reserved anti-infective	
Prismasol 4 ®	haemoflitration fluid	20	R	CRRT (haemofiltration) solution for use in Intensive Care Units.	
Prismocitrate® 18/0	anticoagulant solution		R	for use in Intensive Care Units (NDP September 2016)	
Prism0Cal® B22	dialysis solution		R	for use in Intensive Care Units (NDP September 2016)	
probenecid	tablets 500mg (unlicensed)	10.01.4	R	1. For use with cidofovir. 2. As an adjuvant to therapy with select β-lactams when recommended by ID/micro teams. (NDP January 2026)	
procaine	injection 2% 2ml	15.02	A		
procarbazine	capsules 50mg	8.01.5	A		PBR
prochlorperazine	tablets 5mg, buccal tablets 3mg; injection 12.5mg in 1ml	4.06	A		
Proctosedyl ®	ointment; suppositories	1.07.2	A		
procyclidine	tablets 5mg; oral solution 2.5mg in 5ml; syrup 5mg in 5ml; injection 10mg in 2ml	4.09.2	A		
proflavine	cream 0.1%	13.10.5	A		

progesterone	pessaries 200mg, 400mg; injection 25mg in 1ml, 50mg in 1ml, 100mg in 1ml (unlicensed) capsules, vaginal (micronised) 200mg tablets, vaginal 100mg	6.04.1	A	200mg vaginal capsules (NDP May 2016)	
progesterone	gel 8% (Crinone ®)	6.04.1	A		
proguanil	tablets 100mg	5.04.1	A	Level 1 non-reserved anti-infective	
promethazine hydrochloride	tablets 10mg, 25mg; elixir 5mg in 5ml; injection 25mg in 1ml.	4.01.1	A		
propafenone	tablets 150mg, 300mg	2.03.2	A		
propamidine isethionate	Eye drops, 0.1% (Brolene ®).	11.03.1	A		
propantheline bromide	tablets 15mg	1.02 7.04.2	A		
propofol	injection 1% (200mg in 20ml, 500mg in 50ml, 1g in 100ml); injection 2% (50ml prefilled syringe, 500mg in 50ml) (for use with Diprifusor TCI system); injection 0.5% (ampoules).	15.01.1	A	0.5% ampoules for limited paediatric use only (NDP March 2022)	
propranolol	tablets 10mg, 40mg, 80mg,160mg; MR capsules 80mg, 160mg; injection 1mg in 1ml (unlicensed if licensed product not available); 40mg in 5ml 50mg in 5ml (paediatric strenght)	2.04	A		
ProPrems® probitoic *(Bifidobacterium lactis, Streptococcus thermophiles, Bifidobacterium infantis)*	sachets 0.5g	not classified	R	Probiotics treatment for neonates, 32 weeks gestation and birthweight <1500g in line with the local clinical guideline. (NDP March 2022)	
propylene glycol 40% in Unguentum M	100g (Unlicensed)	13.02.1	A		
propylthoiuracil	tablets 50mg	6.02.2	A		
protamine sulphate	injection 50mg in 5ml (HH), 100mg in 10ml (SMH)	2.08.3	A		
prothrombin complex concentrate	600 units (Prothromplex T ®)	2.11	R		PBR

protionamide (prothionamide)	tablets 250mg (unlicensed)	5.01.9	R	Level 2 anti-infective restricted to specific indications: MDR-TB	
protirelin (thyrotrophin-releasing hormone, TRH)	injection 200mcg in 2ml	6.05.1	A		
proxymetacaine	Minims - 0.5% eye drops	11.07	A		
proxymetacaine 0.5% + fluorescein 0.25%	proxymetacaine 0.5% and fluorescein 0.25% eye drops	11.07	A		
prucalopride	tablets 1mg, 2mg	1.06.7	R	In line with NICE TA guidance no. 211, December 2010, prucalopride is recommended as an option for the treatment of chronic constipation only in women for whom treatment with at least two laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and invasive treatment for constipation is being considered. If treatment with prucalopride is not effective after 4 weeks, the woman should be re-examined and the benefit of continuing treatment reconsidered.	
pseudoephedrine	tablets 60mg; oral solution 30mg in 5ml	3.10	A		
Pylera®	capsules bismuth subcitrate potassium 140mg/ metronidazole 125mg/ tetracycline 125mg	1.02	R	NWL JF committee, March 2025 for use by or on advice of gastroenterology and ID/micro teams	
pyrazinamide	tablets 500mg; suspension 500mg in 5ml (Unlicensed)	5.01.9	A	Level 1 non-reserved anti-infective	
pyridostigmine bromide	tablets 60mg; oral suspension 60mg in 5ml	10.02.1	A		
pyridoxine hydrochloride (Vitamin B6)	tablets 10mg, 20mg, 50mg; injection 25mg in 1ml, 50mg in 2ml, 100mg in	9.06.2	A		
pyrimethamine	tablets 25mg	5.04.1	A	Level 1 non-reserved anti-infective	
quetiapine	tablets 25mg, 100mg 150mg, 200mg, 300mg; MR tablets 50mg, 200mg, 300mg, 400mg	4.02.1	R		
quinine dihydrochloride	injection 600mg in 2ml (unlicensed)	5.04.1	A	Level 1 non-reserved anti-infective Note equivalences. Quinine (anhydrous base) 100mg = Quinine sulphate 121mg = Quinine dihydrochloride 122mg.	
quinine sulphate	tablets 200mg, 300mg	5.04.1	A	Level 1 non-reserved anti-infective	

quizartinib	tablets 17.7mg, 26.5mg	8.01.3	R	In line with NICE TA guidence no. 1013, October 2024: Quizartinib is recommended, within its marketing authorisation, as an option for newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (AML) in adults, when used with standard cytarabine and anthracycline chemotherapy as induction treatment, then with standard cytarabine chemotherapy as consolidation treatment, then alone as maintenance treatment. Quizartinib is only recommended if the company provides it according to the commercial arrangement.	
rabeprazole	tablets 10mg, 20mg	1.03.5	R		
rabies vaccine	injection	14.04	A		
raloxifene	tablets 60mg	6.04.1	R	In line with NICE TA guidance no. 161, Oct-08: Strontium ranelate and **raloxifene** are recommended as alternative treatment options for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate and risedronate, or have a contraindication to or are intolerant of alendronate and risedronate and who also have a combination of T-score, age and number of independent clinical risk factors for fracture as indicated in the following table.	
raltegravir	tablets 400mg, 600mg tablets (chewable) 25mg, 100mg granules for oral suspension 100mg	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
raltitrexed	injection 2mg	8.01.3	Very R	for consultant initiation as palliative chemotherapy for advanced metastatic colorectal cancer for patients who have received and developed angina or ischaemic heart problems whilst on treatment with 5 fluorouracil/folinic acid regimens or have increased toxicity due to dihydropyrimidine dehydrogenase deficiency.	PBR
ramipril	capsules or tablets 1.25mg, 2,5mg, 5mg, 10mg	2.05.5	A		

ranibizumab	Solution for intravitreal injection 10mg per ml	11.08.2	R	1. In line with NICE TA guidance no. 155, August 2008 (updated May 2024): Ranibizumab, within its marketing authorisation, is recommended as an option for the treatment of wet age-related macular degeneration if all of the following circumstances apply: in the eye to be treated the best-corrected visual acuity is between 6/12 and 6/96 there is no permanent structural damage to the central fovea the lesion size is less than or equal to 12 disc areas in greatest linear dimension, there is evidence of recent presumed disease progression (blood vessel growth, as indicated by fluorescein angiography, or recent visual acuity changes) and the manufacturers of ranibizumab (branded or biosimilar) only provide it at a discount level no lower than the discount agreed in the patient access scheme.	PBR RL
ranibizumab	Solution for intravitreal injection 10mg per ml	11.08.2	R	2. In line with NICE TA guidance no. 274, Feb 2013 (rapid reivew of TA 237, Nov-11): Ranibizumab is recommended as an option for treating visual impairment due to diabetic macular oedema only if: the eye has a central retinal thickness of 400 micrometres or more at the start of treatment and the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).	PBR
ranibizumab	Solution for intravitreal injection 10mg per ml	11.08.2	R	3. In line with NICE TA guidance no. 283, May 2013 (updated May 2024): Ranibizumab is recommended as an option for treating visual impairment caused by macular oedema following central retinal vein occlusion or following branch retinal vein occlusion only if treatment with laser photocoagulation has not been beneficial, or when laser photocoagulation is not suitable because of the extent of macular haemorrhage and only if the manufacturers of ranibizumab (branded or biosimilar) provide it at a discount level no lower than the discount agreed in the patient access scheme.	PBR
ranibizumab	Solution for intravitreal injection 10mg per ml	11.08.2	R	4. In line with NICE TA guidance no. 298, Nov-2013 (updated May 2024): Ranibizumab is recommended as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia only if the manufacturers of ranibizumab (branded or biosimilar) provide it at a discount level no lower than the discount agreed in the patient access scheme.	PBR
ranibizumab	Solution for intravitreal injection 10mg per ml Lucentis®	11.08.2	R	5. For treatment of retinopathy of prematurity (ROP) or aggressive opsterior ROP in line with the NHS England commissioning policy, May 2023. (NDP July 2023)	PBR

ranolazine	SR tablets 375mg, 500mg, 750mg	2.06.3	R	as add-on thrapy for the symptomatic treatment of stable angina in patients who are inadequately controlled or intollerant of first line antianginal therapies. Treatment to be initiated by consultant. GPs may be asked to prescribe continuation therapy. (July 2009)	
rasagiline	tablets 1mg	4.09.1	R	For use in line with NICE Clinical Guidance on Parkinson's disease.	
rasburicase	infusion 1.5mg, 7.5mg	10.01.4	R	For the prevention of acute hyperuricaemia in patients with high risk leukaemia or lymphoma undergoing initial chemotherapy.	PBR
rasburicase	infusion 1.5mg, 7.5mg	10.01.4	R	Treatment of severe tophaceous gout/gouty arthritis and treatment of gout in renal patients who are unresponsive to current treatment and/or intollerant to allopurinol, in line with guidelines. Initiation of treatment will be consultant led. (Jan 2009)	PBR
regadenoson	solution for injection 400mcg	not classified	R	For diagnostic purposes only (MRI cardiac stress test) in patients with asthma. NDP September 2024	
regorafenib	tablets 40mg	8.01.5	R	1. In line with NICE TA guidance no 488, November 2017: Regorafenib is recommended as an option for treating unresectable or metastatic gastrointestinal stromal tumours in adults whose disease has progressed on, or who are intolerant to, prior treatment with imatinib and sunitinib, only if their Eastern Cooperative Oncology Group (ECOG) performance status is 0 to 1 and the company provides regorafenib with the discount agreed in the patient access scheme.	PBR RL
regorafenib	tablets 40mg	8.01.5	R	2. In line with NICE TA guidance no 555, January 2019: Regorafenib is recommended as an option for treating advanced unresectable hepatocellular carcinoma in adults who have had sorafenib, only if they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and the company provides it according to the commercial arrangement.	PBR RL
regorafenib	tablets 40mg	8.01.5	R	3. In line with NICE TA guidance no 866, February 2023: Regorafenib is recommended, within its marketing authorisation, as an option for metastatic colorectal cancer in adults who have had previous treatment (including fluoropyrimidine-based chemotherapy, anti-VEGF therapy and anti-EGFR therapy) or when these treatments are unsuitable. Regorafenib is only recommended if the company provides it according to the commercial arrangement.	PBR RL

Relactagel ®	gel 5ml	7.02.2	R	For the treatment and prevention of recurrent bacterial vaginosis (RBV); be used according to the Jefferiss Wing protocol for the treatment of RBV. This is a medical device. Relactagel ® and Balance Activ Rx ® added to the formulary. The less expensive of the two will be used at any one time. The initial supply will be made in the clinic and further supplies in community. (NDP Sept 2010)	
relugolix/ estradiol (as hemihydrate)/ norethisterone acetate	tablets 40mg/1mg/0.5mg	6.04.1	R	In line with NICE TA guidance no. 832, October 2022: Relugolix–estradiol–norethisterone acetate is recommended, within its marketing authorisation, as an option for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.	
relugolix	tablets 120mg	8.03.4	R	In line with NICE TA guidance no. 995, August 2024: Relugolix is recommended, within its marketing authorisation, as an option for treating prostate cancer in adults with hormone-sensitive prostate cancer alongside radiotherapy for high-risk localised or locally advanced hormone-sensitve prostate cancer, as neoadjuvant treatment before radiotherapy for high-risk localised or locally advinced hormone-sensitive prostate cancer.	
relugolix/ estradiol (as hemihydrate)/ norethisterone acetate	tablets 40mg/1mg/0.5mg	6.04.1	R	In line with NICE TA guidance no. 1057, April 2025: Relugolix–estradiol–norethisterone (relugolix combination therapy) can be used, within its marketing authorisation, as an option for treating symptoms of endometriosis in adults of reproductive age who have had medical or surgical treatment for endometriosis.	
remdesivir	vials, 100mg powder for concentrate for solution for infusion	5.03.5	R	For the treatment of coronavirus disease 2019 (COVID-19) in line with the relevant NICE TAGs and local guidelines. (NDP May 2022)	
remifentanil	injection 1mg, 2mg, 5mg	15.01.4	R	For use during induction and maintenance of anaesthesia in theatres; For use in PICU.	
Replens ®		7.02.1	R	Added to the Formulary as suitable for recommending to GPs, but the pharmacy will not purchase. Can be bought over the counter.	
rezafungin	200mg powder for concentrate for solution for infusion	5.02.4	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required. Approved for the treatment of Invasive candidiasis in non-neutropenic adult patients where fluconazole is unsuitable. Anidulafungin to replace caspofuning in this setting. Caspofungin will still be used in paediatric and neutropenic patients. (NDP July 2024)	PBR

Riamet ®	tablets containing artemether 20mg and lumefantrine 120mg	5.04.1	R	Level 1 non-reserved anti-infective	
ribarivin	injection	5.03.5	R	Level 2 anti-infectives restricted to specific indications: As per Haematology anti-infective policy	PBR
ribavirin	capsules 200mg; tablets 200mg oral solution 200mg in 5ml	5.03.5	R	For treatment of Hepatitis C in combination with other anti-viral agents as per relevant NICE and NHS England recommendations.	PBR RL
ribavirin (Virazole ®)	inhalation 6g	5.03.5	R	Level 2 anti-infectives restricted to specific indications: As per Haematology anti-infective policy	PBR RL
ribociclib	tablets 200mg	8.01.5	R	1. In line with NICE TA guidance no. 496, Dec-2018: Ribociclib, with an aromatase inhibitor, is recommended within its marketing authorisation, as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer as initial endocrine-based therapy in adults. Ribociclib is recommended only if the company provides it with the discount agreed in the patient access scheme.	PBR RL
ribociclib	tablets 200mg	8.01.5	R	2. In line with NICE TA guidance no. 687, March 2021: Ribociclib plus fulvestrant is recommended as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy only if exemestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, and the company provides ribociclib according to the commercial arrangement.	PBR RL
ribociclib	tablets 200mg	8.01.5	R	3. In line with NICE TA guidance no 1086, August 2025: Ribociclib with an aromatase inhibitor can be used, within its marketing authorisation, as an option for the adjuvant treatment of hormone receptor positive, HER2-negative, early breast cancer at high risk of recurrence in adults. Combine the aromatase inhibitor with a luteinising hormone-releasing hormone agonist, unless after menopause. Ribociclib is recommended only if the company provides it according to the commercial arrangement.	PBR RL
riboflavin	eye drops 0.1% (medical device)	11.08.2	R	For use during treatment of keratoconus by UVA corneal cross-linking.	
rifabutin	Capsules 150mg; oral liquid 100mg in 5ml (unlicensed)	5.01.9	A	Level 1 non-reserved anti-infective	
rifampicin	capsules 150mg, 300mg; syrup 100mg in 5ml; injection 300mg, 600mg	5.01.9	A	Level 1 non-reserved anti-infective	

rifampicin/isoniazid	dispersible tabelts, 75mg/50mg	5.01.9	A	Level 1 non-reserved anti-infective	
rifampicin/isoniazid/ pyrazinamide	dispersible tabelts, 75mg/50mg/150mg	5.01.9	A	Level 1 non-reserved anti-infective	
rifapentin	tablets 150mg (unlicensed)	not classified	R	Level 2 anti-infective restricted to specific indications: second line treatment of latent TB infaction in adults and children.	
Rifater ®	Tablets containing rifampicin 120mg, isoniazid 50mg and pyrazinamide 300mg.	5.01.9	A	Level 1 non-reserved anti-infective	
rifaximin (Targaxan)®)	tablets 550mg	5.01.7	R	1. In line with NICE TA guidance no 337, March 2015: Rifaximin is recommended, within its marketing authorisation, as an option for reducing the recurrence of episodes of overt hepatic encephalopathy in people aged 18 years or older.	RL
rifaximin (Targaxan)®)	tablets 550mg	5.01.7	R	2. For treatment of small intestinal bacterial overgrowth following oesophagectomy and gastrectomy for cancer. On advice of the surgical (upper GI) and ID team only. Unlicensed indication. (NDP June 2017)	RL
Rifinah 150 ®	Tablets containing rifampicin 150mg and isoniazid 100mg.	5.01.9	A	Level 1 non-reserved anti-infective	
Rifinah 300 ®	Tablets containing rifampicin 300mg and isoniazid 150mg.	5.01.9	A	Level 1 non-reserved anti-infective	
rilpivirine	tablets 25mg	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH) In line with NICE TA guidance no. 757, December 2022: Cabotegravir with rilpivirine is recommended, within its marketing authorisation, as an option for treating HIV-1 infection in adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors. It is recommended only if the company provides it according to the commercial arrangement.	PBR RL
riluzole	tablets 50mg	4.09.3	R	For use in line with NICE TA guidance no.20; Jan-01, for the treatment of individuals with the amyotrophic lateral sclerosis (ALS) form of Motor Neurone Disease.	RL

rimegepant	oral lyophilisate, 75mg	4.07.4	R	In line with NICE TA guidance no. 906, July 2023: Rimegepant is recommended as an option for preventing episodic migraine in adults who have at least 4 and fewer than 15 migraine attacks per month, only if at least 3 preventative treatments have not worked.	
rimegepant	oral lyophilisate, 75mg	4.07.4	R	In line with NICE TA guidance no. 919, October 2023: Rimegepant is recommended as an option for the acute treatment of migraine with or without aura in adults, only if for previous migraines at least 2 triptans were tried and they did not work well enough or triptans were contraindicated or not tolerated, and nonsteroidal antiinflammatory drugs (NSAIDs) and paracetamol were tried but did not work well enough.	
riociguat	tablets 0.5mg, 1mg, 1.5mg, 2mg, 2.5mg	2.5.1	R	For treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) as specified in NHS England commissioning statement. (NDP September 2015) For treatment of PAH as per NHS England commissioning statement (March 2017).	PBR RL
risankizumab	solution for injection 150mg pre-filled syringe 150mg solution for injection, cartridge 360mg concentrate for solution for infusion, 600mg	10.01.3	R	1. In line with NICE TA guidance no 596, August 2019: Risankizumab is recommended as an option for treating plaque psoriasis in adults according to the NICE specified criteria.	PBR
risankizumab	solution for injection 150mg pre-filled syringe 150mg solution for injection, cartridge 360mg concentrate for solution for infusion, 600mg	10.01.3	R	2. In line with NICE TA guidance no 803, July 2022: Risankizumab, alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them according to the NICE specified criteria.	PBR
risankizumab	solution for injection 150mg pre-filled syringe 150mg solution for injection, cartridge 360mg concentrate for solution for infusion, 600mg	10.01.3	R	3. In line with NICE TA guidance no 888, May 2023: Risankizumab is recommended as an option for treating moderately to severely active Crohn's disease in people 16 years and over, only if the disease has not responded well enough or lost response to a previous biological treatment, or a previous biological treatment was not tolerated, or tumour necrosis factor (TNF)-alpha inhibitors are not suitable. Risankizumab is only recommended if the company provides it according to the commercial arrangement.	PBR

risankizumab	solution for injection 150mg pre-filled syringe 150mg solution for injection, cartridge 360mg concentrate for solution for infusion, 600mg	10.01.3	R	4. In line with NICE TA guidance no 998, August 2024: Risankizumab is recommended as an option for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or has lost response to treatment, only if a tumour necrosis factor (TNF)-alpha inhibitor has not worked (that is the condition has not responded well enough or has lost response to treatment), or cannot be tolerated or is not suitable, and the company provides it according to the commercial arrangement.	PBR
risedronate	tablets 5mg, 30mg, 35mg	6.06.2	R	In line with NICE TA guidance no. 161, Dec-2008 (updated as TA guidance 464, August 2017).	
risperidone	tablets 500micrograms, 1mg, 2mg, 3mg, 4mg, 6mg; dispersible tablets 500micrograms, 1mg, 2mg, 4mg; liquid 1mg in 1ml	4.02.1	R		
risperidone	Depot injection 25mg, 37.5mg, 50mg	4.02.2	R	In line with the relevant NICE guidance.	
ritlecitinib	capsules 50mg		R	In line with NICE TA guidance no. 958, March 2024: Ritlecitinib is recommended, within its marketing authorisation, as an option for treating severe alopecia areata in people 12 years and over. Ritlecitinib is only recommended if the company provides it according to the commercial arrangement	PBR RL
ritonavir	tablets 100mg; 100mg oral powder	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
rituximab	injection 100mg in 10ml, 500mg in 50ml solution for subcutaneous injection, 1400mg in 11.7ml	8.02.3	R	1. In line with NICE TA guidance no. 137, Feb-08: Recommended in combination with chemotherapy, as an option for the induction of remission in people with relapsed stage III or IV follicular non-Hodgkin's lymphoma. As monotherapy maintenance therapy, for the treatment of people with relapsed stage III or IV follicular non- Hodgkin' s lymphoma in remission induced with chemotherapy with or without rituximab. As monotherapy for the treatment of people with relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma, when all alternative treatment options have been exhausted.	PBR

rituximab	injection 100mg in 10ml, 500mg in 50ml solution for subcutaneous injection, 1400mg in 11.7ml	8.02.3	R	2. For maintenance treatment as first line therapy for indolent non-Hodgkin's Lymphona responding to induction chemotherapy with rituximab and Hodgkin's Lymphona responding to induction chemotherapy with rituximab and Hodgkin's Lymphona responding to induction chemotherapy with rituximab and CVP (cyclophosphamide, vincristine & prednisolone). Treatment may continue for 2years and is then stopped.	PBR;
rituximab	injection 100mg in 10ml, 500mg in 50ml	8.02.3	R	3. Part of conditioning for reduced intensity conditioning allograft in lymphoid malignancies and for treatment of minimal residual disease in patients with lymphoid malignancies post-allograft.	PBR
rituximab	injection 100mg in 10ml, 500mg in 50ml	8.02.3	R	4. In line with NICE TA guidance no. 174; July-09 rituximab in combination with fludarabine and cyclophosphamide is recommended as an option for the first-line treatment of chronic lymphocytic leukaemia in people for whom fludarabine in combination with cyclophosphamide is considered appropriate. Rituximab in combination with chemotherapy agents other than fludarabine and cyclophosphamide is not recommended for the first-line treatment of chronic lymphocytic leukaemia. (October 2009)	PBR
rituximab	injection 100mg in 10ml, 500mg in 50ml	10.1.03	R	5. In line with NICE TA guidance no. 195, Aug-10: Rituximab in combination with methotrexate is recommended as an option for the treatment of adults with severe active rheumatoid arthritis who have had an inadequate response to, or are intolerant of, other disease-modifying anti-rheumatic drugs (DMARDs), including at least one tumour necrosis factor (TNF) inhibitor. Treatment with rituximab should be given no more frequently than every 6 months. Treatment with rituximab in combination with methotrexate should be continued only if there is an adequate response following initiation of therapy and if an adequate response is maintained following retreatment with a dosing interval of at least 6 months.	PBR
rituximab	injection 100mg in 10ml, 500mg in 50ml	8.02.3	R	6. as 2nd line agent for the treatment for patients with refractory/recurrent immune cytopenia.	PBR
rituximab	injection 100mg in 10ml, 500mg in 50ml	8.02.3	R	7. For use in nephrology and transplantation for the treatment of refractory disease as 2nd line agent for autoimmune disease (SLE, systemic vasculititis) treatment of humoral transplant rejection, desensitising patients with alloantibodies pre- and post- transplantation.	PBR
rituximab	injection 100mg in 10ml, 500mg in 50ml	8.02.3	R	8. For complex non-responsive/resistant nephrotic syndrome in children.	PBR

rituximab	injection 100mg in 10ml, 500mg in 50ml	8.02.3	R	9. for SLE nephritis in children.	PBR
rituximab	injection 100mg in 10ml, 500mg in 50ml	8.02.3	R	10. In line with NICE TA guidance no. 193; Jul-10 rituximab in combination with fludarabine and cyclophosphamide is recommended as a treatment option for people with relapsed or refractory chronic lymphocytic leukaemia except when the condition is refractory to fludarabine (that is, it has not responded to fludarabine or has relapsed within 6 months of treatment) or has previously been treated with rituximab, unless in the context of a clinical trial, at a dose lower than the dose currently licensed for chronic lymphocytic leukaemia or in the context of a clinical trial, in combination with chemotherapy other than fludarabine and cyclophosphamide.	PBR
rituximab	injection 100mg in 10ml, 500mg in 50ml solution for subcutaneous injection 1400mg in 11.7ml	8.02.3	R	11. In line with NICE TA guidance no. 226; Jun-11 rituximab maintenance therapy is recommended as an option for the reatment of people with follicular non-Hodgkin's lymphoma that has responded to first-line induction therapy with rituximab in combination with chemotherapy. .	PBR
rituximab	infusion 100mg in 10ml, 500mg in 50ml	8.02.3	R	12. In line with NICE TA guidance no. 243; Jan-12, Rituximab, in combination with cyclophosphamide, vincristine and prednisolone (CVP), cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP), mitoxantrone, chlorambucil and prednisolone (MCP), cyclophosphamide, doxorubicin, etoposide, prednisolone and interferon-α (CHVPi) or chlorambucil is recommended as an option for the treatment of symptomatic stage III and IV follicular lymphoma in previously untreated people. (This guidance replaces NICE technology appraisal guidance 110 issued in September 2006.)	PBR
rituximab	infusion 100mg in 10ml, 500mg in 50ml	8.02.3	R	13. In line with NICE TA guidance no. 308, March-14: Rituximab, in combination with glucocorticoids, is recommended as an option for inducing remission in adults with anti-neutrophil cytoplasmic antibody [ANCA]-associated vasculitis (severely active granulomatosis with polyangiitis [Wegener's] and microscopic polyangiitis), only if further cyclophosphamide treatment would exceed the maximum cumulative cyclophosphamide dose, or cyclophosphamide is contraindicated or not tolerated or the person has not completed their family and treatment with cyclophosphamide may materially affect their fertility or the disease has remained active or progressed despite a course of cyclophosphamide lasting 3–6 months or the person has had uroepithelial malignancy.	PBR

rituximab	infusion 100mg in 10ml, 500mg in 50ml	8.02.3	R	14. For immune-mediated neurological conditions including myasthenia gravis, autoimmune encephalitis, demyelinating polyneuropathies and CNS vasculitis/angiitis. (NDP September 2017)	PBR
rituximab	infusion 100mg in 10ml, 500mg in 50ml	8.02.3	R	15. In line with NHS England clinical commissioning statement for rituximab for second line treatment of anti-NMDAR autoimmune-encephalitis (all ages), May 2018. ICHNT is the recognised centre for both adult and paediatic neurology.	PBR
rituximab	infusion 100mg in 10ml, 500mg in 50ml	8.02.3	R	16. For treatment of intersticial lung disease in line with the local treatment pathway. (NDP September 2025)	PBR
rivaroxaban	tablets 10mg	2.08.2	A	1. In line with NICE TA guidance no. 170, April 2009: Rivaroxaban is recommended as an option for the prevention of venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery.	
rivaroxaban	tablets 10mg, 15mg, 20mg	2.08.2	A	2. In line with NICE TA guidance no. 256, May 2012: Rivaroxaban is recommended as an option for prevention of stroke and systemic embolism in atrial fibrillation.	
rivaroxaban	tablets 10mg, 15mg, 20mg	2.08.2	A	3. In line with NICE TA guidance no. 262, July-12: Rivaroxaban is recommended as an option for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism after diagnosis of acute deep vein thrombosis in adults.	
rivaroxaban	tablets 10mg, 15mg, 20mg	2.08.2	A	4. In line with NICE TA guidance no. 287, June 2013: Rivaroxaban is recommended as an option for treating pulmonary embolism and preventing recurrent deep vein thrombosis and pulmonary embolism in adults.	

rivaroxaban	tablets 2.5mg	2.08.2	R	5. In line with NICE TA guidance no 335, March 2015: Rivaroxaban is recommended as an option within its marketing authorisation, in combination with aspirin plus clopidogrel or aspirin alone, for preventing atherothrombotic events in people who have had an acute coronary syndrome with elevated cardiac biomarkers. Clinicians should carefully assess the person's risk of bleeding before treatment with rivaroxaban is started. The decision to start treatment should be made after an informed discussion between the clinician and the patient about the benefits and risks of rivaroxaban in combination with aspirin plus clopidogrel or with aspirin alone, compared with aspirin plus clopidogrel or aspirin alone. A decision on continuation of treatment should be taken no later than 12 months after starting treatment. Clinicians should regularly reassess the relative benefits and risks of continuing treatment with rivaroxaban and discuss them with the patient.	
rivaroxaban	tablets 2.5mg	2.08.2	A	6. In line with NICE TA guidance no 607, October 2019: Rivaroxaban plus aspirin is recommended within its marketing authorisation, as an option for preventing atherothrombotic events in adults with coronary artery disease or symptomatic peripheral artery disease who are at high risk of ischemic events. For people with coronary artery disease, high risk of ischaemic events is defined as aged 65 or over, or atherosclerosis in at least 2 vascular territories (such as coronary, cerebrovascular, or peripheral arteries), or 2 or more of the following risk factors: current smoking, diabetes, kidney dysfunction with an estimated glomerular filtration rate (eGFR) of less than 60 ml/min (note that rivaroxaban is contraindicated if the eGFR is less than 15 ml/min) heart failure previous non-lacunar ischemic stroke.	
rivastigmine	capsules 1.5mg, 3mg, 4.5mg, 6mg; oral solution 2mg in 1ml; patches 4.6mg/24 hours, 9.5mg/24 hours, 13.3mg /24hours	4.11	R	In line with NICE TA guidance no. 217, Mar-11 (last updated May 2016): The three acetylcholinesterase (AChE) inhibitors donepezil, galantamine and rivastigmine are recommended as options for managing mild to moderate Alzheimer's disease.	
rizatriptan	tablets 5mg, 10mg; wafers 10mg	4.07.4	A		
rocuronium	injection 50mg in 5ml, 100mg in 10ml	15.01.5	A		

roflumilast	tablets, 500mcg	3.03.3	R	In line with NICE TA fuidance no. 461, July 2017: Roflumilast, as an add-on to bronchodilator therapy, is recommended as an option for treating severe chronic obstructive pulmonary disease in adults with chronic bronchitis, only if the disease is severe, defined as a forced expiratory volume in 1 second (FEV1) after a bronchodilator of less than 50% of predicted normal, and the person has had 2 or more exacerbations in the previous 12 months despite triple inhaled therapy with a long-acting muscarinic antagonist, a long-acting beta-2 agonist and an inhaled corticosteroid. Treatment with roflumilast should be started by a specialist in respiratory medicine.	PBR RL
romiplostim	Injection 250 micrograms, 500micrograms	9.01.4	R	In line with NICE TA guidance no. 221, Apr-11: Romiplostim is recommended for the treatment of adults with chronic immune (idiopathic) thrombocytopenia purpura whose condition is refractory to standard active treatments and rescue therapies or who have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies and if the manufacturer makes romiplostim available with the discount agreed as part of the patient access scheme.	PBR
romosozumab	solution for injection in pre-filled pen 105mg	6.06.2	R	In line with NICE TA guidance no. 791, May 2022: Romosozumab is recommended as an option for treating severe osteoporosis in people after menopause who are at high risk of fracture, only if they have had a major osteoporotic fracture (spine, hip, forearm or humerus fracture) within 24 months (so are at imminent risk of another fracture) and the company provides romosozumab according to the commercial arrangement.	PBR
ropinirole	tablets 250mcg, 500mcg, 1mg, 2mg, 5mg; MR tablets 2mg, 4mg, 8mg; follow-on pack; starter pack	4.09.1	R	Initiation by nerurology and care of the elderly teams only in accordance with NICE guidance on management of Parkinson's disease.	
ropivacaine	solution for infusion 2mg/ml (200ml) ampoules, 10mla (0.75%)	15.02	R	Only infusion approved for formulary inclusion. (NDP July 2019) 0.75% ampoules for obstetrics use only (NDP May 2024)	
rose bengal	Single-use Minims ®, 1%.	11.08.2	A		
rosuvastatin	tablets 5mg, 10mg, 20mg, 40mg	2.12	R	In line with local/national recommendations. (NDP August 2011)	
Rotarix® (rotavirus vaccine)	Oral suspension in a prefilled applicator	14.04	A	(NDP May 2013)	
rotigotine	patches 2mg/24hr, 4mg/24hr, 6mg/24hr, 8mg/24hr	4.09.1	R	Use according to NICE guidance on the treatment of Parkinson's disease.	

roxadustat	tablets, 20mg, 50mg, 70mg, 100mg, 150mg	9.01.3	R	In line with NICE TA guidance no. 807, July 2022: Roxadustat is recommended as an option for treating symptomatic anaemia associated with chronic kidney disease (CKD) in adults only if they have stage 3 to 5 CKD with no iron deficiency, and they are not on dialysis at the start of treatment and the company provides roxadustat according to the commercial arrangement.	PBR RL
rucaparib	tablets 200mg, 250mg 300mg	8.01.5	R	In line with NICE TA guidance no. 1007, September 2024 (replaces NICE TAG no. 611, November 2019): Rucaparib is recommended, within its marketing authorisation, as an option for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy in adults. Rucaparib is only recommended if the company provides it according to the commercial arrangement.	PBR RL
rucaparib	tablets 200mg, 250mg 300mg	8.01.5	R	In line with NICE TA guidance no. 1055, April 2025: Rucaparib is recommended as an option for the maintenance treatment of advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after complete or partial response to first-line platinum-based chemotherapy in adults, only if it is BRCA mutation-negative and homologous recombination deficiency (HRD)-positive, or it is BRCA mutation-negative, and HRD status is negative or unknown, and bevacizumab is not a treatment option because NHS England's BEV3 and BEV10 commissioning approval criteria for having it are not met, or it is contraindicated or not tolerated, and the company provides rucaparib according to the commercial arrangement.	PBR RL
rufinamide	tablets 100mg, 200mg, 400mg oral suspension 200mg in 5mL	4.08.1	R	Adjunctive therapy for seizures in Lennox Gastaut Syndrome (LGS) in children aged 4+ .	
ruxolitinib	tablets 5mg, 15mg, 20mg	8.01.5	R	In line with NICE TA guidance no. 389, March 2016: Ruxolitinib is recommended as an option for treating disease-related splenomegaly or symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only in people with intermediate-2 or high-risk disease, and if the company provides ruxolitinib with the discount agreed in the patient access scheme.	PBR RL

ruxolitinib	tablets 5mg, 15mg, 20mg	8.01.5	R	In line with NICE TA guidance no. 921, October 2023: Ruxolitinib is recommended, within its marketing authorisation, for treating polycythaemia vera in adults who cannot tolerate hydroxycarbamide (also called hydroxyurea) or when the condition is resistant to it. It is only recommended if the company provides it according to the commercial arrangement.	PBR RL
ruxolitinib	tablets 5mg, 15mg, 20mg	8.01.5	R	In line with NICE TA guidance no. 1054, April 2025 (replaces TAG 839, November 2022): Ruxolitinib is recommended, within its marketing authorisation, as an option for treating acute graft versus host disease (GvHD) that has an inadequate response to corticosteroids in people 12 years and over. Ruxolitinib is only recommended if the company provides it according to the commercial arrangement.	PBR RL
sacituzumab govitecan	powder for concentrate for solution for infusion, 180mg	8.01.5	R	In line with NICE TA guidance no. 819, August 2022: Sacituzumab govitecan is recommended, within its marketing authorisation, as an option for treating unresectable locally advanced or metastatic triple-negative breast cancer in adults after 2 or more systemic therapies, at least 1 of which was for advanced disease. It is recommended only if the company provides Sacituzumab govitecan according to the commercial agreement.	PBR
sacubitril/valsartan Entresto®	tablets 24mg/26mg 49mg/51mg 97mg/103mg	2.05.5	R	In line with NICE TA guidance no. 388: Sacubitril valsartan is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction, only in people with New York Heart Association (NYHA) class II to IV symptoms and with a left ventricular ejection fraction of 35% or less and who are already taking a stable dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor-blockers (ARBs). Treatment with sacubitril valsartan should be started by a heart failure specialist with access to a multidisciplinary heart failure team. Dose titration and monitoring should be performed by the most appropriate team member as defined in NICE's guideline on chronic heart failure in adults: management.	
Salactol ®	paint	13.07	A		
salbutamol	Injection 250 micrograms in 5ml, 500 micrograms in 1ml; Solution for intravenous infusion 5mg in 5ml see section 3.01.1	7.01.3	A		

salbutamol	Nebules, 2.5mg in 2.5ml, 5mg in 2.5ml. tablets 2mg; MR tablets 4mg, 8mg; capsules 4mg; syrup 2mg in 5ml; injection 500mcg in 1ml, 250mcg in 5ml; infusion 5mg in 5ml EasyHaler 100mcg, 200mcg per dose Dry Powder Inhaler; Accuhaler, dry powder inhaler; CFC-Free 100mcg pMDI (not Evohaler); All other inhalers are non-formulary	3.01.1	A		
salicylic acid	cream 2%; ointment 2%, 5%, 50% (unlicensed); ointment 2%, 10% in white soft paraffin paste 70%, 75% (unlicensed)	13.07	R	For use by chiropodists.	
salicylic acid 2% + chlorhexidine 0.36% in 50%	spirit 300ml (unlicensed)	13.06.1	A		
salicylic acid 2% and sulphur 2%	cream	13.05.2	A		
salicylic acid and sulphur	cream 1% containing salicylic acid 1% and sulphur 1% in aqueous cream; cream 2% containing salicylic acid 2% and sulphur 2% in aqueous cream; cream 4% containing salicylic acid 4% and sulphur 4% in aqueous cream; All Unlicensed products.	13.06.1	A		
salmeterol	aerosol inhalation 25mcg/metered inhalation; Accuhaler 50mcg/blister	3.01.1	A		
sarilumab	prefilled syringe, pen 150mg, 200mg	10.01.3	R	In line with NICE TA guidance no 485, November 2017: Sarilumab is recommended, in combination with methotrexate or as monotherapy, as an options for management of moderate to severe active RA according to the NICE specified criteria.	PBR
sarilumab	prefilled syringe, pen 150mg, 200mg	10.01.3	R	For the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation, in line with the relevant national and local guidelines. (NDP March 2022) unlicensed indication	

saxagliptin	tablets (as hydrochloride) 2.5mg, 5mg	6.01.2	R	To be prescribed in line with the relevant national guideline. (NDP Sept 2010)	
Secretin	injection (Secrelux - unlicensed)	19.02	A		
secukinumab	solution for injection 150mg pre-filled syringe, pre-filled pen	10.01.3	R	1. In line with NICE TA guidance no. 350, July 2015: Secukinumab is recommended, within its marketing authorisation, as an option for treating adults with plaque psoriasis according to the NICE specified criteria.	PBR
secukinumab	solution for injection 150mg, 300mg pre-filled syringe, pre-filled pen	10.01.3	R	2. In line with NICE TA guidance no. 407, Sep 2016: Secukinumab is recommended, within its marketing authorisation, as an option for treating active ankylosing spondylitis in adults whose disease has responded inadequately to conventional therapy (non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors). The drug is recommended only if the company provides it with the discount agreed in the patient access scheme.	PBR
secukinumab	solution for injection 150mg, 300mg pre-filled syringe, pre-filled pen	10.01.3	R	3. In line with NICE TA guidance no. 445, May 2017: Secukinumab alone, or in combination with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults only if it is used as described in the NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis or the person has had a TNF-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after 12 weeks or TNF-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis). Secukinumab is only recommended if the company provides it as agreed in the patient access scheme.	PBR
secukinumab	solution for injection 150mg, 300mg pre-filled syringe, pre-filled pen	10.01.3	R	4. In line with NICE TA guidance no 719, July 2021: Secukinumab is recommended as an option for treating active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs) in adults. It is recommended only if tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and the company provides secukinumab according to the commercial arrangement.	PBR

secukinumab	solution for injection 150mg, 300mg pre-filled syringe, pre-filled pen	10.01.3	R	5. In line with NICE TA guidance no 734, October 2021: Secukinumab is recommended as an option for treating plaque psoriasis in children and young people aged 6 to 17 years, only if the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and the company provides the drug according to the commercial arrangement.	PBR
secukinumab	solution for injection 150mg, 300mg pre-filled syringe, pre-filled pen	10.01.3	R	6. In line with NICE TA guidance no 935, December 2023: Secukinumab is recommended as an option for treating active moderate to severe hidradenitis suppurativa (acne inversa) in adults when it has not responded well enough to conventional systemic treatment, only if adalimumab is not suitable, did not work or has stopped working, and the company provides secukinumab according to the commercial arrangements.	PBR
selegeline	tablets 1.25mg, 5mg, 10mg; orodispersible tablets 1.25mg	4.09.1	A		
selenium	Injection 50mcg in 1ml	9.05.5	R		
selexipeg	tablets 200mcg, 400mcg, 600mcg, 800 mcg, 1000mcg, 1200mcg,1400mcg, 1600mcg	2.05.1	R	For treatment of pulmonary arterial hypertension in accordance with criteria outlined in the NHS England commissioning statement. Effective from 1st April 2019 (NDP March 2019)	PBR
semaglutide	solution for injection in pre-filled syringe 250mcg in 1.5ml, 500mcg ub 1.5ml, 1mg in 1.5ml tablets 1.5mg, 4mg, 9mg	6.01.2	R	Use in line with the relevant national/local guidelines. NDP September 2019 NDP September 2020, oral semaglutide change of oral formulation - October 2025	
senna	tablets total sennosides 7.5mg; granules 100g, 13g sachet; syrup total sennosides 7.5mg in 5ml	1.06.2	A		
Seretide ®	Accuhaler 100, 250, 500 (dry powder breath-actuated disc inhaler containing 50mcg salmeterol plus 100/250/500mcg fluticasone) Evohaler 50, 125, 250 (CFC-free MDI. containing 25mcg salmeterol plus 50/125/250mcg fluticasone/metered inhalation)	3.02	R	Use according to the relevant national and local guidelines.	

sarmeterol/fluticasone propionate Sereflo® Sirdupla ® pMDI	solution for MD pressurised inhalation 25mcg/125mcg per dose 25mcg/250mcg per dose	3.02	A	Use according to the relevant national and local guidelines. NDP May 2017	
selinexor	tablets 20mg	8.02.4	R	In line with NICE TA guidance no. 970, May 2024: Selinexor plus dexamethasone is recommended, within its marketing authorisation, for treating multiple myeloma in adults when they have had 4 or more treatments, and the condition is refractory to at least 2 proteasome inhibitors, 2 immunomodulatory agents and an anti-CD38 monoclonal antibody (pentarefractory), and the condition has progressed on the last treatment, and the company provides it according to the commercial arrangement.	PBR RL
selinexor	tablets 20mg	8.02.4	R	In line with NICE TA guidance no. 974, May 2024: Selinexor plus bortezomib and dexamethasone is recommended as an option for treating multiple myeloma in adults, only if they have only had 1 previous line of treatment, and their condition is refractory to both daratumumab and lenalidomide, or they have only had 2 previous lines of treatment and their condition is refractory to lenalidomide. Selinexor is only recommended if the company provides it according to the commercial arrangement.	PBR RL
selpercatinib	capsules, 40mg, 80mg	8.01.5	R	1. In line with NICE TA guidance no. 911, July 2023: Selpercatinib is recommended with managed access as an option for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) in adults, only if it is untreated and the conditions in the managed access agreement for selpercatinib are followed.	PBR RL
selpercatinib	capsules, 40mg, 80mg	8.01.5	R	2. In line with NICE TA guidance no. 1038, February 2025 (replaces TAG 742, November 2021): Selpercatinib is recommended as an option in people 12 years and over for treating advanced RET fusion-positive thyroid cancer that is refractory to radioactive iodine (if radioactive iodine is appropriate), only if systemic treatment is needed after sorafenib or lenvatinib advanced RET-mutant medullary thyroid cancer, only if systemic treatment is needed after cabozantinib or vandetanib. Selpercatinib is only recommended if the company provides it according to the commercial arrangement.	PBR RL
selpercatinib	capsules, 40mg, 80mg	8.01.5	R	3. In line with nice TA guidance no. 1039, February 2025: Selpercatinib is recommended as an option for treating advanced RET fusion-positive thyroid cancer that is refractory to radioactive iodine (if radioactive iodine is appropriate) advanced RET-mutant medullary thyroid cancer. It is for people 12 years and over and is recommended only if the cancer has not been treated with a targeted cancer drug, and the company provides it according to the commercial arrangement.	PBR RL

selpercatinib	capsules, 40mg, 80mg	8.01.5	R	4. In line with NICE TA guidance no. 1042, February 2025 (replaced TAG 760, January 2022): Selpercatinib is recommended as an option for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults, only if: it has been treated before and the company provides selpercatinib according to the commercial arrangement.	PBR RL
sertraline	tablets 50mg, 100mg	4.03.3	A		
sevelamer carbonate	tablets 800mg; powder for oral suspension 2.4g	9.05.2	R	To control hyperphosphataemia in dialysis patients with severe hyperparathyroidism who become hypercalcaemic on calcium containing phosphate binders.	
sevoflurane	250ml	15.01.2	R	For use in children; for induction and low-flow maintenance in adults.	
sildenafil	tablets 20mg (Revatio ®); injection 10mg in 12.5mls (Revatio® IV); 10mg/ml powder for suspension, 112ml (Revatio® Oral Suspension)	2.05.1	R	For specialist management of pulmonary hypertension. Use in line with European Society of Cardiology Consensus Guidelines. Will use least costly tablets appropriate for the dose, although only the 20mg tablets are licensed for this indication.	PBR RL
sildenafil	tablets 25mg, 50mg, 100mg (Viagra®)	7.04.5	Very R	Urologists and endocrinologists working in the diabetes clinic may prescribe treatments for impotence on an NHS prescription for men who: i) have had radical pelvic surgery; ii) have had a prostatectomy or been treated for prostate cancer; iii) are undergoing treatment for renal failure; iv) have suffered spinal cord or severed pelvic injury; v) have diabetes, Multiple Sclerosis, Parkinson's Disease; vi) have single gene neurological disease, poliomyelitis, spina bifida; vii) were being already treated for impotence on 14 September 1998. Quantity prescribed should be limited to 1 treatment/patient per week.	
silicone	Fluid, 1000cs, for intra-ocular use (Unlicensed product.); 1300 CS Injection 1 x 10ml vial, oil (oxane HD) VRL700 pre-filled syringe.	11.08.1	A		
siltuximab	concentrate for solution for infusion 400mg, 100mg	10.01.3	R	For treatment of idiopathic Multicentric Castleman Disease (iMCD), in line with NHS England commissioning policy, December 2023.	PBR
silver nitrate	caustic pencil	13.07	A		
silver nitrate caustic	applicators 75%	13.05	A		
silver sulfadiazine (silver sulphadiazine)	cream 1%	13.10.1	A		

Simple linctus, Simple linctus paediatric	liquid	3.09.2	A		
simvastatin	tablets 10mg, 20mg, 40mg, 80mg	2.12	A		
Siopel ®	Barrier cream, 50g. Containing dimeticone '1000' 10%, cetrimide 0.3% and arachis (peanut) oil.	13.02.2	A		
siponimod	tablets 0.25mg, 2mg	8.02.4	R	In line with NICE TA guidance no. 656, November 2020: Siponimod is recommended, within its marketing authorisation, as an option for treating secondary progressive multiple sclerosis with evidence of active disease (that is, relapses or imaging features of inflammatory activity) in adults. It is recommended only if the company provides siponimod according to the commercial arrangement.	PBR RL
sirolimus	tablets 500mcg, 1mg, 2mg; oral solution 1mg in 1ml	8.02.2	R	In line with NICE TA guidance no. 85; Sept-04, for adults as an option as part of an immunosuppressive regimen only in cases of proven intolerance to calcineurin inhibitors (including nephrotoxicity) necessitating complete withdrawal of these treatments. Prophylaxis of renal allograft rejection. Sirolimus will not be used routinely. It will be used as a second or third line agent as an alternative to one of the existing immuno-suppressants. It will replace these in patients with: 1. Nephrotoxicity due to calcineurin inhibitors (CIN) (eg tacrolimus) not controllable by reduction in dose in patients where immunosuppression with steroids and mycophenolate is inadequate; 2. Haemolytic uraemic syndrome (as there is a high risk of recurrence if CNI's are used); 3. Intolerance to mycophenolate not controllable by dose reduction; 4. Delayed graft function where the nephrotoxicity of CIN's may exacerbate the problem.	PBR (renal only) RL
sitagliptin	tablets (as phosphate) 25mg, 100mg	6.01.2	A	To be prescribed in line with the relevant national guideline.	
soda lime	granules	not classified	A		
sodium acetate	injection	9.02.2	A		
sodium acid phosphate	Oral solution, 1mmol per ml	9.05.2	A		
sodium bicarbonate	Powder.	7.04.3	A		
sodium bicarbonate	Ear drops, 5%.	12.01.3	A		
sodium bicarbonate	nasal irrigation 1% (unlicensed); powder	12.02.2	A		

sodium bicarbonate	capsules 500mg (approx 6mmol each of Na+ and HCO3-); oral solution 8.4% (unlicensed); oral solution 500mg in 5ml	9.02.1	A		
sodium bicarbonate	IV infusion 1.26% (500ml); IV infusion 1.4% (500ml); IV infusion 2.74% (500ml); IV infusion 4.2% (10ml - unlicensed); IV infusion 8.4% (10ml, 100ml, 200ml); Min-I-Jet syringe 8.4% (10ml, 50ml); injection 4.2% (10ml)(unlicensed); injection 8.4% (10ml)(unlicensed)	9.02.2	A		
sodium chloride	irrigation 0.9% 3l; Uro-Tainer/Uriflex 0.9% 100ml	7.04.4	A		
sodium chloride	IV infusion 0.18% (500ml); IV infusion 0.45% (500ml); IV infusion 0.9% (5ml, 10ml, 100ml, 250ml, 500ml, 1 litre); IV infusion 1.8% (500ml); IV infusion 2.7%; Injection 30% 5mmol in 1ml (10ml unlicensed), (50ml unlicensed); sterile bottles 30% (1000ml unlicensed)	9.02.2	A		
sodium chloride	Eye drops, 0.43%, isotonic (unlicensed, removed from the formulary September 2012); Eye drops, 0.9%; Eye drops, 0.9% preservative free (unlicensed); Single use Minims eye drops, 0.9%; Eye ointment 5% (unlicensed); Balanced Salt Solution, sterile; 500ml.	11.08.1	A		
sodium chloride	Nasal drops, 0.9%.	12.02.2	A		
sodium chloride	powder	13.05	A		
sodium chloride	Sterile solution 0.9%, 25ml sachets	13.11.1			
sodium chloride	MR tablets 600mg contain approximately 10mmol each of sodium and chloride ions; oral solution 1mmol in 1ml (unlicensed)	9.02.1	A		
sodium chloride	epidural injection 0.9% 10ml (unlicensed)	9.02.2	A		
sodium chloride	irrigation 0.9% (25ml, 100ml, 500ml)	21	A		
sodium chloride	3% sterile solution for nebulisation 7% sterile solution for nebulisation	3.07	A		
sodium citrate	micro-enema (Microlette ® and Microlax ®)	1.06.4	A		

sodium citrate	injection 3.8% 2ml	2.08.1	A		
sodium citrate	injection 46.7%, 5ml vials (DURALOCK ®)	2.08.1	R	for renal dialysis - locked lines when heparin is not suitable	
sodium citrate	oral liquid 0.3 molar (unlicensed)	1.01.1	R	For prevention of acid aspiration in obstetric patients at delivery.	
sodium clodronate	tablets 400mg, 520mg, 800mg	6.06.2	R	For continuation of therapy in patients with hypercalcaemia, objective evidence of bone disease or elevated serum alkaline phosphatase.	
sodium cromoglicate (sodium cromoglycate)	aerosol inhalation 5mg/metered inhalation	3.03.1	A		
sodium cromoglicate (sodium cromoglycate)	Eye drops 2%; Eye ointment 4%; Eye drops preservative free single dose 2%	11.04.2	A		
sodium dichloroisocyanurate	tablets 2.5g (Presept)	16	A		
sodium feredetate (sodium iron edetate)	Elixir 190mg in 5ml (27.5mg iron in 5ml).	9.01.1	A		
sodium glycerophosphate	Injection, 21.6% (10ml) for dilution. 10ml contains: 20mmol sodium and 10mmol phosphate.	9.03	A		
sodium hyaluronate	Injection 8.5mg in 0.5ml disposable syringe (HEALON® PRO); Injection 1.4%, pre-filled syringe (OCU+ 1.4%)	11.08.2	A		
sodium hyaluronate	Injection 40mg in 50ml (medical device)	not classified	R	For temporary replacement of the glycosaminoglycan (GAG) layer in the bladder.	
sodium hyaluronate	eye drops 0.1%, 0.2%	11.08.1	A	Xailin® HA IFU the brand of choice (0.2%)	
sodium lactate compound	IV infusion (500ml, 1 litre)	9.02.2	A		
sodium nitroprusside	injection 50mg	2.05.1	A		
sodium oxybate	oral liquid 500mg in 1ml	4.01.1	R	For management of narcolepsy with cataplexy. (NDP November 2020) Sodium oxybate is schedule 2 CD.	PBR RL
sodium phosphate	injection (15mmol Na+ + 9mmol phosphate in 10ml (unlicensed)	9.05.2	A		
sodium picosulfate	elixir 5mg in 5ml	1.06.2	A		
sodium picosulfate with magnesium citrate	sachets 10mg	1.06.5	A	The product choice as per the procurement contract.	

sodium tetradecyl sulphate	injection 1% 2ml amp, 3% 5ml vial	2.13	A		
sodium thiosulphate	injection 25%, 50% solution for infusion 8%	17	A	In line with NICE TA guidance no. 1034, January 2025: Anhydrous sodium thiosulfate is recommended, within its marketing authorisation, for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised, non-metastatic solid tumours. It is only recommended if the company provides it according to the commercial arrangement. (8% solution for infusion)	PBR
sodium valproate	ec tablets 200mg, 500mg; MR tablets 200mg, 300mg, 500mg; crushable tablets 100mg; liquid (sugar-free) 200mg in 5ml; injection 400mg, 300mg in 3ml	4.08.1	A		
sodium zirconium cyclosilicate	sachets 5g, 10g	9.02.1	R	In line with NICE TA guidance no. 599, September 2019, updated January 2022: Sodium zirconium cyclosilicate is recommended as an option for treating hyperkalaemia in adults only if used in emergency care for acute life-threatening hyperkalaemia alongside standard care or for people with persistent hyperkalaemia and chronic kidney disease stage 3b to 5 or heart failure, if they have a confirmed serum potassium level of at least 6.0 mmol/litre and because of hyperkalaemia, are not taking an optimised dosage of reninangiotensin-aldosterone system (RAAS) inhibitor and are not on dialysis.	
sofosbuvir	tablets 400mg	5.03.3	R	In line with NICE TA guidance no 330, Feb-2015: Sofosbuvir is recommended as an option for treating chronic hepatitis C in adults.	PBR RL
sofosbuvir/ ledipasvir (Harvoni®)	tablets 400mg/90mg coated granules sachets150mg/33.75mg	5.03.3	R	In line with NICE TA guidance no. 363, Nov-2105: Ledipasvir–sofosbuvir is recommended as an option for treating chronic hepatitis C in adults, as detailed in the full NICE document.	PBR RL
sofosbuvir/ velpatasvir (Epclusa®)	tablets 400mg/100mg, 200mg/50mg granules 200mg/50mg, 150mg/37.5mg	5.03.3	R	In line with NICE TA guidance no. 430, Jan-2017: Sofosbuvir–velpatasvir is recommended as an option for treating chronic hepatitis C in adults, as specified by NICE, only if the company provides the drug with the discount agreed in the simple discount agreement.	PBR RL
sofosbuvir/ velpatasvir/ voxilaprevir (Vosevi®)	tablets, 400mg/100mg/100mg	5.03.3	R	In line with NICE TA fuidance no 507, Feb-2018: Sofosbuvir–velpatasvir–voxilaprevir is recommended as an option for treating chronic hepatitis C in adults, only if it is used as specified in table 1 and the company provides the drug at the same price or lower than that agreed with the Commercial Medicines Unit.	PBR RL

Sofradex ®	Drops (for ear or eye) dexamethasone (as sodium metasulphobenzoate) 0.05%, framycetin sulphate 0.5%, gramicidin 0.005%.	11.04.1 12.01.1	A		
Solaraze ® (diclofenac)	gel 3%	13.08.1	A	licenced for solar keratoses - not to be confused with the topical analgesic diclofenac (1%) gel	
solifenacin	tablets 5mg, 10mg	7.04.2	R	3rd line agent (for patients who have failed after treatment with oxybutynin & tolterodine). Restricted to Uro-gynaecology.	
Solivito-N ®	solution	9.03	A		
solriamfetol	tablets, 75mg, 150mg	4.04	R	In line with NICE TA guidance no. 758, January 2022: Solriamfetol is recommended as an option for treating excessive daytime sleepiness in adults with narcolepsy with or without cataplexy. This is only if modafinil and either dexamfetamine or methylphenidate have not worked well enough or are not suitable.	
somatropin	Injection (epr), 5mg/1.5ml; 10mg/1.5ml; 15mg/1.5ml. For subcutaneous injection.	6.05.1	R	In line with NICE TA guidance no. 188, May 2010: Somatropin (recombinant human growth hormone) is recommended as a treatment option for children with growth failure associated with any of the following conditions growth hormone deficiency, Turner syndrome, Prader–Willi syndrome, chronic renal insufficiency, born small for gestational age with subsequent growth failure at 4 years of age or later short stature homeobox-containing gene (SHOX) deficiency. For initiation and discontinuation criteria please refer to the full document.	PBR RL
somatropin (synthetic human growth hormone)	Injection (epr), 5mg/1.5ml; 10mg/1.5ml; 15mg/1.5ml. For subcutaneous injection.	6.05.1	R	In line with NICE TA guidance no. 64, Aug-03: for the treatment of adults with growth hormone (GH) deficiency only if they fulfil all three of the following criteria: • They have severe GH deficiency, • They have a perceived impairment of quality of life (QoL), • They are already receiving treatment for any other pituitary hormone deficiencies as required.	PBR RL
Sonovue®	injection 25mg	18	R	For the use of Sonovue in echocardiography ultrasound imaging to enhance blood echogenicity. For abdominal and peripheral vascular phase scanning, to replace the majority, but not all, of current Levovist use.	
sorafenib	tablets 200mg	8.01.5	R	In line with NICE TA guidance no 474, September 2017: Sorafenib is recommended as an option for treating advanced hepatocellular carcinoma only for people with Child-Pugh grade A liver impairment, only if the company provides sorafenib with the agreed commercial access arrangement.	PBR RL

sorafenib	tablets 200mg	8.01.5	R	In line with NICE TA guidance no 535, Sugust 2018: Lenvatinib and **sorafenib** are recommended as options for treating progressive, locally advanced or metastatic differentiated thyroid cancer (papillary, follicular or Hürthle cell) in adults whose disease does not respond to radioactive iodine, only if they have not had a tyrosine kinase inhibitor before or they have had to stop taking a tyrosine kinase inhibitor within 3 months of starting it because of toxicity (specifically, toxicity that cannot be managed by dose delay or dose modification). Lenvatinib and **sorafenib** are recommended only if the companies provide them according to the commercial arrangements.	PBR RL
sorbitol	solution 70% (unlicensed)	18	A		
sotagliflozin	tablets 200mg	6.01.2	R	In line with NICE TA guidance no 622, February 2020: Sotagliflozin with insulin is recommended as an option for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2 , when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy as specified in the TAG document.	
sotalol	tablets 40mg, 80mg, 200mg; injection 40mg in 4ml	2.04	A		
sparsentan	tablets 200mg, 400mg	2.05.1	R	In line with NICE TA guidance no 1074, June 2025: Sparsentan can be used as option to treat primary immunoglobulin A nephropathy (IgAN) in adults with a urine protein excretion of 1.0 g/day or more, or urine protein-to-creatinine ratio (UPCR) of 0.75 g/g or more. It can only be used if the company provides it according to the commercial arrangement.	PBR RL
special formula B	lotion without ketoprofen	not classified	R	for use with treprostinil for side effects	
spesolimab	concentrate for solurion for infusion, 450mg	10.01.3	R	In line with NICE TA guidance no. 1070, June 2025: Spesolimab is recommended as an option for treating generalised pustular psoriasis (GPP) flares in adults, only if it is used to treat: initial moderate to severe flares when the Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score is 3 or more (at least moderate), and there are fresh pustules (new appearance or worsening of existing pustules), and the GPPGA pustulation subscore is at least 2 (at least mild), and at least 5% of the body's surface area is covered with erythema (abnormal redness of the skin or mucous membranes) and has pustules subsequent flares with a GPPGA pustulation subscore of 2 or more (at least mild), if the last flare was treated with spesolimab and resolved to a GPPGA pustulation subscore of 0 or 1 (clear or almost clear skin). Spesolimab can only be used if the company provides it according to the commercial arrangement.	PBR

spiramycin	tablets 250mg, 500mg, 1g (all unlicensed)	5.04.7	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required.	
spironolactone	tablets 25mg, 100mg; oral suspension 5mg in 5ml, 50mg in 5ml (both unlicensed)	2.02.3	A		
Sprilon ®	spray application	13.02.2	A		
Stalevo ® /Stanek ® (or equivalent generic)	tablets 50mg/12.5mg/200mg, 75mg/18.75mg/200mg, 100mg/25mg/200mg, 125mg/31.25mg/200mg, 150mg/37.5mg/200mg, 200mg/50mg/200mg	4.09.1	A	For the treatment of patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase inhibitor (DDCI) treatment.	
Staloral ®	sublingual (unlicensed)	3.04.1	R	as mainstay treatment for severe allergic rhinoconjunctivits uncontrolled on maximm doses of conventional treatment (antihistamines, nasal sprays, eye drops) in Paediatric Allergy Clinic	
stanozolol	tablets 2mg, 5mg (both unlicensed)	6.04.3	A	SMH - Restricted to HIV teams.	
sterile larvae (maggots)		13.11.7	A	On recommendation by Tissue Viability Nurses only. For management of sloughing wounds .	
Ster-Zac ®	powder	13.11.5	A		
streptokinase	injection 250,000 units, 750,000 units, 1,500,000 units	2.10.2	A	see also NICE TA guidance no. 52; Oct-02.	
streptomycin	injection 1g	5.01.9	R	Level 2 anti-infectives restricted to specific indications: MDR-TB	
streptozocin	injection 1g, 5g (unlicensed)	8.01	A		PBR
Stribild®	tablets (elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir 245mg)	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH) (NDP February 2014)	PBR RL

strontium ranelate	granules 2g	6.06.2	R	In line with NICE TA guidance no. 161, Oct-08: **Strontium ranelate** and raloxifene are recommended as alternative treatment options for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate and risedronate, or have a contraindication to or are intolerant of alendronate and risedronate and who also have a combination of T-score, age and number of independent clinical risk factors for fracture as indicated in the following table.	
sucralfate	tablets 1g; suspension 1g in 5ml	1.03.3	A	Note: If the susupension is unavailable tablets may be dispersed in 10 to 15ml of water. Sucralfate suspension is very restricted, second line to antacid oxetacaine.	
sucroferric oxyhydroxide	tablets (chewable) 500mg	9.05.2	R	For control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis where calcium containing phosphate binders cannot be used. To be used second line to sevelamer. (NDP May 2018)	
sucrose	24% oral solution	not classified	R	for use in neonates and infants as soother	
Sudocrem ®	cream 60g	13.02.2	A		
sugammadex	injection 1ml, 2ml, 5ml (100mg/ml)	15.01.6	R	Reversial of neuromuscular block in anaesthesia induced by rocuronium or vecuronium according to the local protocol. (NDP July 2013)	
sulfacetamide (sulphacetamide)	paint 15% (unlicensed)	13.10.1	A		
sulfadiazine (sulphadiazine)	tablets 500mg; oral suspension 500mg in 5ml	5.01.8	A	Level 1 non-reserved anti-infective	
sulfapyridine	tablets 500mg (unlicensed)	5.01.8	A		
sulfasalazine (sulphasalazine)	tablets 100mg, 500mg; e/c tablets 500mg; suspension 250mg in 5ml; suppositories 500mg	1.05.1	A		
sulpiride	tablets 200mg, 400mg; oral solution 200mg in 5ml.	4.02.1	A		
sumatriptan	tablets 50mg, 100mg; injection pre-filled syringe and cartridges 6mg in 0.5ml; nasal spray 10mg in 0.1ml, 20mg in 0.1ml	4.07.4	A		
sunflower oil	pale yellow oil	13.01.1	A	For neonatal patients. For use as a vehicle to facilitate parents to promote a nurturing touch for their infant.	PBR RL

sunitinib	capsules 12.5mg, 25mg, 37.5mg 50mg	8.01.5	R	1. In line with NICE TA guidance no.169, March 2009) as a first-line treatment option for people with advanced and/or metastatic renal cell carcinoma who are suitable for immunotherapy and have an ECOG performance status of 0 or 1.	PBR RL
sunitinib	capsules 12.5mg, 25mg, 37.5mg, 50mg	8.01.5	R	2. In line with NICE TA guidance no. 179; Sept-09 sunitinib is recommended as a treatment option for people with unresectable and/or metastatic malignant gastrointestinal stromal tumours if: • imatinib treatment has failed because of resistance or intolerance, and • the drug cost of sunitinib for the first treatment cycle will be met by the manufacturer.	PBR RL
sunitinib	capsules 12.5mg, 25mg, 37.5mg, 50mg	8.01.5	R	3. In line with NICE TA guidance no.449, June 2017: Sunitinib is recommended, within their marketing authorisations, as options for treating well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease.	
sunscreen	sunscreen (UVA and UVB-SPF 50+)	13.08.1	R	The most cost effective contract brand will be kept in pharmacy.	
suxamethonium	injection 100mg in 2ml pre-filled syringes 50mg/ml (2mL unlicensed)	15.01.5	A		
Symbicort®	Turbohaler, budesonide (mcg)/formoterol fumarate (mcg) 100/6, 200/6, 400/12	3.02	A	In line with local/national guidelines.	
Synphase®	21 tablets: 7 tablets ethinylestradiol 35 micrograms + norethisterone 500 micrograms, 9 tablets ethinylestradiol 35 micrograms + norethisterone 1mg, 5 tablets ethinylestradiol 35 micrograms + norethisterone 500 micrograms.	7.03.1	A		
Syntometrine ®	Injection, 1ml contains ergometrine maleate 500 micrograms and oxytocin 5 units.	7.01.1	A		
Tachosil ®	collagen sponge coated with fibrinogen and thrombin, 2.5 x 3cm, 4.8 x 4.8cm, 4.8 x 9.5cm	2.11	R	supportive treatment for improvement of haemostasis where standard techniques are not sufficient. Restricted for use in surgery for local visible bleeding control and air sealingfrom lung post resection or trauma. These dressings to supercede aprotinin-containing products. (December 2007)	PBR

tacrolimus	capsules 500mcg, 750mcg, 1mg, 2mg, 5mg (Prograf ® & Adoport ® brands); concentrate for infusion 5mg in 1ml; suspension 2.5mg in 5ml, 1mg in 1ml	8.02.2	R	In line with NICE TA guidance no.85; Sept-04, as an alternative to ciclosporin when a calcineurin inhibitor is indicated as part of an initial or a maintenance immunosuppressive regimen in renal transplantation for adults. The initial choice of tacrolimus or ciclosporin should be based on the relative importance of their side-effect profiles for individual people. For immunosuppression in renal allograft recipients who are at high immunological risk. **NOTE**: Brand of capsules should be specified by prescriber	PBR (renal only) RL
tacrolimus	ointment 0.03%, 0.1%	13.05.3	R	In line with NICE TA guidance no 82, Aug-04: 1. Not recommended for the treatment of mild atopic eczema or as first line treatment for atopic eczema of any severity. 2. Recommended as an option for the second line treatment of moderate to severe atopic eczema in adults and children aged 2 years or older, that has not been controlled by topical corticosteroids, where there is a serious risk of important adverse effects from further topical corticosteroid use, particularly irreversible skin atrophy	PBR (renal only) RL
tacrolimus M/R (Dailiport®) (Advagraff ®)	M/R tablets (Dailport ®) 500mcg, 1mg, 2mg, 3mg, 5mg M/R tablets (Advagraff ®) 500mcg, 1mg, 5mg	8.02.2	R	In line with NICE TA guidance no.85; Sept-04, as an alternative to ciclosporin when a calcineurin inhibitor is indicated as part of an initial or a maintenance immunosuppressive regimen in renal transplantation for adults. The initial choice of tacrolimus or ciclosporin should be based on the relative importance of their side-effect profiles for individual people. For immunosuppression in renal allograft recipients who are at high immunological risk. **Dailiport® - MR preparation of choice as of July 2020 (NDP July 2020)**	PBR (renal only) RL
tacrolimus M/R (Advagraff ®)	M/R tablets (Advagraff ®) 500mcg, 1mg, 5mg	8.02.2	R	for prevention of liver transplant rejection in patients enrolled in the 'Warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C virus infection' study (WAFT-C). (March 2009)	PBR (renal only) RL
tacrolimus MR (Envarsus®)	MR tablets 0.75mg, 1mg, 4mg	8.02.2	very R	For use within type A clinical trial (management of the failed kidney transplant which is left in-situ. (NDP September 2018)	clinical trial funding
Tacrolimus MR (Envarsus®)	MR tablets 0.75mg, 1mg, 4mg	8.02.2	R	For prophylaxis of transplant rejection in adult kidney allograft recipients, second line according to the local protocol. (NDP January 2020)	PBR RL
tadalafil (Adcirca®)	tablets 20mg	2.05.1	R	For treatment of pulmonary arterial hypertension in Functional Class II and III. (NDP March 2015)	PBR (for PH) RL

tadalafil	tablets 5mg, 10mg, 20mg	7.04.5	R		
tafluprost	eye drops, PF 15micrograms in 1ml	11.06	R	In line with national/local guidelines. (NDP March 2012)	
talazoparib	capsules 0.25mg, 1mg	8.01.5	R	In line with NICE TA guidance no. 952, February 2024: Talazoparib is recommended, within its marketing authorisation, for treating HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults who have had an anthracycline or a taxane, or both, unless these treatments are not suitable, and endocrine therapy if they have hormone receptor (HR)-positive breast cancer, unless this is not suitable. Talazoparib is only recommended if the company provides it according to the commercial arrangement.	PBR RL
talc (sterile)	unlicensed/hospital only availability of different preparations may vary from time to time	not classified	R	for management of pleurodesis use by respiratory and thoracic surgary teams (NDP May 2017)	
tamoxifen	tablets 10mg, 20mg, 40mg	8.03.4	A		
tamsulosin	MR capsules 400mcg	7.04.1	A		
tapentadol	Tablets 50mg, 75mg; SR tablets 50mg, 100mg, 150mg, 200mg, 250mg	4.07.2	R	For use by chronic pain team and in palliative care for severe chronic pain where morphine has either failed to provide adequate pain control, is not appropriate or is not tolerated. Immediate release tablets to be prescribed for initial titration and modified release for on-going treatment. On most occasions GPs will be asked to prescribe but some dispensing may be required from our pharmacy initially. (NDP Aug 2011) **Tapentadol is not approved for short term surgical pain.**	
tattooing ink (unlicensed)	injection, 0.5ml	19.02	A		
TauroLock Hep500	injection 5ml	2.08.1	R	Use in line with the relevant local (renal medicine) guideline.	
tebentafusp	concentrate for solution for infusion, 100mcg (200mcg/ml)	8.01.5	R	In line with NICE TA guidance no 1027, January 2025: Tebentafusp is recommended, within its marketing authorisation, for treating HLA-A*02:01-positive unresectable or metastatic uveal melanoma in adults. Tebentafusp is only recommended if the company provides it according to the commercial arrangement.	PBR

teclistamab	solution for injection 10mg/ml (3ml vias). 90mg/ml (1.7ml vials)	8.01.5	R	In line with NICE TA guidence no 1015, November 2024: Teclistamab is recommended as an option for treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody) when the myeloma has progressed on the last treatment. It is only recommended if the company provides teclistamab according to the commercial arrangement.	PBR
teicoplanin	injection 200mg, 400mg	5.01.7	R	Level 2 anti-infectives restricted to specific indications: As per Haematology anti-infective policy As per Paediatric Oncology/Haematology protocols Outpatient antibiotic therapy (OPAT) Vancomycin allergy	
temazepam	tablets 10mg, 20mg; oral solution 10mg in 5ml	4.01.1	A		
temocillin	injection 1g	5.01.1	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required	
temozolomide	capsules 5mg, 20mg, 100mg, 140mg, 180mg	8.01.5	R	1. In line with NICE TA guidance, no. 23, Apr-01 (updated March 2016) : Temozolomide is recommended as an option for treating malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy only if the person has a Karnofsky performance status score greater than or equal to 70 and a life expectancy of 12 weeks or more. 2. In line with NICE TA guidance no. 121, Jul-07: as first line treatment of patients with newly diagnosed glioblastoma multiforme (GBM)1 in patients with a World Health Organization (WHO) performance status of 0 or 1. To be administered concurrently with radiotherapy. For use in patients who are fit enough to receive full 60Gy radiotherapy and are most likely to benefit (see algorithm). It will not be offered as palliation.	PBR
temsirolimus	concentrate for intravenous infusion 25mg in 1 ml, 1.2ml amp	8.01.5	R	For use in a selected subgroup of patients with non-clear cell renal carcinoma on the grounds of more favourable outcome data in this subgroup. This treatment to be used as a substitute for sunitinib and not as second line to failed sunitinib. (April 2010)	PBR

tenecteplase	power and solvent for solution for injection, 25mg, 50mg	2.10.2	R	For the treatment of acute ischaemic stroke in line with the local guideline. (NDP, July 2023) In line with NICE TA guidance no 990, July 2024: Tenecteplase is recommended, within its marketing authorisation, as an option for the thrombolytic treatment of an acute ischaemic stroke in adults: within 4.5 hours of the onset of stroke symptoms, and when intracranial haemorrhage has been excluded.	
tenofovir disoproxil	tablets 245 mg; tablets 123mg, 163mg, 204mg; granules 33mg per scoop (1g of granules) .	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
tenofovir disoproxil	tablets 245 mg	5.03.1	R	For management of Hepatitis B in line with the latest NICE Clinical Guideline (CG165).	PBR RL
tenofovir alafenamide	not available as single ingredient tablet	5.03.1	R	Level 2 anti-infectives restricted to specific indications In combination with other antiretorviral agents as Descovy®, Genvoya® and Odefsey® brands. As per the relevant NHS England commissioning policy. (NDP December 2016)	PBR RL
tenofovir alafenamide/ emtricitabine	tablets 10/mg/200mg (Descovy® 10) 25mg/200mg (Descovy® 25)	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
tenofovir alafenamide/ /emtricitabine/ bictegravir Biktarvy®	tablets 25mg/200mg/50mg	5.03.1	R	Level 2 anti-infectives restricted to specific indications As per relevant NHS England commissioning policy (NDP September 2019)	PBR RL
tenofovir alafenamide/ emtricitabine/ rilpivirine	tablets 25mg/200mg/25mg (Odefsey®)	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
tenofovir alafenamide/ emtricitabine/ elvitegravir/ cobicistat	tablets 10mg/200mg/150mg/150mg (Genvoya®)	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL

tepotinib	tablets 225mg	8.01.5	R	In line with NICE TA guidance no. 789, May 2022: Tepotinib is recommended, within its marketing authorisation, as an option for treating advanced non-small-cell lung cancer (NSCLC) with METex14 skipping alterations in adults, only if the company provides tepotinib according to the commercial arrangement.	PBR RL
terbinafine	tablets 250mg	5.02.5	A	Level 1 non-reserved anti-infective	
terbinafine	cream 1%	13.10.2	R	Dermatologists only.	
terbutaline	Turbohaler 500mcg/inhalation; Respules 5mg in 2ml; tablets 5mg; injection 500micrograms in 1ml, 2.5mg in 5ml	3.01.1	A		
terbutaline sulphate	Injection, 500 micrograms in 1ml	7.01.3	A		
teriflunomide	tablets 14mg	8.02.4	R	In line with NICE TA guidance no 303, Janunary 2014: Teriflunomide is recommended for treating adults with active relapsing–remitting multiple sclerosis (normally defined as 2 clinically significant relapses in the previous 2 years), only if they do not have highly active or rapidly evolving severe relapsing–remitting multiple sclerosis and the manufacturer provides teriflunomide with the discount agreed in the patient access scheme.	PBR RL
teriparatide	Injection, 250 micrograms in 1ml, 3ml Pre-filled Pen	6.06.1	R	In line with NICE TA guidance no. 161, October 2008: Teriparatide is recommended as an alternative treatment option for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are unable to take alendronate and either risedronate or etidronate, or have a contraindication to or are intolerant of alendronate and either risedronate or etidronate, or who have a contraindication to, or are intolerant of strontium ranelate, or who have had an unsatisfactory response to treatment with alendronate, risedronate or etidronate and who are 65 years or older and have a T-score of – 4.0 SD or below, or a T-score of – 3.5 SD or below plus more than two fractures, or who are aged 55–64 years and have a T-score of – 4 SD or below plus more than two fractures.	RL
teriparatide	Injection, 250 micrograms in 1ml, 3ml Pre-filled Pen	6.06.1	R	In line with NHS Clinical Commissioning Policy, August 2024: Teriparatide is recommended to be available as a routine commissioning treatment option for osteoporosis in men (adults) within the criteria set out in commissioning document.	RL
terlipressin	solution for injection, 1mg	6.05.2	A		

Terra-Cortril ®	ointment containing hydrocortisone 1% and oxytetracycline 3%	13.04	A		
testosterone	implant 25mg, 100mg (unlicensed), 200mg (unlicensed);	6.04.2	R		
testosterone	gel, 2% (10mg per dose) gel, 40.5mg in 2.5g sachets	6.04.2	A		
testosterone undecanoate	injection (oily) 1000mg	6.04.2	R	For testosterone replacement therapy for male hypogonadism in testicular cancer patients and in other medical patients (eg endocrinology). GPs may be asked to administer the injections.	
tetanus immunoglobulin	injection	14.05	A		
tetrabenazine	tablets 25mg	4.09.3	A		
tetracaine	gel 4% (Ametop ®)	15.02	A		
tetracaine hydrochloride (amethocaine hydrochloride)	Single use Minims ® eye drops, 0.5%, 1%.	11.07	A		
tetracosactide (tetracosactrin)	injection 250 micrograms in 1ml (as acetate); depot injection 1mg in 1ml (as acetate) (Synacthen Depot ®)	6.05.1	A		
tetracycline	tablets 250mg	5.01.3	A	Level 1 non-reserved anti-infective	
tetracycline hydrochloride	topical solution 0.22% in an alcoholic basis (Topicycline ®).	13.06.1	A		
Teysuno® (tegafur with gimeracil and oteracil)	capsules (tegafur 15mg, gimeracil 4.35mg oteracil 11,8mg) and (tegafur 20mg, gimeracil 5.8mg and oteracil 15.8mg)	8.01.4	R	For treatment of gastric carcinoma (with cisplatin) where capecitabine is unsuitable. (NDP February 2014)	PBR
tezepelumab	pre-filled syringe, 210mg	3.04.2	R	In line with NICE TA guidance no. 880, April 2023: Tezepelumab as an add-on maintenance treatment is recommended as an option for severe asthma in people 12 years and over, when treatment with high-dose inhaled corticosteroids plus another maintenance treatment has not worked well enough. It is recommended only if people have had 3 or more exacerbations in the previous year, or are having maintenance oral corticosteroids. Tezepelumab is recommended only if the company provides it according to the commercial arrangement.	PBR
thalidomide	capsules 50mg; tablets 25mg, 50mg, 100mg (all tablets are unlicensed)	8.02.4	R	NICE TA guidance no. 228; Jul-11. Thalidomide in combination with an alkylating agent and a corticosteroid is recommended as an option for the first-line treatment of multiple myeloma in people for whom high-dose chemotherapy with stem cell transplantation is considered inappropriate.	PBR RL

theophylline	MR tablets (Uniphyllin Continus) 200mg, 300mg, 400mg; MR capsules (Slo-Phyllin) 60mg, 125mg	3.01.3	A		
thiamine (Vitamin B1)	tablets 50mg, 100mg; injection 50mg in 1ml	9.06.2	A		
thiopental sodium (thiopentone sodium)	injection 500mg pre-filled syringe 25mg/ml (20ml - unlicensed)	15.01.1	A		PBR
thiotepa	injection 15mg	8.01.1	A		PBR
thrombin	topical solution 5000 units (unlicensed)	2.11	A		
thyrotropin alfa (recombinant human thyroid stimulating hormone, rhTSH)	injection 900mcg	6.05.1	A		
tiabendazole (thiabendazole)	tablets chewable 500mg (unlicensed)	5.05.7	A	Level 1 non-reserved anti-infective	
tiagabine	tablets 5mg, 10mg, 15mg	4.08.1	R	To be used in line with NICE guidance for control of epilepsy.	
tibolone	tablets 2.5mg	6.04.1	A		
ticagrelor	tablets 90mg	2.09	R	1. In line with NICE TA guidance no.236, Oct-11: Ticagrelor in combination with low-dose aspirin is recommended for up to 12 months as a treatment option in adults with acute coronary syndromes (ACS). That is, people with ST-segment-elevation myocardial infarction (STEMI) that cardiologists intend to treat with primary percutaneous coronary intervention (PCI), or with non-ST-segment-elevation myocardial infarction (NSTEMI) or admitted to hospital with unstable angina. Before ticagrelor is continued beyond the initial treatment, the diagnosis of unstable angina should first be confirmed, ideally by a cardiologist.	
ticagrelor	tablets 60mg	2.09	R	2. Inline with NICE TA guidance no. 420, December 2016 : Ticagrelor, in combination with aspirin, is recommended within its marketing authorisation as an option for preventing atherothrombotic events in adults who had a myocardial infarction and who are at high risk of a further event. Treatment should be stopped when clinically indicated or at a maximum of 3 years.	
ticagrelor	tablets 60mg, 90mg soluble tablets 90mg	2.09	R	3. For use by interventional neuroradiology in line with the local protocol. NDP May 2022	
tigecycline	injection 50mg	5.01.3	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required	

tildrakizumab	pre-filled syringe 100mg	10.01.3	R	In line with NICE TA guidance no. 575, April 2019: Tildrakizumab is recommended as an option for treating plaque psoriasis in adults, only if the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and the company provides the drug according to the commercial arrangement.	PBR
Timodine ®	cream containing hydrocortisone 0.5%, nystatin 100,000units/g, benzalkonium chloide solution 0.2%, and dimeticone '350' 10%	13.04	A		
timolol	eye drops 0.25%, 0.5%; unit dose eye drops, 0.5% - preservative free; eye gel 0.1% (single dose Tiopex®, 0.25%, 0.5%	11.06	A	For use In line with the national/local guidelines.	
tinzaparin	injection 20,000units/ml: syringe 10,000u in 0.5ml, 14,000u in 0.7ml, 18,000u in 0.9ml, 40,000u in 2ml; Injection, 10,000 units/ml: syringe 4,500unit in 0.45ml	2.08.1	R	Use in line with the relevant local guidelines.	
tioconazole	cutaneous solution 28%	13.10.2	R	Restricted for use by Dermatology teams only.	
tioguanine	tablets 40mg; oral liquid 50mg in 5ml (unlicensed)	8.01.3	A		PBR
tiopronin	250mg tablets (unlicensed) 300mg tablets (unlicensed)	not classified	R	For management of cystinuria in the specialist setting. NDP May 2017 Hospital only	RL
tiotropium	Respimat ® solution for inhalation 2.5mcg/metered inhalation; Braltus ® Zonda ® dry powder inhaler 10mcg capsule	3.01.2	A	For COPD according to the latest national and local guidelines.	
tiotropium/olodaterol	Spiolto® Respimat® 2.5mcg/2.5mcg solution for inhalation	3.01.2	A	For COPD according to the latest national and local guidelines. (NDP June 2017)	
tipranavir	capsules 250mg	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL

tirbanibulin	ointment 10mg/g	13.09	A	NDP March 2023	
tirofiban	concentrate for IV infusion 12.5mg in 50ml; intravenous infusion, 12.5mg in 250ml	2.09	R	1. For use in line with NICE TA guidance no. 47, September 2010 update.	
tirofiban	concentrate for IV infusion 12.5mg in 50ml	2.09	R	2. For use in low risk patients undergoing percutaneous transluminal coronary angioplasty (PTCA).	
tirzepatide	solution for injection in pre-filled pen, all strenghts	6.01.2	R	In line with NICE TA guidance no. 924, October 2023 (last updated September 2025): Tirzepatide is recommended for treating type 2 diabetes alongside diet and exercise in adults when it is insufficiently controlled only if triple therapy with metformin and 2 other oral antidiabetic drugs is ineffective, not tolerated or contraindicated, and they have a body mass index (BMI) of 35 kg/m2 or more, and specific psychological or other medical problems associated with obesity, or they have a BMI of less than 35 kg/m2, and insulin therapy would have significant occupational implications, or weight loss would benefit other significant obesity-related complications. Use lower BMI thresholds (usually reduced by 2.5 kg/m2) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.	
tisagenlecleucel	cells dispersion for infusion	8.01.5	R	In line with NICE TA guidance no. 975, May 2024 (replaces TAG 554): Tisagenlecleucel is recommended, within its marketing authorisation, as an option for people 25 years and under for treating B-cell acute lymphoblastic leukaemia that is relapsed after a transplant, or relapsed for a second or later time, or refractory. It is only recommended if the company provides it according to the commercial arrangement.	PBR
Tisept ®	solution (sterile) containing chlorhexidine gluconate 0.015% and cetrimide 0.15%	13.11.2	A	no longer pharmacy; ordered from supplies	
Tisseel RTU	2mL, 4ml. 10ml (Fibrinogen 91mg/mL, Aprotinin 3000KIU/mL, Thrombin 500IU/mL, Calcium chloride 40micromoles/mL)	2.11	R		PBR
Tobradex ®	eye drops	11.04.1	R	Combined tobramycin and dexamethasone eye drops to replace Maxitrol (neomycin and dexamethasone) or separately dexamethasone and chloramphenicol drops for the reduction of inflammation and prophylaxis against infection following cataract/intra-ocular/squint surgery.	

tobramycin	injection 20mg in 2ml, 40mg in 1ml, 80mg in 2ml; nebuliser solution 300mg in 5ml (non reserved)	5.01.4	R	Level 1 non-reserved anti-infective	
tocilizumab	infusion 80mg in 4ml, 200mg in 10ml, 400mg in 20ml	10.01.3	R	1. In line with NICE TA guidance no. 238; Dec-11. Tocilizumab is recommended for the treatment of systemic juvenile idiopathic arthritis in children and young people aged 2 years and older whose disease has responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs), systemic corticosteroids and methotrexate if the manufacturer makes tocilizumab available with the discount agreed as part of the patient access scheme.	PBR
tocilizumab	infusion 80mg in 4ml, 200mg in 10ml, 400mg in 20ml solution for subcutaneous injection 162mg (pre-filled syringe)	10.01.3	R	2. In line with NICE TA guidance no. 375, Jan-2016 : Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, **tocilizumab** and abatacept, all in combination with methotrexate, are recommended as options for treating rheumatoid arthritis only if disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and disease has not responded to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs) and the companies provide certolizumab pegol, golimumab, abatacept and **tocilizumab** as agreed in their patient access schemes. Adalimumab, etanercept, certolizumab pegol or **tocilizumab** can be used as monotherapy for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the aforementioned criteria are met.	PBR
tocilizumab	infusion 80mg in 4ml, 200mg in 10ml, 400mg in 20ml solution for subcutaneous injection 162mg (pre-filled syringe)	10.01.3	R	3. In line with NICE TA guidance no. 373, December 2015: Abatacept, adalimumab, etanercept and **tocilizumab** are recommended, within their marketing authorisations, as options for treating polyarticular juvenile idiopathic arthritis (JIA), including polyarticular-onset, polyarticular-course and extended oligoarticular JIA. That is for tocilizumab, people 2 years and older whose disease has responded inadequately to previous therapy with methotrexate.	PBR
tocilizumab	infusion 80mg in 4ml, 200mg in 10ml, 400mg in 20ml solution for subcutaneous injection 162mg (pre-filled syringe)	10.01.3	R	4. In line with NICE TA guidance no.518, March 2018: Tocilizumab, when used with a tapering course of glucocorticoids (and when used alone after glucocorticoids), is recommended as an option for treating giant cell arteritis in adults, only if they have relapsing or refractory disease, they have not already had tocilizumab, tocilizumab is stopped after 1year of uninterrupted treatment at most and the company provides it with the discount agreed in the patient access scheme.	PBR

tocilizumab	infusion 80mg in 4ml, 200mg in 10ml, 400mg in 20ml solution for subcutaneous injection 162mg (pre-filled syringe)	10.01.3	R	5. For the treatment of adult-onset Still's disease refractory to second-line therapy as per NHS England commissioning policy. (NDP November 2018)	PBR
tocilizumab	infusion 80mg in 4ml, 200mg in 10ml, 400mg in 20ml	10.01.3	R	6. For the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation, in line with the relevant local and national guidelines. (NDP March 2022) In line with NICE TA guidance 878, April 2023 (updated May 2025)	PBR
tocilizumab	infusion 80mg in 4ml, 200mg in 10ml, 400mg in 20ml	10.01.3	R	7. For third line treatment of steroid resistant thyroid eye disease. (NDP January 2026)	
tofacitinib	tablets 5mg, 10mg	10.01.3	R	1. In line with NICE TA guidance, no 480, October 2017: Tofacitinib, with methotrexate or as monotherapy, is recommended as an option for treating active rheumatoid arthritis in adults under specific criteria and if the company provides tofacitinib with the discount agreed in the patient access scheme.	PBR RL
tofacitinib	tablets 5mg, 10mg	10.01.3	R	2. In line with NICE TA guidance, no 543, October 2018: Tofacitinib, with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults as outlined in the technology appraisal document. Tofacitinib is only recommended if the company provides it according to the commercial arrangement.	PBR RL
tofacitinib	tablets 5mg, 10mg	10.01.3	R	3. In line with NICE TA guidance, no 547, November 2018: Tofacitinib is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated or the disease has responded inadequately or lost response to treatment. It is recommended only if the company provides tofacitinib with the discount agreed in the commercial arrangement.	PBR RL
tofacitinib	tablets 5mg, 10mg	10.01.3	R	4. In line with NICE TA guidance no. 735, October 2021: Tofacitinib is recommended as an option for treating active polyarticular juvenile idiopathic arthritis (JIA; rheumatoid factor positive or negative polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis in people 2 years and older. This is if their condition has responded inadequately to previous treatment with disease-modifying antirheumatic drugs (DMARDs), and only if a tumour necrosis factor (TNF)-alpha inhibitor is not suitable or does not control the condition well enough, and the company provides tofacitinib according to the commercial arrangement.	PBR RL

tofacitinib	tablets 5mg, 10mg	10.01.3	R	5. In line with NICE TA guidance no.920, October 2023: Tofacitinib is recommended as an option for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults, only if tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and the company provides tofacitinib according to the commercial arrangement.	PBR RL
tolazoline	injection 10mg in 1ml, 25mg in 1ml (both unlicensed)	2.06.4	A		
tolazoline	injection 10mg in 1ml, 25mg in 1ml (both unlicensed)	2.06.4	R	For use in neonates	
tolbutamide	tablets 500mg	6.01.2	A		
tolterodine	tablets 1mg, 2mg; tablets MR 4mg	7.04.2	A		
tolvaptan	tablets 15mg, 30mg, 45mg, 60mg, 90mg	6.05.2	R	In line with NICE TA guidance no. 358, October 2015: Tolvaptan is recommended as an option for treating autosomal dominant polycystic kidney disease in adults to slow the progression of cyst development and renal insufficiency only if they have chronic kidney disease stage 2 or 3 at the start of treatment there is evidence of rapidly progressing disease and the company provides it with the discount agreed in the patient access scheme. NHS Engaland commissioning statement, December 2016	PBR RL
topiramate	tablets 25mg, 50mg, 100mg, 200mg; sprinkle capsules 15mg, 25mg, 50mg; oral liquid 50mg in 5ml	4.08.1	R	1. To be used in line with NICE guidance for control of epilepsy. 2. For migraine prophylaxis. Atenolol or propranolol will remain fist line agents, followed by pizotifen, then valproate, then either topiramate or methysergide.	
topotecan	intravenous infusion 1mg, 4mg	8.01.5	R	As first line therapy in combination with cisplatin for the treatment of recurrent or metastatic cervical cancer to replace current first line treatment - carboplatin with paclitaxel.	PBR
topotecan	intravenous infusion 1mg, 4mg	8.01.5	R	In line with NICE TA guidance no. 183, October 2009: Topotecan, in combination with cisplatin, is recommended as a treatment option for women with recurrent or stage IVB cervical cancer only if they have not previously received cisplatin.	PBR

topotecan	capsules 250mcg, 1mg	8.01.5	R	In line with NICE TA guidance no. 184, November 2009: Oral topotecan is recommended as a treatment option only for people with relapsed small-cell lung cancer for whom re-treatment with the first-line regimen is not considered appropriate and the combination of cyclophosphamide , doxorubicin and vincristine is contraindicated. Intravenous topotecan is not recommended for people with relapsed small-cell lung cancer.	PBR
torasemide	tablets 2.5mg, 5 mg, 10mg	2.02.2	R	For the first line use in high risk patients with chronic refractory heart failure who are admitted to hospital, once their intravenous frusemide is stopped.	
tralokinumab	solution for injection in pre-filled syringes, 150mg	10.01.3	R	In line with NICE TA guidance no. 814, August 2022: Tralokinumab is recommended as an option for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in adults, only if the disease has not responded to at least 1 systemic immunosuppressant, or these are not suitable the company provides tralokinumab according to the commercial arrangement.	PBR
tramadol	capsules 50mg; injection 100mg in 2ml orodispersible tablets 50mg MR capsules 50mg; MR tablets 100mg	4.07.2	A		
trametinib	tablets 0.5mg, 2mg	8.01.5	R	In line with NICE TA guidance no. 396, June 2016: Trametinib in combination with dabrafenib is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation only when the company provides trametinib and dabrafenib with the discounts agreed in the patient access schemes.	PBR RL
trandalopril	capsules 500micrograms, 1mg, 2mg.	2.05.5	R	Restricted for use by Endocrinology teams.	
tranexamic acid	tablets 500mg; syrup 500mg in 5ml (unlicensed); injection 500mg in 5ml, 1g in 10ml; mouthwash 5% (unlicensed)	2.11	A		
tranylcypromine	tablets 10mg	4.03.2	A		

trastuzumab	vial 150mg (powder for solution for intravenous infusion) vial 600mg in 5mL (solution for subcutaneous injection) - NDP February 2014	8.01.5	R	1. In line with NICE guidance no. 34; Mar-02, in combination with paclitaxel for the treatment of metastatic breast cancer in patients with tumours expressing human epidermal growth factor receptor 2 (HER2) scored at levels of 3+ who have not received chemotherapy for metastatic breast cancer and in whom anthracycline treatment is inappropriate.	PBR
trastuzumab	vial 150mg (powder for solution for intravenous infusion) vial 600mg in 5mL (solution for subcutaneous injection) - NDP February 2014	8.01.5	R	2. In line with NICE guidance no. 34; Mar-02, as monotherapy for the treatment for people with tumours expressing HER2 scored at levels of 3+ who have received at least two chemotherapy regimens for metastatic breast cancer.	PBR
trastuzumab	vial 150mg (powder for solution for intravenous infusion) vial 600mg in 5mL (solution for subcutaneous injection) - NDP February 2014	8.01.5	R	3. In line with NICE TA guidance no. 107; Aug-06, as a treatment option for women with early-stage HER2-positive breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy. Treatment to be started within 6 months of last dose of adjuvant chemotherapy for a maximum treatment period of 12 months.	PBR
trastuzumab	vial 150mg (powder for solution for intravenous infusion) vial 600mg in 5mL (solution for subcutaneous injection) - NDP February 2014	8.01.5	R	4. In line with NICE TA guidance no. 208; Nov-10, trastuzumab, in combination with cisplatin and capecitabine or 5-fluorouracil, is recommended as an option for the treatment of people with human epidermal growth factor receptor 2 (HER2)-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior treatment for their metastatic disease and have tumours expressing high levels of HER2.	PBR
trastuzumab emtansine	powder for solution for infusion 100mg, 160mg	8.01.5	R	In line with NICE TA guidance no. 458, July 2017: Trastuzumab emtansine is recommended, within its marketing authorisation, as an option for treating human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or metastatic disease or developed disease recurrence during or within 6 months of completing adjuvant therapy. Trastuzumab emtansine is recommended only if the company provides it in line with the commercial access agreement with NHS England.	PBR

trastuzumab emtansine	powder for solution for infusion 100mg, 160mg	8.01.5	R	In line with NICE TA guidance no. 632, June 2020: Trastuzumab emtansine is recommended, within its marketing authorisation, as an option for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy. It is recommended only if the company provides trastuzumab emtansine according to the commercial arrangement.	PBR
trastuzumab deruxtecan	powder for solution for infusion 100mg	8.01.5	R	In line with NICE TA guidance no 704, May 2021: Trastuzumab deruxtecan is recommended for use within the **Cancer Drugs Fund**as an option for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies. It is recommended only if the conditions in the managed access agreement are followed.	PBR
trastuzumab deruxtecan	powder for solution for infusion 100mg	8.01.5	R	In line with NICE TA guidance no. 862, February 2023: Trastuzumab deruxtecan is recommended with managed access as an option for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults. It is only recommended if the conditions in the managed access agreement for trastuzumab deruxtecan are followed.	PBR
travoprost	eye drops 40mcg/ml eye drops 40mcg/ml PF	11.06	A	In line with national/local guidelines. PF ED - NDP meeting January 2024	
travoprost/timolol.	eye drops 40mcg/5mg per ml	11.06	A	For use In line with the national/local guidelines.	
trazodone	capsules 50mg, 100mg; tablets 150mg; liquid 50mg in 5ml (Jan 2009)	4.03.1	A		
treosulfan	capsules 250mg; powder for solution for infusion 1g, 5g	8.01.1	R	Available in the Formulary without specified indications. March 2008 approved for the treatment of metastatic uveal melanoma in combination with gemcitabine.	PBR
treosulfan	powder for solution for infusion 1g, 5g	8.01.1	R	In line with NICE TA guidance no. 640, August 2020: Treosulfan (Trecondi, Medac) in combination with fludarabine (generic) is indicated 'as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and nonmalignant diseases, and in paediatric patients older than 1 month with malignant diseases'.	PBR

treprostinil	injection 5mg in 1ml (Unlicensed), 10mg in 1ml (unlicensed) (UT15)	2.05.1	R	for specialist management of pulmonary hypertension. Use in line with European Society of Cardiology Consensus Guidelines.	RL
tretinoin (trans-retinoic acid)	capsules 10mg	8.01.5	A		
triamcinolone acetonide	Injection, aqueous suspension, 40mg in 1ml.	6.03.2	A		
triamcinolone acetonide	injection 10mg in 1ml, 50mg in 5ml (Adcortyl ® Intra-articular/Intradermal); injection 40mg in 1ml (Kenalog ® Intra-articular/Intramuscular)	10.01.2	A		
triamcinolone acetonide (Intracinol®)	ophthalmic solution, 4%	not classified	A	Medical Device (injectable) For the staining of the vitreus	
trichloroacetic acid	solution 50% (unlicensed); crystals (100%) (unlicensed)	13.07	A		
triclosan	solution, bath concentrate 2% (Ster-Zac Bath Concentrate ®).	13.11.5	A	no longer pharmacy; ordered from supplies	
trifluoperazine	tablets 1mg, 5mg; MR capsules 2mg, 10mg, 15mg; syrup 1mg in 5ml, 5mg in 5ml; suppositories 5mg, 25mg; injection 12.5mg in 1ml.	4.02.1	A		
trifluorothymidine (F3T)	Eye drops, 1%. Eye drops, 1% preservative free (Unlicensed product.)	not classified	A		
trihexyphenidyl	tablets 2mg, 5mg; syrup 5mg in 5ml	4.09.2	A		
trimethoprim	tablets 100mg, 200mg; suspension 50mg in 5ml; injection 100mg in 5ml	5.01.8	A	Level 1 non-reserved anti-infective	
Trimovate ®	cream containing clobetasone butyrate 0.05%, oxytetracycline 3% and nystatin 100,000units/g	13.04	A	Level 1 non-reserved anti-infective	
triptorelin	Injection 3mg, 11.25mg (Decapeptyl SR ®); Pre-filled syringe 3.75mg (Gonapeptyl Depot ®)	6.07.2	A		
triptorelin	Decapeptyl®SR 3mg, 11.25mg, 22.5mg powder fo suspension for intramuscular injection.	8.03.4	A	The least costly gonadorelin analogue will be used for their licensed indication. **Note**: Pharmacy will only stock this brand of triptorelin and the brand should be clearly specified when GPs are asked to prescribe/administer triptorelin.	

trisodium citrate	solution 46.7% (Citralock ®)	2.08.1	R	Renal Medicine only	
Trizivir ®	tablets abacavir (as sulphate) 300mg, lamivudine 150mg, zidovudine 300mg.	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
trometamol (THAM)	injection 3.6%, 7.2% (5ml - unlicensed)(THAM)	9.02.2	A		
tropicamide	Single use Minims ® eye drops, 0.5%, 1%.	11.05	A		
tropicamide and phenylephrine	eye drops tropicamide 1% and phenylephrine 2.5% (single dose preservative free)	11.05	A		
Truvada ®.	tablets containing emtricitabine 200 mg and tenofovir disoproxil 245 mg	5.03.1	R	Level 2 anti-infectives restricted to specific indications: As per HIV guidance As per Paediatric HIV guidance As per Maternity & neonatal Guidelines got HIV positive mothers (QCCH & SMH)	PBR RL
tryptophan	tablets 500mg	4.03.4	A		
Tuberculin Purified Protein Derivative (Tuberculin PPD)	20 units per ml (2 units in 0.1ml); 100 units per ml (10 units in 0.1ml) undiluted for Heaf test 100,000 units/ml	14.04	A		
typhoid vaccine	injection polysaccharide vaccine (Typhim Vi ®)	14.04	R	For Occupational Health.	
typhoid vaccine, live oral	capsules (Vivotif ®)	14.04	A		
ublituximab	concentrate for solution for infusion, 150mg (25mg/mL)	8.02.4	R	In line with NICE TA guidance, no. 1025, December 2024: Ublituximab is recommended as an option for treating relapsing forms of multiple sclerosis, defined as active by clinical or imaging features in adults, only if: the multiple sclerosis is relapsing–remitting, and the company provides it according to the commercial arrangement.	
ulipristal acetate (ellaOne®)	tablets 30mg	7.03.5	R	For emergency contraception for women at high risk of pregnancy presenting at the Jefferiss Wing/Haven within 72 and 120 hours of UPSI and where copper IDU is unsuitable or declined. (NDP Aug 2011) For prescribing in ED in line with FSRH algorithm. (March 2025)	
Ultravist®	injection 300 (50ml); injection 370 (50ml)	18	A		

umeclidinium (Incruse® Ellipta®)	Dry powder for inhalation 55mcg per dose	3.02	A	For use in COPD as per the relevant national guidelines. (NDP November 2015)	
umeclidinium/ vilanterol (Anoro® Ellipta®)	Dry powder for inhalation 55mcg/22mcg per dose	3.02	A	For use in COPD as per the relevant national guidelines. (NDP November 2015)	
umeclidinium/vilanterol/fluticasone furoate) (Trelegy® Ellipta®)	Dry powder for inhalation 55mcg/22mcg92/mcg per dose	3.02	R	For use in COPD as per the relevant national guidelines. (NDP September 2019) On recommendation by respiratory team.	
Unguentum M ®	cream 50g, 500g	13.02.1	A		
upadacitinib	modified release tablets, 15mg	10.01.3	R	1. In line with NICE TA guidance, no. 665, December 2020: Upadacitinib with methotrexate or as monotherapy is recommended as an option for treating severe active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs), as described in the NICE TAG and the company provides upadacitinib according to the commercial arrangement.	PBR RL
upadacitinib	modified release tablets, 15mg	10.01.3	R	2. In line with NICE TA guidance, no. 744, November 2021: Upadacitinib with methotrexate or as monotherapy is recommended as an option for treating moderate active rheumathoid arthritis in adults whose disease has responded inadequately to intensive therapy with 2 or more conventional disease-modifying antirheumatic drugs (DMARDs), as described in the NICE TAG and the company provides upadacitinib according to the commercial arrangement.	PBR RL
upadacitinib	modified release tablets, 15mg	10.01.3	R	3. In line with NICE TA guidance no 768, February 2022: Upadacitinib, alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have peripheral arthritis with 3 or more tender joints and 3 or more swollen joints and they have had 2 conventional DMARDs and at least 1 biological DMARD or TNF-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis). Upadacitinib is recommended only if the company provides it according to the commercial arrangement.	PBR RL

upadacitinib	modified release tablets, 15mg, 30mg, 45mg	10.01.3	R	4. In line with NICE TA guidance no 814, August 2022: Abrocitinib and **upadacitinib** are recommended as options for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in adults and young people 12 years and over, only if the disease has not responded to at least 1 systemic immunosuppressant, or these are not suitable the companies provide abrocitinib and upadacitinib according to the commercial arrangement.	PBR RL
upadacitinib	modified release tablets, 15mg, 30mg, 45mg	10.01.3	R	5. In line with NICE TA guidance no. 829, September 2022: Upadacitinib is recommended as an option for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults, only if tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and the company provides upadacitinib according to the commercial arrangement.	PBR RL
upadacitinib	modified release tablets, 15mg, 30mg, 45mg	10.01.3	R	6. In line with NICE TA guidance no. 856, January 2023: Upadacitinib is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or if the condition has not responded well enough or has stopped responding to these treatments, and if the company provides upadacitinib according to the commercial arrangement.	PBR RL
upadacitinib	modified release tablets, 15mg, 30mg, 45mg	10.01.3	R	7. In line with NICE TA guidance no. 861, February 2023: Upadacitinib is recommended as an option for treating active nonradiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs) in adults. It is recommended only if tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and the company provides upadacitinib according to the commercial arrangement.	PBR RL
upadacitinib	modified release tablets, 15mg, 30mg, 45mg	10.01.3	R	8. In line with NICE TA guidance no. 905, June 2023: Upadacitinib is recommended as an option for treating moderately to severely active Crohn's disease in adults, only if the disease has not responded well enough or lost response to a previous biological treatment or a previous biological treatment was not tolerated or tumour necrosis factor (TNF)-alpha inhibitors are contraindicated. Upadacitinib is only recommended if the company provides it according to the commercial arrangement.	PBR RL
urea	cream 10% (Aquadrate ®)	13.02.1	A		
urea	lotion 10% (Eucerin ® Intensive)	13.02.1	A		
urea breath test	tablets	not classified	R		

uridine triacetate	tablets	8.01.3	R	Uridine triacetate is recommended as a treatment option through routine commissioning for the treatment of patients exhibiting early-onset severe toxicities following 5-fluorouracil or capecitabine administration within the criteria set out in this document. NHS England commissioning policy, March 2020	PBR RL
Uristix		19.01	A		
Urografin	injection 150 (250ml); injection 325 (50ml); injection 370 (50ml)	18	A		
urokinase	injection 10,000 international units; injection 25,000 international units; injection 100,000 international units;	2.10.2	A		
Uromune®	spray (subluingual) unlicensed	not classified	R	Prophylaxis of urinary tract infection in line with the local urology and renal transplant protocols.	
ursodeoxychloic acid	tablets 150mg; capsules 250mg; suspension 250mg in 5ml	1.09.1	A		
ustekinumab	solution for injection, 45mg, 90mg - pre-filled syringe; solution for infusion (concentrate), 130mg	13.05.3	R	1. In line with NICE guidance no. 180, September 2009 (last updated March 2017), as a treatment option for adults with palque psoriasis when: • The disease is severe; • The psoriasis has not responded to standard systemic therapies, including ciclosporin, methotrexate and PUVA, or the person is intolerant of or has a contraindication to these treatments; • The manufacturer provides the 90 mg dose (two 45 mg vials) for people who weigh more than 100 kg at the same total cost as for a single 45 mg vial. Ustekinumab treatment should be stopped in people whose psoriasis has not responded adequately by 16 weeks after starting treatment.	PBR

ustekinumab	solution for injection, 45mg, 90mg - pre-filled syringe; solution for infusion (concentrate), 130mg	13.05.3	R	2. In line with NICE TA guidance no. 340, June 2015 (last updated March 2017): Ustekinumab is recommended as an option, alone or in combination with methotrexate, for treating active psoriatic arthritis in adults only when: treatment with tumour necrosis factor (TNF) alpha inhibitors is contraindicated but would otherwise be considered (as described in NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis and golimumab for the treatment of psoriatic arthritis) **or** the person has had treatment with 1 or more TNF–alpha inhibitors. Ustekinumab is recommended only if the company provides the 90 mg dose of ustekinumab for people who weigh more than 100 kg at the same cost as the 45 mg dose, as agreed in the patient access scheme.	PBR
ustekinumab	solution for injection, 45mg, 90mg - pre-filled syringe; solution for infusion (concentrate), 130mg	13.05.3	R	3. In line with NICE TA guidance no. 456, July 2017: Ustekinumab is recommended, within its marketing authorisation, as an option for treating moderately to severely active Crohn's disease, that is, for adults who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-alpha inhibitor or have medical contraindications to such therapies.	PBR
ustekinumab	solution for injection, 45mg, 90mg - pre-filled syringe; solution for infusion (concentrate), 130mg	1.05.3	R	4. In line with NICE TA guidance no 633, June 2020: Ustekinumab is recommended as an option for treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated, or the disease has responded inadequately or lost response to treatment, only if a tumour necrosis factor-alpha inhibitor has failed (that is the disease has responded inadequately or has lost response to treatment) or a tumour necrosis factor-alpha inhibitor cannot be tolerated or is not suitable, and the company provides ustekinumab at the same price or lower than that agreed with the Commercials Medicines Unit.	PBR
vadadustat	tablets 150mg, 300mg, 450mg	9.01.3	R	In line with NICE TA guidance no. 1035, January 2025: Vadadustat is recommended, within its marketing authorisation, as an option for treating symptomatic anaemia caused by chronic kidney disease in adults having maintenance dialysis. Vadadustat is only recommended if the company provides it according to the commercial arrangement.	PBR RL
valaciclovir	tablets 250mg, 500mg	5.03.2	R	Level 2 anti-infectives restricted to specific indications: As per Haematology anti-infective policy As per HIV guidance As per Jefferiss Wing GUM handbook	RL

valganciclovir	tablets 450mg; oral solution 250mg in 5ml	5.03.2	R	Level 2 anti-infectives restricted to specific indications: As per Renal anti-infective policy As per HIV guidance As per Paediatric Oncology/ Haematology protocols As per Paediatric congenital CMV guideline	RL
valproic acid	tablets 250mg, 500mg; capsules 300mg	4.02.3	A		
valsartan	capsules 40mg, 80mg, 160mg	2.05.5	A		
Vaminolact ®	IV infusion (100ml, 500ml)	9.03	A		
vancomycin	injection 500mg, 1g; intrathecal injection 20mg in 4ml (unlicensed)	5.01.7	A	Level 1 non-reserved anti-infective	
vancomycin	intrathecal injection 20mg in 4ml (unlicensed)	N/A	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required	
vancomycin	capsules 125mg	5.01.7	R	Level 2 anti-infectives restricted to specific indications: As per Adult/paediatric anti-infective policy	
vancomycin	2mg in 0.1ml, intravitreal injection – pre-pack	not classified	R	for ophthalmology use (NDP December 2017)	
vardenafil	tablets 5mg, 10mg, 20mg	7.04.5	R	Urologists and endocrinologists working in the diabetes clinic may prescribe treatments for impotence on an NHS prescription for men in line with guidance in BNF. Quantity prescribed should be limited to one treatment/patient per week.	RL
varenicline	tablets (as tartrate) 500mcg, 1mg imitiation pack	4.10.2	R	NICE TA guidance no. 123, Jul-07: Varenicline is recommended as an option for smokers who have expressed a desire to quit smoking. It should normally be prescribed only as part of a programme of behavioural support.	
varicella-zoster immunoglobulin	injection	14.05	A	On advice from virology only	
varidase	Topical powder	13.11.7	A		
vasopressin - see argipressin		6.05.2			
vecuronium	injection 10mg	15.01.5	A		
vedolizumab	powder for infusion, 30mg soution for subsutaneous injection, 108mg in 0.68ml	1.05.1	R	In line with NCE TA guidance no, 342, June 2015: Vedolizumab is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults only if the company provides vedolizumab with the discount agreed in the patient access scheme. Treatment monitoring and progress reivew to be performed as specified by NICE.	PBR

vedolizumab	powder for infusion, 30mg soution for subsutaneous injection, 108mg in 0.68ml	1.05.1	R	In line with NICE TA guidance no, 352, August 2015: Vedolizumab is recommended as an option for treating moderately to severely active Crohn's disease only if: a tumour necrosis factor-alpha inhibitor has failed (that is, the disease has responded inadequately or has lost response to treatment) or a tumour necrosis factor-alpha inhibitor cannot be tolerated or is contraindicated. Vedolizumab is recommended only if the company provides it with the discount agreed in the patient access scheme.	PBR
vemurafenib	tablets 240mg	8.01.5	R	In line with NICE TA guidance no. 269, Dec-2012: vemurefenib is recommended as an option for treating BRAF V600 mutation positive unresectable or metastatic melanoma only if the manufacturer provides vemurafenib with the discount agreed in the patient access scheme.	PBR RL
venetoclax	tablets, 10mg, 50mg, 100mg	8.01.5	R	1. In line with NICE TA guidance no. 561, February 2019: Venetoclax with rituximab is recommended, within its marketing authorisation, as an option for treating chronic lymphocytic leukaemia in adults who have had at least one previous therapy. It is recommended only if the company provides it according to thecommercial arrangement.	PBR RL
venetoclax	tablets, 10mg, 50mg, 100mg	8.01.5	R	2. In line with NICE TA guidence no 663, December 2020: 1.1 Venetoclax plus obinutuzumab is recommended as an option for untreated chronic lymphocytic leukaemia (CLL) in adults, only if: • there is a 17p deletion or TP53 mutation, or • there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab (FCR), or bendamustine plus rituximab (BR), is unsuitable, and • the companies provide the drugs according to the commercial arrangements. 1.2 Venetoclax plus obinutuzumab is recommended for use within the **Cancer Drugs Fund** as an option for untreated CLL in adults, only if: • there is no 17p deletion or TP53 mutation, and FCR or BR is suitable, and • the conditions in the managed access agreement for venetoclax plus obinutuzumab are followed.	PBR RL

venetoclax	tablets, 10mg, 50mg, 100mg	8.01.5	R	3. In line with NICE TA guidance no 765, February 2022: Venetoclax with azacitidine is recommended, within its marketing authorisation, as an option for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable. It is recommended only if the company provides venetoclax according to the commercial arrangement.	PBR RL
venetoclax	tablets, 10mg, 50mg, 100mg	8.01.5	R	4. In line with NICE TA guidance no 787, April 2022: Venetoclax with low dose cytarabine is recommended as an option for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable, only if they have over 30% bone marrow blasts the company provides venetoclax according to the commercial arrangement.	PBR RL
venetoclax	tablets, 10mg, 50mg, 100mg	8.01.5	R	5. In line with NICE TA guidance, no 796, June 2022 (replaces TA guidance no 487, November 2017): Venetoclax monotherapy is recommended, within its marketing authorisation, for treating chronic lymphocytic leukaemia (CLL) in adults with a 17p deletion or TP53 mutation and when a B-cell receptor pathway inhibitor is unsuitable, or whose disease has progressed after a B-cell receptor pathway inhibitor or without a 17p deletion or TP53 mutation, and whose disease has progressed after both chemo-immunotherapy and a B-cell receptor pathway inhibitor. It is recommended only if the company provides venetoclax according to the commercial arrangement.	PBR RL
venlafaxine	tablets 37.5mg, 50mg, 75mg; MR capsules 75mg, 150mg	4.03.4	A		
verapamil	tablets 40mg, 120mg; MR tablets (Securon SR) 240mg; oral solution 40mg in 5ml; injection 5mg in 2ml	2.06.2	A		
VeraSeal®	4mL, 10mL (human fibrinogen 80mg/mL, human thrombin 500IU/mL)	2.11	R	for use by cardiothoracic surgery (NDP, July 2023)	
verteporfin	Injection, powder for reconstitution, 15-mg vial (Visudyne ®)	11.08.2	R		RL
vibegron	tablets 75mg	7.04.2	A	In line with NICE TA guideance no. 999, September 2024: Vibegron is recommended as an option for treating the symptoms of overactive bladder syndrome in adults. It is only recommended if an anti-muscarinic medicines are not suitable, do not work well enough or have unacceptable side-effects.	

vigabatrin	tablets 500mg; powder 500mg/sachet	4.08.1	A	Powder is restricted for use by Paediatric teams only.	
vinblastine	injection 10mg	8.01.4	A		PBR
vincristine	injection 1mg, 2mg	8.01.4	A		PBR
vindesine	injection 5mg	8.01.4	A		PBR
vinorelbine	injection 10mg in 1ml, 50mg in 5ml; capsules 20mg, 30mg	8.01.4	R	1. In line with NICE TA guidance no.54; Dec-02, as monotherapy as one treatment option for second line or later therapy for the treatment of advanced breast cancer when anthracycline-based regimens have failed or are unsuitable.	PBR
vinorelbine	injection 10mg in 1ml, 50mg in 5ml; capsules 20mg, 30mg	8.01.4	R	2. Capsules may be used for metastatic breast cancer patients who would otherwise receive IV vinorelbine but are unable to tolerate the IV route of administration.	PBR
vinorelbine	injection 10mg in 1ml, 50mg in 5ml; capsules 20mg, 30mg	8.01.4	R	3. In line with NICE TA guidance no. 26; Jun-01, as part of first-line therapy for advanced (stage III and IV) non-small cell lung cancer (NSCLC).	PBR
Vioform-Hydrocortisone	cream containing hydrocortisone 1% and clioquinol 3%; ointment containing hydrocortisone 1% and clioquinol 3%	13.04	A		
Vipera Berus Antiserum		not classified	R	Following the recent advice by the College of Emergency Medicine 2 vials will be kept at the A&E department at SMH for the Trust. (NDP February 2011)	
Visipaque ®	injection	18	A	NDP Sept 2010	
vismodegib	capsules 150mg	8.01.5	R	For adults with either Gorlin syndrome or non-Gorlin syndrome related multiple basal cell carcinomas. In line with NHS England commissioning policy, February 2023.	PBR RL
Vitaline® renal multivitamin	tablets	9.06.7	A		
vitamin B compound	Tablets containing nicotinamide 15mg, riboflavin 1mg and thiamine hydrochloride 1mg.	9.06.2	A		
vitamin B compound strong	Tablets containing nicotinamide 20mg, pyridoxine hydrochloride 2mg, riboflavin 2mg and thiamine hydrochloride 5mg.	9.06.2	A		

vitamins B and C (Pabrinex ®)	Injection I/V High potency, for intravenous use only; each pair of ampoules contains: ascorbic acid 500mg, anhydrous glucose 1g, nicotinamide 160mg, pyridoxine hydrochloride 50mg, riboflavin 4mg, thiamine hydrochloride 250mg; Injection I/M High potency, for intramuscular use only; each pair of ampoules contains: ascorbic acid 500mg, nicotinamide 160mg, pyridoxine hydrochloride 50mg, riboflavin 4mg, thiamine hydrochloride 250mg.	9.06.2	A	When available as licensed product.	
Vitlipid-N ®	emulsion adult (10ml); emulsion infant (10ml)	9.03	A		
voclosporin	capsules 7.9mg	8.02.2	R	In line with NICE TA guidance no. 882, May 2023: Voclosporin with mycophenolate mofetil is recommended, within its marketing authorisation, as an option for treating active class 3 to 5 (including mixed class 3 and 5, and 4 and 5) lupus nephritis in adults. It is only recommended if the company provides voclosporin according to the commercial arrangement.	PRB RL
Volumatic	adult, paediatric	3.01.5	A		
vonicog-alfa	powder and solvernt for solution for injection 650iunits, 1300iunits	2.11	R	In line with NHS England clinical commissioning policy, Nov 2020	PBR
Voractiv®	tablets containing rifampicin 150mg, isoniazid 75mg, ethambutol 275mg, pyrazinamide 400mg	5.01.9	A	Level 1 non-reserved anti-infective	PBR
voriconazole	tablets 50mg, 200mg; oral suspension 200mg in 5ml; Intravenous infusion 200mg	5.02.1	R	Level 3 Restricted anti-infective – Microbiology/ Infectious Diseases approval required except Haematology/Paediatric Haematology/Renal if within their policy	
Vyxeos® daunorubicin/cytarabine liposomal	44 mg/100 mg powder for concentrate for solution for infusion.	8..1.03	R	In line with NICE TA guidance no 552, December 2018: Liposomal cytarabine–daunorubicin is recommended, within its marketing authorisation, as an option for untreated therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes in adults. It is recommended only if the company provides it according to the commercial arrangement.	PBR
warfarin	tablets 1mg, 3mg, 5mg	2.08.2	A		
water	irrigation 100ml, 500ml, 1l	21	A		

water for injection	5ml, 10ml, 20ml, 100ml, 500ml	9.02.2	A		
water for irrigation	Irrigation, 3 litre Uromatic.	7.04.4	A		
xylometazoline hydrochloride	Nasal drops, 0.05%, 0.1%; nasal spray 0.1%	12.02.2	A		
Xyloproct ® lidocaine 5%/hydrocortisone 0.275%	ointment	1.07.2	A		
Yasmin®	21 tablets, ethinylestradiol 0.03mg/drospirenone 3mg	7.03.1	A	as per NW London JF, NDP meeting January 2024	
yellow fever vaccine	injection	14.04	A		
zaleplon		4.01.1	R	NICE TA guidance no. 77; Apr-04. It is recommended that, because of the lack of compelling evidence to distinguish between zaleplon, zolpidem, zopiclone or the shorteracting benzodiazepine hypnotics, the drug with the lowest purchase cost (taking into account daily required dose and product price per dose) should be prescribed.	
zanamivir	powder for inhalation (Disks) 5mg/blister.	5.03.4	R	Level 2 anti-infectives restricted to specific indications: As per haematology anti-infective policy Per NICE or HPA guidelines/Virology involvement In line with NICE TA guidance no. 158; Sept-08, zanamivir are recommended for the postexposure prophylaxis of influenza if all of the following circumstances apply; National surveillance schemes have indicated that influenza virus is circulating; the person is in an at-risk group; the person has been exposed to an influenza-like illness and is able to begin prophylaxis within the timescale specified in the marketing authorisations of the individual drugs; the person has not been effectively protected by vaccination. Zanamivir are not recommended for seasonal prophylaxis of influenza.	

zanamivir	powder for inhalation (Disks) 5mg/blister.	5.03.4	R	Level 2 anti-infectives restricted to specific indications: As per haematology anti-infective policy Per NICE or HPA guidelines/Virology involvement In line with NICE TA guidance no. 168; Feb-09 (replaces TA guidance no. 58), for the treatment of influenza in at-risk adults a who present with influenza-like illness and who can start therapy within 48 hours of the onset of symptoms.and children who present with influenza-like illness and who can start therapy within 36 hours of the onset of symptoms	
zanubrutinib	capsules 80mg	8.01.5	R	1. In line with NICE TA guidance no. 833, October 2022: Zanubrutinib is recommended as an option for treating Waldenstrom's macroglobulinaemia in adults who have had at least 1 treatment, only if bendamustine plus rituximab is also suitable and the company provides it according to the commercial arrangement.	PBR RL
zanubrutinib	capsules 80mg	8.01.5	R	2. In line with NICE TA guidance no. 931, November 2023: Zanubrutinib is recommended as an option for treating chronic lymphocytic leukaemia (CLL) in adults. It is only recommended if the CLL is untreated and there is a 17p deletion or tumour protein 53 (TP53) mutation or there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab (FCR), or bendamustine plus rituximab (BR) is unsuitable, or relapsed or refractory. Zanubrutinib is recommended only if the company provides it according to the commercial arrangement.	PBR RL
zanubrutinib	capsules 80mg	8.01.5	R	3. In line with NICE TA guidance no. 1001, September 2024: Zanubrutinib is recommended, within its marketing authorisation, as an option for treating marginal zone lymphoma in adults who have had at least 1 anti-CD20-based treatment. It is only recommended if the company provides it according to the commercial arrangement.	PBR RL
zanubrutinib	capsules 80mg	8.01.5	R	4. In line with NICE TA guidance no. 1081, July 2025: Zanubrutinib can be used as an option to treat relapsed or refractory mantle cell lymphoma in adults who have had 1 line of treatment only. Zanubrutinib can only be used if the company provides it according to the commercial arrangement.	PBR RL
Zerobase®	Cream, 50g & 500g	13.02.1	A	Replaces Diprobase® as emollient of choice (NDP March 2022)	
Zerocream®	cream 50g, 500g (containing lanolin/white soft paraffin/liquid paraffin)	13.02.1	A	To replace E45 (NDP September 2021)	

Zerolatum®	fragrance-free bath emollient containing liquid paraffin 65%, wool alcohols 5% 500ml	13.02.1	A	To replace Balneum bath oil in line with NWL formulary (NDP September 2012)	
zidovudine (Azidothymidine, AZT)	capsules 100mg, 250mg; oral solution 50mg in 5ml; intravenous infusion 200mg in 10ml	5.03.1	R		PBR RL
zinc sulphate	Tablets, effervescent, 125mg (45mg zinc). Capsules, 220mg (50mg zinc).	9.05.4	A		
zinc sulphate	effervescent tablets 125mg; injection 5micromol in 1ml, 40micromol in 3ml, 1000micromol in 20ml (all unlicensed)	9.05.4	A		
zoledronic acid	injection 4mg	6.06.2	R	1.For the treatment of metastatic bone disease, to limit the progression of bone disease and for the treatment of bone pain in patients with prostate cancer. 2. For the treatment of tumour-induced hypercalcaemia in multiple myeloma only. 3. For use in patients with breast cancer for the treatment of tumour-induced hypercalcaemia and for the treatment of bone pain in patients with bone metastasis associated with breast cancer. 4mg infusions of zoldedronic acid to replace 90mg infusion of pamidronate. Zoledronic acid should not be used to replace low dose pamidronate. 4. for treatment of tumour induced hypercalcaemia except inpatients or patients with impaired renal function.	RL
zoledronic acid	injection 4mg	6.06.2	R	Adjuvant for early breast cancer treatment, in post-menopausal women. (unlicensed indication, NDP September 2016)	RL
zoledronic acid	5mg in 100ml	6.06.2	R	1.a. In line with NICE TA guideline 464, August 2017. b. osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture. 2. Approved as 1st line for treatment of Paget's disease of the bone (NDP November 2009)	RL
zolmitriptan	tablets 2.5mg; nasal spray 5mg/0.1ml unit dose	4.07.4	R	for acute migraine attacks. Not to be stocked by Trust pharmacies but to allow it to be recommended to GP's when appropriate.	

zolpidem		4.01.1	R	In lien with NICE TA guidance no. 77, AprIL 2004: It is recommended that, because of the lack of compelling evidence to distinguish between zaleplon, zolpidem, zopiclone or the shorteracting benzodiazepine hypnotics, the drug with the lowest purchase cost (taking into account daily required dose and product price per dose) should be prescribed.	
zonisamide	capsules 25mg, 50mg, 100mg	4.08.1	R	In line with the relevant NICE guideline.	
zopiclone	tablets 3.75mg, 7.5mg	4.01.1	A	In line with NICE TA guidance no. 77, Apr-04: It is recommended that, because of the lack of compelling evidence to distinguish between zaleplon, zolpidem, zopiclone or the shorteracting benzodiazepine hypnotics, the drug with the lowest purchase cost (taking into account daily required dose and product price per dose) should be prescribed.	
zuclopenthixol decanoate	injection (oily) 200mg in 1ml, 500mg in 1ml	4.02.2	A		